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The protozoan parasite Plasmodium falciparum is responsible for the deadliest form 
of malaria, which causes 584,000 fatalities annually and whose complications include 
coma, anemia, respiratory distress, and renal failure. Although malaria eradication 
efforts were hindered by the rise of chloroquine (CQ) resistance (CQR), CQ continues 
to be clinically deployed in resistance-free regions. CQR is primarily mediated by 
mutations in the P. falciparum chloroquine resistance transporter (pfcrt) gene, which 
also modulates parasite susceptibility to first-line artemisinin-based combination 
therapies (ACTs). In certain geographical regions (e.g. Africa), mutant pfcrt alleles 
display considerable fitness costs and have undergone attrition in the absence of CQ 
pressure. Surveillance of resistant field isolates presently centers on the PfCRT 
mutation K76T, ubiquitous among CQ-resistant parasites and always accompanied 
by ≥3 additional mutations. Despite the global adoption of K76T as a molecular 
marker of CQR, the contributions of this and other mutations to P. falciparum drug 
resistance versus fitness had not been previously defined. 
 
Aims:  We aimed to address the following: (1) Do PfCRT mutations beyond PfCRT 
K76T directly contribute to CQR? (2) Do PfCRT mutations contribute to parasite 
fitness during the pathogenic asexual blood stage? (3) Are there predictable 
mutational paths in the evolution of pfcrt-mediated drug resistance? (4) How do 
PfCRT mutations impact current antimalarials, including the first-line ACTs? 
 
 
Approach: Using zinc finger nucleases, we generated isogenic, pfcrt-modified blood-
stage P. falciparum parasites encoding wild-type (CQ-sensitive) or variant PfCRT 
haplotypes. Variants included a combinatorial library of alleles harboring 1-4 
mutations comprising the simplest CQ-resistant haplotype (Ecu1110). Additional 
genetic dissections of full-length or partial pfcrt alleles encompassed the most common 
variants found in Africa and Asia, including a unique fitness-neutral mutant allele 
(Cam734) that has undergone expansion in Southeast Asia. Parasite antimalarial 
drug susceptibility was determined using IC50-based (cytostatic) assays or parasite 
survival-based (cytocidal) assays and was combined with data from flow cytometric 
parasite growth competition assays to computationally model mutant pfcrt evolution. 
To further define the biochemical impacts of PfCRT mutations, our studies leveraged 
metabolomic, heme fractionation, and drug transport studies. 
 
Results: Key findings emerging from our studies included the following: (1) PfCRT 
K76T is insufficient for CQR and an inaccessible first mutational step in pfcrt 
evolution; (2) Alongside proliferation rates, parasite resistance gains dictate a 
constrained pfcrt mutational landscape and predict important roles for the active 
metabolites of CQ and amodiaquine in guiding pfcrt evolution; (3) To various degrees, 
PfCRT polymorphisms beyond K76T increase the potency of both the artemisinin and 
partner drug components of first-line ACT regimens; (4) Emerging PfCRT mutations 
(e.g. A144F) directly contribute to the enhanced fitness of pfcrt alleles and are 







Conclusions: Our studies uncovered multiple pleiotropic contributions of PfCRT 
mutations to antimalarial drug resistance, countering earlier dogma that non-K76T 
mutations are merely compensatory. Evolutionary modeling revealed parasites’ ability 
to navigate constrained mutational landscapes and evolve drug resistance via rare 
mutational bursts. These results collectively highlight the capacity of PfCRT to acquire 
novel mutations that successfully balance parasite multidrug resistance with the 
essential role of PfCRT in maintaining digestive vacuole physiology. Our studies are of 
direct relevance to the regional recommendations of antimalarials, whose activity is 
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HISTORY AND BURDEN OF MALARIA 
Etiology and phylogeny of malaria, an ancient disease 
Malaria predates recorded history and remains a leading infectious scourge. 
References to malaria abound across vast tracts of time and land and include ancient 
medical scripts, religious texts, and various bodies of literature.1 In ancient 
Mesopotamia, a series of cuneiform writings offered dire warnings about a febrile 
disease associated with marshy lowlands. The symptoms of this illness were highly 
evocative of severe malaria: 
If when it comes over him, his left/right eye makes bobbing 
movements similar to what a spindle does when it spins and 
his right/left eye is full of blood, he continually opens his 
mouth, and he bites his tongue, Lugal-Girra afflicts him.2 
In this context, Lugal-Girra is an alternate name for Nergal, the Babylonian god of 
devastation and pestilence.2 Intriguingly, depictions of Nergal placed him in the 
company of fleas and flies,3 hinting at the future discovery that insects can serve as a 
vessel of disease. The term “mal’aria” – meaning “bad air” in Italian – is now the sole 
remnant of the belief that toxic vapors emerging from marshes caused disease. This 
notion was fundamentally challenged beginning in 1880 with the work of Charles 
Louis Alphonse Laveran.   
Attending to solders suffering from malaria during his time as a military 
physician in Algeria, the scientifically curious Laveran collected blood samples and 
closely examined them by light microscopy. To his amazement, in erythrocytes from 




motile filaments and bore pigmented granules.1 Less than two decades following 
Laveran’s landmark discovery of blood-stage malarial parasites, a British physician 
in the Indian Medical Service, Sir Ronald Ross, clarified the remainder of the parasite 
life cycle. His painstaking observations included the development of parasites in the 
mosquito gut, the identification of the mosquito salivary gland as a site of parasite 
accumulation, and transmission of an avian malarial strain from Culex mosquitos to 
previously healthy birds.1 Extending Ross’s findings, the Italian physician Giovanni 
Grassi subsequently demonstrated that human malarial species are transmitted by 
female Anopheles mosquitos.1 
The protozoan parasites first noted by Laveran belong to the genus 
Plasmodium, which require both an invertebrate (i.e. mosquito or sandfly) and a 
vertebrate (i.e. mammal, bird, or reptile) host.4 Of the more than 250 existing 
Plasmodium species, five cause human malaria: P. falciparum, P. vivax, P. malariae, 
P. ovale (recognized as a pair of sub-species5), and P. knowlesi. Macaques serve as the 
natural reservoir of P. knowlesi parasites,6 and zoonotic infection with other 
Plasmodium  species  is possible.7 Interrogations of Plasmodium infection in vivo have 
greatly benefited from the availability of rodent-infecting species, which include P. 
berghei, P. chabaudi, P. vinckei, and P. yoelii.8 A generalized depiction of malarial 
parasite evolutionary relationships is shown in Figure 1.1. Recent advances in 
molecular diagnostic methods have provided important insights into Plasmodium 
evolutionary phenomena, including host switching (e.g. between bat and rodent 
species), host restriction (e.g. between human P. falciparum and the highly related 
ape Laverania species), and specific transmission histories (e.g. identification of 








Figure 1.1. Schematic of malarial parasite phylogenetic relationships. Previously inferred 
molecular phylogenies among Plasmodium and related species have been a subject of 
controversy and can vary substantially depending on the parasite taxa and molecular loci used for 
analyses.4 Shown are proposed evolutionary relationships among representative species 
comprising the genus Plasmodium and sub-genus Laverania.9 Several human-infecting 
Plasmodium species (e.g. P. falciparum and P. vivax) belong to clades that have expanded 
extensively in the related ape and monkey hosts. Image reproduced with permission from Keeling 











 Plasmodium species are more broadly classified as Apicomplexa, a phylum of 
obligate intracellular protists bearing (1) an apical complex, used for adhesion and 
invasion, as well as (2) an apicoplast, an essential organelle derived from the 
engulfment of a red algal organism.11 Collectively, apicomplexans are responsible for 
a diverse set of diseases of humans and animals, in part caused by parasites in the 
genera Plasmodium, Babesia, Cryptosporidium, Isospora, Toxoplasma, Neospora, 
Theileria, Sarcocystis, and Eimeria.4 Comparative studies between Plasmodium and 
related apicomplexan species have identified key differences in parasite genomic 
structures, metabolism, and host invasion strategies, greatly enhancing our 
understanding of Plasmodium biology and phylogenetic relationships.12 
 
Epidemiology and socioeconomic burden of malaria 
The global burden of human malaria is disproportionately concentrated in Africa, 
where up to 90% of the 214 million yearly cases and 438,000 yearly deaths occur.13 
Although the past two decades have witnessed a decline in mortality rates, malaria 
continues to claim the life of a child every two minutes.13 Globally, the majority of 
malarial morbidity is attributable to P. falciparum, the most virulent of the causative 
agents of malaria. The related species P. vivax accounts for ~3% of worldwide cases, 
occurring primarily in Southeast Asia and the Eastern Mediterranean region.13 
Although P. malariae and P. ovale have achieved global spread, their contributions to 
the overall burden of malaria are minimal. In recent years, Southeast Asian countries 
have seen a rise in infections caused by zoonotically transmitted P. knowlesi species.6 
The ecology of mosquito vectors – influenced by mosquito longevity, density, 




high-transmission regions with tropical climates, Anopheles mosquitos breed 
extensively, and individuals are bitten multiple times per year.15 These include sub-
Saharan Africa and parts of Oceania, where P. falciparum is a common cause of 
malaria. In contrast, low-transmission regions with cooler climates support 
significantly lower rates of infection (≤1 bites per year) and are more likely to harbor 
P. vivax parasites, which tolerate cooler climates.14,15  
In addition to its deleterious impact on human health, malaria also poses a 
significant socioeconomic burden. Malaria cases cost $300 million per year, an 
exorbitant expense for malaria-stricken regions whose incomes likely represent a 
small fraction of the income of a non-malarious country.13,16 Aside from posing medical 
costs, malaria inhibits population growth, worker productivity, investment, and 
foreign trade, collectively hindering economic growth.16 Consistent with this, 
retrospective cross-country analyses have revealed that countries with malaria 
experience slowed economic growth (-1.3% per person per year) as compared to 
malaria-free regions, even after correcting for possible confounding factors.16 Thus, in 
a vicious cycle, poverty sustains malaria, and malaria contributes to further poverty.  
 
Antimalarial eradication and control efforts  
The wise adage “hope for the best, prepare for the worst” aids in conceptualizing the 
deficiencies of previous malaria eradication campaigns, which fell short of 
anticipating worst-case scenarios. In 1955, following aggressive 
dichlorodiphenyltrichloroethane (DDT) spraying and an ensuing reduction in malaria 
transmission in the United States and other regions with temperate climates, the 




Program (GMEP).17 In a plan relying on aggressive DDT spraying, the GMEP aimed 
to disrupt malaria transmission in malaria-endemic regions.18 Control efforts also 
deployed chloroquine (CQ), a gold-standard antimalarial drug at the time, as a means 
of treatment and disease prevention.17 Nevertheless, the following two decades saw a 
rise in DDT and CQ resistance (CQR; see “Antimalarial Drug Resistance” section 
below) that coincided with financial crises, declining political commitments, 
inadequate health systems, and lack of agreement on standards for long-term 
surveillance. Accordingly, the eradication campaign was suspended.17,18 
 Launched in 1998, the Roll Back Malaria Partnership heralded a reprise in 
political and financial commitment to malaria control. Comprised of politicians, 
leaders from the private sector and nongovernmental organizations, research 
scientists, epidemiologists, and economists, the Roll Back Malaria Partnership 
spearheaded the Global Malaria Action Plan (GMAP).19 Among the goals articulated 
by the GMAP for the period 2000-2015 were to reduce global malaria incidence by 75% 
and to fully provide preventive and therapeutic coverage. Recent (2015) assessments 
of progress revealed both laudable achievements and an urgent need to expand future 
efforts. For instance, the majority (54%) of malarious countries achieved the target of 
75% reduction in malaria incidence. Less remarkably, despite calls for universal 
treatment access, only 16% of children aged five or younger received an appropriate 
first-line antimalarial upon infection with P. falciparum.13 The success of future 
strategies will hinge upon increased funding, continued political willpower, active 
engagement with the research community, and improved surveillance measures. 
Furthermore, as malarious countries achieve milestones on the path to elimination, 




transmission settings, which may include changes in demographics, rises in imported 
cases, lesser immunity, and shifts in the predominant infecting Plasmodium species.20 
 
PARASITE BIOLOGY 
Life cycle of human malarial parasites 
Plasmodium parasites require two types of hosts for their full development: an 
invertebrate and a vertebrate. In the case of human malaria, these are female 
Anopheles mosquitos and humans, respectively. The life cycle of human malarial 
parasites is complex and entails parasite progression through liver and blood stages 
in the human and sexual development in the mosquito (Figure 1.2). As an infected 
Anopheles mosquito probes for blood vessels during a blood meal (Figure 1.2A), it 
injects ~10-100 motile sporozoites into the human dermis.21 Initiating the liver stage 
of infection (Figure 1.2B–D), some of these sporozoites enter the bloodstream, 
penetrate the liver sinusoids, and invade hepatocytes in a series of traversals that 
culminate with the infection of a single hepatocyte. Of note, P. vivax and P. ovale 
parasites have the capacity to remain dormant in hepatocytes (weeks to ≥1 year) as 
hypnozoites, which cause the clinical relapses associated with these infections.14  For 
all species, over the course of ~5-16 days, actively infected hepatocytes support the 
development of thousands of merozoites that enter the bloodstream and proceed to 
infect red blood cells (RBCs).22 
The ensuing blood stage of the Plasmodium life cycle (Figure 1.2E–I) is directly 
responsible for the clinical course of malaria (see “Clinical manifestations and 






Figure 1.2. The natural life cycle of Plasmodium species. (A) Transmission of Plasmodium from 
the Anopheles mosquito vector to the human host begins via the injection of sporozoites into the 
dermis during a mosquito blood feed. (B) Sporozoites enter the bloodstream and (C) migrate to 
the liver, initiating the asexual liver stage of infection. In the liver, sporozoites traverse multiple 
hepatocytes and ultimately infect one. In infections with P. vivax and P. ovale, parasites may 
remain latent in hepatocytes for an extended period of time as hypnozoites. (D) Following growth 
and replication in the hepatocyte, parasite merozoite forms enter the bloodstream and (E) infect 
erythrocytes, initiating the asexual blood stage of infection. Infected erythrocytes support parasite 
development into (F) ring, (G) trophozoite, and (H) schizont parasite forms, culminating with the 
rupture of erythrocytes and release of merozoites that infect new erythrocytes and propagate the 
blood stage of infection. (J) In the blood, a subset of parasites differentiate into sexual gametocyte 
forms, which are (K) transmitted to the mosquito during a subsequent blood feed. (L) The sexual 
stage of Plasmodium infection occurs in the mosquito midgut, where fertilized gametes form diploid 
zygotes. These progress through ookinete and oocyst forms that ultimately (M) form and release 
haploid sporozoites. (N) Sporozoites migrate to the salivary glands, where they accumulate until 





As they mature in host RBCs, parasites progress through ring, trophozoite, and 
schizont stages, followed by lysis of RBCs and release of 6-30 merozoites that invade 
new RBCs.22  Depending on the infecting Plasmodium species, the asexual blood stage 
exhibits one of three possible durations: ~24 hours (P. knowlesi), ~48 hours (P. 
falciparum, P. vivax, and P. ovale), or ~72 hours (P. malariae). In the absence of 
treatment, successive rounds of parasite replication may occur for months, yielding a 
parasite burden as high as ~1012 parasites.24 Over a period of about two weeks, a small 
proportion of blood-stage parasites differentiate into sexual gametocytes (Figure 
1.2J), which are required for transmission to the mosquito vector. 
 The Plasmodium sexual stage (Figure 1.2K–M) is initiated following a 
mosquito blood feed and ingestion of male and female gametes. These haploid cells 
are fertilized in the mosquito midgut, forming the diploid zygote. The zygote matures 
into an ookinete, which then forms an oocyst beneath the mosquito’s gut wall. After 
8-15 days, the oocyst bursts, releasing thousands of sporozoites that travel via the 
hemolymph to the salivary gland. Deposition of these sporozoites into the human 
dermis in subsequent blood feeds (Figure 1.2N) propagates the parasite life cycle. 
 
Plasmodium morphology 
Elucidation of Plasmodium morphology enhances our understanding of parasite 
biology and directly informs disease diagnosis. In 1891, the Russian physician Dmitri 
Romanowsky found that a mixture of eosin Y and methylene blue differentially 
stained the nuclei and cytoplasm of blood-stage Plasmodium parasites red and blue, 
respectively.25 The reproducibility of this stain was subsequently improved by the 




mixture of eosin Y and azure B that would become a mainstay in malarial diagnosis.25  
Beyond aiding with actual identification of Plasmodium parasites in patient 
peripheral blood, microscopic examination of Giemsa-stained blood smears facilitates 
speciation (Table 1.1). As such, it plays an integral role in clinical decision-making 
and treatment plans. Thin blood smears illustrating representative points in the blood 
stage of the P. falciparum life cycle are shown in Figure 1.3. 
 In addition to light microscopy, several whole cell imaging methods have 
provided critical insights into the organization of parasite subcellular compartments. 
Among them are real-time microscopic tracking of fluorescently tagged parasite 
proteins as well as a variety of electron microscopy (EM)-based techniques, including 
transmission EM (TEM) of immunolabeled samples and 3D reconstructions of serial 
thin sections by electron tomography.26 Collectively, these tools have been particularly 
effective in clarifying Plasmodium ultrastructural architecture during the pathogenic 
asexual blood stage of infection (Figure 1.4A-B). 
In order to simultaneously support their development and avoid phagocytic 
clearance in the spleen, P. falciparum parasites modify the morphology and physiology 
of their host cell, the RBC. Key alterations include RBC membrane rigidification, 
orchestration of metabolite partitioning, and formation of membrane knobs that 
facilitate adhesion of infected RBCs to blood vessel endothelium.27,28 Essential to these 
changes is an interplay between the parasite-derived exomembrane system that is 
found in the host cytoplasm and a set of specialized trafficking pathways that mediate 
the export of parasite proteins across the parasitophorous vacuole (PV) membrane 





aAdapted from Roberts & Janovy (2005)30 and Lee et al. (2009).31 Representative images of P. falciparum parasites are shown in Figure 1.3. 
 
Table 1.1. Morphological features of human blood-stage Plasmodium parasites.a 
 P. falciparum P. vivax P. ovale P. malariae P. knowlesi 
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Figure 1.3. Thin blood smears of P. falciparum blood-stage parasites. Shown are microscopy 
images of asexual (A) ring, (B) trophozoite, (C) schizont, and sexual (D) gametocyte parasite 
forms that encompass the blood stage of the P. falciparum life cycle. (A) Ring forms possess 
a delicate cytoplasm, thick chromatin dots (1-2), and a diameter approximately one-fifth of the 
RBC diameter. Infection of RBCs with more than one ring form is common. (B) Maturing 
trophozoites are dense and compact, and occupy an increased proportion of total RBC volume 
as they develop. They are rarely observed in peripheral blood smears. (C) Schizonts harbor 
8-24 merozoites situated around a clumped pigment mass and are rarely found in peripheral 
blood smears. (D) Gametocytes are crescent-shaped and distort RBC morphology. The 
diameter of gametocytes is approximately 1.5× that of RBCs. As compared to 
microgametocytes (male), macrogametocyte (female) exhibit a darker cytoplasm and more 

















Figure 1.4. Ultrastructural illustrations of P. falciparum-infected erythrocytes.  Shown are (A) schematics and (B) thin section TEM images of 
parasite forms occurring over the course of the P. falciparum asexual intraerythrocytic cycle. Following invasion of RBCs by merozoites, 
parasites progress through ring, trophozoite, and schizont stages, ultimately leading to the release of a new generation of merozoites. (C) 
Ultrastructural illustrations of an infected RBC during the metabolically active trophozoite parasite stage. Images collectively show the 
presence of the following structures: apicoplast (a), acidocalcisomes (Ac), cytostome, digestive vacuole (DV), Golgi apparatus (g), hemozoin 
(Hz), knobs (k), Maurer’s cleft (MC), mitochondrion (m), nucleus (N), parasitophorous vacuole (PV). Images adapted with permission from 






















The capacity of P. falciparum to equip a differentiated, compartment-poor cell with an 
assortment of organelles, trafficking networks, and virulence factors (Figure 1.4C) is 
a prime example of cellular co-optation and remodeling by a parasitic organism. 
 
Plasmodium metabolism and homeostasis 
Publication of the full genome sequence of P. falciparum in 2002 provided a valuable 
lens into the inner workings of human malarial parasites. Harboring over 5,000 genes 
distributed among 14 chromosomes, the P. falciparum genome was reported to encode 
a higher fraction of immune evasion and cell adhesion proteins than previously 
sequenced eukaryotic genomes.33 Additionally, it encoded fewer enzymes and 
transporters.33 In light of the unusually high A+T content (>80%) of the P. falciparum 
genome, these predictions came with the caveat that sequence similarity-based 
genome comparisons will miss sequences that are novel or highly divergent.33 
 It is increasingly apparent that Plasmodium parasites have fine-tuned 
canonical metabolic pathways to meet their specific, stage-dependent growth 
requirements.34,35 For example, during the blood stage of infection, central carbon 
metabolism in non-proliferating gametocytes resembles the citric acid cycle-driven 
respiration of glucose that is observed in other eukaryotic organisms. In rapidly 
proliferating asexual blood-stage parasites, however, the majority of parasite 
biosynthetic intermediates derive from aerobic fermentative glycolysis, reminiscent of 
the metabolic reprogramming that occurs in cancer cells.35 Nutrient deprivation is a 
known stimulus for gametocyte differentiation, corroborating the hypothesis that 
metabolic cues govern progression through the parasite life cycle, possibly through 




Recent 13C-based carbon flux analyses performed on blood-stage Plasmodium 
parasites lacking functional pyruvate dehydrogenase (PDH) highlight important 
nuances in parasite metabolic rewiring. In most eukaryotes, the central metabolic 
intermediate acetyl-CoA is largely synthesized via the PDH complex in the 
mitochondria. Interestingly, PDH disruption did not appreciably affect acetyl-CoA 
synthesis or growth of blood-stage P. falciparum parasites.34 However, it inhibited 
liver-stage development of the rodent strains P. berghei and P. yoelii and prevented 
generation of sporozoites in the mosquito vector for P. falciparum, effects attributed 
to defective fatty acid synthesis.34,36 This reappropriated role of PDH is consistent with 
its location in the parasite apicoplast, which plays essential roles in fatty acid, 
isoprenoid, and heme synthesis.11 
 Plasmodium parasites are equipped to establish and maintain specific 
physiologic conditions that enable them to progress through their life cycle. During 
blood-stage infection, parasites facilitate nutrient exchange by inducing an array of 
external channels with broad solute specificity, termed new permeability pathways 
(NPPs), that alter (primarily) Na+ and K+ ion flow across RBC membranes.37 Dynamic 
flux of other ions (e.g. Zn2+) is also known to be indispensable during the blood stage.38  
In the parasite itself, a network of channels and transporters, some still putative, 
ensure tight control of ion, pH, and volume homeostasis.37 Previous mathematical 
modeling suggests that parasites prevent excessive RBC swelling and rupture of 
deformed RBC membranes by digesting the internal supply of host hemoglobin (Hb) 
well beyond the levels needed to meet its amino acid requirements (see next section, 
“Hemoglobin processing in Plasmodium”).39,40 




oxidative insults.41,42 These are mediated by reactive oxygen (ROS) and nitrogen 
(RNS) species that are generated, for instance, as a host immune response or by toxic 
species (e.g. Hb-derived heme).43 To cope with oxidative stress, parasites are equipped 
with a specialized system for redox homeostasis, comprised of the thioredoxin 
reductase-thioredoxin couple, the glutathione reductase-glutathione couple, a set of 
peroxiredoxins, as well as members of the thioredoxin protein superfamily.44 Of these, 
redox state in Plasmodium parasites is governed largely by the ratio of the reduced 
(GSH) and oxidized (GSSG) forms of the tripeptide glutathione, the most abundant 
redox-active thiol in parasites. Maintenance of a highly reducing environment (>30:1 
GSH:GSSG ratio) is important for Plasmodium parasites, which actively synthesize 
GSH to keep up with its constant efflux.45 
 
Hemoglobin processing in Plasmodium 
During their intraerythrocytic growth, Plasmodium parasites engulf up to 80% of host 
Hb through cytostomes and, through vesicular transport, direct it to their digestive 
vacuole (DV), a lysosome-like organelle with a pH (~5.4) suitable for Hb digestion 
(Figure 1.5A).46-49 In addition to providing osmotic stability,40 processing of host Hb in 
infected RBCs (Figure 1.5B–F) majorly contributes to the parasite’s amino acid pool, 
which is required for synthesis of parasite proteins.50 Hb breakdown also unleashes 
heme (ferrous protoporphyrin X, Fe[II]PIX) (Figure 1.5G). Lacking a heme oxygenase 
system that is used by many other organisms to dispose of toxic heme species,49 the 
parasite detoxifies and incorporates free heme into an inert, crystalline waste product 









Figure 1.5. Processing of host hemoglobin (Hb) in a Plasmodium-infected erythrocyte.  
(A) Following internalization by the parasite’s cytostome-vesicle trafficking system, host Hb is 
directed to the parasite digestive vacuole (DV). There, it undergoes semi-ordered hydrolysis 
by (B) plasmepsins and falcipains, (C) falcilysin, (D) dipeptidyl amino peptidase 1 (DPAP1), 
and (E) aminopeptidase P (APP), followed by (F) export of amino acids (AAs) to the parasite 
cytoplasm. Small peptides may also be transported to the cytoplasm and undergo processing 
to AAs by cytosolic aminopeptidases. Breakdown of Hb also releases (G) oxidative damage-
promoting heme prosthetic groups, which the parasite (H) sequesters in an inert crystal 









An assortment of parasite proteases with partly overlapping functions is 
responsible for degrading Hb in the parasite DV, a multi-step process that is critical 
for parasite survival.50 In P. falciparum, these include aspartic proteases 
(plasmepsins), cysteine proteases (falcipains), a metalloprotease (falcilysin), at least 
one dipeptidyl aminopeptidase, and aminopeptidases.53 In recent investigations 
performed with P. falciparum DV lysates, Chugh et al. identified a multi-protein 
complex consisting of Hb proteases (falcipains, plasmepsins) and a Hz polymerase 
(heme detoxification protein, HDP).54 The association of these proteins suggests that 
the breakdown of Hb in the parasite DV is a concerted process intimately linked to 
the formation of Hz. This is supported by the observation that falcipain 2 and HDP 
can efficiently catalyze conversion of Hb to Hz in vitro.54 
The notion that parasites readily sequester chemically labile heme into 
chemically inert Hz in parallel with Hb degradation is biologically plausible. 
Detoxification of heme into Hz is essential for parasite survival55 and is likely 
supplemented by additional mechanisms, including GSH-mediated and peroxidative 
degradation.56,57 As toxic heme (Fe[II]PIX) gets released in the highly acidic DV 
environment, it is rapidly oxidized to ferric protoporphyrin IX (Fe[III]PIX).58 
Thenceforth, regardless of the oxidative state of the Fe atom (Fe2+ or Fe3+), heme has 
the potential to generate ROS, as per the Fenton or Haber-Weiss chemical reactions.59 
Respectively, these are as follows: 
Fe2+ + H2O2 → Fe3+ + ˙OH + –OH 
Fe3+ + ˙O2– → Fe2+ + O2 
As a pro-oxidant, free heme contributes to lipid peroxidation, DNA damage, as well as 




microscopy methods performed on blood-stage P. falciparum trophozoites have shown 
that parasites harbor ~60% of the total Fe present in infected RBCs, with the vast 
majority (~90%) concentrated in the parasite DV.61 Consistent with the essentiality of 
heme detoxification,61 ~95% of Hb-derived Fe present in parasites is incorporated into 
Hz. Importantly, heme prosthetic groups are required by parasites for proper 
mitochondrial cytochrome function,49 suggesting an important balance between heme 
utilization and disposal. Presumably, the parasite’s redox defense system (see 
“Plasmodium metabolism and homeostasis” section above) is sufficient to counteract 
oxidative damage by any residual pro-oxidant heme species.  
 The mechanism by which heme (Fe[III]PIX) is formed into Hz in situ remains 
unsettled. Using chemical analysis and spectroscopic methods, Slater et al. discovered 
that Hz is nearly identical to β-hematin, a synthetic aggregate of Fe[III]PIX.62  This 
was corroborated by Raman spectroscopic comparisons of Hz in living parasites, 
extracted Hz, and synthesized β-hematin.63 Crystallization of head-to-tail dimeric 
units is thought to underlie the polymerization of heme into Hz (Figure 1.6). 
Specifically, electrostatic interactions between Fe3+ of one Fe(III)PIX and a 
carboxylate group of a second Fe(III)PIX facilitate dimerization, with additional 
stability provided by hydrogen bonds.62,64 The head-to-tail dimer can interconvert with 
monomeric, µ-oxo dimeric, and non-crystalline aggregated forms (see Figure 1.6), and 
the extent to which it does so is influenced by ambient pH, ionic composition, and 
mode of catalysis.58 Catalysis of Hz polymerization can occur by Hz itself, through the 
action of the functionally conserved Plasmodium protein HDP, and/or via interactions 
with neutral lipids that were earlier found to associate with Hz in lipid droplets.65-67  












Figure 1.6.  Schematic of heme-to-hemozoin polymerization pathways. Shown are observed (black arrows) and hypothetical (gray arrow) 
pathways leading to the formation of hemozoin (Hz) from heme (ferriprotoporphyrin IX, Fe(III)PIX). The depicted form of the heme monomer 
is hematin, in which Fe is bound to hydroxide (–OH). Intermediate steps include [Fe(III)PIX]2 dimers and non-crystalline aggregates. The 
prototypical head-to-tail dimer comprises a Fe3+ center of one Fe(III)PIX molecule bonded to a propionate group of a second Fe(III)PIX 
molecule. The µ-Oxo dimer is composed of oxygen-bridged Fe3+ centers of two Fe(III)PIX molecules. The occurrence and directionality of 
interconversions is influenced by several factors, including solvent type, pH, ionic composition, and presence of lipid catalyst. Image 














Figure 1.7. Microscopic and gross manifestations of Plasmodium malarial pigment. Hemozoin, 
also known as malarial pigment, can be visualized (A) microscopically or (B) macroscopically. 
Shown above are (A) an electron micrograph, revealing hemozoin crystals (red arrow) 
concentrated within the digestive vacuole of a trophozoite, blood-stage Plasmodium parasite, 
and (B) a gross specimen of human spine bone marrow from a patient repeatedly infected with 
Plasmodium, with dark pigmentation characteristic of hemozoin (red arrow). Images 












Grossly, parasite Hz corresponds to the dark brown pigment that Laveran observed 
in the 19th century as he examined Plasmodium-infected RBCs and that can be found 
in tissue specimens isolated from infected patients (Figure 1.7B).1  
 Of note, a number of antimalarials from distinct chemical classes access the 
DV and have been proposed to interfere with parasite heme detoxification and/or 
require heme for their activity against asexual blood-stage parasites (see Antimalarial 
compounds).54,55,69-71 Moreover, studies of liver-stage and mosquito-stage parasites 
suggest a critical role for de novo heme synthesis.72 Complementing host-derived heme 
in the blood stage, heme during the exoerythrocytic stages is derived through a 
complex heme biosynthetic pathway with components in the parasite cytosol, 
mitochondrion, and apicoplast.49 Given this knowledge, active elucidation of parasite 
heme metabolism should be a research priority. 
 
MALARIAL DISEASE 
Clinical manifestations and diagnosis 
Together, human malarial parasites cause a wide spectrum of clinical presentations 
that span asymptomatic infection through fulminant, possibly lethal, disease. The 
predominant etiological agents of disease are P. falciparum and P. vivax. Africa bears 
the largest global burden of P. falciparum malaria, which disproportionately affects 
the pediatric population.13 Outside of Africa, adult populations are at higher risk for 
severe disease, and about half of malaria cases are caused by P. vivax.13 Though not 
as pathogenic as P. falciparum, P. vivax may occasionally cause severe disease. 
Individuals infected with P. vivax (but not P. falciparum) are prone to disease relapse 




Of note, co-infections consisting of Plasmodium and other viral, bacterial, or parasitic 
pathogens occur among a subset of malaria patients and have various effects on 
Plasmodium replication as well as the pathogenesis, diagnosis, and outcome of 
disease.17,73 
Uncomplicated malaria is characterized by a constellation of non-specific 
clinical symptoms. These include fever (≥40°C), malaise, headache, myalgias, and 
abdominal discomfort.14,15,74 Although regularity of disease paroxysms has been 
previously described as pathognomonic of malarial disease, irregular febrile episodes 
are common. Reflecting chronic infection in malaria-endemic regions, a palpable 
spleen may be observed on physical exam.14 Resolution of uncomplicated malaria is 
expected (<0.1% mortality rate), provided that parasites are cleared before achieving 
a high parasitemia (~2% parasitemia, equivalent to ~1012 parasites).14,15 Mortality 
risk increases substantially with increased blood parasitemia.15  
A small subset (1-2%) of Plasmodium infections progress to severe malaria, 
which differs between children and adults (Figure 1.8).74 In endemic areas, malarial 
disease is especially marked among children, who lack robust immunity.75 However, 
increased age is an independent risk factor for malaria mortality and is associated 
with impairments in multiple organ systems.74,75 Key pediatric complications include 
cerebral malaria (CM), anemia, and acidosis, all of which suggest a grim clinical 
outcome.76 The clinical picture of adult severe malaria is more expansive and includes 
CM, respiratory distress, jaundice, and acute kidney injury.74 Plasmodium infection 
of pregnant women may also result in termination of pregnancy or stillbirths.14 Table 
1.2 summarizes clinical manifestations that are prominent in severe malaria, along 





Figure 1.8. Clinical features of severe malaria in children and adults. The main manifestations of severe malaria differ between pediatric and 
adult populations. In children, anemia (pallor), metabolic acidosis, and cerebral malaria are predominant features of severe disease. In adults, 
metabolic acidosis and cerebral malaria are accompanied by injury to multiple organs, including the liver (jaundice), kidney (acute kidney 







Typified by coma, CM is one of the most important complications of malarial 
disease, particularly among children aged <5 in sub-Saharan Africa.13,77 CM is 
refractory to standard antimalarial treatments, may lead to debilitating 
neurocognitive impairments,  and results in death in  up to 20% of cases.77 Lethality 
in CM occurs, in part, due to a rapid increase in intracranial pressure.73 In addition 
to brain swelling, as detected by neuroimaging, the clinicopathological features of CM 
(Figure 1.9) include characteristic and diagnostically useful retinal changes, termed 
malarial retinopathy.73 
 In addition to clinical assessment, full malaria diagnosis requires confirmation 
of infection. The gold standard of parasite identification and classification is analysis 
of Giemsa-stained thin and thick blood smears by light microscopy. Thick blood 
smears detect parasites with high sensitivity (0.001% parasitemia), and both thin and 
thick smears can help to differentiate among various Plasmodium species (see Table 
1.1 for key morphological differences).14 Rapid diagnostic tests (RDTs), have gained 
traction as another diagnostic tool, particularly in resource-poor settings. RDTs entail 
the interaction of parasite antigens with antigen-specific antibodies embedded on a 
dipstick or paper card. One of these antigens, P. falciparum Histidine-Rich Protein 2 
(PfHRP2) detects infection with sensitivity comparable to light microscopy and, in the 
absence of a precise determination of parasitemia, serves as an indirect marker of 
parasite biomass.78 Of note, quantification of serum PfHRP2 levels can provide 
important information regarding disease prognosis.74 Other antigens used in RDTs 
include lactate dehydrogenase (LDH) and aldolase.14 PCR-based detection methods 
are used primarily for surveillance and detection of submicroscopic infections, of 





Table 1.2. Clinical manifestations of severe malarial disease.a 
Clinical manifestation Indicator of poor prognosis 
Cerebral malaria; seizures Deep coma; agitation; ↑ convulsions 
Acidosis 
Arterial pH <7.3; HCO3– <15 mM; 
lactate >5 mM 
Normochromic, normocytic anemia PCV <15% 
Renal failure Anuria; creatinine >265 µM 
Pulmonary edema; respiratory distress Hyperventilation 
Hypoglycemia Glucose <2.2 mM 
Systemic inflammation 
Shock; hypothermia (<36.5°C);  
WBC count >12,000/µl; urate >600 µM 
Bleeding; coagulopathy 
Thrombocyte count <50,000/µl;  
PT >3 sec; ↑ PTT; FG <200 mg/dL 
Muscular weakness; myopathy ↑ CPK; ↑ myoglobin 
Hyperparasitemia 
>105 parasites/µl; >20% mature forms; 
>5% PMNLs with malaria pigment 
Jaundice 
Total bilirubin >50 µM 
AST/ALT ratio >3× ULN 
 
a ↑, increased; PCV, packed cell volume; PfHRP2, P. falciparum Histidine-rich Protein 2; CSF, 
cerebrospinal fluid; WBC, white blood cell; PT, prothrombin time; PTT, partial thromboplastin 
time; FG, fibrinogen; CPK, creatinine phosphokinase; PMNLs, polymorphonuclear leukocytes; 
AST, aspartate transaminase; ALT, alanine transaminase; ULN, upper limit of normal. Adapted 











Figure 1.9. Manifestations of cerebral malaria (CM). (A) Funduscopic image depicting the 
white-centered hemorrhages of malarial retinopathy. Additional ocular findings in CM include 
retinal whitening and discoloration of blood vessels. (B) A feature of cerebral cortex pathology 
in CM is the presence of hemorrhages throughout the white matter. (C) Brain swelling in 
pediatric CM. Shown are representative MRI T2 images depicting the transition from no 
disease to severe CM. Key changes include flattening of the gyri, narrowing of the sulci, and 
downward herniation of the cerebellum with resulting crowding of the brainstem. Image 









Pathogenesis and immunity 
Malaria pathogenesis is a multifactorial process, and its underlying molecular 
mechanisms are incompletely understood. Nevertheless, insights from an array of in 
vivo and in vitro studies aid in conceptualizing the diverse and complex clinical 
manifestations of malarial disease. Anemia during blood-stage Plasmodium infection 
arises, in part, from the destruction of RBCs, through both direct lysis and splenic 
clearance. Release of parasite and host products upon RBC lysis triggers cytokine 
secretion; clinical consequences include fever and sepsis. Inflammation-induced 
dyserythropoiesis exacerbates anemia and causes thrombocytopenia. Additionally, 
utilization of glucose by rapidly proliferating, glycolysis-dependent blood-stage 
parasites contributes to hypoglycemia and acidosis. This is compounded by reduced 
delivery of oxygen to host tissues.14,15,80 
  A distinctive property of P. falciparum parasites is their ability to sequester in 
the microvasculature, which helps them avoid immune clearance and prompts 
endothelial dysfunction (Figure 1.10). During each round of their intraerythrocytic life 
cycle, P. falciparum parasites express an antigenically unique form of the P. 
falciparum Erythrocyte Membrane Protein 1 (PfEMP1), an adhesion protein localized 
to parasite-induced knobs that are present on the RBC surface. Through 
recombination among ~60 PfEMP1-encoding var genes, parasites achieve a wide 
repertoire of PfEMP1 molecules.81 These antigenically diverse proteins bind to 
endothelial receptors with varying affinities and play a key role in parasite immune 
evasion.74,81 PfEMP1 may also interact with molecules present on uninfected RBCs, 
leading to blockage of the microvasculature. The degree of blockage corresponds to 





Figure 1.10. Interactions between infected erythrocytes and endothelial cells during P. falciparum infection. Shown is a schematic of cellular 
and molecular events occurring in the microvasculature that contribute to the pathogenesis of P. falciparum infection. Found on the surface 
of an infected RBC is a distinct, parasite-encoded PfEMP1 molecule. In the example above, the PfEMP1 variant is specific for the host 
endothelial cell receptor CD36. The specific set of receptors expressed by endothelial cells is tissue-dependent. In the placenta and brain, 
for example, interactions of PfEMP1 variants with the receptors CSA and EPCR, respectively, contribute to the pathogenesis of placental and 
cerebral malaria. RBC-endothelial cell interactions facilitate sequestration in host tissues, causing a clinical syndrome directly related to the 
site of sequestration. Ensuing endothelial dysfunction is characterized by alterations in receptor expression, secretion of pro-inflammatory 
cytokines (e.g. IL-1, TNF-α), fibrin deposition, and increased basement membrane permeability that allows for perivascular infiltration. Image 







PfEMP1 engagement of endothelial receptors causes secretion of pro-inflammatory 
cytokines, fibrin deposition, and disruption of the endothelial basement membrane.82 
Inflammation subsequently extends into the surrounding tissue, which is subjected to 
hypoxia and lactic acidosis caused by microvessel occlusion.80 Roles for heme species 
in mediating endothelial dysfunction have also been described. These include direct 
exposure to heme, as well as indirect effects, such as depletion of nitric oxide (NO), an 
important mediator of endothelial homeostasis.80,83  
Depending on the parasite adhesion molecules and the specific host tissues 
that are involved, the abovementioned cellular and molecular events may produce one 
or more of the various clinical syndromes of severe malaria (see “Clinical 
manifestations and diagnosis” section above). Pregnancy-associated malaria, for 
example, is associated with a PfEMP1 variant that binds to the placental chondroitin 
sulfate A (CSA) receptor. Another receptor, endothelial protein C receptor (EPCR), 
has been implicated in the pathogenesis of CM. The levels of EPCR are diminished in 
CM, and PfEMP1 engagement of EPCR has been proposed to further inhibit the 
ability of EPCR to regulate the host Protein C cascade, resulting in coagulopathy.74,82 
With regard to pathogenesis, CM manifests itself differently in children and in adults. 
In children, RBC sequestration occurs either in the presence or absence of vascular 
pathology and coagulative defects, whereas in adults, intermediate phenotypes may 
be observed.73,74 Continued investigation of the pathogenic features that define 
different subtypes of severe malaria will undoubtedly direct future diagnosis and 
treatment of this potentially devastating disease. 
   The pathogenesis and clinical course of malarial disease are greatly influenced 




Plasmodium infection in high-transmission, endemic settings such as sub-Saharan 
Africa confers premunition – protection from disease, but not from infection itself. 
With time and sustained exposure to infections, protection from parasite replication 
is also conferred.15 This effect wanes with reduced exposure.84 Disease surveillance is 
therefore called for in low-transmission settings, where disease outbreaks are a threat 
due to weak immunity.17 
  Aside from the sophisticated immune evasion strategies with which 
Plasmodium parasites are equipped,81 a number of stage-dependent parasite 
interactions with the host immune system contribute to malaria pathogenesis. Liver-
resident parasites, for instance, temporarily escape sensing by the innate immune 
system, whereas blood-stage parasites activate innate immunity through the release 
of stimulatory parasite or host-derived ligands, such as Hz, 
glycosylphosphatidylinositol (GPI), and uric acid.85,86 Through its activation of tumor 
necrosis factor-alpha (TNF-α), which in turn induces activation of a basement 
membrane-degrading matrix metalloprotease, Hz has been postulated to contribute 
to loss of endothelial basement membrane integrity.87 
The humoral and cellular arms of the adaptive immune system are, likewise, 
important, although their roles are not fully understood.14 Previous studies have 
correlated certain antibody class and sub-class profiles with specific transmission 
settings and disease states.88 Despite this, the specific correlates for the various 
degrees of human immunity observed in different transmission settings remain 
unclear.84 
A role for dysregulated immune responses in mediating slow acquisition of 




based on studies in the P. berghei ANKA rodent model. Severe malarial infection 
inhibited differentiation of T follicular helper (Tfh) cells, which normally induce the 
establishment of germinal centers that are critical for the development of humoral 
immunity.89 This effect was diminished upon blockade of the pro-inflammatory 
cytokines TNF-α and interferon-gamma (IFN-γ), which confer protection against high 
parasitemia and, yet, also drive the pathogenesis of severe malaria.89 The complex 
interplay between malarial disease and immunity is further  highlighted by the ability 
of human genetic TNF variants to modulate malarial disease susceptibility.90 
P. falciparum and P. vivax possess distinctive biological and molecular features 
that mediate their different cell tropisms, degrees of virulence, and disease 
presentations. As compared to infection with P. falciparum, P. vivax infection is 
associated with a more benign clinical course, in part due to its preference for 
reticulocytes and reduced RBC sequestration in host tissues. Still, P. vivax instigates 
profound inflammation, with a pyrogenic threshold lower than P. falciparum and the 
capacity to sustain chronic infections via the hypnozoite stage of its life cycle.74 Of 
note, a significant portion of African individuals are null for the Fya and Fyb Duffy 
antigens that are required for P. vivax invasion of RBCs, rendering them resistant to 
infection.14 P. falciparum, on the other hand, encodes multiple functionally redundant 
ligands, with the exception of the P. falciparum Reticulocyte-binding homolog 5 
(PfRh5) protein. PfRh5 is essential for invasion through its interaction with host 
Basigin (CD147).91 While some Basigin variants have been documented,91 other RBC-
altering genetic variations play a more pronounced role in protecting individuals from 
diseases caused by P. falciparum. Among them are hemoglobinopathies, thalassemias, 




Prophylaxis and treatment 
In July 2015, the European Medicine Agency’s Committee for Medicinal Products for 
Human Use approved the recombinant P. falciparum circumsporozoite (CSP)-based 
RTS,S/AS01 vaccine, which targets the pre-erythrocytic stages of P. falciparum.93 This 
vaccine requires four doses and was found to reduce malarial cases by <40% in 
children aged 5-17 months.13 Given the enduring challenge of generating a highly 
immunogenic vaccine capable of halting parasite progression through its biologically 
complex life cycle, approval of RTS,S/AS01 represents a milestone for malaria vaccine 
efforts.94 However, it remains to be seen how the moderate efficacy of RTS,S/AS01, 
assessed in a controlled trial, will translate into the real-world setting. Presently, 
vaccination does not play a role in global antimalarial prophylaxis.  
 Apart from mosquito avoidance and control measures, antimalarial drugs 
represent the best mode of antimalarial prophylaxis. In this section, general 
recommendations are considered. Specific regimens and their pharmacology are 
detailed in the next section (Antimalarial compounds). Recommendations for 
chemoprophylaxis depend on the drug resistance profiles of the relevant geographical 
region and on the absence of contraindications (Table 1.3). As malaria can cause 
adverse pregnancy outcomes, travel by pregnant women to malaria-endemic regions 
is discouraged.95 CQ and mefloquine (MFQ) are appropriate chemoprophylactic agents 
for pregnant women traveling to areas with CQ-sensitive and CQ-resistant parasites, 
respectively. These drugs may also be prescribed to infants.95 Use of primaquine 
(PMQ) in regions where P. vivax is the dominant species is recommended to prevent 
hypnozoite-mediated relapse of disease. PMQ is also used following travel to an 








Table 1.3. Antimalarial drugs used for chemoprophylaxis.a 
Usage Drug Contraindications 
All areas 
Atovaquone-proguanil 
Renal impairment; children <5 kg; 
pregnant women; women with 
infants <5 kg 
Doxycycline 
Children <8 years; pregnant women; 




MFQ, QN, or QD allergy; psychiatric 
disorder; seizures; heart conditions 
CQ-sensitive  
P. falciparum  
or P. vivax 
Chloroquine or 
Hydroxychloroquine 
Known drug hypersensitivity 
P. vivax  
or P. ovale 
Primaquine 
G6PD deficiency (must be checked); 
pregnant women; breast-fed infants 
 
aMFQ, mefloquine; QN, quinine; QD, quinidine; CQ, chloroquine; G6PD, glucose-6-
phosphate dehydrogenase. Recommendations may change with time. Adapted from CDC 













Recently, in sub-Saharan Africa, two major intermittent preventive therapy regimens 
have been implemented, namely sulfadoxine-pyrimethamine (SP) for pregnant 
women and amodiaquine (AQ)-SP for children aged 3 months – 5 years.15 
 Beyond their role as chemoprophylactic agents, antimalarial drugs serve as 
the cornerstone of malaria treatment (Figure 1.4), chiefly via their action against 
pathogenic, asexual blood-stage parasites. The first-line artemisinin-based 
combination therapies (ACTs), which pair two antimalarials with distinct modes of 
action, are now ubiquitously employed to treat uncomplicated P. falciparum infection. 
While CQ remains the first-line treatment against P. vivax, P. ovale, P. malariae, and 
P. knowlesi, ACTs effectively clear infections caused by these species.14 Of note, the 
vast majority of manufactured ACTs is destined for the African continent, where use 
of ACTs has increased >30-fold in the past decade.13 In areas with low transmission 
of P. falciparum parasites, a single gametocytocidal dose of PMQ should be 
administered in conjunction with an ACT.15 
 Treatment of severe malaria requires hospitalization of the infected individual. 
Patient monitoring should include determination of serum glucose levels, acid-base 
status, hematocrit, and parasitemia.14 Parenteral artesunate (AS) is the first-line 
agent for treatment of severe malaria and has been shown to reduce patient mortality 
in randomized controlled trials.15  As needed, patients should also receive glucose for 
hypoglycemia, packed RBCs for anemia (hematocrit <20%), benzodiazepines for 









Table 1.4. Antimalarial drugs used for treatment of malaria.a 
Usage Drug regimen Targeted parasite stage(s) Contraindications 
Severe malaria AS (parenteral) Blood: asexual, sexual – 
Pf and unknown 
species first-line; 
effective against Pv, 
Po, Pm, and Pk;  
ATM-LUM, AS-AQ, 
AS-MFQ, or DHA-
PPQ for Pf in 2nd-3rd 
trimesters pregnancy  
ATM-LUM Blood: asexual (ATM, LUM), sexual (ATM) 1st trimester pregnancy 
AS-AQ Blood: asexual (AS, AQ), sexual (AS) 1st trimester pregnancy 
AS-MFQ Blood: asexual (AS, MFQ), sexual (AS) 1st trimester pregnancy; as for MFQ 
DHA-PPQ Blood: asexual (DHA, PPQ), sexual (DHA) 1st trimester pregnancy 
AS-SP Blood: asexual (AS, SP), sexual (AS) 
1st trimester pregnancy; known drug 
hypersensitivity; hepatic or renal impairment 
PvCQS, Po, Pm, and 
Pk first-line; PfCQS 
CQ; hCQ Blood: asexual Known drug hypersensitivity 
PfCQR; Pv ATQ-PG Liver (not hypnozoites); blood: asexual 
Renal impairment; children <5 kg; pregnant 
women; women with infants <5 kg 
PfCQR; PvCQR 
 
DOX Blood: asexual 
Children <8 years; pregnant women; significant 
sun exposure 
QN Blood: asexual Known drug hypersensitivity 
   (continued) 
 
 
Table 1.4. continued 
Usage Drug regimen Targeted parasite stage(s) Contraindications 
PfCQR; PvCQR; Pf in 1st 
trimester pregnancy 
QN-CLI Blood: asexual As for QN 
PfCQR,MFQS; PvCQR MFQ Blood: asexual 
Psychiatric disorder; seizures; heart conditions 
(e.g. conduction abnormalities) 
Pv, Po radical cure PMQ Liver; hypnozoite; blood: sexual only 
G6PD deficiency; pregnant women; breast-fed 
infants 
 
aRecommended regimens may change with time. Plasmodium drug sensitivity profiles in applicable regions of usage are indicated in 
superscript. Pf, P. falciparum; Pv, P. vivax; Po, P. ovale; Pm, P. malariae; Pk, P. knowlesi; CQR, CQ-resistant; CQS, CQ-sensitive; MFQS, 
mefloquine-sensitive; AS, artesunate; ATM, artemether; DHA, dihydroartemisinin; LUM, lumefantrine; AQ, amodiaquine; MFQ, mefloquine; 
PPQ, piperaquine; SP, sulfadoxine-pyrimethamine; CQ, chloroquine; hCQ, hydroxy-CQ; ATQ, atovaquone; PG, proguanil; DOX; doxycycline; 
QN, quinine; CLI, clindamycin; PMQ, primaquine; G6PD, glucose-6-phosphate dehydrogenase. Adapted from CDC Health Information for 








Antimalarial drugs, which comprise distinct chemical classes and modes of action, are 
central to the prevention, treatment, and global containment of malarial disease. A 
comprehensive understanding of the pharmacology, molecular targets, and resistance 
mechanisms associated with these drugs is pertinent to their continued success. A 
summary of the chemical classifications, pharmacologic properties, and toxicities of 
clinically employed antimalarial regimens is provided in Table 1.5. Chemical 
structures of representative antimalarial compounds are shown in Figure 1.11. 
ACTs represent the first-line treatment option for individuals infected with P. 
falciparum, including women during the second and third trimesters of pregnancy.97 
These drugs are also effective in treating non-falciparum infections and should be 
used when the etiology of malarial infection is unknown.96 With the aim of rapidly 
clearing the majority of the parasite biomass and ensuring that remaining parasites 
do not have an opportunity to expand, ACTs combine a potent but short-lived 
artemisinin (ART) compound with a much more long-lived partner drug. While the 
majority of clinically employed antimalarials target the pathogenic asexual blood 
stage of parasites (see Table 1.4), an added benefit of using ARTs is their activity 
against sexual blood-stage parasites (gametocytes), which decreases parasite 
transmission.98 Formulations of ACTs recommended by the WHO include artemether-
lumefatrine (ATM-LUM), AS-amodiaquine (AS-AQ), AS-mefloquine (AS-MFQ) 
dihydroartemisinin-piperaquine (DHA-PPQ), and AS-SP.96 
Of note, to various degrees, many antimalarial compounds – including ACT 
component drugs – impact DV physiology and morphology (Figure 1.12) and/or require 




Table 1.5. Pharmacologic properties of antimalarial drugs.a 



























Pruritis; cardiac abnormalities; 





































2–66 33–275 0.4–8.9 0.08–0.10 2.1E5–2.7E6 Hypersensitivity reactions 
PMQ 8-Aminoquinoline 65–295 1.8–4.0 3.5–8.0 2.92–7.94 0.31–1.19 443–2.0E3 Hemolysis in G6PD deficiency 
DHA Endoperoxide 366–698 0.97–2.8 0.85–1.40 1.47–3.59 1.19–2.16 0.84–1.95 
Hypersensitivity reactions; 
reticulocytopenia; neutropenia 
AS Endoperoxide 34–451 0.5–1.4 0.9 0.6–3.4 0.61–15.4 113-419 
Hypersensitivity reactions; 
reticulocytopenia; neutropenia 
        (continued) 







Table 1.5. continued 














Adverse effects and toxicities 












PYR Antifolate 86–860 2.4–41.1 60-450 2.32–7.20 0.34–1.78 2.2E4–1.1E5 
Megaloblastic anemia; 




5.1–5.7 29–134 4.7–13 9E-2–0.32 6.4E4–6.6E5 
Hypersensitivity reactions; 
gastrointestinal discomfort 
PG Antifolate 560–751 29–134 8.0–17.6 13.4–22.9 0.71–1.23 7.2E3–1.5E4 





1.5–6.0 8.8–22.4 0.75–1.83 29.5–112.0 3.9E4–1.1E5 
Renal impairment; 
photosensitivity; bone growth 
retardation in young children 
CLI Lincosamide 2.5–14 0.75-3.0 1.9–3.6 49.1–132.6 10.0–26.5 2.5E4–2.7E4 Diarrhea; nausea; pruritis 
 
aPharmacologic data report mean or median (range) values, compiled from studies of drug prophylaxis or treatment of acute malaria. For CQ 
and AQ, values for the corresponding major in vivo metabolites (monodesethyl-CQ and monodesethyl-AQ, respectively) are indicated 
parenthetically. CQ, chloroquine; QN, quinine; AQ, amodiaquine; PPQ, piperaquine; MFQ, mefloquine; LUM, lumefantrine; PMQ, primaquine; 
DHA, dihydroartemisinin; AS, artesunate; ATM, artemether; SDX, sulfadoxine; PYR, pyrimethamine; ATQ, atovaquone; PG, proguanil; DOX, 
doxycycline; CLI, clindamycin; Cmax, peak serum concentration; Tmax, time of maximum concentration observed; T1/2, half-life; VD/F, volume 
of distribution; CL/F, clearance; AUC, area under the curve of plasma drug concentration vs. time; G6PD, glucose-6-phosphate 








Figure 1.11. Chemical structures of representative antimalarial compounds. Shown are chemical structures of the clinically employed 









Figure 1.12. Ultrastructural changes of trophozoite blood-stage P. falciparum parasites treated 
with antimalarial drugs. Shown are TEM images of P. falciparum blood-stage parasites treated 
with (A) no drug, (B) artesunate, (C) quinine, or (D) piperaquine. (A) A normal parasite (P), 
exhibiting an electron-dense digestive vacuole (DV), where the byproducts of hemoglobin 
digestion are incorporated into hemozoin (Hz) crystals. (B) A parasite treated for 4 h with 
artesunate, showing amorphous parasite contents with an indistinguishable DV. (C) A parasite 
treated for 8 h with quinine, showing an electron-lucent DV containing very few Hz crystals. 
(D) A parasite treated for 8 hr with piperaquine, showing interrupted DV formation and 
aggregation of vesicles containing undigested hemoglobin. Adapted with permission from 








This clinically important subset of drugs will be emphasized in this dissertation. In 
addition to ACTs, these drugs include CQ, a relatively safe and inexpensive quinoline-
type compound used in the prevention and treatment of infection by CQ-sensitive 
Plasmodium species. The following sub-sections highlight key features of antimalarial 
drugs, including chemical and pharmacological properties, clinical indications, and 
insights into mode of action. Specific resistance mechanisms are further discussed in 
the subsequent section, Antimalarial drug resistance. 
 
Quinolines 
Following the historic adoption of CQ as a component of malaria control, a number of 
chemically related compounds surfaced and ultimately strengthened our 
armamentarium of antimalarial therapies. A common structural feature of these 
compounds is a quinoline (or quinoline-like) scaffold, which is known to be growth-
inhibitory to a variety of pathogens.101 The consensus regarding the modes of action 
of different quinoline-type antimalarials is that they interfere with the parasite’s 
heme detoxification system in the DV. Previous studies of quinoline drug–Hz 
interactions have uncovered key differences that depend on the specific drug and 
experimental conditions used.58,102  Ensuring that these interactions are reflective of 
what occurs in situ is, consequently, both a challenge and an impetus for further 
investigations. 
 As a whole, the quinoline-type antimalarials have played a laudable role in the 
treatment and control of malarial disease and continue to retain clinical efficacy, 
primarily as components of the first-line ACTs. In part due to their ability to target 




appealing group of compounds. Further dissection of their pharmacological features, 
cellular action, and molecular basis of resistance is applicable to the design of new 
quinoline-type compounds exhibiting little to no cross-resistance to our current set of 
drugs (see “Quinoline-type compounds in development” section). 
 
Chloroquine 
Originally named resochin after it was discovered in 1934 by the German scientist 
Hans Andersag, chloroquine (CQ) resurfaced in 1946 in the United States, where it 
was rigorously tested and deemed safe and highly effective for clinical use.95 
Chemically, CQ is an alkylated 4-aminoquinoline compound (see Figure 1.11). CQ and 
its hydroxyl analog, hydroxy-CQ (h-CQ), are amphiphilic weak bases that diffuse 
across cell membranes.103 CQ possesses two basic groups, a nitrogen within the 
quinoline ring and a second diethyl-amino nitrogen, with pKa values of 8.1 and 10.2, 
respectively.103 
CQ is indicated for prophylaxis against non-falciparum Plasmodium species, 
as well as P. falciparum in select, CQ-sensitive regions. The prophylactic weekly doses 
for children and adults, respectively, are 5 mg/kg (up to 300 mg) and 300 mg. CQ is 
used to treat P. falciparum in areas without CQR, namely parts of Central America, 
Haiti, the Dominican Republican, and a part of the Middle East.95 The total standard 
treatment dose is 25 mg/kg CQ base. Of note, CQ has no activity against liver-stage 
parasites and is paired with PMQ as a first-line radical therapy against P. vivax.15 
 The pharmacokinetics and pharmacodynamics associated with CQ are 
complex. Following ingestion, CQ is almost fully absorbed in the gastrointestinal tract 




distributed throughout multiple body compartments, including melanin-expressing 
tissues.96 More than half of drug present in the blood is bound to plasma proteins. 
Metabolism of CQ occurs in the liver, via CYP2C8, CYP3A4, and CYP2D6 enzymes,104 
which metabolize it to its primary and clinically relevant metabolite, monodesethyl-
CQ (md-CQ) as well as a second, minor metabolite, bisdesethyl-CQ (bd-CQ).105 Blood 
concentrations of md-CQ may be up to half of the CQ concentration.106 Importantly, 
the extent of CQ distribution, not the rate of elimination, governs blood CQ levels 
(peak: 3-5 hours), which show wide interindividual variability.96 In a group of 
Tanzanian individuals who received a standard oral dose of 25 mg/kg CQ base, the 
range of peak serum concentrations (Cmax) was 0.8-2.7 μM,106 with another study 
reporting >10-fold interindividual differences in CQ and md-CQ levels.107  As CQ gets 
released from various tissue stores and eliminated, primarily through the kidney, its 
elimination half-life (T1/2) increases from days to weeks. The terminal T1/2 is 1-2 
months.   
 In general, the safety profile of CQ is very favorable. Infrequent side effects 
include pruritis, headache, hepatitis, and gastrointestinal disturbances. When used 
chronically, side effects may include retinopathy, myopathy, reduced hearing, 
photosensitivity, and hair loss. Cardiac side effects, associated with 
electrocardiographic abnormalities, are rare and primarily an issue in the case of 
overdose or co-administration with other antiarrhythmic agents. CQ is 
contraindicated for patients with known hypersensitivity.96,98  
 CQ interferes with the essential process of Hb and heme disposition in asexual 
blood-stage parasites.55 After diffusing through multiple cell membranes, CQ reaches 




and Fe(III)PIX was first observed in aqueous solution,109 and has since been 
investigated with various modalities, including resonance Raman spectroscopy of CQ-
treated P. falciparum trophozoites, which revealed a reduced intensity of bands 
corresponding to Fe(III)PIX aggregates and no signal for CQ.110 This was interpreted 
as π-π binding of CQ to the intersection of dimeric Fe(III)PIX units110 and is consistent 
with nuclear magnetic resonance-based studies of Fe(III)PIX monomer-dimer 
equilibria, which documented a CQ-biased shift favoring the Fe(III)PIX dimer (Figure 
1.13A).111 Suggesting that CQ can also bind to Hz, [3H]-CQ was previously observed 
to associate with Hz by electron microscope autoradiography.112 CQ and/or CQ-
Fe(III)PIX may directly interfere with the growth of Hz at its crystal face.58 CQ-
induced inhibition of Hz formation was recently associated with cellular redistribution 
of iron (Fe) content within trophozoite-stage P. falciparum (Figure 1.13B).55 
  How exactly CQ kills parasites has not been resolved and likely involves 
mechanisms beyond the inhibition of Hz formation. This is underscored by the fact 
that, although CQ and heme interact, the Hz inhibition potency of CQ correlates well 
with its cytocidal, but not cytostatic, potency against Plasmodium parasites.113 
Cytotoxicity may be attributed to a constellation of factors, including an increase in 
toxic free heme, induction of oxidative damage, formation of toxic heme-CQ complexes, 























Figure 1.13. Heme-chloroquine (CQ) interactions and effects of CQ on distribution of iron 
during blood-stage P. falciparum infection. (A) Schematic of interactions of CQ with monomeric 
and dimeric forms of heme (Fe[III]PIX). CQ exhibits a preference for the µ-oxo Fe(III)PIX dimer, 
although changes in composition of  the liquid phase can alter this equilibrium. Adapted with 
permission from Gorka et al. (2013).58 (B and C) Iron (Fe) distribution in asexual blood-stage 
P. falciparum trophozoites treated with (B) no drug or (C) 30 nM CQ. Shown are TEM (top 
image) and electron spectroscopic imaging (ELI; bottom image) images. Fe distribution (blue 
dots) was determined by electron energy loss spectroscopy (EELS).55 Parasite DV, parasite 
cytosol, and RBC cytosol compartments are represented by dotted/dashed yellow, red, and 
blue lines, respectively. (B) In untreated parasites, Fe is concentrated in hemozoin crystals 
(blue arrow) in the parasite DV and is also observed throughout the cytoplasm of host RBCs. 
(C) In CQ-treated parasites, iron is found in concentrated foci in the parasite cytosol (see 
yellow star for example). Fe is also detected in disrupted Hz crystals and the RBC cytosol. In 
parasites, Fe is present mostly as heme species and, in CQ-treated cells, largely corresponds 
to the free heme fraction. R, RBC; P, parasite; Hz, hemozoin; DV, digestive vacuole; N, 
nucleus; er, endoplasmic reticulum; m, mitochondria. Adapted with permission from 




















CQR is common among P. falciparum strains throughout the world, with the 
key exceptions of the Caribbean, Central America, and the Middle East, where CQ 
use is still appropriate.95 Interestingly, data from Guinea-Bissau indicates that 
clinical CQR can be overcome by doubling the standard CQ dose, suggesting that CQR 
is a saturable process.115 Most geographical regions in which P. vivax is endemic, 
notably Asia and the Pacific, are now known to harbor CQ-resistant strains.116 CQR 
in P. vivax is less understood than P. falciparum CQR and likely involves distinct 
mechanisms.117 The mechanism of P. falciparum CQR is discussed in detail in the 
section “CQ resistance and PfCRT” below. P. falciparum CQR occurs at least in part 
due to the reduced access of CQ to its heme target within the DV.118 CQ-sensitive P. 
falciparum parasites accumulate significantly more drug than CQ-resistant forms.119 
Mutations in the P. falciparum chloroquine resistance transporter (pfcrt) gene reduce 
CQ accumulation and are sufficient to confer parasite CQR.120 The P. falciparum 
multidrug resistance 1 (pfmdr1) gene plays a less pronounced, modulatory role in 
mediating CQR (see “The role of PfMDR1 in antimalarial drug resistance” below). 
 
Quinine 
The quinoline methanol (arylaminoalcohol) compound quinine (QN) is the oldest 
antimalarial drug still used today. QN is one of the active ingredients found in quina, 
the Incan expression for the bark of cinchona trees. Cinchona bark powder was used 
therapeutically in South America and, later, in Europe prior to the isolation of QN in 
1817 by French chemists.1,98 As the synthesis of QN is challenging, QN and its 
stereoisomer quinidine (QD) are routinely isolated from botanical sources.98 Although 




drug for the treatment of CQ-resistant Plasmodium infections. Used intravenously, it 
is also a second-line option for the treatment of severe malaria.13 Synergistic effects 
have been documented for QN paired with certain broad-spectrum antibiotics that, 
like QN, target Plasmodium asexual blood stages. These combinations include QN 
combined with either doxycycline (DOX) or clindamycin (CLI).121 Of note, QN-CLI is 
recommended for the treatment of pregnant women with uncomplicated P. falciparum 
during the first trimester of pregnancy.13 
 Upon administration, QN is rapidly absorbed and extensively distributed to 
various body tissues. QN is metabolized in the liver by multiple enzymes, particularly 
CYP3A4. Its multiple metabolites include 3-hydroxyquinidine, which has the most 
antimalarial activity (~10% of QN). In patients not experiencing clinical recovery, the 
standard dose of QN must be lowered, in part due to the inhibitory effect of malarial 
disease on QN clearance and distribution to peripheral tissues. The therapeutic index 
of QN is narrow and may result in hypotension, hypoglycemia, and/or cinchonism, a 
syndrome characterized by auditory and visual disturbances, headache, 
gastrointestinal symptoms, and dysphoria. QN increases the cardiac QTc interval, 
although cardiac side effects are more frequently associated with QD. QN should be 
avoided in individuals with known hypersensitivity to QN or other alkaloids derived 
from cinchona plants.13 
Similar to CQ, QN is thought to interfere with the detoxification of free heme 
in the parasite DV, consistent with the capacity of QN to inhibit Hz formation55 and 
with spectroscopic reports that documented an interaction between QN and 
Fe(III)PIX.122 A chemical dissection analysis of QN functional groups revealed that 




interaction with Fe(III)PIX.122 Interestingly, in contrast to CQ (see Figure 1.13A), 
which shifts the Fe(III)PIX monomer-dimer equilibrium toward dimer formation, QN 
exhibits a preference for the monomeric form.58 This observation highlights the 
existence of distinctions in the activities of different quinoline-type antimalarials. 
QN resistance has been detected in multiple geographical regions, including 
Southeast Asia and the Amazon basin in South America.123 Despite the shared 
features in the mechanisms of action of CQ and QN, QN resistance is relatively more 
complex, involving multiple genetic loci that have parasite strain-specific 
contributions to resistance. Among known determinants of parasite QN susceptibility 
are a number of transporters, including PfCRT, PfMDR1, the P. falciparum Multidrug 
Resistance Protein 1 (PfMRP1) transporter, and the P. falciparum Sodium-Proton 
Exchanger (PfNHE).123,124 The effects of pfcrt mutations on QN resistance are allele-
specific, parasite genetic background-dependent, and can yield divergent parasite 
responses to QN as compared to QD.120,125,126 Amplification and/or mutation of pfmdr1 
has been shown to reduce QN susceptibility.127,128 Additionally, a novel P. falciparum 
HECT ubiquitin-protein ligase was found to modulate parasite susceptibility to QN 
and QD in certain parasite genetic backgrounds.129 
 
Amodiaquine 
Amodiaquine (AQ) is a 4-aminoquinoline compound related to CQ (see Figure 1.11). 
It was developed by Parke-Davis and clinically employed as CQR began to take hold. 
In the 1960s and 1970, it was distributed in select regions as a medicated salt, 
supplementing mass drug distribution efforts that largely relied on CQ.130 Presently, 




indicated for treatment of uncomplicated Plasmodium malaria. AQ is also 
administered in conjunction with SP to very young children in Africa for the purpose 
of seasonal malaria chemoprevention.15  
Upon ingestion, AQ is very rapidly absorbed and metabolized by CYP2C8 into 
its more potent and long-lived metabolite, monodesethyl-AQ (md-AQ). The Cmax 
achieved by md-AQ is ~20-fold greater than that of the parent compound. Moreover, 
the T1/2 of md-AQ and AQ are, respectively, ~2 weeks and ~3 hrs. As compared to other 
ACT regimens, AS-AQ is associated with more frequent gastrointestinal disturbances. 
AQ is not recommended for prophylaxis, due to the risk of agranulocytosis, hepatitis, 
and myelotoxicity, which are attributable to the bioactivation of AQ to toxic quinone 
imine and aldehyde quinone imine metabolites.131 Additional, rare side effects include 
cardiac conduction abnormalities, neurological effects, and hypersensitivity reactions. 
AQ should not be administered to individuals with hepatic impairments or known 
hypersensitivity.  
AQ is thought to interfere with parasite heme detoxification during the asexual 
blood stage of infection, similar to CQ. This is supported by the observations that, like 
CQ, AQ forms a dimeric complex with Fe(III)PIX (see Figure 1.13A).132 In addition, 
AQ treatment of parasites inhibits the formation of non-toxic Hz with a concomitant 
increase in toxic free heme.55 AQ is effective against some CQ-resistant strains, 
although cross-resistance with CQ does occur and renders it an ineffective therapy in 
certain geographical regions, including South America. Parasite resistance to AQ is 
mediated by pfcrt and pfmdr1 alleles, which can interact to yield differential parasite 






Piperaquine (PPQ) is a bisquinoline compound, characterized by a pair of quinoline 
groups joined by an aliphatic linker (see Figure 1.11). PPQ was first synthesized in 
the 1960s and was clinically employed soon after throughout China and Indochina 
due to its potency against CQ-resistant parasites.134 Currently, PPQ is used only in 
conjunction with DHA in the first-line ACT formulation DHA-PPQ, used to treat 
uncomplicated Plasmodium infections. 
The lipophilic drug PPQ is rapidly absorbed and widely distributed throughout 
the body, with 99% of drug binding to plasma proteins. A feature of PPQ is its very 
long T1/2 (~1 month). The formulation DHA-PPQ is generally well tolerated. Similar 
to CQ, PPQ can increase the QT interval on electrocardiography, although adverse 
cardiac events are improbable. PPQ should be avoided in patients with known 
hypersensitivity or with QT prolongation.96,98  
PPQ resistance is actively spreading in Southeast Asia135-138 and has also been 
detected in French Guiana, possibly due to inappropriate use by migrant miners.137 
The genetic basis of PPQ resistance is presently undefined and likely multigenic. 
Novel PfCRT mutations associated with Southeast Asian PPQ-resistant isolates have 
been reported,139 but a causal relationship has not been established to date. 
In Africa, in recent comparative studies of the efficacy of ACT regimens, DHA-
PPQ was found to cure more patients than ATM-LUM and was associated with more 
long-lived protection from subsequent malarial infection.140,141 In addition, in a 
controlled, randomized clinical trial assessing the efficacy of regimens for the 
prevention of malaria in pregnant African women, DHA-PPQ was found to confer 





Mefloquine (MFQ) is a quinoline methanol (arylaminoalcohol). It was discovered as a 
potent antimalarial as part of a screen of chemical compounds at the Walter Reed 
Army Institute of Research.98 MFQ is presently employed for P. falciparum 
prophylaxis and is a partner drug comprising the first-line regimen AS-MFQ, used in 
MFQ-sensitive areas to treat uncomplicated malaria. 
 Upon ingestion, MFQ is rapidly absorbed, with significant interindividual 
variability in the time needed to reach Cmax (~15-72 hrs). MFQ is metabolized in the 
liver by CYP3A4, to an inactive metabolite. MFQ is widely distributed to body tissues 
and permeates the blood-brain barrier, placenta, and mammary glands. ~98% of MFQ 
is plasma protein-bound. T1/2 for MFQ is ~2 weeks. It is excreted primarily by the fecal 
route. Infrequent side effects associated with MFQ use include hepatitis, 
gastrointestinal disturbances, and neuropsychiatric abnormalities (e.g. seizures, 
hallucinations, depression). MFQ should not be administered to individuals with 
known hypersensitivity, who require fine motor coordination, who are mentally ill, or 
who have suffered from cerebral malaria.96,98 
  MFQ is a highly effective schizonticide. The mechanism of its action against 
blood-stage parasites is not entirely clear. MFQ interferes with Hz formation in the 
parasite DV55 and is also thought to be active against an as yet unidentified target in 
the parasite cytosol.142,143. Mutations and copy number alterations of the pfmdr1 locus 
are implicated in modulating parasite susceptibility to MFQ.128,144 Amplification of 







Lumefantrine (LUM), also known as benflumetol, was discovered as part of a 
clandestine antimalarial discovery project organized by the Chinese military.146 
Chemically, LUM is an arylaminoalcohol fluorine derivative (see Figure 1.11) and 
shares structural features with the related drugs halofantrine (HF), QN, and MFQ. 
Clinically, LUM is used solely in combination with an ART compound, namely ATM. 
ATM-LUM is indicated for the treatment of uncomplicated Plasmodium infections. 
LUM is very lipophilic and ingesting it with fat-rich food enhances its absorbance. 
LUM undergoes hepatic metabolism by CYP3A4 enzymes to its active metabolite, 
desbutyl-LUM. Plasma protein binding is 99.7%. Due to the lipophilicity of LUM, wide 
interindividual variability in LUM Cmax has been observed (e.g. 4.5-28.3 μg/ml). Its 
T1/2 is 3-5 days. Side effects associated with LUM are rare, although use should be 
avoided in the case of known hypersensitivity.96,98 
LUM is thought to interfere with heme detoxification, similar to other 
quinoline-type compounds. Consistent with this, LUM was found to inhibit Hz 
formation in drug-treated P. falciparum trophozoites.55 A role for LUM in inhibiting 
Hz polymerization is further corroborated by the finding that the related drug HF 
interacts with Fe(III)PIX monomers.147 Roles for mutations in the parasite pfcrt and 
pfmdr1 genes in modulating LUM susceptibility have been described (detailed in 
corresponding sections below). Of note, ATM-LUM is the most widely employed ACT 








Primaquine (PMQ) is an 8-aminoquinoline compound that was first synthesized by 
Robert Elderfield of Columbia University.150 It stands out among presently employed 
antimalarials due to its ability to target exoerythrocytic stages of Plasmodium 
infection. During the parasite blood stage, PMQ is only active against sexual 
gametocytes. With the exception of chemoprophylaxis, PMQ should always be used 
together with another antimalarial compound or regimen that targets the parasite 
asexual blood stages, such as an ACT or, when applicable, CQ. PMQ represents a 
powerful tool for control of malaria transmission. It has been recommended that a 
single, low dose of PMQ be administered to patients in low-transmission settings in 
order to prevent onward transmission. Furthermore, PMQ is indicated for the radical 
cure and terminal prophylaxis of infections caused by P. vivax and P. ovale, which are 
characterized by a dormant hypnozoite stage that can lead to relapse of malarial 
disease.15,96,98 
PMQ is almost fully absorbed from the GI tract and extensively distributed 
throughout the body, akin to CQ. PMQ achieves peak levels in the blood in 1-4 hrs 
and is excreted primarily in the urine. Metabolism of PMQ in the liver yields the 
relatively inactive metabolite carboxy-PMQ as well as reactive metabolites that 
produce hemolytic anemia in predisposed individuals, including those with glucose-6-
phosphate dehydrogenase (G6PD) deficiency. For this reason, screening individuals 
for G6PD deficiency is a necessity prior to administration of PMQ. 
With the exception of hemolysis in predisposed patients, the side effect profile 
of PMQ is favorable. Patients may experience gastrointestinal discomfort, and cardiac 




hypersensitivity or G6PD deficiency. Unless the G6PD status of the embryo is first 




The Mannich base pyronaridine was developed in China in 1970, at around the same 
time that LUM was discovered. It was deployed in China for over three decades.151 
PND is a partner drug comprising the ACT formulation AS-PND. This regimen is one 
of several ACTs (including arterolane-PPQ, ART-PPQ, and ART-napthoquine) that 
are registered and clinically used but presently not formally endorsed by the WHO.96 
In Cambodia, where the need to adopt new first-line drug combinations is urgent, AS-
PND efficacy was unfortunately found to fall below the WHO threshold for 
medications with long half-lives.151 
PND is potent against Plasmodium asexual blood stages, including those of 
multidrug-resistant parasites. PND is widely distributed upon absorption and 
concentrates in erythrocytes. Its T1/2 is ~10-13 days. PND is not associated with major 
side effects, and its toxicity profile is comparable or better than that of CQ, which is 
well-tolerated. In rodent models, embryotoxicity, but not teratogenicity, has been 
observed. This warrants clarifying whether PND use should be avoided in pregnancy. 
Croft et al. have recently provided a detailed review of the in vitro and in vivo 
pharmacology, toxicology, and clinical features of PND.152 
The mechanisms of action of PND are thought to overlap with those of other 
quinoline-type compounds. PND has been reported to interact with hematin and also 




have not yet been defined. The prolonged use of PND as a monotherapy in China 
suggests that resistance does not evolve easily.151 A single report in which ex vivo  
PND responses of African parasite isolates were examined suggested that reduced 
PND susceptibility was associated with the presence of PfCRT mutation K76T.155  
 
Artemisinins 
ART and its derivatives, collectively called ARTs, are a group of sequiterpene lactone 
endoperoxide compounds. First extracted from the medicinal sweet wormwood plant 
Artemisia annua by the Chinese chemist Youyou Tu,156 ART has reduced potency and 
bioavailability as compared to the several semi-synthetic derivatives that are 
clinically employed, which include the following: DHA (see Figure 1.11), the active in 
vivo metabolite and reduced derivative of ART; ATM, a lipophilic methyl ethyl; and 
AS, a water-soluble hemisuccinate derivative. ART compounds are active against 
Plasmodium asexual and sexual blood-stage parasites. These compounds are paired 
with significantly more long-lasting partner drugs in the WHO-sanctioned ACT 
regimens ATM-LUM, AS-AQ, AS-MFQ, DHA-PPQ, and AS-SP. ACTs are the first-
line treatment against uncomplicated P. falciparum malaria and are also indicated 
for women with uncomplicated P. falciparum malaria during their second or third 
trimester of pregnancy. Of note, intravenous AS is the first-line treatment of severe 
malaria and has been shown to be superior to intravenous QN.15,96-98  
Relative to other ART compounds, ATM is highly lipophilic, and its otherwise 
erratic absorption is improved with concurrent ingestion of fatty foods. In contrast, 
AS is water-soluble, which partly explains the preference for AS in intravenous ART 




≤30% and yield variable degrees of plasma protein binding. Metabolism of the ART 
parent compounds in the liver produces DHA, which accounts for the majority of 
antimalarial activity of orally (but not intravenously) administered ART compounds. 
DHA is extensively distributed, and its Tmax and T1/2 are of a comparable duration (~1-
3 hrs). The ARTs are generally well tolerated and rare side effects include 
gastrointestinal disturbances, dizziness, hepatitis, reticulocytopenia, and 
neutropenia. ACTs should be avoided in patients with known severe hypersensitivity 
reactions as well as during the first trimester of pregnancy. 
  The mechanism of ART action is still elusive, although several important 
insights have recently emerged. The activity of ARTs depends on the reductive 
cleavage of the ART-defining endoperoxide bridge.100 A contributory role for 
hemoglobinases in ART activation was recently demonstrated by Xie et al., who 
observed that reduced expression of P. falciparum falcipains 2 and 3 conferred ART 
resistance to early ring-stage parasites.157 Through various mechanisms, activated 
ARTs are thought to promote the generation of toxic species, including free heme, 
whose incorporation into nonreactive Hz is inhibited by ARTs.54,55 
Alarming evidence that suggested declining clinical efficacy of ARTs in 
Southeast Asia motivated the identification of mutations in the parasite kelch13 (k13) 
gene as critical drivers of resistance in this region.158 A number of distinct K13 
mutations have been associated with in vivo and in vitro indicators of resistance. 
These are, respectively, delayed parasite clearance from patient blood and enhanced 
parasite survival in ring-stage survival assays (RSAs) that measure parasite survival 
following a short-term pulse with 0.7 µM DHA.158-162 Whole-genome analysis of 




level of genetic complexity, indicating that multiple secondary genetic mediators 
(including pfcrt) equip parasites with a genetic background conducive to the spread of 
resistance.159 Of note, an ART-associated K13 mutation (C580Y) was recently 
identified in Guyana.163 K13 mutations are also present in low frequencies in African 
parasites, prompting vigilance and preemptive efforts to characterize the capacity of 
these parasites to mediate ART resistance.164 
 
Other antimalarials in clinical use 
Sulfonamide-based antifolates 
Sulfadoxine (SDX) is a sulfonamide compound with broad antimicrobial activity. It is 
often paired with pyrimethamine (PYR) in the synergistic combined therapy SDX-
PYR (SP).  SDX and PYR inhibit folate synthesis during the asexual blood stage of 
infection by acting against the dihydropteroate synthase (DHPS) and dihydrofolate 
reductase (DHFR) enzymes, respectively. Multiple mutations acquired in both of these 
enzymes confer resistance to these compounds and arise readily when either 
component is used in isolation. The SP formulation has played an important, albeit 
temporary, role in the treatment of CQ-resistant P. falciparum infections.  P. 
falciparum resistance to this regimen quickly developed and spread worldwide (see 
“Antimalarial drug resistance: a recurrent problem” section below). In the case of PYR 
resistance, mutations are acquired in a predictable fashion. In Africa, the triple DHFR 
mutant (N51I C59R S108N), predominates, whereas in Southeast Asia, the quadruple 
mutant (N51I C59R S108N I164L) is common.96,98,165 
SP is generally well tolerated, and rare adverse reactions are often due to the 




syndrome, leukopenia, thrombocytopenia, and megaloblastic anemia. SP should not 
be taken by individuals with known hypersensitivity, megaloblastic anemia secondary 
to folate deficiency, or infants <2 months. Of note, SP increases gametocyte carriage 
rates.96,98 
In Africa, SP has been employed for the prevention of malaria in pregnant 
women and, in conjunction with AQ, as a seasonal chemoprophylactic strategy in 
infants. The ACT regimen AS-SP is one of the ACT regimens sanctioned for clinical 
use by the WHO.96 
 
Napthoquinone-antifolate combinations 
Atovaquone (ATQ) is a ubiquinone-like hydroxynapthoquinone antimicrobial that is 
paired with proguanil (PG; also known as chloroguanide), a biguanide compound. The 
combination ATQ-PG is clinically employed for malaria prophylaxis and may also be 
used in conjunction with AS and PMQ to treat patients in regions where malaria is 
not endemic (e.g. treatment of travelers).96  
Before PG is converted by liver CYP enzymes into its active metabolite, 
cycloguanil, it mediates synergy with ATQ by augmenting the capacity of ATQ to 
collapse the mitochondrial membrane potential. Specifically, ATQ targets the 
cytochrome bc1 complex of the parasite’s electron transport chain. This mitochondria-
localized system is primarily responsible for regenerating ubiquinone, a cofactor for 
the essential pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase 
(DHODH). This is supported by the fact that transgenic expression of a yeast, 
ubiquinone-independent form of DHODH confers Plasmodium ATQ resistance, even 




inhibit the DHFR enzyme that is also inhibited by PYR, although evidence for DHFR-
independent mechanisms of toxicity have also been described. ATQ and PG are active 
against asexual blood-stage as well as liver-stage parasites. However, they do not 
target the dormant hypnozoite stages of P. vivax and P. ovale. When used singly, ATQ 
and PG very readily select for resistant Plasmodium parasites. High-level resistance 
to ATQ is mediated by mutations in the cytochrome b (cytB) gene. PG is generally not 
synergistic with ATQ in cytB-mutant parasites.96,98,123,167 
  Absorption of ATQ is highly variable, whereas absorption of PG proceeds more 
readily. Ingestion of ATQ-PG with a fatty meal improves the absorption of drug. 
Plasma protein binding of ATQ and PG are 99% and 75%, respectively. The T1/2 of 
ATQ is 2-3 days. Metabolism of ATQ is minimal, and it is excreted primarily via the 
fecal route. ~50% of PG is excreted in the urine. ATQ-PG is generally well-tolerated, 
and hepatitis, rash, neutropenia, and anemia are among its rare side effects. ATQ-PG 
should not be given to individuals with known hypersensitivity.98  
 
 
Tetracyclines, lincosamides, and macrolides 
A number of broad-spectrum antibiotics have been clinically employed as antimalarial 
chemotherapies, including the tetracycline compound doxycycline (DOX), the 
lincosamide compound clindamycin (CLI), and the macrolide compound azithromycin. 
These compounds are generally paired with another potent antimalarial (e.g. AS or 
QN). DOX is also used for malaria prophylaxis. QN-CLI is indicated for the treatment 
of P. falciparum-infected women in their first trimester of pregnancy. These 
antibiotics inhibit prokaryotic protein synthesis, and their antimalarial activity is 




as “delayed death”, whereby the progeny of drug-treated parasites die. Side effects 
include gastrointestinal disturbances, which may progress to include 
pseudomembranous colitis. Hypersensitivity reactions may occur, and use in persons 
with known hypersensitivity should be avoided.  DOX should not be used in children 
<8 years or in pregnant women.96,98,121,168 
 
Quinoline-type compounds in development 
Despite the wide spread of resistance that cost it its gold-standard status, CQ is 
regarded as one of the safest, most efficacious antimalarial compounds in the history 
of malaria prophylaxis and treatment and continues to be used in resistance-free 
regions. The highly favorable pharmacological profile of CQ has revived interest in 
developing CQ-like compounds that, through the modification and/or addition of new 
chemical groups, confer efficacy against both CQ-sensitive and CQ-resistant 
parasites. 
 Given the established antimicrobial activity of the quinoline ring that is the 
hallmark of CQ and related quinoline-containing compounds, a popular strategy 
employed for the design of new antimalarials has been the conjugation of the quinoline 
scaffold to a chemically unrelated group. Among the quinoline-conjugated compounds 
explored to date are quinoline-ART hybrids, quinoline-peroxide hybrids, quinoline 
hybrids with resistance chemosensitizers, and quinolines conjugated to novel 
chemical groups with demonstrated antimicrobial activity.169 Of note, quinoline-based 
resistance chemosensitizers have previously been shown to interact with Fe(III)PIX 
and to inhibit parasite formation of Hz. These include the dibemequines, which are 





Myriad efforts169-173 have already produced a large collection of compounds that 
exhibit antiplasmodial activity in vitro and in vivo and that could be employed in the 
future to treat drug-resistant strains. The critical role of chemotherapy in the control 
and treatment of malaria calls for precise characterization of the pharmacology and 
resistance mechanisms of novel compounds that will inevitably replace ones with 
waning efficacy. 
 
ANTIMALARIAL DRUG RESISTANCE 
Antimalarial drug resistance: a recurrent problem 
In the context of Plasmodium infection, resistance is the ability of parasites to 
continue growing in the presence of an appropriately administered drug. Early 
manifestations of resistance include slowed clearance of parasites from the 
bloodstream, parasite recrudescence, and increased gametocytemia.96 In this 
dissertation, resistance refers to decreased parasite susceptibility to a particular drug, 
as compared with a fully sensitive parasite line. When applicable, the degree of 
resistance (e.g. low-level, moderate, high-level, clinical) is emphasized.  
 A number of distinct factors can promote parasite evolution of drug resistance 
by yielding sub-therapeutic levels of drug. Among them are drug-drug interactions 
and interindividual pharmacokinetic and/or pharmacodynamic differences, including 
reduced rates of absorption, drug metabolism, and/or blood levels of drug. Other 
contributors include mass drug administrations, counterfeit medications, 
inappropriate dosing by prescribers, and patient non-compliance.24,96,174,175 It is 




metabolite md-CQ were previously detected in the blood of asymptomatic African 
patients.106 The propensity of parasites to develop resistance can also be influenced by 
non-pharmacological factors, including clonality of infections, parasite biomass, and 
the parasite’s environment within the host (e.g. host genetic predisposition to 
infection, immunity, nutritional status).24,176 
Considered to be one of the most powerful drugs used against a major global 
pathogen, CQ played a seminal role in decreasing malaria morbidity and mortality 
following its deployment in the mid-20th century.177 However, the highpoint of CQ 
efficacy was short-lived. P. falciparum CQR was first detected in the late 1950s in 
South America and Southeast Asia. In the following years, CQR spread throughout 
these regions and into the Indian subcontinent. CQR was not reported in Africa until 
the late 1970s, where it spread from east to west. By 1989, CQR had been detected in 
almost all regions where P. falciparum was endemic.174,177 In the subsequent five 
years, childhood mortality in sub-Saharan Africa rose markedly, representing a 
reversal of the downward trend in mortality during the period 1960-1989, when CQ 
efficacy was still largely retained.178 Indeed, CQR is thought to be the most important 
factor that contributed to this setback.178 The origins and spread of CQR are depicted 
in Figure 1.14. 
In response to reports of CQ treatment failure, the affordable and well-
tolerated drug regimen SP was briefly employed as a new first-line antimalarial, only 
to suffer a fate similar to that of CQ (see Figure 1.14). SP resistance soon spread to 
many CQR-endemic regions, and efforts to find replacement medications, including 








Figure 1.14. Emergence and spread of chloroquine and pyrimethamine resistance. Illustrated are the origins and migration of resistance to 
the former first-line antimalarials chloroquine (clear ovals and black arrows) and pyrimethamine (tan ovals and arrows). Map colors indicate 
2010 P. falciparum entomological inoculation rates (Pf EIR), which reflect the parasite burden in a particular geographical region. Adapted 







resistance, particularly in the low-transmission setting of Southeast Asia, which is 
now recognized as an epicenter of multidrug-resistant parasites.180 This is consistent 
with the low levels of host immunity and preponderance of monoclonal infections that 
are known to occur in low-transmission areas, an optimal environment for the growth 
and transmission of drug-resistant parasite strains. 
Of note, ART resistance is now present in Southeast Asia and was also recently 
detected in South America.163,181 More recently, it has become evident that Southeast 
Asia harbors parasites resistant to both the short-lived ART and long-lived partner 
drug components of first-line ACTs. A notable example is DHA-PPQ, which is failing 
as a therapy in Cambodia.135 Thus, throughout the globe, P. falciparum parasites 
presently exist that, together, show resistance to each component of the four WHO-
recommended regimens AS-AQ, AS-MFQ, DHA-PPQ, and AS-SP.  
As for the LUM component of the widely used formulation ATM-LUM, whether 
overt clinical resistance exists in the field has been debated. Assessing adequate 
clinical and parasitological responses (ACPRs) in patients from Zaire 28 days 
following treatment with ATM-LUM or DHA-PPQ, Plucinski et al. observed ACPRs 
of 88% (296/320 patients) and 100%, respectively.148 This prompted the suggestion 
that LUM resistance is evolving in this region, which Hamed and Kuhen subsequently 
challenged, citing the presence of confounding factors (e.g. subtherapeutic dosing, 
differences in parasite burden).182 Additional studies focusing on ATM-LUM 
treatment cases have reported increased rates of parasite recrudescence and 
decreased in vitro LUM susceptibility of parasite isolates derived from recurrent 
infections.149,183 In light of these findings, concern regarding the therapeutic efficacy 




  History shows us that the emergence and spread of antimalarial drug 
resistance is a recurring problem. As antimalarials are central to the control and 
treatment of malarial disease, dedicated research should be invested into 
understanding the ways in which parasites develop resistance, defining the molecular 
mechanisms of resistance, and formulating appropriate drug regimens with the 
potential to slow parasite resistance evolution. 
 
CQ resistance and PfCRT 
Identification of pfcrt as the primary genetic mediator of CQR was a major milestone 
in the ongoing quest to understand the molecular bases of P. falciparum drug 
resistance. CQR was initially mapped to a segment of the parasite’s seventh 
chromosome through analysis of parasite clones derived from a genetic cross between 
CQ-sensitive (HB3; Central America) and CQ-resistant (Dd2; Southeast Asia) 
parasites.184,185 In a seminal study that pinpointed pfcrt as the gene responsible for 
the CQR phenotype, transgenic expression of pfcrt alleles conferred CQR to otherwise 
CQ-sensitive parasites.186 The authors observed PfCRT to localize to the parasite DV, 
where CQ exerts its action, and proposed that CQR occurs via (1) mutant PfCRT-
mediated CQ efflux outside of the DV and/or (2) reduced CQ binding to its heme target, 
through mutant PfCRT-mediated effects on DV physiology.186  
CQ-resistant parasites are known to accumulate less CQ in their DV than CQ-
sensitive parasites.112,119,187 Accordingly, a long-standing model for CQR has been that 
CQ-resistant parasites are equipped to reduce CQ access to its heme target in the DV. 
This model is in line with multiple lines of evidence showing that CQ and heme 




PfCRT in mediating reduced DV accumulation of CQ was demonstrated using [3H]-
CQ accumulation assays performed with pfcrt-modified parasite lines bearing an 
otherwise isogenic background.120 Of note, subsequent studies revealed that reduced 
CQ accumulation can only partly account for the mechanism of PfCRT-mediated CQR.  
In a striking finding, parasites encoding mutant (Dd2) pfcrt were fully protected from 
CQ cytotoxicity, whereas wild-type (HB3) pfcrt-expressing parasites showed 50% 
survival, even though both lines were treated with CQ doses (750 nM and 250 nM CQ, 
respectively) that yielded equivalent levels of intravacuolar CQ accumulation.189,190 
Mutant PfCRT–CQ interactions are now appreciated to play a predominant role in 
mediating parasite cytostatic CQR and contribute to the relatively more multigenic 
basis of cytocidal CQR.191,192 Elucidation of these complex aspects of parasite CQR is 
an area of active pursuit.   
 Using purified plasma membranes isolated from Pichia pastoris strains that 
heterologously expressed PfCRT variants, Zhang et al. previously observed the ability 
of CQ to bind both wild-type (HB3) and mutant (Dd2) PfCRT isoforms (with Kd values 
of 435 and 385 nM, respectively).193 In a subsequent study that used reconstituted 
proteoliposomes harboring wild-type (HB3) or mutant (Dd2 and 7G8) PfCRT isoforms, 
an  interaction was documented between a DV-disposed region of PfCRT helices 9-10 
and a perfluorophenylazido biotinylated CQ (AzBCQ) probe.194 Interestingly, the 
extent to which pH influenced this interaction was PfCRT isoform-specific. The 
authors posited that the AzBCQ attachment site positioned the CQ quinoline ring in 
close proximity to the many transmembrane domain-localized and DV-disposed 
PfCRT polymorphic residues that are known to be involved in CQR.194 These findings 




pathways, CQ may interfere with the as yet unclear native function of PfCRT (see 
“Insights into PfCRT biological function” section below).  
 Studies using parasites encoding wild-type and mutant PfCRT isoforms have 
previously demonstrated that PfCRT mutations can alter the physiology of the 
parasite DV, eliciting alterations in the pH (pHDV) and volume of the DV.195-197 A ~0.4-
unit reduction in pHDV was ascribed to mutant pfcrt alleles by Bennett et al.197 Of 
note, the equilibria of quinoline drug–heme interactions are highly pH-dependent,58 
suggesting a role for PfCRT mutations in modulating parasite susceptibility to CQ 
and quinoline compounds beyond their contributions to drug efflux. 
 Allelic exchange experiments previously showed that, in the context of 
additional mutations comprising a CQ-resistant isoform of PfCRT, the mutation K76T 
is indispensable for parasite CQR and the ability of mutant PfCRT to remove CQ from 
its Fe(III)PIX target in the DV.126 Clinically, K76T has historically served as a 
sensitive, although not specific, marker of CQ treatment failure.198,199 In Xenopus 
laevis oocytes, removal of K76T abrogated mutant PfCRT-mediated CQ transport. By 
itself, K76T was insufficient to confer CQ transport.200 As P. falciparum PfCRT-
mediated CQR is governed by factors beyond drug transport, the sufficiency of K76T 
for parasite CQR has been unclear. This question was explored in Chapter 2 of this 
dissertation. A potential role for K76T in proton transport was suggested in studies 
heterologously expressing wild-type or mutant (Dd2) PfCRT isoforms in the lysosomal 
membranes of HEK293 human embryonic kidney cells, both of which induced 
acidification. Of note, acidification was higher for cells expressing Dd2 PfCRT, and 
K76T was both necessary and sufficient to confer this phenotype.201 




differing hypotheses evoked by distinct experimental systems. A number of groups 
have advocated for the description of PfCRT as a carrier/pump,202-204 whereas others 
have proposed that it functions as a voltage-gated channel.205,206 An important aspect 
of parasite DV physiology is maintenance of an electrochemical gradient, which is 
comprised of the pH and membrane potential differences (ΔpH and Δψ, respectively) 
across the DV membrane. This gradient is maintained, in part, through the action of 
a DV H+-ATPase and a DV H+-pyrophosphatase.207 The notion that PfCRT mediates 
electrochemical gradient-driven transport is supported by several independent 
heterologous expression studies.200,201,208-210 Interestingly, as compared to isogenic 
parasites expressing wild-type (CQ-sensitive) pfcrt,  mutant (CQ-resistant) pfcrt-
expressing parasites were previously found to enhance alkalinization of the DV upon 
treatment with the V-type H+-ATPase-inhibiting agent concanamycin A, raising the 
prospect that mutant PfCRT facilitates H+-coupled drug transport.211 
  A schematic highlighting proposed mechanisms of CQ action and the 
involvement of mutant PfCRT in mediating CQR is shown in Figure 1.15. Of note, the 
chemical and mode-of-action features of CQ are shared with many first-line 
antimalarials, and a pleiotropic role for PfCRT mutations in mediating resistance to 
these agents is becoming increasingly appreciated (see “The pleiotropic role of PfCRT 
in mediating antimalarial drug resistance” section below). This knowledge calls for 
continued refinement of our understanding of mechanisms contributing to PfCRT-
mediated drug resistance, collectively encompassing drug transport and binding, 









Figure 1.15. Schematic of P. falciparum digestive vacuole (DV) physiology, hemoglobin (Hb) 
processing, and possible modes of chloroquine (CQ) action. (A) Parasites import host Hb into 
the DV, where (B) resident proteases digest it into peptides that serve as a source of (C) amino 
acids (AAs) for the generation of new proteins. (D) Hb degradation also unleashes heme 
prosthetic groups in the form of ferrous (Fe2+) protoporphyrin IX (Fe[II]PIX). (E) In the DV 
environment, Fe(II)PIX is rapidly oxidized to ferric (Fe3+) protoporphyrin IX (Fe[III]PIX). (F) 
Through direct and indirect mechanisms, DV-localized Fe(II)PIX and Fe(III)PIX are able to 
promote oxidative damage (represented by purple lightening bolt). (G) Fe(III)PIX may also 
promote oxidative damage in the parasite cytosol. This is countered by the parasite’s redox 
system (represented by yellow star), in part via glutathione-dependent degradation of free 
heme. (H) Parasites avert heme-mediated toxicity in the DV by transforming it into inert, 
insoluble hemozoin (Hz) crystals. (I) The weak base CQ diffuses into the acidic DV, where it 
becomes diprotonated (CQ2+) and trapped. (J) CQ2+ interferes with Hz polymerization and (K) 
may also inhibit PfCRT function. (L) Mutant forms of PfCRT mediate CQ resistance, in part by 







The pleiotropic role of PfCRT in mediating antimalarial drug resistance 
Several antimalarial agents are structurally similar to CQ and are thought to likewise 
interfere with heme detoxification (see Antimalarial compounds section above). 
Among them are the first-line ACT partner drugs, whose long half-lives effectively 
render them monotherapies following the rapid clearance of the ART component.212 
Field and in vitro studies implicate PfCRT as a modulator of parasite susceptibility to 
these drugs.114 For example, a Tanzanian study investigating molecular markers 
associated with tolerance to the widely used ACT formulation ATM-LUM revealed 
that mutant PfCRT K76T enhances parasite LUM susceptibility, a finding that was 
verified in experiments using genetically-modified, isogenic parasites.213 In contrast, 
mutant, CQR-conferring PfCRT haplotypes cause reduced susceptibility to AQ, used 
in the ACT regimen AS-AQ.214 Although the relationship between parasite 
susceptibility to PPQ, the partner drug comprising DHA-PPQ, and parasite pfcrt 
genotype is less clear, partial cross-resistance between PPQ and CQ has previously 
been observed in vitro.215,216 Valderramos et al. previously reported that certain 
mutant pfcrt alleles could confer increased PPQ susceptibility in a specific genetic 
background (D10).217 In a separate study, one of the genetic changes acquired by CQ-
resistant (Dd2) parasites exposed to PPQ pressure was the mutation PfCRT C101F.218 
Interestingly, this mutation was also acquired by an amantadine-pressured CQ-
resistant line (FCB), conferring a 2-fold decrease in parasite susceptibility to PPQ.196 
 Additional lines of evidence highlight the ability of pfcrt mutations to modulate 
parasite susceptibility to chemically diverse antimalarial compounds. In experiments 
performed with genetically modified parasites, Sidhu et al. observed pfcrt-mediated 




parasite pfcrt evolution and acquisition of novel drug resistance phenotypes was 
recently reported by Pelleau et al., who described the evolution in French Guiana of 
the novel mutation C350R in the background of the CQ-resistant 7G8 PfCRT 
haplotype. This mutational event fully abolished CQR and, interestingly, conferred 
increased PPQ resistance.137 In a separate study, pressure of CQ-resistant (Dd2) 
parasites with the thiazepine amide compound IDI-3783 yielded IDI-3783-resistant 
parasites that acquired the PfCRT mutation Q352R.219 This mutation was associated 
with restored CQ sensitivity, highlighting the combination of CQ and IDI-3783 as a 
parasite “evolutionary trap”, a scenario with clear applications for the design of future 
drug regimens.219 The recently noted ability of PfCRT to interact with and transport 
tricyclic compounds in a heterologous expression system further suggests the notion 
that PfCRT is a pleiotropic multidrug resistance transporter.220 These observations 
collectively advocate for the active monitoring of parasite pfcrt genotypes, for at least 
two purposes: to detect existing drug resistance and to guide selection of drug 
regimens that can preemptively inhibit evolution of additional resistance pathways. 
 
The role of PfMDR1 in antimalarial drug resistance 
After pfcrt, the most important secondary genetic determinant of parasite 
susceptibility to CQ and quinoline-type drugs is pfmdr1. The parasite pfmdr1 gene 
encodes a 162-kDa DV-resident, 12-transmembrane domain protein that shows 
homology to P-glycoproteins, which mediate multidrug resistance in cancer cells.221 
The native function of PfMDR1 is unclear, although it has been postulated to be 
involved in the transport of solutes across the DV membrane.142 Various PfMDR1 




differential parasite responses to a wide array of clinically employed antimalarials. 
Increased pfmdr1 copy number is associated with reduced parasite susceptibility to 
MFQ, QN, LUM, and AS and heightened susceptibility to PPQ.145,222,223  
The five most common PfMDR1 mutations are N86Y, Y184F, S1034C, N1042D 
and D1246Y. Studies performed by Veiga et al., in which the pfmdr1 locus of P. 
falciparum parasites was genetically modified, recently revealed that PfMDR1 N86Y 
increases parasite resistance to CQ and AQ and increases susceptibility to LUM, 
MFQ, and DHA.143 These results are consistent with clinical data that show that AQ-
based regimens select for PfMDR1 N86Y, whereas LUM-based regimens select for 
N86. AQ-based and LUM-based regimens also select for PfMDR1 D1246Y and D1246, 
respectively.123 As also seen for pfcrt alleles, this highlights that opposite selective 
forces may operate on the pfmdr1 locus, providing a rationale for cycling first-line ACT 
regimens. 
Of note, a linkage disequilibrium exists between pfcrt and pfmdr1,224,225 and 
these loci can interact to produce differential parasite drug responses that are genetic 
background-specific. As an example, analysis of the progeny of a genetic cross between 
parasites from geographically distinct regions previously highlighted that certain 
South American pfcrt and pfmdr1 alleles can interact to confer higher levels of AQ 
resistance as compared to CQR. In contrast, a Southeast Asian pfcrt allele yielded 
greater CQR in the context of different pfmdr1 alleles.133 In a recent study in Ghana, 
significant associations were observed between PfCRT K76T and polymorphisms at 
PfMDR1 residues 86, 184, and 1034, evoking the suggestion that a synergism between 
pfcrt and pfmdr1 could explain the unusually slow attrition of mutant pfcrt-expressing 




and pfmdr1 interact to confer drug resistance is an area of active investigation. 
Beyond their role in transport of drugs, pfmdr1 mutations may have direct impacts 
on parasite physiology that, in turn, affect pfcrt-mediated resistance and/or that offset 
physiological constraints associated with pfcrt mutations.114  
 
PFCRT 
Insights into PfCRT biological function 
The parasite pfcrt gene is comprised of 13 exons, which encode a 424-amino acid 
transmembrane protein that is localized to the parasite DV.186 The localization and 
trafficking of PfCRT during the course of the intraerythrocytic life cycle was 
previously elucidated using live cell imaging of P. falciparum parasites expressing 
inducible GFP-tagged PfCRT. PfCRT-GFP expression was first noted at the 
membrane of pre-DV compartments in mid-stage rings, which formed the Hz-
containing DV in the trophozoite stage. In schizonts, punctate localization of PfCRT-
GFP was also noted.227 Mutational analysis of PfCRT trafficking by Kuhn et al. 
showed that a threonine residue at PfCRT position 416 is critical for sorting of PfCRT 
to the DV membrane. Additionally, mass spectroscopy revealed that this threonine, 
as well as a serine at position 411, are phosphoresidues, suggesting that PfCRT 
sorting and/or function can be modulated by phosphorylation.228 
Correct processing of host Hb in the DV is required by the parasite, in part to 
avoid the rapid influx of fluid that would otherwise induce premature cell lysis.40 
Given this, it is conceivable that at least one function of PfCRT entails osmolyte 
regulation, perhaps through the partitioning of ions across the DV membrane. 




knowledge that (1) previous efforts to fully disrupt pfcrt did not succeed;229 (2) 
mutation or reduced expression of pfcrt may promote DV swelling;196,230 and (3) PfCRT 
isoforms have differential effects on the acidification of lysosomal or lysosome-like 
compartments, as discussed in the section above. Earlier studies have implicated roles 
for PfCRT in the transport of H+, Cl–, as well as organic cations (e.g. 
tetraethylammonium, TEA).195,201,209,231 Whether these observations translate to the 
native environment of PfCRT is unclear and poses an experimental challenge.  
 Another possible function that has been proposed for PfCRT is the transport of 
amino acids and/or peptides, which are abundantly generated in the DV.193,209,232-234 
Several lines of evidence support this notion. First, mutant isoforms of PfCRT impart 
a characteristic Hb degradation defect, whereby Hb-derived peptides accumulate in 
the parasite DV.232 In addition, drug transport studies performed in Escherichia coli 
or X. laevis oocytes have collectively observed that certain charged amino acids and/or 
peptides can antagonize PfCRT-mediated transport of TEA or CQ, respectively.200,209 
In an independent set of studies using X. laevis oocytes, Patzewitz et al. demonstrated 
that mutant PfCRT isoforms are capable of selectively transporting the tripeptide 
GSH.234 In light of the suspected role of GSH in heme degradation and the ability of 
PfCRT isoforms to alter the access of CQ to heme,56,126 one may postulate that PfCRT 
is involved in parasite GSH homeostasis. This prospect is in line with the known 
homology between PfCRT and plastid-localized CRT-like transporters (CLTs), which 
transport GSH and regulate cytosolic redox potential in Arabidopsis thaliana.235 
Bioinformatic analyses of PfCRT have revealed that it belongs to a superfamily 
of proteins called the drug/metabolite transporters (DMTs).233,236 Despite sharing key 




substrates, including sugars, ions, weak bases, and organic cations. A number of 
DMTs, including PfCRT, are thought to have undergone a gene duplication event that 
resulted in the doubling of an ancestral 5-transmembrane domain protein to one with 
10 transmembrane segments.233,236 Consistent with this, PfCRT is thought to form 
dimers, and these have been found to occur in the laboratory setting.194 Residues 
comprising the transmembrane domains of DMTs are important for substrate 
specificity and translocation, and submolecular regions spanning a single 
transmembrane domain can be sufficient to confer substrate specificity.237 
In the context of drug resistance, it is now appreciated that mutations in 
PfCRT can confer differential stereospecificities, more than one binding site, and the 
ability to transport structurally diverse chemical compounds.125,220,238 Does this 
pleiotropic property of PfCRT extend to its native function as a putative polyspecific 
nutrient transporter? Can PfCRT mutations alter the permeability of the DV 
membrane and promote a leak of one or more endogenous metabolites? Apart from 
interfering with PfCRT native function, can PfCRT mutations impart novel substrate 
specificities to PfCRT? Using various experimental systems, pursuit of these 
outstanding questions will undoubtedly broaden our understanding of PfCRT and will 
provide novel insights into the druggable features of parasite physiology.  
 
PfCRT polymorphisms 
Sequencing of the complete pfcrt open reading frame of geographically distinct, CQ-
resistant P. falciparum isolates has shed light on a general mutational requirement 
for CQR, namely a non-synonymous mutation at PfCRT residue 76 accompanied  by 




clinical and laboratory isolates bear the PfCRT mutation K76T, with rare reports of 
alternative mutations affecting residue 76 (K76A, K76I, and K76N).114 To date, over 
50 distinct PfCRT haplotypes have been reported,208 although parasite CQ 
susceptibility data is available for only a fraction of these haplotypes. The highly 
polymorphic nature of PfCRT haplotypes is highlighted in Table 1.6 and Figure 1.16, 




Parasite determinants of fitness 
The fitness of pathogenic organisms refers to their ability to successfully complete 
their life cycle and generate new progeny. A number of biological factors directly or 
indirectly impact fitness. In the case of Plasmodium parasites, key factors include 
parasite replication, survival, transmission, vectorial selection, and host vulnerability 
(Figure 1.17). In the laboratory setting, parasite fitness is often quantified using 
competitive parasite growth assays or by studying a proxy, such as the activity of an 
essential parasite protein. These approaches are complemented by epidemiological, 
clinical, and laboratory-based investigations of transmission dynamics, parasite 
virulence, and determinants of host immunity.239-241 
  The relative fitness differences between Plasmodium strains can be gauged via 
parasite growth rates, as determined in vitro or ex vivo. These are assessed during 
the pathogenically relevant setting of asexual blood-stage infection, during which the 









aShown are representative PfCRT haplotypes, which emphasize variants investigated in this dissertation. Polymorphisms shaded in gray 
differ from those comprising wild-type (GC03; CQ-sensitive) PfCRT. The relative fitness associated with a given PfCRT haplotype, as 
compared to wild-type (GC03), was inferred from published growth rates determined in isogenic, blood-stage P. falciparum parasites.242,243 ↑ 
and ↓ indicate increased and decreased parasite fitness, respectively, with the number of arrows representing the degree of difference. –, no 
















Table 1.6. Representative PfCRT haplotypes.a 
    Polymorphic PfCRT residue 
PfCRT haplotype CQ Region Fitness 72 74 75 76 144 148 194 220 271 326 333 356 371 
GC03 S All – C M N K A L I A Q N T I R 
Ecu1110 R SA ↓↓ C M N T A L I S Q D T L R 
7G8 R SA; WP ↓ S M N T A L I S Q D T L R 
GB4 R Af ↓ C I E T A L I S E N T I I 
Dd2 R Af; SeA ↓↓ C I E T A L I S E S T T I 










Figure 1.16. Schematic of PfCRT topology. PfCRT is a drug/metabolite transporter with 424 residues and 10 predicted transmembrane 
domains that span the membrane of the parasite digestive vacuole (DV).233 N and C termini of the protein are oriented toward the parasite 
cytoplasm. Representative residues that are mutated among different PfCRT variants are indicated in red. These correspond to PfCRT 











Figure 1.17. Schematic of factors contributing to the fitness of Plasmodium parasites. Fitness 
refers to the ability of organisms to replicate, generate new progeny, and propagate their life 
cycle. The complex life cycle of Plasmodium parasites requires replication in distinct cellular 
environments. Parasite numbers increase exponentially and directly contribute to malaria 
pathogenesis during the human blood stage of infection. Before they can be successfully 
transmitted to the mosquito vector, parasites must withstand host defenses (e.g. antioxidant 
and immune systems) and survive possible exposure to chemotherapeutics. Parasite fitness 
is also influenced by the number of gametocytes transmitted to the mosquito vector and their 
subsequent replicative success. In vitro measurements of fitness include biochemical and 
functional characterizations of essential parasite proteins, assessment of parasite replication 
in competitive growth assays, and monitoring of specific parasite genotypes via sequencing-
based approaches. These are complemented with epidemiological, clinical, and laboratory-










host in the absence of drug.24,123 While it is possible that growth rates in culture might 
differ from those that would be observed within humans, performing controlled 
experiments in the setting of the human host is not an option, for obvious reasons. 
Factors that call for caution in interpreting the results of parasite growth competition 
experiments include the confounding roles of host immunity, clonality of infections, 
rates of cross-over, drug levels, vector-specific selection, and modulation of virulence 
by co-infecting microbes.240,241,244,245 Despite this, meaningful correlations emerge from 
comparisons of laboratory-based parasite growth rates and other field-based markers 
of parasite fitness, as discussed in the next section. Leveraged with focused 
comparative assessments of parasite growth, the application of whole-genome, 
transcriptome, and proteome analysis of parasite populations that have been 
subjected to particular selective forces will collectively aid in identifying parasite-
specific signatures of fitness.244 
 
PfCRT and the balancing act of parasite drug resistance versus fitness 
Parasites evolve resistance to an antimalarial drug by acquiring one or more gene 
mutations and/or altering gene expression. These changes may interfere with 
activation of drug, impair drug-target interactions, and/or enhance efflux of drug away 
from its target site.240 Particularly for proteins that serve essential functions, as is the 
case for PfCRT,229 the fitness of a protein is directly linked to the organism’s overall 
fitness. Consistent with this, the impacts of resistance mutations on protein stability 
and function evoke the drug resistance mutation-fitness tradeoffs observed for an 
organism.246  




contextualized by mapping all possible mutational configurations within a gene or 
genes against the degree of fitness that they confer, collectively referred to as an 
adaptive landscape.239 Importantly, the topography of adaptive landscapes is largely 
influenced by the organism’s drug environment.245 Typically, drug resistance 
mutations have a deleterious impact on parasite protein function and, consequently, 
impart a fitness cost. In the absence of drug pressure, these mutations represent low-
fitness “valleys” in the parasites’ adaptive landscape, and natural selection will act to 
eliminate them. However, in the scenario of drug pressure, the fitness of parasites is 
influenced by their ability to survive in the presence of drug, and previously 
inaccessible mutational paths in the parasite adaptive landscape may become 
accessible. Sustained drug pressure may facilitate the evolution of additional 
intragenic or intergenic compensatory mechanisms that reduce fitness costs, further 
modifying the parasite’s adaptive landscape.240 Of note, mutations may occasionally 
arise that simultaneously confer drug resistance and impart either no fitness cost or 
enhanced fitness. In rare instances, this degree of fitness may be comparable to that 
conferred by the wild-type allele, even in the absence of drug.240,243,247 
The degree to which mutant resistance alleles are fixed in the population is 
influenced by their rates of formation, exposure to drug pressure, and relative fitness 
as compared to other circulating alleles.240 De novo resistance mediated by two major 
P. falciparum drug resistance genes – dhfr and pfcrt  – has been previously estimated 
to emerge with per-parasite probabilities of 10-12 and 10-20, respectively.24 The 
discrepancy in these rates can be attributed to the fundamentally distinct modes of 
resistance conferred by mutations in these genes. Identification of mutational 




facilitated by approaches that leverage combinatorial genetic phenotyping of a fitness 
proxy (e.g. drug resistance in the scenario of drug pressure, growth, protein function) 
with computational models that simulate drug resistance evolution.239 This entails 
generating an allelic panel comprising all possible combinations of mutations that 
make up a drug resistance allele. Combinatorial genetic strategies were previously 
applied to model the evolution of dhfr-mediated pyrimethamine resistance, which 
revealed a subset of preferred mutational pathways that correlated with field 
data.165,248 Importantly, such studies had not been previously performed for pfcrt and 
form the basis of the work presented in Chapter 2. 
 A wide collection of laboratory and field-based studies provide insights into the 
influence of drug pressure on the prevalence of pfcrt alleles, as well as impacts of pfcrt 
mutations on various aspects of parasite fitness.114,241 A historic example is the fate of 
the mutant PfCRT CVIET haplotype (residues 72-76) in Africa. Following its evolution 
in Asia,249 this mutant haplotype migrated to the African continent, contributing to 
the loss of CQ efficacy and resurgence in childhood malaria mortality.178 However, this 
devastating trend was reversed when concerted withdrawal of CQ use was 
implemented in regions of Africa, leading to the rapid attrition of mutant PfCRT, with 
a concomitant expansion of the fitter, wild-type (CQ-sensitive) CVMNK haplotype.250-
252 This phenomenon has also been observed in a few parts of Asia,253,254 although these 
represent exceptions; the CVIET haplotype presently dominates in Asia, despite 
declined CQ use. In South America255-257 and elsewhere,258-260 the SVMNT haplotype 
has also persisted in the absence of CQ pressure.  
 Region-specific differences in the prevalence of mutant pfcrt alleles can be 




the various stages of their complex life cycle, the extent of drug pressure, and 
gametocyte carriage rates. As well, regional differences in the extent of parasite 
transmission have established impacts on host immunity and parasite natural 
selection, with increased roles for immunity and a higher preponderance of polyclonal 
infections observed in high-transmission settings, such as Africa.241,261 
  Previous experiments using isogenic asexual blood-stage P. falciparum lines 
engineered to express variant pfcrt alleles have collectively shown that, compared to 
wild-type pfcrt, mutant pfcrt alleles consistently reduce parasite proliferation, with a 
single exception (a fitness-enhancing allele identified in Cambodia262 that is the 
subject of Chapter 3 and Appendix A).232,243 This defect in parasite blood-stage fitness 
was previously associated with defective Hb catabolism, resulting in the abnormal 
accumulation of Hb-derived peptides in the DV.232  
 Studies in the field setting support the idea that mutant pfcrt genotypes 
negatively impact parasite fitness. In a study in the Gambia, before the start of the 
high-transmission wet season, wild-type PfCRT-encoding parasites predominated, 
and mutant PfCRT-encoding parasites only increased in prevalence with drug use.263 
In a separate retrospective study examining associations between pfcrt mutational 
status and the clinical presentation of parasitemic children in Uganda, it was found 
that the prevalence of mutant pfcrt genotypes was lower in febrile children as 
compared to asymptomatic children.264 In this region, the widely-used regimen ATM-
LUM selects against the mutant pfcrt genotype, which can be counteracted by 
employing the AS-AQ regimen that selects for mutant pfcrt.265 In studies in Zambia, 





  Of note, mutant pfcrt alleles may play an important role in facilitating 
transmission. In Sudan, for example, mutant pfcrt genotypes were implicated in 
facilitating increased gametocyte carriage.267 This is in line with experiments 
performed by Ecker et al., which showed that a mutant pfcrt allele (7G8) that was 
transgenically expressed in P. berghei enhanced the transmission of CQ-exposed 
gametocytes to mosquitos.268 These observations raise the prospect that some mutant 
pfcrt alleles have evolved to offset fitness costs associated with their intraerythrocytic 
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The emergence of drug resistance continuously threatens global control of infectious 
diseases, including malaria caused by the protozoan parasite P. falciparum. A critical 
parasite determinant is PfCRT, the primary mediator of CQR and a pleiotropic 
modulator of susceptibility to first-line ACT partner drugs. Aside from the validated 
CQR molecular marker K76T, P. falciparum parasites have acquired at least three 
additional pfcrt mutations, whose contributions to resistance and fitness have been 
heretofore unclear. Focusing on the quadruple-mutant Ecuadorian PfCRT haplotype 
Ecu1110 (K76T/A220S/N326D/I356L), we genetically modified the pfcrt locus of 
isogenic, asexual blood-stage P. falciparum parasites using zinc finger nucleases to 
produce all possible combinations of intermediate pfcrt alleles. Our analysis included 
the related quintuple-mutant PfCRT haplotype 7G8 (Ecu1110+C72S) that is 
widespread throughout South America and the Western Pacific. Drug susceptibilities 
and in vitro growth profiles of our combinatorial pfcrt-modified parasites were used 
to simulate the mutational trajectories accessible to parasites as they evolved CQR. 
Our results uncover unique contributions to parasite drug resistance and growth for 
mutations beyond K76T and predict critical roles for the CQ metabolite md-CQ and 
the related quinoline-type drug AQ in driving mutant pfcrt evolution. Modeling 
outputs further highlight the influence of parasite proliferation rates alongside gains 
in drug resistance in dictating successful trajectories. Our findings suggest that P. 
falciparum parasites have navigated constrained pfcrt adaptive landscapes by means 
of probabilistically rare mutational bursts that led to the infrequent emergence of 






Drug resistance in Plasmodium parasites continuously threatens global efforts to 
control malaria, a leading infectious cause of human morbidity and mortality. 
Malarial disease is caused by asexual intra-erythrocytic protozoan parasites 
belonging to the genus Plasmodium, with life-threatening cases largely attributed to 
infection with Plasmodium falciparum.15 Among the most critical parasite 
determinants of existing and emerging antimalarial drug resistance is the P. 
falciparum Chloroquine Resistance Transporter (PfCRT), a 424-amino acid 
transmembrane protein with putative involvement in nutrient transport and osmotic 
balance across the parasite digestive vacuole (DV) membrane.114,188 Fittingly named 
for its direct role in conferring resistance to the quinoline-type drug chloroquine (CQ), 
as validated through genetic linkage184 and allelic exchange186 studies, PfCRT has 
gained recognition as a multidrug resistance transporter with pleiotropic effects on 
parasite susceptibility to multiple first-line antimalarials.114,243,269 
 Coinciding with the demise of the short-lived Malaria Eradication Program, 
the arrival of CQ resistance (CQR) heralded a dramatic increase in severe malaria 
cases.270 A significant association between CQR and pfcrt was observed in 
microsatellite typing studies of parasites isolated during this period, which detected 
four distinct geographical origins of CQR, namely Southeast Asia (with subsequent 
spread into Africa), the Western Pacific, and two foci in South America.249 Factors that 
likely sustained sub-therapeutic levels of CQ in the population and thus facilitated 
the evolution of CQ-resistant pfcrt alleles include aggressive deployment of CQ as a 
monotherapy and unregulated use of prophylactic chloroquinated salts.130 Despite the 




reducing the global burden of malaria.271 CQ continues to be employed for the 
treatment of uncomplicated P. falciparum malaria in regions with no or low-level 
CQR272 as well as to treat infection with the related malarial parasite P. vivax.273  
 Mechanistically, CQ interacts with host hemoglobin-derived heme in the DV, 
where it inhibits detoxification of heme species that are otherwise toxic to parasites.55 
Mutant PfCRT facilitates CQR by reducing the ability of CQ to access its heme 
target.108,274 This is accomplished by mutant PfCRT-mediated CQ efflux out of the DV 
and may be further attributed to modulation of PfCRT native function.114,188,275 
Chemical and molecular features shared among clinically employed antimalarials, 
including constituents of the first-line artemisinin-based combination therapies 
(ACTs), collectively include the presence of a CQ-like structural scaffold, accumulation 
of drug in the DV, inhibition of heme detoxification, and/or drug activation via 
heme.180,276 Consistent with their ability to alter DV physiology, pfcrt alleles modulate 
susceptibility to the first-line ACTs and are selected either for or against depending 
on the specific drug regimen.114 This is underscored by a recent meta-analysis of the 
clinical efficacy of two widely employed ACTs, artesunate-amodiaquine (AS-AQ) and 
artemether-lumefantrine (ATM-LUM), which revealed a reduction in time to 
reinfection for parasites encoding mutant PfCRT in patients treated with AS-AQ, and 
vice versa for ATM-LUM.265 Monitoring resistance to ACT partner drugs is paramount 
due to the very short half-lives of artemisinins, which leave their long-acting partner 
drugs solely responsible for clearing any remaining parasites.277 Intriguingly, in vitro 
and field studies indicate that pfcrt mutations may even modulate parasites’ 
susceptibility to artemisinins themselves.120,159,278  




the pfcrt locus have historically centered on a single-nucleotide polymorphism (SNP) 
encoding a lysine-to-threonine substitution (K76T) that is highly prevalent among 
CQ-resistant parasites.114 In parasites expressing CQ-resistant pfcrt alleles, targeted 
genetic reversion of PfCRT K76T back to the wild-type residue abolished CQR and its 
characteristic reversibility by the calcium channel blocker verapamil (VP), in part by 
enhancing access of CQ to its heme target.126 In line with these in vitro findings, K76T 
has been associated with in vivo CQR and has served as a sensitive, although not 
highly specific, marker of CQ treatment failure.198,199, in part due to pre-existing host 
immunity in areas with high transmission.279 Mutant pfcrt-mediated CQR can also be 
augmented by secondary factors, including mutant pfmdr1.133,280 Of note, 
geographically distinct CQ-resistant isolates consistently harbor at least three PfCRT 
mutations in addition to K76T.275,281,282 These have been conventionally described as 
compensatory mutations that arose to preserve the essential function of PfCRT229, 
although their precise contributions to parasite drug resistance and fitness have not 
been defined. 
 Antimalarial drugs exert selective pressures on multiple facets of the parasite 
life cycle, which collectively determine parasite fitness.241,244 Among these are growth 
of intra-erythrocytic parasites, mosquito transmissibility, and within-host virulence, 
each of which is influenced by the parasite’s pfcrt genotype.114,232,243,263,264,266 A notable 
example is the mutational status of PfCRT residues 72-76 and its association with the 
outcome of CQ cessation programs in regions with high-level CQR. In regions in 
Africa251,283,284 and Asia253,254, where the CVIET PfCRT haplotype predominates among 
CQ-resistant parasites, removal of CQ pressure promoted regional resurgences of CQ-




contrast, in South America255-257,285 and in select regions elsewhere258,260,286,287, the 
predominant mutant PfCRT haplotype, SVMNT, persists despite a decline in CQ use. 
The prospect that this haplotype is less deleterious to parasites than CVIET259 is 
supported by recent in vitro studies, in which isogenic intra-erythrocytic parasites 
expressing the CVIET-encoding Dd2 pfcrt allele demonstrated a higher fitness cost 
than parasites expressing the SVMNT-encoding 7G8 pfcrt allele.243 Accordingly, as 
they acquire drug resistance-conferring mutations, parasites traverse discrete 
adaptive landscapes, defined as an organism’s fitness as a function of the mutational 
events incurred.288 The ability to ascertain evolutionary histories of pfcrt alleles and 
identify predictable mutational pathways would be of particular relevance to region-
specific treatment recommendations, which are routinely informed by pfcrt genotypes. 
 To date, the adaptive landscapes of drug resistance alleles consisting of n 
mutations have been explored through rigorous combinatorial approaches, in which 
an experimental proxy for fitness is determined for all 2n possible mutational 
intermediates and used to quantify the accessibility of the n! possible stepwise 
evolutionary trajectories leading to the full-length resistance allele.239,289 Subsequent 
comparison of accessible trajectories can illuminate preferred mutational pathways 
and uncover epistatic interactions between mutant residues that may constrain the 
evolutionary potential of a gene of interest.290,291 For Plasmodium, such combinatorial 
analyses have not previously been performed for PfCRT and have been limited to 
heterologous expression studies that explored the mutational acquisition of 
dihydrofolate reductase (DHFR)-mediated antifolate resistance.165,248,292,293 
 The feasibility of mapping mutational trajectories accessible to P. falciparum 




the present study, we utilized pfcrt-specific zinc finger nucleases (ZFNs) to conduct a 
combinatorial genetic dissection of the CQ-resistant South American pfcrt allele 
Ecu1110 during the pathogenically relevant parasite asexual blood stage. Consisting 
of the fewest number of mutations observed in a CQ-resistant parasite, the Ecu1110 
PfCRT haplotype (K76T, A220S, N326D, I356L) is closely related to the highly 
prevalent 7G8 haplotype, which differs by the presence of a single additional mutation 
(C72S). Here, we profiled the drug susceptibility and in vitro growth of isogenic 
parasites expressing all possible pfcrt alleles spanning the evolutionary transition 
from CQ-sensitive (wild-type) to CQ-resistant (Ecu1110), as well as the CQ-resistant 
pfcrt allele 7G8. These experimentally derived genotype-phenotype relationships were 
subsequently applied to an evolutionary model in order to probe the adaptive 
landscape of parasites as they acquire drug resistance. This is the first combinatorial 
description of the trade-offs experienced by P. falciparum parasites as they acquire 















P. falciparum-infected human erythrocytes were cultured at 4% hematocrit in 0.5% 
Albumax II (Invitrogen)-supplemented RPMI-1640 culture medium160 at 37°C, 5% O2 
/ 5% CO2 / 90% N2.  
 
Allelic replacement plasmids, parasite transfections, and verification of 
genetic editing. 
To construct donor plasmids for ZFN-based allelic replacement of pfcrt, we used 
previously generated plasmids that encode an assortment of pfcrt alleles (GC03, 7G8, 
Ecu1110, as well as all allelic permutations of Ecu1110 pfcrt mutations) as templates 
for PCR amplification of pfcrt exons 2 through 13 with primers p1 + p2 (see Table 2.1 
for primer details). Amplicons were subsequently cloned into the pcrtDd2-hdhfr donor 
plasmid backbone295 via SalI and NcoI restriction sites. The plasmid pZFNcrt-bsd, 
which encodes pfcrt-specific ZFNs, has been described previously.295 The composition 
of donor and ZFN-encoding plasmids is further detailed in Figure 2.1.  
 To genetically modify the pfcrt locus of 7G8 parasites, parasites were 
electroporated with 40 μg purified donor plasmid (pcrt-hdhfr), as detailed 
elsewhere,167 and subsequently pressured with 2.5 nM WR99210 (Jacobus 
Pharmaceuticals). Donor plasmid-enriched parasites were electroporated with 40 μg 
pZFNcrt-bsd and pressured with 2.5 nM WR99210 and 2 μg/ml Blasticidin HCl 





aNucleotides corresponding to restriction sites are underlined. F, forward; R, reverse; gDNA, genomic DNA; pbcrt, P. berghei chloroquine 
resistance transporter; UTR, untranslated region; GSP, gene-specific primer. 
Table 2.1. Primers used in this study.a 
Primer Oligonucleotide sequence (5’ → 3’) Description Lab name 
p1 AACCATGGATTTATTGTGTAATAATTGAATCGACG NcoI-pfcrt exon 13 R p1640 
p2 CCCTTGTCGACCTTAACAGATGGCTC SalI-pfcrt intron1-exon 2 F p3519 
p3 TCAAACATGACAAGGGAAATAGT pfcrt exon 5 F p2427 
p4 CCAAGAATAAACATGCGAAACC pfcrt exon 7 R p3806 
p5 CTTGAATTCGACCTTAACAGATGGCTCAC pfcrt exon 2 F p3264 
p6 CTTATCGATAAGCAGAAGAACATATTAATAGGAATACTTAATTG pfcrt exon 3 R p3265 
p7 CTTGGGCCCAAGTTGTACTGCTTCTAAGC pfcrt gDNA 5′ UTR F p3404 
p8 CTCGAGATGGTTGGTTCGCTAAACTGC hDHFR F p3315 
p9 TTGACCCTTATATATTCCACCCA pfcrt gDNA 3′ UTR R p3403 
p10 GAGGCGCCTATTTCAAAAATCTTAGCATAAGGATT pbcrt 3′ UTR R p1644 
p11 CATACTTCTTTATAACTTTATGTGACATTTAC pbcrt 3′ UTR R GSP RT-PCR p4397 
p12 CCGTTAATAATAAATACACGCAG pfcrt 5′ UTR F RT-PCR p4396 






Bulk cultures of recombinant parasites were subjected to direct blood PCR analysis (2 
µl packed red blood cells per 20 µl 1× KAPA Blood Mix B PCR reaction; KAPA 
Biosystems) to assess for allelic exchange at the pfcrt locus. PCR-based screening for 
genetic editing is further detailed in Figure 2.1. Genetically-edited bulk cultures were 
cloned by limiting dilution.296 For each recombinant pfcrt allele, a minimum of two 
parasite clones demonstrating appropriate genetic editing by PCR (Figure 2.1) were 
selected for further analysis. Sequence integrity was verified upon initial isolation of 
parasite clones and during the course of drug susceptibility and in vitro growth assays 
by PCR-amplifying the genetically modified pfcrt locus with primers p10 + p7 and 
sequencing with primers p3 and p4. All clones were additionally subjected to RT-PCR 
to verify the sequence of pfcrt transcripts. Briefly, parasite pellets were resuspended 
in 1 ml TRI Reagent (MRC) and subjected to extraction with chloroform, as detailed 
elsewhere.297 The upper aqueous phase was transferred to a new Eppendorf tube, 
mixed with an equal volume of 70% ethanol, and transferred to a RNeasy Mini spin 
column to isolate RNA, as per manufacturer’s instructions (Qiagen). RNA was 
subsequently DNAse-treated with RQ1 DNAse (Promega), and ~100 ng was used as a 
template for first-strand cDNA synthesis with gene-specific primer p11 (pbcrt 3′ UTR 
reverse) using the SuperScript III First-Strand Synthesis System for RT-PCR 
(Invitrogen). The pfcrt locus was subsequently PCR-amplified from cDNA using 
primers p12 + p13 and sequenced with primers p3 and p4. All primer details are found 







Quantification of PfCRT protein expression 
Following two synchronizations with 5% sorbitol, trophozoite-stage parasites were 
lysed with 0.1% saponin. Protein lysates were washed with PBS and resuspended in 
RIPA lysis buffer (Boston BioProducts) supplemented with Halt Protease Inhibitor 
Cocktail (ThermoFisher Scientific). Proteins extracted from ~107 parasites were 
subsequently incubated at 65°C for 10 min in sample buffer, electrophoretically 
separated on a 4-12% Criterion XT Bis-Tris Gel (BioRad), and transferred onto a 
PVDF membrane (Millipore). Membranes were incubated with rabbit polyclonal anti-
PfCRT186 or anti-PfERD2 (MRA-1; MR4, BEI Resources, NIAID, NIH) primary 
antibodies, followed by anti-rabbit horseradish peroxidase-conjugated secondary 
antibody. Protein was visualized by chemiluminescence and quantified using Image 
Studio software (LI-COR). Levels of PfCRT protein were normalized to those of the 
PfERD2 loading control and expressed relative to isogenic parasites encoding the 
wild-type pfcrt allele (7G8GC03) for a total of three independent protein harvests. Data 
are summarized in Table 2.2. 
 
Drug susceptibility assays 
To assess in vitro drug susceptibility, parasites were dispensed into 96-well plates 
containing a two-fold dilution series of CQ ± 0.8 μM VP, md-CQ, md-AQ, LUM, or AS, 
pre-aliquoted with a BioTek Precision Pipetting System. Parasites were incubated at 
2% final hematocrit in culture medium containing 50 mM HEPES. After 72 h, 
parasites were stained with SYBR Green I and MitoTracker Deep Red, and growth 
was determined using an Accuri C6 flow cytometer.168 Drug inhibitory concentrations 







Table 2.2. PfCRT protein expression levels in pfcrt-modified and reference parasite lines.a 
Line    Line    Line   
 mean 1.00 ± 0.2   mean 0.97 ± 0.40   mean 0.76 ± 0.19 
7G8GC03 n 3  7G8EcuAD n 3  7G87G8 n 3 
 P –   P 0.90   P 0.40 
 mean 0.98 ± 0.07   mean 0.71 ± 0.32   mean 0.76 ± 0.27 
7G8EcuA n 3  7G8EcuACD n 3  7G8 n 3 
 P 0.90   P 0.70   P 0.70 
 mean 1.16 ± 0.21   mean 0.87 ± 0.19     
7G8EcuAC n 3  7G8EcuABCD n 3     
 P 0.70   P 0.70     
 
aPfCRT protein expression was evaluated for parasite lines exhibiting significant differences in chloroquine IC50 values 
(Table 2.5) and/or in vitro growth rates (Table 2.9) as compared to the recombinant reference line 7G8GC03, which encodes 
the wild-type pfcrt allele. Protein lysates from three independent cultures of doubly sorbitol-synchronized, trophozoite-stage 
parasites were subjected to SDS-PAGE, probed with rabbit anti-PfCRT or anti-ERD2 antibodies, and quantified by 
densitometry. For each parasite strain, signals of PfCRT protein bands were normalized to those of the loading control 
(PfERD2) and are expressed above as mean ± SEM values, relative to the 7G8GC03 parasite line. n, number of independent 
protein harvests; P, P value, as determined in a non-parametric Mann-Whitney U test versus the comparator line 7G8GC03. 
Of note, PfCRT protein levels showed no significant correlation with either degree of CQR (R2=0.23, P=0.34) or in vitro 








calculated as previously described.217 Reversibility of CQR by 0.8 μM VP is expressed 
as the CQ RMI, equivalent to the quotient of the CQ+VP IC50 divided by the CQ IC50.298 
Statistical significance was determined via non-parametric Mann-Whitney U tests 
using GraphPad Prism 6 software. 
 
In vitro growth assays 
In vitro fitness of recombinant and reference parasite lines was assessed in 1:1 co-
culture assays with the fluorescent reporter line NF54eGFP (RGFP). To generate RGFP, a 
cassette encoding the eGFP fluorescence probe flanked by 5′ hsp70 and 3′ hsp86 UTRs 
was genomically integrated into CQ-sensitive (wild-type pfcrt) NF54-attB parasites 
via attB×attP-based recombination catalyzed by the mycobacteriophage Bxb1 
integrase.296 The robustness of this fluorescence reporter line was recently validated 
in in vitro fitness studies conducted in blood-stage parasites.299 Assays were initiated 
by preparing co-cultures consisting of RGFP (GFP+) and a single pfcrt-modified test line 
(GFP–) in a 1:1 ratio with respect to final parasitemia of each line. Using flow 
cytometric detection of eGFP, expressed by the reporter line, as well as the far-red 
fluorescent dye SYTO61, which facilitates differentiation between uninfected and 
infected red blood cells,300 the GFP– proportion of parasites was monitored for 10 
generations and used to derive the per-generation selection coefficient (s) for each test 
strain. Statistical significance was assessed via two-way ANOVA with Sidak’s post-
hoc test using GraphPad Prism 6 software.  
  Parasite growth was determined every third day for 10 generations, and the 
parasitemia of each co-culture was maintained between 0.3% and 8%. For each co-




(GFP+) are represented as pt and qt, respectively. The relative fitness (ω) of the test 
allele is equivalent to em, where m corresponds to the slope of the graph of ln(pt/qt) 
versus t as per the relationship ln(pt/qt)= ln(p0/q0)+tln(ω), which holds true for haploid 
organisms.301 The relative fitness for each test strain was normalized to that of the 
7G8GC03 parasite line, which encodes the wild-type (GC03) pfcrt allele, yielding the 
normalized relative fitness (ω′). The per-generation selection coefficient (s) for each 
test strain was then computed as per the relationship ω′=1+s.247 Statistical 
significance was assessed via two-way ANOVA with Sidak’s post-hoc test using 
GraphPad Prism 6 software. In vitro growth data are summarized in Table 2.9. 
 
Modeling of pfcrt evolutionary trajectories 
In our mutational model, the total fitness associated with each pfcrt allele (fT) was 
derived from the relationship fT =afD+(1–a)fG, where fD is the fitness index attributable 
to drug resistance, fG is the fitness index attributable to parasite growth in the absence 
of drug, and a is the drug pressure coefficient (range for each parameter: 0 to 1). The 
fD index is equivalent to the IC50 value for a parasite line, normalized to the highest 
IC50 value observed among all combinatorial lines for a given drug. Similarly, the fG 
index is equivalent to the relative in vitro growth (ω′) of a parasite line in the absence 
of drug, normalized to the highest observed ω′ value. Thus, in the case of full drug 
pressure (a=1), the highest fT value is ascribed to the pfcrt allele that confers the 
highest degree of resistance, whereas in the completely drug-free environment (a=0), 
the highest fT value is shown by the pfcrt allele that confers maximum parasite 
growth. 




mutational scenarios that lead to the evolution of Ecu1110 pfcrt from the GC03 (wild-
type) pfcrt allele. These mutational scenarios are as follows: 0→1→2→3→4; 
0→1→2→4; 0→1→3→4; 0→2→3→4; 0→1→4; 0→2→4; and 0→3→4, where each 
number corresponds to the number of total mutations acquired. For all hypothetical 
pfcrt alleles comprising each mutational scenario, adaptive landscapes were 
generated by random sampling of fD and fG values from normal distributions based on 
pfcrt allele-specific means and SEMs. To examine the role of drug pressure on 
mutational pathway accessibility, the drug pressure coefficient a was varied from 0 to 
1, in increments of 0.1. We note that fT and the experimentally derived growth 
selection coefficient s were in agreement (R2=0.974) for growth experiments performed 
with 7.5 nM CQ (a=0.04). Evolutionary excursions along each landscape were then 
simulated by randomly choosing one or more mutations, depending on the mutational 
scenario. The probability of a new mutant allele occurring is equal to the total fitness 
difference (∆fT) between the new allele and the precursor allele. In our simulations, a 
uniform random number (r) was selected. The new allele was accepted only if r<∆fT. A 
new mutant was only accepted if its fT value was larger than that of its precursor 
allele. To calculate pathway probabilities, we simulated 104 normal-distributed 
adaptive landscapes and explored each with 105 independent iterations. The pathway 
probability was then calculated from the formula Pi = Ni / Ntotal, where Pi is the 
probability that parasites evolve along pathway i, Ni is the number of times that the 
simulations achieve the EcuABCD allele by traversing pathway i, and Ntotal is the total 






Generation of a combinatorial panel of pfcrt alleles in isogenic P. 
falciparum parasites 
Surveys of PfCRT haplotypes in geographically distinct CQ-resistant isolates of P. 
falciparum indicate that CQR requires at least four mutations, namely K76T and at 
least three accompanying non-synonymous mutations.114 While this suggests that CQ-
resistant parasites necessitate compensatory mutations to maintain PfCRT function, 
several key questions remain unanswered: Which SNPs directly influence drug 
resistance, which neutralize fitness costs, and which contribute in both regards? Are 
there predictable mutational trajectories in the evolution of PfCRT-mediated drug 
resistance? To address these questions, our study centered on the CQ-resistant 
Ecuadorian pfcrt allele Ecu1110,186 which harbors four mutations and is therefore 
amenable to a comprehensive dissection of the genetic determinants of parasite drug 
resistance and fitness. 
 To perform a combinatorial analysis of pfcrt, we used ZFNs (Figure 2.1) to 
genetically engineer a series of intra-erythrocytic parasites encoding all 16 
combinations of the four mutations that comprise the Ecu1110 allele. These are K76T, 
A220S, N326D, and I356L, which we respectively refer to as EcuA, EcuB, EcuC, and 
EcuD, with the quadruple-SNP Ecu1110 haplotype represented as EcuABCD (Table 2.3). 
Due to the slow growth of the Ecu1110 parasite strain in culture, we chose to introduce 
the full set of combinatorial alleles into the South American recipient strain 7G8. This 
line is derived from a Brazilian clinical isolate303 and was recently used with success 





Figure 2.1. Zinc finger nuclease (ZFN)-mediated genomic modification of the pfcrt locus. Shown 
are schematics of the (A) parasite genome editing workflow and (B) pfcrt allelic replacement 
strategy. Briefly, parasites were transfected with a donor template plasmid (pcrt-hdhfr) comprising 
a compacted pfcrt coding sequence with mutations of interest (indicated in red), an adjacent P. 
berghei crt (pbcrt) 3′ UTR element, the human dhfr (hdhfr) selection cassette, as well as flanking 
left (~0.4 kb upstream of the intron 1-exon 2 boundary) and right (~1 kb native 3′ UTR) homology 
regions. A complete list of PfCRT haplotypes included in this study is found in Table 2.3. Parasites 
were subsequently transfected with pZFNcrt-bsd, which encodes the blasticidin S deaminase (bsd) 
selection cassette and facilitates 2A peptide-linked co-expression of ZFN monomers (ZFNL and 
ZFNR) via the calmodulin (cam) promoter. These ZFNs introduce a double-stranded DNA break in 
the intron 1-exon 2 boundary of pfcrt (indicated by red bolt). Homology-directed DNA repair yields 
the recombinant pfcrt locus, which is amenable to PCR-based screening due to the absence of 
pfcrt introns 2 through 12. Recombinant parasites were cloned by limiting dilution and sequenced 
at the DNA and RNA levels. (C) PCR-based verification of representative ZFN-edited (7G8Ecu1110 
and 7G87G8) parasites. Controls include parental parasites (7G8), unedited donor plasmid-
enriched parasites (7G8 + pcrt-hdhfr), and the donor plasmid alone (pcrt-hdhfr). Primer (p) 
locations are illustrated in panel B. ZFN-edited lines showed the expected band sizes of 0.4 kb 

































aMutations different from the GC03 (wild-type) 
PfCRT haplotype are indicated in gray. DNA 
substitutions encoding each PfCRT mutation are as 
follows: C72S: TGT→AGT; K76T: AAA→ACA; 








Table 2.3. Summary of PfCRT haplotypes.a 
 PfCRT residue 
PfCRT haplotype 72 76 220 326 356 
GC03 (WT) C K A N I 
EcuA C T A N I 
EcuB C K S N I 
EcuC C K A D I 
EcuD C K A N L 
EcuAB C T S N I 
EcuAC C T A D I 
EcuAD C T A N L 
EcuBC C K S D I 
EcuBD C K S N L 
EcuCD C K A D L 
EcuABC C T S D I 
EcuABD C T S N L 
EcuACD C T A D L 
EcuBCD C K S D L 
Ecu1110 (Ecu
ABCD
) C T S D L 




The highly prevalent, quintuple-SNP 7G8 PfCRT haplotype is distinguished from 
Ecu1110 PfCRT by one additional mutation (C72S; see Table 2.3) and was included in 
our allelic panel. This parasite line, 7G87G8 (recombinant pfcrt allele indicated in 
superscript), served as a control for ZFN-based modification of pfcrt and was 
comparable to genetically unedited 7G8 parasites with regard to CQ susceptibility and 
growth rates.  
 Our ZFN-based genetic engineering strategy is depicted in Figure 2.1A. 
Briefly, we constructed a donor plasmid for each combinatorial pfcrt allele (see Table 
2.3), which was transfected into 7G8 recipient parasites. Donor plasmid-enriched 
parasites were subsequently transfected with a plasmid encoding pfcrt-specific ZFNs 
that were previously validated.295 Homology-directed repair of DNA breaks catalyzed 
by these ZFNs yielded the recombinant pfcrt locus (Figure 2.1B). For each 
recombinant line, two individual clones were isolated for subsequent analysis. Genetic 
editing of the pfcrt locus was evaluated by diagnostic PCRs (Figure 2.1C), followed by 
sequencing of parasite gDNA and cDNA using primers listed in Table 2.1. 
Additionally, pfcrt sequence integrity was monitored in all recombinant parasite lines 
throughout the duration of all assays. Phenotypic differences between parasite strains 
were not attributable to levels of PfCRT expression (see Table 2.2).  
 
Effect of pfcrt combinatorial alleles on parasite CQ susceptibility 
To evaluate the contribution of PfCRT mutations to parasite resistance to CQ and its 
primary active metabolite, md-CQ, we subjected our panel of pfcrt-modified isogenic 
parasite lines to flow cytometry-based drug susceptibility assays and determined drug 




also analyzed the genetically unmodified reference lines GC03, Ecu1110, and 7G8 
(corresponding PfCRT haplotypes listed in Table 2.3). Antimalarial IC50 and IC90 
values are summarized in Table 2.4 and Table 2.5, respectively. For all strains tested, 
drug responses were compared against those of isogenic 7G8GC03 parasites, which 
encode the wild-type (GC03) pfcrt allele.  
 Our drug susceptibility findings for CQ (Figure 2.2A) and md-CQ (Figure 2.2B) 
revealed that the CQR-associated mutation K76T is insufficient for parasite CQR. 
Intriguingly, as compared to 7G8GC03 parasites, 7G8EcuA parasites exhibited significant 
md-CQ hypersensitivity (mean IC50 values of 20.9 and 15.1 nM, respectively; Table 
2.4), highlighting a critical role for mutations beyond K76T in conferring CQR. This 
is further corroborated by the md-CQ responses of multiple lines with PfCRT 
haplotypes lacking K76T (7G8EcuC, 7G8EcuD, 7G8EcuBC, 7G8EcuCD, 7G8EcuBCD), which 
showed modest (1.5 to 2.5-fold) yet significant elevations in md-CQ IC50 as compared 
to 7G8GC03 parasites (Figure 2.2B; Table 2.4). The reduced md-CQ susceptibility of 
these lines was accentuated at the IC90 level (Table 2.5). 
  To dissect the impact of specific SNPs on parasite drug resistance, we 
compared the drug responses of PfCRT haplotype pairs differing at only one residue. 
For every combinatorial PfCRT haplotype, we determined the successive contribution 
of each Ecu1110 PfCRT-specific SNP to CQ and md-CQ resistance (Table 2.6). We 
considered all instances in which mutational acquisition conferred a significant 
change in CQ or md-CQ IC50 values as compared to the precursor PfCRT haplotype. 
Invariably, in all such instances, EcuC N326D served to increase drug resistance. EcuD 
I356L similarly conferred increased drug resistance, with one exception 






Figure 2.2. Chloroquine resistance profiles of pfcrt-modified and reference parasite lines. Parasite 
growth inhibition was determined by flow cytometry after 72 h exposure to serial dilutions of (A) 
chloroquine (CQ), (B) monodesethyl-chloroquine (md-CQ), or (C) CQ in the presence or absence 
of 0.8 μM verapamil (VP). Bar graphs represent (A and B) mean ± SEM IC50 values or (C) mean 
± SEM CQ response modification index (RMI) values, equivalent to (IC50 for CQ+VP) ÷ (IC50 for 
CQ only). Results encompass 5 to 15 independent assays conducted in duplicate. Statistical 
differences were determined via non-parametric Mann-Whitney U tests, using the mean IC50 value 
of wild-type pfcrt-expressing 7G8GC03 parasites (dotted black line) as the comparator. The total 
number of pfcrt mutations encoded by parasite lines is indicated in gray. When applicable, the y-
axis was split to illustrate subtle, statistically significant differences in IC50 values. IC50, IC90, and 
CQ RMI values are summarized along with corresponding statistical tests in Table 2.4, Table 2.5, 





Table 2.4. Antimalarial IC50 values of pfcrt-modified and reference parasite lines.a 
Line  CQ IC50 CQ+VP IC50 md-CQ IC50 md-AQ IC50 LUM IC50 AS IC50 
7G8GC03 
IC50 14.2 ± 0.9 16.5 ± 0.9 20.9 ± 1.0 18.1 ± 1.0 0.90 ± 0.10 1.32 ± 0.08 
n 15 15 15 15 13 17 
P –  – – – – – 
7G8EcuA 
IC50 11.3 ± 0.7 11.8 ± 0.5 15.1 ± 1.6 20.8 ± 0.9 0.68 ± 0.10 0.83 ± 0.09 
n 5 5 5 5 6 6 
P 0.076 0.010 0.010 0.22 0.27 0.0026 
7G8EcuB 
IC50 13.9 ± 1.4 15.5 ± 1.0 22.5 ± 2.2 20.2 ± 1.7 1.12 ± 0.12 1.38 ± 0.16 
n 5 5 5 5 6 6 
P 0.72 0.63 0.56 0.26 0.20 0.61 
7G8EcuC 
IC50 16.6 ± 1.6 20.8 ± 0.6 52.1 ± 3.2 26.1 ± 0.8 0.94 ± 0.11 1.39 ± 0.12 
n 5 5 5 5 6 6 
P 0.17 0.015 0.0001 0.0003 0.78 0.93 
7G8EcuD 
IC50 16.5 ± 1.8 19.4 ± 0.9 31.6 ± 3.8 19.1 ± 1.4 1.31 ± 0.20 1.43 ± 0.17 
n 5 5 5 5 6 6 
P 0.17 0.098 0.0037 0.67 0.044 0.44 
7G8EcuAB 
IC50 10.2 ± 0.8 11.8 ± 1.2 10.8 ± 0.8 17.9 ± 1.1 0.86 ± 0.11 0.80 ± 0.07 
n 5 5 5 5 4 5 
P 0.010 0.014 0.0001 0.82 0.93 0.0009 
7G8EcuAC 
IC50 8.7 ± 0.6 8.0 ± 0.8 33.2 ± 1.9 24.6 ± 2.6 0.62 ± 0.09 0.64 ± 0.06 
n 5 5 5 5 4 5 
P 0.0001 0.0001 0.0003 0.042 0.056 < 0.0001 
7G8EcuAD 
IC50 14.6 ± 0.9 15.9 ± 1.1 26.7 ± 1.8 24.0 ± 1.4 0.71 ± 0.07 1.19 ± 0.12 
n 5 5 5 5 4 5 
P 0.40 0.82 0.011 0.0077 0.30 0.32 
7G8EcuBC 
IC50 15.2 ± 1.3 17.9 ± 1.4 38.3 ± 1.9 27.1 ± 2.4 0.80 ± 0.11 1.30 ± 0.15 
n 5 5 5 5 4 5 
P 0.31 0.44 0.0001 0.0005 0.84 0.80 














Table 2.4. continued 
Line  CQ IC50 CQ+VP IC50 md-CQ IC50 md-AQ IC50 LUM IC50 AS IC50 
7G8EcuBD 
IC50 13.8 ± 0.9 16.9 ± 1.5 16.1 ± 1.0 20.0 ± 0.9 1.20 ± 0.13 1.34 ± 0.13 
n 5 5 5 5 4 5 
P 0.80 0.73 0.024 0.55 0.16 0.82 
7G8EcuCD 
IC50 15.4 ± 1.3 18.8 ± 1.7 38.9 ± 1.9 28.0 ± 3.1 0.75 ± 0.07 1.30 ± 0.13 
n 5 5 5 5 4 5 
P 0.27 0.31 0.0001 0.0015 0.64 0.97 
7G8EcuABC 
IC50 19.8 ± 2.1 16.0 ± 1.9 111 ± 8.6 44.6 ± 5.5 0.44 ± 0.07 0.68  ± 0.06 
n 5 5 5 5 4 6 
P 0.020 0.82 0.0001 0.0001 0.010 < 0.0001 
7G8EcuABD 
IC50 19.4 ± 1.9 21.7 ± 2.1 52.4 ± 2.7 23.8 ± 1.0 0.69 ± 0.10 1.44 ± 0.10 
n 5 5 5 5 4 6 
P 0.019 0.042 0.0001 0.0054 0.60 0.60 
7G8EcuACD 
IC50 26.7 ± 1.9 16.9 ± 2.4 176 ± 9.9 60.8 ± 2.5 0.62 ± 0.04 0.98 ± 0.07 
n 5 5 5 5 4 6 
P 0.0005 0.95 0.0001 0.0001 0.12 0.037 
7G8EcuBCD 
IC50 16.7 ± 1.9 18.7 ± 2.4 33.4 ± 1.6 25.2 ± 1.1 0.78 ± 0.11 1.63 ± 0.10 
n 5 5 5 5 4 6 
P 0.20 0.50 0.0005 0.0005 0.76 0.019 
7G8EcuABCD 
IC50 75.2 ± 7.5 46.9 ± 2.7 455 ± 44.3 113 ± 6.1 0.81 ± 0.14 0.79 ± 0.09 
n 5 5 5 5 6 6 
P 0.0001 0.0001 0.0001 0.0001 0.65 0.0013 
7G87G8 
IC50 137 ± 7.7 89.4 ± 5.1 634 ± 30.1 154 ± 5.8 0.64 ± 0.06 0.89 ± 0.05 
n 15 15 15 15 13 17 
P < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.023 < 0.0001 
GC03 
IC50 17.0 ± 2.2 19.9 ± 2.7 20.9 ± 1.6 19.2 ± 1.7 1.99 ± 0.10 1.44 ± 0.10 
n 5 5 5 5 4 6 
P 0.23 0.27 0.93 0.57 0.0008 0.40 


































Table 2.4. continued 
Line  CQ IC50 CQ+VP IC50 md-CQ IC50 md-AQ IC50 LUM IC50 AS IC50 
Ecu1110 
IC50 79.3 ± 6.5 64.4 ±7.6 370 ± 15.0 86.1 ± 4.0 1.22 ± 0.21 0.96 ± 0.08 
n 5 5 5 5 4 6 
P 0.0001 0.0001 0.0001 0.0001 0.26 0.038 
7G8 
IC50 160 ± 16.1 102 ± 9.1 749 ± 54.4 174 ± 10.2 0.54 ± 0.07 0.69 ± 0.08 
n 5 5 5 5 6 6 
P 0.0001 0.0001 0.0001 0.0001 0.0087 0.0001 
 
aIC50 values (nM) indicate the mean IC50 ± SEM, as determined in 4 to 17 independent assays. CQ + VP assays were performed with 0.8 μM 
VP. CQ, chloroquine; VP, verapamil; md-CQ, monodesethyl-chloroquine; md-AQ, monodesethyl-amodiaquine; LUM, lumefantrine; AS, 
artesunate;  n, number of assays; P, P value, as determined in a non-parametric Mann-Whitney U test versus the wild-type pfcrt-encoding 









Table 2.5. Antimalarial IC90 values of pfcrt-modified and reference parasite lines.a 
Line  CQ IC90 CQ+VP IC90 md-CQ IC90 md-AQ IC90 LUM IC90 AS IC90 
7G8GC03 
IC90 25.4 ± 1.8 31.9 ± 2.2 40.5 ± 2.7 29.1 ± 1.3 3.77 ± 0.20 3.71 ± 0.18 
n 15 15 15 15 14 17 
P – – – – – – 
7G8EcuA 
IC90 25.6 ± 2.8 27.7 ± 1.1 39.5 ± 4.8 33.9 ± 4.4 3.21 ± 0.41 2.60 ± 0.34 
n 5 5 5 5 6 6 
P 0.93 0.41 0.95 0.40 0.11 0.0095 
7G8EcuB 
IC90 27.1 ± 1.8 29.3 ± 0.3 44.5 ± 5.1 33.2 ± 3.8 3.92 ± 0.28 3.56 ± 0.47 
n 5 5 5 5 6 6 
P 0.45 0.92 0.61 0.40 0.66 0.99 
7G8EcuC 
IC90 30.8 ± 1.5 36.8 ± 2.8 111 ± 7.3 50.6 ± 5.5 3.87 ± 0.27 3.64 ± 0.40 
n 5 5 5 5 6 6 
P 0.066 0.042 0.0001 0.0005 0.84 0.91 
7G8EcuD 
IC90 30.5 ± 2.1 30.7 ± 0.4 56.4 ± 3.8 32.4 ± 3.0 4.81 ± 0.73 3.92 ± 0.51 
n 5 5 5 5 6 6 
P 0.14 0.23 0.015 0.36 0.27 0.55 
7G8EcuAB 
IC90 21.5 ± 3.2 27.1 ± 3.9 29.5 ± 2.9 31.9 ± 2.4 2.97 ± 0.46 2.22 ± 0.19 
n 5 5 5 5 4 5 
P 0.25 0.18 0.014 0.44 0.082 0.0003 
7G8EcuAC 
IC90 25.3 ± 2.1 25.3 ± 1.1 111 ± 9.4 57.0 ± 3.0 2.77 ± 0.39 2.60 ± 0.82 
n 5 5 5 5 4 5 
P 0.93 0.024 0.0001 0.0001 0.043 0.046 
7G8EcuAD 
IC90 29.2 ± 1 33.5 ± 2.6 57.8 ± 4.4 33.5 ± 2.7 3.96 ± 0.26 3.29 ± 0.32 
n 5 5 5 5 4 5 
P 0.20 0.23 0.008 0.080 0.80 0.44 
7G8EcuBC 
IC90 31.4 ± 2.3 38.5 ± 3.8 91 ± 10.3 43.1 ± 4.3 4.30 ± 0.32 3.32 ± 0.32 
n 5 5 5 5 4 5 
P 0.081 0.14 0.0003 0.0009 0.10 0.26 













Table 2.5. continued 
Line  CQ IC90 CQ+VP IC90 md-CQ IC90 md-AQ IC90 LUM IC90 AS IC90 
7G8EcuBD 
IC90 27.7 ± 0.9 32.2 ± 3.7 36.1 ± 3.1 30.7 ± 1.1 4.66 ± 0.28 3.58 ± 0.15 
n 5 5 5 5 4 5 
P 0.44 0.80 0.46 0.31 0.046 0.75 
7G8EcuCD 
IC90 31.5 ± 2.3 38.6 ± 2.9 79.3 ± 7.9 40.2 ± 5.3 4.36 ± 0.65 3.65 ± 0.25 
n 5 5 5 5 4 5 
P 0.12 0.17 0.0001 0.0037 0.44 0.93 
7G8EcuABC 
IC90 45.2 ± 6.2 47.1 ± 3.8 377 ± 58.7 117 ± 13.0 1.96 ± 0.15 2.17 ± 0.31 
n 5 5 5 5 4 6 
P 0.0054 0.0077 0.0001 0.0001 0.0007 0.0012 
7G8EcuABD 
IC90 40.7 ± 4.7 47.1 ± 6.5 125 ± 9.1 47.4 ± 4.3 3.57 ± 0.21 3.26 ± 0.22 
n 5 5 5 5 4 6 
P 0.0054 0.011 0.0001 0.0005 0.53 0.22 
7G8EcuACD 
IC90 70.8 ± 9.1 52.9 ± 5.2 475 ± 25.6 130 ± 13.2 2.40 ± 0.15 2.34 ± 0.17 
n 5 5 5 5 4 6 
P 0.0001 0.0025 0.0001 0.0001 0.0046 0.0001 
7G8EcuBCD 
IC90 35.7 ± 3.7 42.0 ± 5.6 85.5 ± 12.4 51.3 ± 2.8 3.61 ± 0.15 3.77 ± 0.22 
n 5 5 5 5 4 6 
P 0.033 0.019 0.0003 0.0003 0.56 0.85 
7G8EcuABCD 
IC90 170 ± 21.9 115 ± 3.6 1005 ± 64.0 245 ± 28.0 3.36 ± 0.41 2.84 ± 0.47 
n 5 5 5 5 6 6 
P 0.0001 0.0001 0.0001 0.0001 0.47 0.090 
7G87G8 
IC90 289 ± 17.3 212 ± 11.2 1392 ± 88.1 282 ± 14.8 3.42 ± 0.30 2.60 ± 0.17 
n 15 15 15 15 14 17 
P < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.12 < 0.0001 
GC03 
IC90 30.3 ± 3.3 39.6 ± 5.4 45.1 ± 4.5 27.3 ± 1.3 8.27 ± 0.11 4.51 ± 0.25 
n 5 5 5 5 4 6 
P 0.20 0.27 0.35 0.45 0.0007 0.029 


































Table 2.5. continued 
Line  CQ IC90 CQ+VP IC90 md-CQ IC90 md-AQ IC90 LUM IC90 AS IC90 
Ecu1110 
IC90 187 ± 20.5 164 ± 19.4 881 ± 28.6 167 ± 14.1 5.49 ± 0.98 3.29 ± 0.38 
n 5 5 5 5 4 6 
P 0.0001 0.0001 0.0001 0.0001 0.061 0.46 
7G8 
IC90 309 ± 40.5 226 ± 9.0 1509 ± 160 312 ± 32.8 2.22 ± 0.16 2.46 ± 0.48 
n 5 5 5 5 6 6 
P 0.0001 0.0001 0.0001 0.0001 0.0002 0.023 
 
aIC90 values (nM) indicate the mean IC90 ± SEM, as determined in 4 to 17 independent assays. CQ + VP assays were performed with 0.8 μM 
VP. CQ, chloroquine; VP, verapamil; md-CQ, monodesethyl-chloroquine; md-AQ, monodesethyl-amodiaquine; LUM, lumefantrine; AS, 
artesunate;  n, number of assays; P, P value, as determined in a non-parametric Mann-Whitney U test versus the wild-type pfcrt-encoding 









Table 2.6. Successive contributions of Ecu1110 PfCRT mutations to CQ resistance.a 
Preceding  
haplotype 
 + K76T (EcuA) + A220S (EcuB) + N326D (EcuC) + I356L (EcuD) 
GC03 
(WT) 
Succeeding haplotype EcuA EcuB EcuC EcuD 
CQ IC50 ns ns ns ns 
md-CQ IC50 ↓ (*) ns ↑ (***) ↑ (**) 
EcuA 
Succeeding haplotype  EcuAB EcuAC EcuAD 
CQ IC50 – ns ns ↑ (*) 
md-CQ IC50  ↓ (*) ↑ (**) ↑ (**) 
EcuB 
Succeeding haplotype EcuAB  EcuBC EcuBD 
CQ IC50 ↓ (*) – ns ns 
md-CQ IC50 ↓ (**)  ↑ (**) ns 
EcuC 
Succeeding haplotype EcuAC EcuBC  EcuCD 
CQ IC50 ↓ (**) ns – ns 
md-CQ IC50 ↓ (**) ↓ (*)  ↓ (*) 
EcuD 
Succeeding haplotype EcuAD EcuBD EcuCD  
CQ IC50 ns ns ns – 
md-CQ IC50 ns ↓ (**) ns  
EcuAB 
Succeeding haplotype   EcuABC EcuABD 
CQ IC50 – – ↑ (**) ↑ (**) 
md-CQ IC50   ↑ (**) ↑ (**) 
EcuAC 
Succeeding haplotype  EcuABC  EcuACD 
CQ IC50 – ↑ (**) – ↑ (**) 
md-CQ IC50  ↑ (**)  ↑ (**) 
EcuAD 
Succeeding haplotype  EcuABD EcuACD  
CQ IC50 – ns ↑ (**) – 
md-CQ IC50  ↑ (**) ↑ (**)  
     (continued) 
 
 











Table 2.6. continued 
Preceding  
haplotype 
 + K76T (EcuA) + A220S (EcuB) + N326D (EcuC) + I356L (EcuD) 
EcuBC 
Succeeding haplotype EcuABC   EcuBCD 
CQ IC50 ns – – ns 
md-CQ IC50 ↑ (**)   ns 
EcuBD 
Succeeding haplotype EcuABD  EcuBCD  
CQ IC50 ↑ (*) – ns – 
md-CQ IC50 ↑ (**)  ↑ (**)  
EcuCD 
Succeeding haplotype EcuACD EcuBCD   
CQ IC50 ↑ (**) ns – – 
md-CQ IC50 ↑ (**) ns   
EcuABC 
Succeeding haplotype    EcuABCD 
CQ IC50 – – – ↑ (**) 
md-CQ IC50    ↑ (**) 
EcuABD 
Succeeding haplotype   EcuABCD  
CQ IC50 – – ↑ (**) – 
md-CQ IC50   ↑ (**)  
EcuACD 
Succeeding haplotype  EcuABCD   
CQ IC50 – ↑ (**) – – 
md-CQ IC50  ↑ (**)   
EcuBCD 
Succeeding haplotype EcuABCD    
CQ IC50 ↑ (**) – – – 
md-CQ IC50 ↑ (**)    
 
aChloroquine (CQ) and monodesethyl-chloroquine (md-CQ) IC50 values (Table 2.4) were subjected to non-parametric Mann-Whitney U 
tests to determine whether acquisition of the indicated Ecu1110 PfCRT mutation by a precursor PfCRT haplotype caused a significant 
increase (↑) or decrease (↓) in the IC50 value of the succeeding haplotype. Significant (P<0.05) differences are shaded in grey. PfCRT 








In contrast, EcuB A220S only increased resistance in the context of triple-SNP PfCRT 
haplotypes, while conferring decreased md-CQ resistance for double-SNP haplotypes. 
The mutational milieu was likewise important for EcuA K76T, which decreased drug 
resistance for haplotypes leading up to the triple-SNP stage, at which point it 
conferred increased resistance. In addition, as compared to EcuABCD, we observed 
significantly increased CQ (Figure 2.2A; P<0.001) and md-CQ (Figure 2.2B; P<0.01) 
IC50 values for 7G8 PfCRT, indicating a direct role for C72S, the sole distinction 
between these two haplotypes (see Table 2.3). 
  A characteristic trait of in vitro parasite CQR is its reversibility by VP, which 
was previously linked to the parasite pfcrt locus via quantitative trait loci mapping.280 
To examine the roles of specific pfcrt mutations on VP reversibility of CQR, we 
assessed parasite susceptibility to CQ in the presence or absence of 0.8 μM VP and 
computed the CQ response modification index (RMI), defined as the ratio between the 
IC50 for CQ plus VP and the IC50 for CQ alone (Figure 2.2C; Table 2.7). Consistent 
with published VP reversibility profiles,133 Ecu1110 and 7G8 reference parasites 
exhibited comparable VP chemosensitization of CQR (1.5 to 1.9-fold reductions in CQ 
RMI relative to the CQ-sensitive line GC03). This finding was recapitulated by 
isogenic parasites expressing the corresponding pfcrt alleles (1.7 to 1.8-fold reductions 
in CQ RMI for 7G8EcuABCD and 7G87G8 relative to 7G8GC03). Moreover, we noted direct 
roles for K76T and N326D in the VP reversibility effect, as the mutational acquisition 
of EcuA K76T by the EcuBCD PfCRT haplotype and the acquisition of EcuC N326D by 
the EcuABD haplotype both conferred VP-reversible CQR to parasites encoding the 





Table 2.7. Verapamil-mediated CQ resistance reversibility of pfcrt-modified and reference parasite lines.a 
Line    Line    Line   
7G8GC03 
RMI 1.18 ± 0.05  
7G8EcuAD 
RMI 1.09 ± 0.04  
7G8EcuBCD 
RMI 1.13 ± 0.07 
n 15  n 5  n 5 
P –  P 0.60  P 0.82 
7G8EcuA 
RMI 1.06 ± 0.04  
7G8EcuBC 
RMI 1.18 ± 0.05  
7G8EcuABCD 
RMI 0.64 ± 0.05 
n 5  n 5  n 5 
P 0.11  P 0.92  P 0.0001 
7G8EcuB 
RMI 1.14 ± 0.06  
7G8EcuBD 
RMI 1.22 ± 0.05  
7G87G8 
RMI 0.70 ± 0.02 
n 5  n 5  n 15 
P 0.38  P 0.60  P < 0.0001 
7G8EcuC 
RMI 1.28 ± 0.13  
7G8EcuCD 
RMI 1.22 ± 0.06  
GC03 
RMI 1.17 ± 0.05 
n 5  n 5  n 5 
P 0.82  P 0.69  P 0.85 
7G8EcuD 
RMI 1.24 ± 0.11  
7G8EcuABC 
RMI 0.81 ± 0.07  
Ecu1110 
RMI 0.81 ± 0.06 
n 5  n 5  n 5 
P 0.92  P 0.0002  P 0.0015 
7G8EcuAB 
RMI 1.15 ± 0.03  
7G8EcuABD 
RMI 1.12 ± 0.05  
7G8 
RMI 0.62 ± 0.05 
n 5  n 5  n 5 
P 0.85  P 0.48  P 0.0001 
7G8EcuAC 
RMI 0.91 ± 0.07  
7G8EcuACD 
RMI 0.62 ± 0.06     
n 5  n 5  
 
  
P 0.0086  P 0.0001    
 
aReversibility of chloroquine (CQ) resistance by 0.8 µM verapamil (VP) is indicated as the CQ response modification index (RMI), 
equivalent to (IC50 for CQ+VP) ÷ (IC50 for CQ only). Shown are mean RMI ± SEM values, as determined in 5 to 15 independent assays. 
n, number of assays; P, P value, as determined in a non-parametric Mann-Whitney U test versus the parasite line 7G8GC03. P values 








Effect of pfcrt combinatorial alleles on parasite susceptibility to ACT 
component drugs 
In view of the role of PfCRT as a determinant of parasite multidrug resistance,114 we 
investigated the influence of combinatorial PfCRT haplotypes on parasite 
susceptibility to the artemisinin compound AS and the ACT partner drugs AQ and 
LUM (Figure 2.3), which comprise the widely used ACT formulations AS-AQ and 
ATM-LUM.180 The quinoline-type antimalarial AQ is of particular interest due to its 
historical use in regions with parasites harboring the Ecu1110 and 7G8 pfcrt alleles.259 
Focusing on the clinically relevant metabolite of AQ, md-AQ, we observed substantial 
overlap between parasites’ susceptibility to md-AQ (Figure 2.3A; Table 2.4) and md-
CQ (Figure 2.2B; Table 2.4). This is consistent with cross-resistance between CQ and 
AQ that is mediated in part by PfCRT variants.114 Similar to our results for CQ, K76T 
was insufficient to confer md-AQ resistance (Figure 2.3A; Table 2.4). Of note, an 
important role in mediating md-AQ resistance was uncovered for EcuC N326D, as 
acquisition of N326D by any PfCRT haplotype lacking this mutation consistently 
conferred elevated md-AQ IC50 and/or IC90 values (Tables 2.4–2.5). As 7G87G8 
parasites showed significantly higher md-AQ IC50 values than 7G8EcuABCD parasites 
(P<0.01), we also identified a contributory role for PfCRT C72S in md-AQ resistance.  
 Treatment of parasite lines with the arylaminoalcohol drug LUM yielded more 
subtle differences in drug responses (Figure 2.3B; Table 2.4). Compared to the 7G8GC03 
line, we observed a modest (1.4-fold), although significant, increase in LUM 
susceptibility for 7G87G8 parasites, in line with previous reports that CQ-resistant 






Figure 2.3. Susceptibility of pfcrt-modified and reference parasite lines to first-line antimalarial 
compounds monodesethyl-amodiaquine (md-AQ), lumefantrine (LUM), and artesunate (AS). 
Parasite growth inhibition was determined by flow cytometry after 72 h exposure to serial 
dilutions of (A) md-AQ, (B) LUM, or (C) AS. Bar graphs indicate mean IC50 values ± SEM, as 
determined in 4 to 17 independent assays conducted in duplicate. Statistical differences were 
determined via non-parametric Mann-Whitney U tests, using the mean IC50 value of wild-type 
pfcrt-expressing 7G8GC03 parasites (dotted black line) as the comparator. The total number of 
pfcrt mutations encoded by parasite lines is indicated in gray. When applicable, the y-axis was 
split to illustrate subtle, statistically significant differences in IC50 values. IC50 and IC90 values, 
numbers of assays, and corresponding statistical tests are summarized in Tables 2.4-2.5. 




constricted range of observed LUM IC50 values to the high sensitivity of the 7G8 
genetic background to LUM at baseline.243 Our LUM susceptibility findings 
nevertheless illustrate that pfcrt mutations exert opposing forces on parasite LUM 
resistance (e.g. 7G8EcuABC and 7G8EcuD respectively showed elevated and reduced LUM 
IC50 values, as compared to 7G8GC03; Figure 2.3B; Table 2.4).  
 Consistent with previous in vitro investigations,120 our collection of 
combinatorial pfcrt alleles modulated parasite susceptibility to the artemisinin 
compound AS (Figure 2.3C; Table 2.4). As anticipated, full-length mutant pfcrt alleles 
significantly increased AS sensitivity (1.5 to 1.7-fold decrease in AS IC50 for 7G8EcuABCD 
and 7G87G8 as compared to 7G8GC03). Interestingly, K76T was sufficient to confer 
increased parasite AS sensitivity (1.6-fold decrease in AS IC50 for 7G8EcuA versus 
7G8GC03). Additionally, increased parasite AS resistance was afforded upon acquisition 
of EcuD I356L, with two distinct mutational trajectories (EcuAB→EcuABD and 
EcuAC→EcuACD; Figure 2.3C; Table 2.4) conferring significant elevations in AS IC50 
values (P<0.01 and P<0.05, respectively). 
 
Effect of pfcrt combinatorial alleles on in vitro parasite growth 
As organisms acquire mutations in response to drug pressure, they experience fitness 
constraints that affect the course of their adaptive evolution. Accordingly, we 
evaluated the impact of our set of combinatorial pfcrt alleles on the in vitro growth of 
intra-erythrocytic parasites, which serves as a proxy for fitness.239,240 To initiate the 
growth assays, we seeded co-cultures with equal (1:1) proportions of CQ-sensitive 
(wild-type pfcrt) GFP-positive (GFP+) reporter parasites and pfcrt-modified GFP-




presence of a sub-lethal dose of CQ (7.5 nM; 0.5×CQ IC50 of CQ-sensitive reporter line). 
Using flow cytometry, we regularly determined the proportion of co-culture expressing 
the test pfcrt allele (GFP– parasite population). The relative proportions of parasite 
populations were recorded every third day for 10 generations (Figure 2.4A), natural 
log-transformed (Figure 2.4B), and subjected to a linear regression analysis.239,243 To 
quantify parasite fitness costs, we derived the relative fitness (ω') of a given parasite 
line as compared to isogenic, wild-type pfcrt-expressing parasites (7G8GC03) in the 
absence of drug pressure and computed the per-generation selection coefficient (s) for 
each line as per the relationship s=ω'–1. Thus, as compared to the wild-type pfcrt 
allele, s=0, s>0, and s<0 signify alleles that are selectively neutral, advantageous, and 
disadvantageous, respectively.  
 As compared to the 7G8GC03 parasite line, our isogenic, pfcrt-modified parasites 
exhibited various degrees of in vitro fitness (range of mean s values: -0.26 to 0.11), 
with the majority of pfcrt alleles conferring comparable (s=0) or inferior (s<0) relative 
fitness (Figure 2.5; Table 2.8). A notable exception was the EcuAD haplotype, which 
demonstrated significantly enhanced relative fitness (s=0.07 to 0.11, i.e. 7% to 11% 
growth advantage per parasite generation). Although we did not observe a selective 
advantage for any pfcrt alleles in the presence of 7.5 nM CQ, this sub-therapeutic CQ 
concentration had a significantly deleterious impact on the growth of parasites 
encoding haplotypes EcuA, EcuC, and EcuAB (Figure 2.5; Table 2.8). Notably, in this 
genetic background, PfCRT K76T was insufficient for CQ resistance and had a 
deleterious impact on parasite growth that was exacerbated by CQ. Interestingly, 
expression of the full-length Ecu1110 PfCRT haplotype in the Ecu1110 genetic 





Figure 2.4. In vitro asexual blood stage growth data for pfcrt-modified and reference parasites. 
Co-cultures consisting of equal proportions of a single GFP-negative (GFP–) test line and a GFP-
positive (GFP+) reporter line (RGFP) were initiated at day 0 and monitored by flow cytometry for 10 
parasite generations. Three independent assays were conducted in duplicate in the absence or 
presence of a sub-lethal dose of CQ (7.5 nM; 0.5×CQ IC50 of the CQ-sensitive RGFP line). (A) Plots 
of mean ± SEM proportions of the GFP– test (pfcrt-modified or reference) line (p) as a function of 
time (t, equivalent to number of parasite generations). GFP+ (RGFP only) and GFP– (7G87G8 only) 
controls were included and showed levels of fluorescence that were consistent across time. (B) 
Plots of mean ± SEM natural log-transformed ratios of the GFP– test line to the GFP+ reporter line 
at time t (pt/qt) for each co-culture. These parameters were used to derive the in vitro growth 











Figure 2.5. In vitro growth of pfcrt-modified and reference parasite lines. To assess parasite in 
vitro growth, co-cultures initially consisting of a 1:1 ratio of a single GFP– test (recombinant or 
reference) line and a GFP+ reporter line (RGFP) were monitored by flow cytometry for 10 
generations. Three independent assays were conducted in duplicate in the absence or presence 
of a sub-lethal dose of chloroquine (CQ; 7.5 nM, equivalent to 0.5×CQ IC50 of CQ-sensitive RGFP 
line). The per-generation selection coefficient (s) for each test strain was derived from parasite 
growth curves (see Figure 2.4). Shown are mean ± SEM s values for lines subjected to no drug 
or 7.5 nM CQ. The total number of pfcrt mutations encoded by parasite lines is indicated in gray. 
Mean s values, as well as results of inter-strain and intra-strain statistical tests are summarized 









Table 2.8. In vitro growth selection coefficients of pfcrt-modified and reference parasite lines.a 
Line  No drug 7.5 nM CQ Line  No drug 7.5 nM CQ Line  No drug 7.5 nM CQ 
7G8GC03 
s 0.00 ± 0.011 -0.01 ± 0.008 
7G8EcuAD 
s 0.11 ± 0.011 0.07 ± 0.011 
7G8EcuBCD 
s -0.05 ± 0.013 -0.08 ± 0.009 
P1 – – P1 < 0.0001 < 0.0001 P1 0.011 < 0.0001 
P2 > 0.99 P2 0.081 P2 0.26 
7G8EcuA 
s -0.08 ± 0.010 -0.15 ± 0.006 
7G8EcuBC 
s -0.03 ± 0.010 -0.07 ± 0.010 
7G8EcuABCD 
s -0.14 ± 0.009 -0.15 ± 0.011 
P1 < 0.0001 < 0.0001 P1 0.2563 0.0002 P1 < 0.0001 < 0.0001 
P2 < 0.0001 P2 0.11 P2 > 0.99 
7G8EcuB 
s -0.01 ± 0.011 -0.04 ± 0.009 
7G8EcuBD 
s 0.04 ± 0.010 0.01 ± 0.012 
7G87G8 
s -0.05 ± 0.009 -0.05 ± 0.009 
P1 > 0.99 0.74 P1 0.17 0.95 P1 0.013 0.069 
P2 0.56 P2 0.73 P2 > 0.99 
7G8EcuC 
s -0.01 ± 0.011 -0.06 ± 0.012 
7G8EcuCD 
s -0.05 ± 0.010 -0.09 ± 0.009 
GC03 
s 0.07 ± 0.010 0.06 ± 0.010 
P1 > 0.99 0.026 P1 0.0064 < 0.0001 P1 < 0.0001 < 0.0001 
P2 0.018 P2 0.095 P2 0.99 
7G8EcuD 
s -0.01 ± 0.012 -0.03 ± 0.011 
7G8EcuABC 
s -0.22 ± 0.006 -0.25 ± 0.007 
Ecu1110 
s -0.28 ± 0.009 -0.29 ± 0.009 
P1 0.99 0.81 P1 < 0.0001 < 0.0001 P1 < 0.0001 < 0.0001 
P2 0.96 P2 0.91 P2 > 0.99 
7G8EcuAB 
s -0.14 ± 0.009 -0.20 ± 0.008 
7G8EcuABD 
s -0.01 ± 0.013 -0.04 ± 0.010 
7G8 
s -0.09 ± 0.010 -0.07 ± 0.012 
P1 < 0.0001 < 0.0001 P1 0.99 0.52 P1 < 0.0001 0.0002 
P2 0.0005 P2 0.72 P2 0.99 
7G8EcuAC 
s -0.23 ± 0.008 -0.26 ± 0.007 
7G8EcuACD 
s -0.17 ± 0.007 -0.19 ± 0.008 
 
   
P1 < 0.0001 < 0.0001 P1 < 0.0001 < 0.0001    
P2 0.17 P2 0.99    
 
aParasite in vitro growth was evaluated in the absence or presence of a sub-lethal dose of CQ (7.5 nM; 0.5×CQ IC50 of the CQ-sensitive 
reference line 7G8GC03) and normalized against 7G8GC03 in the absence of drug pressure (6 total replicates per condition). The per-generation 
selection coefficient (indicated above as s ± SEM) was derived from the relative fitness index (ω') as per the relationship s = ω' – 1, such that 
s<0 and s>0 respectively indicate growth inferior or superior to the 7G8GC03 parasite line, which encodes wild-type pfcrt. CQ, chloroquine; P1, 
P value for inter-strain comparisons, determined versus the parasite line 7G8GC03 using two-way ANOVA with Sidak’s post-hoc test; P2, P value 
for intra-strain comparisons, determined for a given parasite strain in the absence versus presence of 7.5 nM CQ using two-way ANOVA with 








as compared to the 7G8 background (14% per-generation growth disadvantage for 
Ecu1110 versus 7G8Ecu1110 parasites, regardless of CQ pressure; P<0.0001). This 
suggests the presence of additional fitness-enhancing genetic factors in the 7G8 
genetic background.   
  We further examined the specific contribution of PfCRT SNPs to parasite 
growth by identifying all instances in which mutational acquisition conferred a 
significant change in growth as compared to the precursor PfCRT haplotype (Table 
2.9). In all such cases, K76T, A220S, and N326D (EcuA, EcuB, and EcuC, respectively) 
had a deleterious impact on parasite growth, with a single exception for EcuA K76T 
(increased growth for EcuD→EcuAD; see Table 2.9). In contrast, EcuD I356L 
consistently increased in vitro growth. Additionally, as compared to EcuABCD, 7G8 
PfCRT conferred enhanced in vitro growth (10% growth advantage per generation for 
7G87G8 versus 7G8EcuABCD parasites, regardless of CQ pressure; P<0.0001). Thus, in 
this genetic background, the 7G8 hallmark mutation C72S (see Table 2.3) positively 
contributed to both parasite drug resistance and growth rate.  
 
Modeling the evolution of pfcrt-mediated CQR 
The course of P. falciparum drug resistance evolution is shaped by the adaptive 
landscapes parasites traverse as they acquire drug resistance mutations. To further 
explore pfcrt adaptive landscapes, we employed a modified computational model 
based on previously established algorithms.165,248,302 Briefly, experimentally derived 
drug resistance and growth data for isogenic parasites encoding all pfcrt alleles 
spanning the transition from CQ-sensitive (wild-type; GC03) to CQ-resistant 




Table 2.9. Successive contributions of Ecu1110 PfCRT mutations to in vitro parasite growth.a 
Preceding  
haplotype 
 + K76T (EcuA) + A220S (EcuB) + N326D (EcuC) + I356L (EcuD) 
GC03 
(WT) 
Succeeding haplotype EcuA EcuB EcuC EcuD 
No drug ↓ (****) ns ns ns 
7.5 nM CQ ↓ (****) ns ns ns 
EcuA 
Succeeding haplotype  EcuAB EcuAC EcuAD 
No drug – ↓ (**) ↓ (****) ↑ (****) 
7.5 nM CQ  ↓ (*) ↓ (****) ↑ (****) 
EcuB 
Succeeding haplotype EcuAB  EcuBC EcuBD 
No drug ↓ (****) – ns ns 
7.5 nM CQ ↓ (****)  ns ns 
EcuC 
Succeeding haplotype EcuAC EcuBC  EcuCD 
No drug ↓ (****) ns – ns 
7.5 nM CQ ↓ (****) ns  ns 
EcuD 
Succeeding haplotype EcuAD EcuBD EcuCD  
No drug ↑ (****) ns ns – 
7.5 nM CQ ↑ (****) ns ↓ (*)  
EcuAB 
Succeeding haplotype   EcuABC EcuABD 
No drug – – ↓ (****) ↑ (****) 
7.5 nM CQ   ns ↑ (****) 
EcuAC 
Succeeding haplotype  EcuABC  EcuACD 
No drug – ns – ↑ (*) 
7.5 nM CQ  ns  ↑ (***) 
EcuAD 
Succeeding haplotype  EcuABD EcuACD  
No drug – ↓ (****) ↓ (****) – 
7.5 nM CQ  ↓ (****) ↓ (****)  
     (continued) 
 
 








Table 2.9. continued 
Preceding  
haplotype 
 + K76T (EcuA) + A220S (EcuB) + N326D (EcuC) + I356L (EcuD) 
EcuBC 
Succeeding haplotype EcuABC   EcuBCD 
No drug ↓ (****) – – ns 
7.5 nM CQ ↓ (****)   ns 
EcuBD 
Succeeding haplotype EcuABD  EcuBCD  
No drug ns – ↓ (****) – 
7.5 nM CQ ns  ↓ (****)  
EcuCD 
Succeeding haplotype EcuACD EcuBCD   
No drug ↓ (****) ns – – 
7.5 nM CQ ↓ (****) ns   
EcuABC 
Succeeding haplotype    EcuABCD 
No drug – – – ↑ (****) 
7.5 nM CQ    ↑ (****) 
EcuABD 
Succeeding haplotype   EcuABCD  
No drug – – ↓ (****) – 
7.5 nM CQ   ↓ (****)  
EcuACD 
Succeeding haplotype  EcuABCD   
No drug – ns – – 
7.5 nM CQ  ns   
EcuBCD 
Succeeding haplotype EcuABCD    
No drug ↓ (****) – – – 
7.5 nM CQ ↓ (**)    
 
aIn vitro parasite growth selection coefficient values (Table 2.8) were analyzed by two-way ANOVA with Sidak’s post-hoc test to 
determine whether acquisition of the indicated Ecu1110 PfCRT mutation by a precursor PfCRT haplotype resulted in a significant 
increase (↑) or decrease (↓) in the per-generation selection coefficient (s) of the succeeding PfCRT haplotype. Significant (P<0.05) 
differences are shaded in grey. PfCRT haplotypes are detailed in Table 2.3. CQ, chloroquine; WT, wild-type; *, P<0.05; **, P<0.01; ***, 








accessibility was subsequently determined for each landscape. Pathways were deemed 
accessible only if each mutational step led to a progressive increase in the total fitness 
(fT) of parasites. In our evolutionary model, fT is comprised of normalized parasite 
growth (fG) and drug resistance (fD) indices as per the relationship fT = afD + (1–a)fG, 
where fD represents normalized IC50 values, fG represents normalized relative in vitro 
growth values (ω') in the absence of drug, and the drug pressure coefficient a 
represents drug inhibitory level.  In our simulations, fD and fG indices were generated 
from normal distributions based on the means and SEMs of pfcrt allele-specific IC50 
and ω' values, respectively. Our model considers the role of drug pressure in 
facilitating CQR evolution via the drug pressure coefficient a (range: 0 to 1). Thus, 
selection is based solely on parasite growth rates for a=0 and on parasite drug 
resistance for a=1. Inspection of the parasite growth index (fG) plotted as a function of 
the drug resistance index (fD) based on simulations performed for CQ and md-CQ 
(Figure 2.6) revealed comparable trade-off profiles for the parent drug and its active 
metabolite, with no significant correlation observed between fG and fD, as per 
Pearson’s correlation analysis (CQ: R2=0.057, P=0.37; md-CQ: R2=0.15, P=0.13).  
 Evolutionary modeling was first performed to determine the realization 
probabilities for the mutational pathways (p) leading from wild-type to the full-length 
Ecu1110 pfcrt allele via sequential acquisition of single mutations (0→1→2→3→4; 
Figure 2.7A). Modeling was performed for a range of drug pressure scenarios by 
varying the coefficient a from 0 to 1 in 0.1 increments. For every a value, each of 104 
adaptive landscapes was subjected to 105 evolutionary excursions (109 total 







Figure 2.6. Trade-offs between parasite in vitro growth and drug resistance. For each pfcrt-modified strain, relative growth (fG) in the absence 
of drug pressure was plotted as a function of the parasite’s relative resistance (fD) to chloroquine or monodesethyl-chloroquine. Calculation of fG 










Figure 2.7. Modeling of chloroquine (CQ) and monodesethyl-chloroquine (md-CQ)-directed pfcrt 
evolution. (A) Schematic of the 24 theoretical pathways (p1 to p24) leading from wild-type (GC03) 
to Ecu1110 (ABCD) PfCRT via the sequential (0→1→2→3→4) acquisition of single mutations A, 
B, C, and D (K76T, A220S, N326D, and I356L, respectively). (B and C) Accessibility of mutational 
pathways for (B) CQ-directed and (C) md-CQ-directed evolutionary modeling. Adaptive 
landscapes were simulated based on experimentally derived parasite drug resistance and growth 
indices and used to quantify the realization probability for a given mutational pathway. Simulations 
explored the effect of drug pressure (a), from a=0 (i.e. growth rates fully dictate trajectory) through 
a=1 (i.e. parasite resistance fully dictates trajectory). Heat map color intensity corresponds to log10-
transformed pathway realization probability. (D and E) Adaptive landscapes illustrating the 
interplay of total parasite fitness (fT), mutations acquired, and extent of drug pressure (a). With 
regard to the total realization probability for all a values, the top two realized (D) CQ-directed and 
(E) md-CQ-directed mutational pathways are p19 and p20. Shown are trajectories for each of 
these mutational pathways based on mean fT values, which encompass the complete set of 
simulated adaptive landscapes for each drug. Accessible (i.e. fT increases progressively) and 
inaccessible (i.e. fT valleys are present) trajectories are indicated by thick lines/circles and dotted 





recorded for modeling based on CQ (Figure 2.7B) and md-CQ (Figure 2.7C) data. The 
ith pathway absolute realization probability (Pi) was calculated from the formula Ni / 
Ntotal, where Ni is the number of times that the simulations achieve the EcuABCD allele 
by traversing pathway i, and Ntotal is the total number of runs. Pathway realization 
probabilities for evolutionary modeling of CQ and md-CQ resistance are reported in 
Table 2.10 and Table 2.11, respectively. For both drugs, p20 (see Figure 2.7A) showed 
the maximum realization probability, with a >10-fold increase in predictive ability for 
the active metabolite as compared to the parent drug (9.43×10–7 for CQ versus 
1.39×10–5 for md-CQ). Highlighting the important interaction between parasite 
resistance (fD) and growth (fG) in dictating drug resistance evolution, the highest 
realization probabilities in both cases occurred for simulations in which total parasite 
fitness (fT) was informed by both fD and fG indices (a=0.8).  
 Based on total pathway realization probabilities for both CQ and md-CQ 
modeling, the top two Ecu1110 pfcrt evolutionary pathways were p20 and p19 (Tables 
2.10–2.11), which feature EcuD I356L as the first mutation acquired (see Figure 2.7A). 
Remarkably, although accessible trajectories were observed for both pathways for a 
wide range of drug pressure scenarios (Figure 2.8), many excursions through these 
pathways were inaccessible due to the existence of adaptive valleys (i.e. fT not 
progressively increasing), as highlighted by plots of mean fT values encompassing all 
adaptive landscapes generated in our analysis for both CQ (Figure 2.7D) and md-CQ 
(Figure 2.7E) modeling. Our data show that, out of 109 total excursions simulated for 
each a value for the 0→1→2→3→4 mutational scenario, CQ-directed and md-CQ-
directed evolution of the full-length Ecu1110 pfcrt allele were respectively supported 






Table 2.10. Mutational pathway realization probabilities for CQ evolutionary modeling.a 
Mutational scenario: 0 → 1 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p1 0 0 0 0 0 0 0 0 0 0 0 0 
p2 0 0 0 0 0 0 0 0 0 0 0 0 
p3 0 0 0 0 0 0 0 0 0 0 0 0 
p4 0 0 0 0 0 0 0 0 0 0 0 0 
p5 0 0 0 0 0 0 0 0 0 0 2.0E-09 2.0E-09 
p6 0 0 0 0 0 0 0 0 0 0 1.0E-09 1.0E-09 
p7 0 0 0 0 0 0 0 0 0 0 0 0 
p8 0 0 0 0 0 0 0 0 0 0 0 0 
p9 0 0 0 0 0 0 0 0 0 0 4.0E-09 4.0E-09 
p10 0 0 0 0 0 0 0 0 0 0 2.0E-09 2.0E-09 
p11 0 0 0 0 0 0 0 0 1.0E-09 1.0E-09 4.0E-09 6.0E-09 
p12 0 0 0 0 0 0 0 0 0 0 5.0E-09 5.0E-09 
p13 0 0 0 0 0 0 0 0 0 0 0 0 
p14 0 0 0 0 0 0 0 0 0 0 0 0 
p15 0 0 0 0 0 0 0 0 0 0 0 0 
p16 0 0 0 0 0 0 0 0 0 0 0 0 
p17 0 0 0 0 0 0 0 0 0 0 1.1E-08 1.1E-08 
p18 0 0 0 0 0 0 0 0 0 1.0E-09 0 1.0E-09 
p19 0 0 0 0 0 8.0E-09 5.6E-08 2.4E-07 3.7E-07 3.0E-07 1.7E-07 1.1E-06 
p20 0 0 0 0 0 0 2.1E-08 5.5E-07 9.4E-07 8.1E-07 5.0E-07 2.8E-06 
p21 0 0 0 1.0E-09 7.0E-09 2.1E-08 3.2E-08 3.7E-08 4.3E-08 4.6E-08 3.4E-08 2.2E-07 
p22 0 0 0 0 0 1.0E-09 4.0E-09 1.1E-08 1.2E-08 1.5E-08 1.8E-08 6.1E-08 
p23 0 0 0 0 0 0 2.0E-09 2.8E-08 9.3E-08 2.7E-07 4.9E-07 8.8E-07 
p24 0 0 0 0 0 0 0 2.0E-09 7.0E-09 2.5E-08 4.2E-08 7.6E-08 
p1-p24 0 0 0 1.0E-09 7.0E-09 3.0E-08 1.2E-07 8.7E-07 1.5E-06 1.5E-06 1.3E-06 5.2E-06 










Table 2.10. continued 
Mutational scenario: 0 → 1 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p25 0 0 0 0 0 0 0 0 0 0 1.0E-09 1.0E-09 
p26 0 0 0 0 0 0 0 0 0 0 0 0 
p27 0 0 0 0 0 0 0 0 0 0 0 0 
p28 0 0 0 0 0 0 0 0 0 0 0 0 
p29 0 0 0 0 0 0 0 0 0 6.0E-09 1.4E-07 1.5E-07 
p30 0 0 0 0 0 0 0 0 0 4.7E-08 1.7E-07 2.2E-07 
p31 0 0 0 0 0 0 0 0 0 0 0 0 
p32 0 0 0 0 0 0 0 0 0 0 1.9E-08 1.9E-08 
p33 0 0 0 0 0 0 0 0 0 8.0E-09 1.1E-07 1.1E-07 
p34 0 0 7.0E-09 2.0E-06 7.5E-06 1.8E-05 2.7E-05 2.9E-05 1.9E-05 1.1E-05 4.3E-06 1.2E-04 
p35 0 0 1.4E-07 7.2E-07 1.5E-06 2.1E-06 2.1E-06 2.0E-06 1.6E-06 1.2E-06 8.2E-07 1.2E-05 
p36 0 0 0 0 0 1.7E-08 1.4E-07 7.1E-07 1.7E-06 3.1E-06 4.0E-06 9.6E-06 
p25-p36 0 0 1.5E-07 2.7E-06 9.0E-06 2.0E-05 2.9E-05 3.2E-05 2.2E-05 1.5E-05 9.6E-06 1.4E-04 
Mutational scenario: 0 → 1 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p37 0 0 0 0 0 0 0 0 3.7E-08 2.8E-07 1.5E-06 1.9E-06 
p38 0 0 0 0 0 0 0 0 2.7E-08 2.8E-07 1.3E-06 1.6E-06 
p39 0 0 0 0 0 0 0 0 6.9E-08 5.1E-07 2.5E-06 3.1E-06 
p40 0 0 0 0 0 0 0 2.1E-08 9.5E-07 9.4E-06 3.8E-05 4.8E-05 
p41 0 0 0 0 0 0 1.4E-08 2.8E-07 3.1E-06 1.3E-05 3.4E-05 5.1E-05 
p42 0 0 0 0 0 0 3.0E-09 1.0E-07 1.1E-06 5.0E-06 1.3E-05 2.0E-05 
p43 0 0 0 0 0 0 0 2.5E-07 7.2E-06 5.7E-05 2.1E-04 2.8E-04 
p44 0 0 0 0 0 0 9.9E-08 8.6E-06 8.1E-05 3.0E-04 7.0E-04 1.1E-03 
p45 0 0 0 0 0 0 9.2E-08 1.4E-06 6.7E-06 2.1E-05 4.8E-05 7.7E-05 
p46 0 0 5.5E-08 3.2E-07 2.0E-06 6.5E-06 2.0E-05 5.2E-05 1.1E-04 2.1E-04 3.3E-04 7.2E-04 
p47 0 0 0 0 0 5.7E-07 1.6E-05 9.3E-05 2.9E-04 6.7E-04 1.2E-03 2.3E-03 
p48 0 0 0 0 1.0E-09 2.1E-07 1.7E-06 7.3E-06 2.0E-05 4.7E-05 9.2E-05 1.7E-04 
p37-p48 0 0 5.5E-08 3.2E-07 2.0E-06 7.3E-06 3.8E-05 1.6E-04 5.2E-04 1.3E-03 2.7E-03 4.8E-03 










Table 2.10. continued 
Mutational scenario: 0 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p49 0 0 0 0 0 0 0 0 0 0 1.4E-07 1.4E-07 
p50 0 0 0 0 0 0 0 0 0 0 1.5E-07 1.5E-07 
p51 0 0 0 0 0 0 0 0 0 0 0 0 
p52 0 0 0 0 0 0 0 0 0 0 0 0 
p53 0 0 0 0 0 0 0 0 0 0 4.7E-07 4.7E-07 
p54 0 0 0 0 0 0 0 0 0 3.5E-08 1.0E-06 1.1E-06 
p55 0 0 0 0 0 0 0 0 1.9E-08 1.2E-06 9.8E-06 1.1E-05 
p56 0 0 0 0 0 0 0 0 2.5E-08 3.5E-07 2.8E-06 3.2E-06 
p57 0 0 0 0 0 0 3.0E-09 1.9E-07 1.2E-06 7.7E-06 2.4E-05 3.3E-05 
p58 0 0 0 0 0 0 0 2.7E-08 3.6E-07 3.1E-06 1.2E-05 1.5E-05 
p59 0 0 0 0 0 1.0E-08 6.5E-08 1.0E-06 9.1E-06 5.5E-05 1.9E-04 2.6E-04 
p60 0 0 0 0 0 1.0E-09 2.1E-08 2.9E-07 1.4E-06 7.3E-06 2.5E-05 3.4E-05 
p49-p60 0 0 0 0 0 1.1E-08 8.9E-08 1.5E-06 1.2E-05 7.5E-05 2.7E-04 3.6E-04 
Mutational scenario: 0 → 1 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p61 0 0 0 0 0 0 0 0 4.5E-08 1.6E-06 1.6E-05 1.7E-05 
p62 0 0 1.2E-07 2.9E-07 4.4E-07 1.5E-06 9.9E-06 3.0E-05 1.3E-04 3.6E-04 8.6E-04 1.4E-03 
p63 0 2.0E-09 4.1E-06 1.7E-05 4.1E-05 1.5E-04 4.6E-04 1.1E-03 2.4E-03 4.8E-03 7.9E-03 1.7E-02 
p64 0 7.0E-09 1.3E-05 6.1E-05 2.1E-04 6.2E-04 1.5E-03 3.2E-03 5.9E-03 9.6E-03 1.4E-02 3.5E-02 
p61-p64 0 9.0E-09 1.7E-05 7.8E-05 2.5E-04 7.7E-04 2.0E-03 4.3E-03 8.4E-03 1.5E-02 2.3E-02 5.3E-02 
Mutational scenario: 0 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p65 0 0 0 0 0 0 0 0 0 0 1.9E-06 1.9E-06 
p66 0 0 0 0 0 0 0 0 0 0 0 0 
p67 0 0 0 0 0 0 0 0 0 3.7E-07 7.1E-06 7.4E-06 
p68 0 0 0 0 0 0 0 0 2.1E-06 3.6E-05 2.9E-04 3.2E-04 
p69 0 0 0 0 0 0 7.6E-07 2.4E-06 3.2E-05 1.6E-04 4.9E-04 6.8E-04 
p70 0 0 0 1.4E-07 0 8.0E-07 3.1E-06 2.0E-05 1.5E-04 6.7E-04 2.0E-03 2.8E-03 
p65-p70 0 0 0 1.4E-07 0 8.0E-07 3.9E-06 2.2E-05 1.8E-04 8.7E-04 2.8E-03 3.8E-03 


















Table 2.10. continued 
Mutational scenario: 0 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p71 0 0 0 0 0 0 2.4E-05 1.5E-03 9.5E-03 2.5E-02 4.5E-02 8.1E-02 
p72 0 0 0 0 3.7E-07 1.2E-04 2.6E-03 1.2E-02 2.3E-02 3.3E-02 4.2E-02 1.1E-01 
p73 0 0 0 0 0 2.9E-04 7.4E-03 2.4E-02 4.2E-02 6.4E-02 8.8E-02 2.3E-01 
p74 0 0 0 0 1.9E-06 2.8E-04 2.3E-03 5.5E-03 9.9E-03 1.5E-02 2.2E-02 5.5E-02 
p71-p74 0 0 0 0 2.3E-06 6.9E-04 1.2E-02 4.3E-02 8.4E-02 1.4E-01 2.0E-01 4.8E-01 
 
aAdaptive landscapes were generated for seven distinct mutational scenarios and subjected to evolutionary excursions to determine the 
realization probability for a given mutational pathway (p). Excursions were performed for a range of drug pressure scenarios, with the drug 
pressure coefficient (a) varying from 0 (no pressure) to 1 (full pressure). For each mutational pathway, we report individual realization 
probabilities for each a value, as well as the total pathway realization probability for all a values. The highest total realization probabilities 
(top three probabilities for four-step and three-step mutational scenarios and top two probabilities for two-step scenarios) are underlined. We 
also report the sum of realization probabilities for the full set of pathways comprising a mutational scenario, shown in bolded italics. 










Table 2.11. Mutational pathway realization probabilities for md-CQ evolutionary modeling.a 
Mutational scenario: 0 → 1 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p1 0 0 0 0 0 0 0 0 0 0 0 0 
p2 0 0 0 0 0 0 0 0 0 0 0 0 
p3 0 0 0 0 0 0 0 0 0 0 0 0 
p4 0 0 0 0 0 0 0 0 0 0 0 0 
p5 0 0 0 0 0 0 0 0 0 0 0 0 
p6 0 0 0 0 0 0 0 0 0 0 0 0 
p7 0 0 0 0 0 0 0 0 0 0 0 0 
p8 0 0 0 0 0 0 0 0 0 0 0 0 
p9 0 0 0 0 0 0 0 0 0 0 5.0E-08 5.0E-08 
p10 0 0 0 0 0 0 0 0 0 0 0 0 
p11 0 0 0 0 0 0 0 0 0 0 0 0 
p12 0 0 0 0 0 0 0 0 0 0 0 0 
p13 0 0 0 0 0 0 0 0 0 0 0 0 
p14 0 0 0 0 0 0 0 0 0 0 0 0 
p15 0 0 0 0 0 0 0 0 0 0 0 0 
p16 0 0 0 0 0 0 0 0 0 0 0 0 
p17 0 0 0 0 0 0 0 0 0 0 0 0 
p18 0 0 0 0 0 0 0 0 0 0 0 0 
p19 0 0 0 0 0 0 6.0E-09 5.9E-07 1.9E-06 1.2E-06 1.5E-07 3.8E-06 
p20 0 0 0 0 0 2.1E-07 4.9E-06 1.3E-05 1.4E-05 5.7E-06 6.3E-07 3.8E-05 
p21 0 0 0 1.0E-09 1.1E-08 5.8E-08 6.9E-08 1.0E-08 0 0 0 1.5E-07 
p22 0 0 0 0 0 0 1.0E-09 0 0 0 0 1.0E-09 
p23 0 0 0 0 1.0E-09 6.0E-09 8.1E-08 4.2E-07 6.5E-07 9.8E-07 1.1E-06 3.2E-06 
p24 0 0 0 0 0 0 0 1.0E-09 0 0 0 1.0E-09 
p1-p24 0 0 0 1.0E-09 1.2E-08 2.7E-07 5.1E-06 1.4E-05 1.7E-05 7.9E-06 1.9E-06 4.5E-05 










Table 2.11. continued 
Mutational scenario: 0 → 1 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p25 0 0 0 0 0 0 0 0 0 0 0 0 
p26 0 0 0 0 0 0 0 0 0 0 1.0E-08 1.0E-08 
p27 0 0 0 0 0 0 0 0 0 0 1.9E-08 1.9E-08 
p28 0 0 0 0 0 0 0 0 0 0 0 0 
p29 0 0 0 0 0 0 0 0 0 0 4.6E-07 4.6E-07 
p30 0 0 0 0 0 0 0 0 0 0 0 0 
p31 0 0 0 0 0 0 0 0 0 0 0 0 
p32 0 0 0 0 0 0 0 0 0 0 0 0 
p33 0 0 0 0 0 0 0 0 0 0 0 0 
p34 0 0 2.0E-07 5.3E-06 1.8E-05 4.3E-05 9.3E-05 1.3E-04 1.0E-04 3.6E-05 3.3E-06 4.3E-04 
p35 0 0 5.1E-07 2.0E-06 3.8E-06 5.0E-06 3.0E-06 4.5E-07 9.0E-09 0 0 1.5E-05 
p36 0 0 0 1.0E-09 6.0E-09 8.4E-08 9.9E-07 3.7E-06 4.9E-06 6.0E-06 6.3E-06 2.2E-05 
p25-p36 0 0 7.1E-07 7.3E-06 2.2E-05 4.8E-05 9.7E-05 1.3E-04 1.0E-04 4.2E-05 1.0E-05 4.7E-04 
Mutational scenario: 0 → 1 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p37 0 0 0 0 0 0 0 0 0 0 2.0E-07 2.0E-07 
p38 0 0 0 0 0 0 0 0 0 0 6.6E-08 6.6E-08 
p39 0 0 0 0 0 0 0 0 0 0 2.5E-07 2.5E-07 
p40 0 0 0 0 0 0 9.0E-09 2.7E-08 6.0E-08 2.0E-06 3.8E-05 4.0E-05 
p41 0 0 0 0 0 3.0E-09 1.6E-08 1.8E-08 3.4E-08 7.9E-07 1.4E-05 1.5E-05 
p42 0 0 0 0 0 0 0 0 0 1.8E-07 4.3E-06 4.5E-06 
p43 0 0 0 0 0 0 4.1E-06 1.7E-04 8.3E-04 2.2E-03 4.3E-03 7.5E-03 
p44 0 0 0 0 0 8.0E-06 1.6E-04 7.3E-04 2.0E-03 4.2E-03 7.3E-03 1.5E-02 
p45 0 0 0 0 0 0 0 0 0 0 0 0 
p46 0 0 1.2E-07 1.1E-06 4.9E-06 1.8E-05 6.0E-05 1.5E-04 2.8E-04 4.5E-04 6.7E-04 1.6E-03 
p47 0 0 0 1.4E-08 9.4E-06 6.4E-05 2.5E-04 6.8E-04 1.3E-03 2.2E-03 3.4E-03 7.9E-03 
p48 0 0 0 0 1.8E-08 2.3E-08 1.6E-07 1.1E-06 6.2E-06 2.3E-05 6.5E-05 9.6E-05 
p37-p48 0 0 1.2E-07 1.1E-06 1.4E-05 9.0E-05 4.7E-04 1.7E-03 4.4E-03 9.1E-03 1.6E-02 3.2E-02 










Table 2.11. continued 
Mutational scenario: 0 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p49 0 0 0 0 0 0 0 0 0 0 0 0 
p50 0 0 0 0 0 0 0 0 0 0 0 0 
p51 0 0 0 0 0 0 0 0 0 0 5.4E-04 5.4E-04 
p52 0 0 0 0 0 0 0 0 0 0 8.0E-04 8.0E-04 
p53 0 0 0 0 0 0 0 0 0 1.4E-05 4.4E-04 4.6E-04 
p54 0 0 0 0 0 0 0 0 1.0E-08 7.2E-05 1.8E-03 1.9E-03 
p55 0 0 0 0 0 0 0 2.9E-07 4.8E-05 1.4E-03 3.5E-03 4.9E-03 
p56 0 0 0 0 0 0 0 0 5.0E-09 2.3E-07 1.1E-06 1.3E-06 
p57 0 0 0 0 1.0E-09 1.0E-08 1.5E-07 1.5E-06 1.4E-05 1.4E-06 2.0E-09 1.7E-05 
p58 0 0 0 0 0 0 0 8.4E-08 3.3E-06 5.4E-07 1.0E-09 4.0E-06 
p59 0 0 0 0 3.0E-08 2.0E-07 3.5E-06 5.4E-05 8.3E-04 2.7E-03 4.0E-03 7.6E-03 
p60 0 0 0 0 0 0 1.4E-08 6.0E-08 3.4E-07 4.3E-07 3.6E-07 1.2E-06 
p49-p60 0 0 0 0 3.1E-08 2.1E-07 3.7E-06 5.6E-05 9.0E-04 4.2E-03 1.1E-02 1.6E-02 
Mutational scenario: 0 → 1 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p61 0 0 0 0 0 0 0 0 0 0 1.3E-06 1.3E-06 
p62 0 0 3.4E-07 2.0E-07 8.0E-07 3.0E-07 9.1E-07 2.6E-07 2.0E-06 2.3E-05 3.0E-04 3.2E-04 
p63 0 1.0E-08 1.6E-05 6.3E-05 2.3E-04 7.7E-04 2.7E-03 7.5E-03 1.7E-02 2.9E-02 4.3E-02 1.0E-01 
p64 0 3.0E-09 3.0E-05 1.3E-04 3.9E-04 1.1E-03 3.0E-03 6.0E-03 9.5E-03 1.4E-02 1.8E-02 5.2E-02 
p61-p64 0 1.3E-08 4.6E-05 1.9E-04 6.2E-04 1.9E-03 5.7E-03 1.4E-02 2.7E-02 4.3E-02 6.1E-02 1.5E-01 
Mutational scenario: 0 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p65 0 0 0 0 0 0 0 0 0 0 0 0 
p66 0 0 0 0 0 0 0 0 0 0 4.4E-03 4.4E-03 
p67 0 0 0 0 0 0 0 0 9.4E-07 4.1E-04 9.3E-03 9.7E-03 
p68 0 0 0 0 0 0 0 4.4E-06 7.1E-04 1.4E-02 2.9E-02 4.4E-02 
p69 0 0 0 0 0 6.E-07 4.8E-06 5.2E-05 3.3E-04 2.4E-05 2.6E-07 4.1E-04 
p70 0 0 0 0 0 3.2E-06 3.5E-05 5.2E-04 6.1E-03 1.7E-02 2.2E-02 4.5E-02 
p65-p70 0 0 0 0 0 3.8E-06 4.0E-05 5.8E-04 7.1E-03 3.1E-02 6.5E-02 1.0E-01 

















Table 2.11. continued 
Mutational scenario: 0 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p71 0 0 0 0 0 3.6E-04 1.3E-02 3.3E-02 5.9E-02 8.9E-02 1.2E-01 3.2E-01 
p72 0 0 0 0 5.6E-05 5.5E-03 1.5E-02 2.2E-02 3.0E-02 4.0E-02 5.1E-02 1.6E-01 
p73 0 0 0 0 2.4E-03 2.3E-02 4.3E-02 6.8E-02 9.8E-02 1.3E-01 1.7E-01 5.4E-01 
p74 0 0 0 6.8E-08 4.0E-05 1.6E-04 7.0E-04 2.8E-03 7.4E-03 1.4E-02 2.1E-02 4.6E-02 
p71-p74 0 0 0 6.8E-08 2.5E-03 2.9E-02 7.2E-02 1.3E-01 1.9E-01 2.7E-01 3.6E-01 1.1E+00 
 
aAdaptive landscapes were generated for seven distinct mutational scenarios and subjected to evolutionary excursions to determine the 
realization probability for a given mutational pathway (p). Excursions were performed for a range of drug pressure scenarios, with the drug 
pressure coefficient (a) varying from 0 (no pressure) to 1 (full pressure). For each mutational pathway, we report individual realization 
probabilities for each a value, as well as the total pathway realization probability for all a values. The highest total realization probabilities 
(top three probabilities for four-step and three-step mutational scenarios and top two probabilities for two-step scenarios) are underlined. We 
also report the sum of realization probabilities for the full set of pathways comprising a mutational scenario, shown in bolded italics. 









Figure 2.8. Representative accessible (A) chloroquine (CQ)-directed and (B) monodesethyl-
chloroquine (md-CQ)-directed pfcrt mutational trajectories. Shown are trajectories for the top 
two pathways (p19 and p20) for the 0→1→2→3→4 mutational scenario. The higher the drug 
pressure coefficient a, the greater the impact of drug resistance (and the lower the contribution 
of parasite growth) on the total fitness index, fT. Corresponding trajectories encompassing the 
complete set of simulated adaptive landscapes (based on mean fT values) are shown in Figure 



















appreciable effect on total parasite fitness (fT) until the three-SNP intermediate 
(EcuABD or EcuACD). 
  In the scenario of CQR evolution via sequential acquisition of single mutations 
(0→1→2→3→4), three distinct mutational intermediates spanned the transition from 
wild-type to Ecu1110 pfcrt. Given the apparent adaptive constraints associated with 
this evolutionary course, we next explored trajectories in which up to three mutations 
were acquired simultaneously, thus requiring fewer intermediates. These scenarios 
could occur with pre-existing alleles and/or with pressure from other antimalarials. 
Evolutionary modeling was performed as for the 0→1→2→3→4 mutational scenario, 
with 109 total evolutionary excursions examined for various drug pressure scenarios 
(range of a values: 0 to 1). Results for CQ and md-CQ mutational pathways requiring 
either two (0→1→2→4; 0→1→3→4; or 0→2→3→4) or one (0→1→4; 0→2→4; or 
0→3→4) intermediate steps are illustrated in Figure 2.9 and Figure 2.10, respectively. 
Pathway probabilities are listed in Tables 2.10–2.11. Consistent with our results for 
the 0→1→2→3→4 mutational scenario, the top realized pathways overwhelmingly 
featured initial acquisition of EcuD I356L and/or EcuC N326D. Notably, for both CQ 
and md-CQ modeling, mutational sequences 0→1→3→4 and 0→3→4 yielded 
realization probabilities up to ~105-fold greater than those for the 0→1→2→3→4 
scenario (e.g. compare total probabilities for p1-24 and p71-p74 in Tables 2.10–2.11). 
This suggests the possibility that rare bursts of multiple mutations facilitated the 







Figure 2.9. Modeling of chloroquine (CQ) and monodesethyl-chloroquine (md-CQ)-directed 
Ecu1110 pfcrt evolution via two mutational intermediate steps. (A) Schematic of the 12 theoretical 
pathways (p25 to p36) in the 0→1→2→4 mutational scenario, leading from wild-type (GC03) to 
Ecu1110 (ABCD) PfCRT. A, B, C, and D correspond to mutations K76T, A220S, N326D, and 
I356L, respectively. (B and C) Accessibility of mutational pathways p25 to p36 as informed by (B) 
CQ and (C) md-CQ data. Color map intensity corresponds to log10-transformed pathway realization 
probability. Simulations explored the combined effect of drug resistance and growth rates by 
modulating the coefficient a, varied from a=0 (no drug pressure, full contribution of growth rates) 
through a=1 (full drug pressure, no contribution of growth rates). (D) Schematic of the 12 theoretical 
pathways (p37 to p48) in the 0→1→3→4 mutational scenario. (E and F) Accessibility of mutational 
pathways p37 to p48 for (E) CQ and (F) md-CQ. (G) Schematic of the 12 theoretical pathways 
(p49 to p60) in the 0→2→3→4 mutational scenario. (H and I) Accessibility of mutational pathways 






Figure 2.10. Modeling of chloroquine (CQ) and monodesethyl-chloroquine (md-CQ)-directed 
Ecu1110 pfcrt evolution via one mutational intermediate step. (A) Schematic of the four theoretical 
pathways (p61 to p64) in the 0→1→4 mutational scenario, leading from wild-type (GC03) to 
Ecu1110 (ABCD) PfCRT. A, B, C, and D correspond to mutations K76T, A220S, N326D, and 
I356L, respectively. (B and C) Accessibility of mutational pathways p61 to p64 as informed by (B) 
CQ and (C) md-CQ data and determined via computational modeling. Color map intensity 
corresponds to log10-transformed pathway realization probability. Simulations explored the effect 
of drug pressure (a), from a=0 (no pressure) through a=1 (full pressure). (D) Schematic of the six 
theoretical pathways (p65 to p70) in the 0→2→4 mutational scenario. (E and F) Accessibility of 
mutational pathways p65 to p70 for (E) CQ and (F) md-CQ. (G) Schematic of the four theoretical 
pathways (p71 to p74) in the 0→3→4 mutational scenario. (H and I) Accessibility of mutational 





Modeling of md-AQ-directed pfcrt evolution 
Given the known cross-resistance between CQ and AQ and the historical use of AQ in 
South America, where the Ecu1110 and 7G8 PfCRT haplotypes are common (see 
Discussion), we also explored the impact of AQ drug pressure on Ecu1110 pfcrt 
evolution. Similar to the CQ and md-CQ evolutionary modeling, we performed 
evolutionary modeling for md-AQ, the primary active metabolite of AQ. Our results 
are shown in Figure 2.11 for a range of mutational scenarios, with pathway 
probabilities detailed in Table 2.12. Indicating extensive overlap between CQ and AQ 
in directing pfcrt evolution, the majority (77.8%) of top pathways based on md-AQ 
modeling (see Table 2.12) coincided with top pathways as identified by md-CQ 
modeling (see Table 2.11). A role for md-AQ in aiding pfcrt evolution is further evident 
from comparisons of total realization probabilities associated with different quinoline-
type drugs (Table 2.13). As compared to CQ and md-CQ, md-AQ-directed pfcrt 
evolution yielded, respectively, upwards of >10-fold and >100-fold increases in 
accessibility for the sequential, single-step mutational scenario (0→1→2→3→4; see 
p23 in Table 2.13). Similar to CQ and md-CQ, for scenarios in which mutational 
intermediates were skipped due to simultaneous acquisition of more than one 
mutation, md-AQ-directed evolution was comparably associated with a substantial 
increase in pathway accessibility (e.g. compare p23 and p73 in Table 2.13 and compare 
total probabilities for p1-24 and p71-p74 in Table 2.12).  
  It is noteworthy that the CQR-conferring 7G8 pfcrt allele remains the most 
prevalent allele in South America, despite declines in CQ and AQ use in this 
region.257,259 As 7G8 pfcrt is distinguished from the Ecu1110 pfcrt allele by the 













Figure 2.11. Modeling of monodesethyl-amodiaquine (md-AQ)-directed evolution of Ecu1110 
pfcrt. (A) Mutational pathway accessibility for the 0→1→2→3→4 scenario, as informed by md-
AQ data and determined via computational modeling. Color map intensity corresponds to 
log10-transformed pathway realization probability. Simulations explored the effect of drug 
pressure (a), from a=0 (no pressure) through a=1 (full pressure). (B) Adaptive landscapes 
illustrating the interplay of total parasite fitness (fT), mutations acquired, and extent of drug 
pressure (a) for the top three realized md-AQ-directed mutational pathways (p17, p20, p23) 
for the 0→1→2→3→4 scenario. Shown are trajectories based on mean fT values, which 
encompass the complete set of simulated adaptive landscapes. Accessible (i.e. fT increases 
progressively) and inaccessible (i.e. fT valleys are present) trajectories are indicated by thick 
lines/circles and dotted lines/crosses, respectively. (C) Accessibility of pathways requiring two 
mutational intermediate steps in md-AQ-directed evolution of Ecu1110 pfcrt. (D) Accessibility 
of pathways requiring a single mutational intermediate step in md-AQ-directed evolution of 
Ecu1110 pfcrt. Schematics of the theoretical mutational pathways for all mutational scenarios 























Table 2.12. Mutational pathway realization probabilities for md-AQ evolutionary modeling.a 
Mutational scenario: 0 → 1 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p1 0 0 0 0 0 0 0 0 0 6.0E-09 1.2E-07 1.3E-07 
p2 0 0 0 0 0 0 0 0 0 0 2.2E-08 2.2E-08 
p3 0 0 0 0 0 0 0 0 7.9E-08 2.9E-06 2.3E-05 2.6E-05 
p4 0 0 0 0 0 0 0 0 1.6E-07 4.6E-06 3.5E-05 4.0E-05 
p5 0 0 0 0 0 0 0 0 7.0E-09 1.1E-07 8.4E-07 9.5E-07 
p6 0 0 0 0 0 0 5.0E-09 4.8E-07 6.1E-06 2.7E-05 5.5E-05 8.9E-05 
p7 0 0 0 0 0 0 0 0 0 9.0E-09 3.5E-07 3.6E-07 
p8 0 0 0 0 0 0 0 0 0 3.0E-09 6.7E-08 7.0E-08 
p9 0 0 0 0 0 0 0 1.4E-07 2.0E-06 1.2E-05 3.6E-05 5.0E-05 
p10 0 0 0 0 0 0 0 0 9.0E-09 5.1E-08 3.1E-07 3.7E-07 
p11 0 0 0 0 0 0 3.0E-09 7.0E-08 2.7E-07 4.8E-07 6.6E-07 1.5E-06 
p12 0 0 0 0 0 0 2.0E-09 6.1E-08 3.2E-07 6.5E-07 9.4E-07 2.0E-06 
p13 0 0 0 0 0 0 0 0 4.4E-08 1.9E-06 2.0E-05 2.2E-05 
p14 0 0 0 0 0 0 0 0 6.6E-08 3.2E-06 3.1E-05 3.4E-05 
p15 0 0 0 0 0 0 0 1.0E-08 5.3E-07 6.4E-06 3.2E-05 3.9E-05 
p16 0 0 0 0 0 0 0 0 0 1.0E-09 2.6E-08 2.7E-08 
p17 0 0 0 0 0 0 2.0E-09 2.9E-07 5.3E-06 3.0E-05 9.3E-05 1.3E-04 
p18 0 0 0 0 0 0 0 0 0 4.0E-09 1.0E-08 1.4E-08 
p19 0 0 0 0 0 0 0 1.0E-09 1.7E-08 1.5E-07 8.0E-07 9.7E-07 
p20 0 0 0 0 0 3.9E-08 2.6E-06 9.8E-06 2.0E-05 3.3E-05 4.5E-05 1.1E-04 
p21 0 0 0 1.0E-09 1.0E-09 1.8E-08 6.1E-08 2.4E-07 4.5E-07 7.0E-07 8.3E-07 2.3E-06 
p22 0 0 0 0 0 0 2.7E-08 2.0E-07 5.6E-07 9.3E-07 1.3E-06 3.0E-06 
p23 0 0 0 1.0E-09 7.4E-08 7.6E-07 3.1E-06 9.1E-06 2.1E-05 4.2E-05 7.5E-05 1.5E-04 
p24 0 0 0 0 0 0 2.1E-08 3.7E-08 1.3E-07 2.5E-07 4.8E-07 9.2E-07 
p1-p24 0 0 0 2.0E-09 7.5E-08 8.2E-07 5.8E-06 2.0E-05 5.7E-05 1.7E-04 4.5E-04 7.0E-04 










Table 2.12. continued 
Mutational scenario: 0 → 1 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p25 0 0 0 0 0 0 0 0 0 4.7E-08 8.0E-07 8.4E-07 
p26 0 0 0 0 0 0 0 0 1.0E-06 3.0E-05 2.0E-04 2.3E-04 
p27 0 0 0 0 0 4.0E-09 2.5E-07 6.7E-06 5.6E-05 1.9E-04 3.2E-04 5.7E-04 
p28 0 0 0 0 0 0 0 0 0 8.3E-08 2.1E-06 2.2E-06 
p29 0 0 0 0 0 1.0E-09 9.9E-08 4.2E-06 3.7E-05 1.4E-04 3.4E-04 5.2E-04 
p30 0 0 0 0 0 4.7E-08 1.2E-06 9.4E-06 2.2E-05 2.6E-05 2.6E-05 8.5E-05 
p31 0 0 0 0 0 0 0 0 4.7E-07 2.2E-05 1.8E-04 2.1E-04 
p32 0 0 0 0 0 0 0 1.5E-07 9.1E-06 9.0E-05 3.3E-04 4.2E-04 
p33 0 0 0 0 0 0 1.2E-08 2.9E-06 4.5E-05 2.3E-04 5.9E-04 8.7E-04 
p34 0 0 8.0E-09 6.6E-06 2.4E-05 5.3E-05 9.0E-05 1.3E-04 1.8E-04 2.2E-04 2.6E-04 9.7E-04 
p35 0 0 5.0E-07 3.7E-06 9.3E-06 1.7E-05 2.4E-05 3.1E-05 3.5E-05 3.5E-05 3.6E-05 1.9E-04 
p36 0 0 5.0E-09 2.8E-07 2.8E-06 1.3E-05 3.9E-05 8.7E-05 1.7E-04 2.9E-04 4.6E-04 1.1E-03 
p25-p36 0 0 5.1E-07 1.1E-05 3.6E-05 8.3E-05 1.5E-04 2.7E-04 5.6E-04 1.3E-03 2.7E-03 5.2E-03 
Mutational scenario: 0 → 1 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p37 0 0 0 0 0 1.0E-07 4.4E-06 6.9E-05 3.9E-04 1.2E-03 2.5E-03 4.2E-03 
p38 0 0 0 0 0 1.1E-07 2.4E-06 2.5E-05 1.0E-04 2.4E-04 3.9E-04 7.5E-04 
p39 0 0 0 0 0 3.9E-07 9.0E-06 1.1E-04 5.7E-04 1.6E-03 3.3E-03 5.6E-03 
p40 0 0 0 0 6.0E-09 3.5E-06 5.8E-05 2.9E-04 7.1E-04 1.3E-03 2.1E-03 4.4E-03 
p41 0 0 0 0 1.1E-08 1.7E-06 1.6E-05 5.6E-05 1.2E-04 2.0E-04 3.0E-04 7.0E-04 
p42 0 0 0 0 3.0E-09 5.9E-07 9.3E-06 5.0E-05 1.4E-04 2.7E-04 4.5E-04 9.2E-04 
p43 0 0 0 0 1.3E-08 1.3E-05 2.0E-04 8.4E-04 2.0E-03 3.6E-03 5.7E-03 1.2E-02 
p44 0 0 0 0 1.6E-06 1.8E-04 8.5E-04 2.0E-03 3.6E-03 5.7E-03 8.4E-03 2.1E-02 
p45 0 0 0 0 2.0E-09 8.6E-08 5.8E-07 2.5E-06 9.0E-06 2.8E-05 7.4E-05 1.1E-04 
p46 0 0 1.4E-07 9.6E-07 4.1E-06 1.2E-05 2.7E-05 5.5E-05 9.6E-05 1.6E-04 2.5E-04 6.1E-04 
p47 0 0 0 4.5E-07 1.7E-05 6.6E-05 1.6E-04 3.3E-04 6.1E-04 1.1E-03 1.6E-03 3.9E-03 
p48 0 0 0 4.8E-08 7.5E-07 4.5E-06 1.8E-05 4.9E-05 1.1E-04 2.0E-04 3.4E-04 7.2E-04 
p37-p48 0 0 1.4E-07 1.5E-06 2.3E-05 2.8E-04 1.4E-03 3.9E-03 8.5E-03 1.6E-02 2.5E-02 5.5E-02 










Table 2.12. continued 
Mutational scenario: 0 → 2 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p49 0 0 0 0 0 0 0 0 1.1E-06 5.6E-05 5.1E-04 5.7E-04 
p50 0 0 0 0 0 0 0 0 4.0E-07 1.7E-05 1.3E-04 1.5E-04 
p51 0 0 0 0 0 0 0 6.1E-07 1.0E-04 1.4E-03 4.4E-03 5.8E-03 
p52 0 0 0 0 0 0 0 1.3E-06 1.7E-04 2.0E-03 6.3E-03 8.5E-03 
p53 0 0 0 0 0 0 0 3.0E-09 1.5E-06 2.7E-05 1.3E-04 1.6E-04 
p54 0 0 0 0 0 0 1.2E-05 3.9E-04 2.1E-03 4.7E-03 6.4E-03 1.4E-02 
p55 0 0 0 0 0 1.4E-06 9.0E-05 7.0E-04 1.9E-03 3.7E-03 6.0E-03 1.2E-02 
p56 0 0 0 0 0 4.0E-08 1.7E-06 1.1E-05 3.1E-05 5.9E-05 9.8E-05 2.0E-04 
p57 0 0 0 4.0E-09 1.5E-08 2.1E-06 2.3E-05 8.4E-05 1.6E-04 2.6E-04 3.5E-04 8.8E-04 
p58 0 0 0 0 0 1.4E-07 8.1E-06 7.1E-05 2.0E-04 3.4E-04 4.9E-04 1.1E-03 
p59 0 0 0 1.0E-07 1.3E-05 2.0E-04 8.7E-04 2.1E-03 3.9E-03 6.4E-03 9.7E-03 2.3E-02 
p60 0 0 0 1.4E-08 1.6E-07 1.7E-06 6.9E-06 1.7E-05 3.3E-05 5.5E-05 8.8E-05 2.0E-04 
p49-p60 0 0 0 1.2E-07 1.3E-05 2.1E-04 1.0E-03 3.4E-03 8.6E-03 1.9E-02 3.5E-02 6.7E-02 
Mutational scenario: 0 → 1 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p61 0 0 0 0 4.0E-07 4.8E-06 9.3E-05 9.0E-04 4.0E-03 9.7E-03 1.8E-02 3.2E-02 
p62 0 0 1.5E-06 1.2E-05 8.7E-05 4.4E-04 1.8E-03 4.4E-03 7.8E-03 1.1E-02 1.5E-02 4.0E-02 
p63 0 0 3.0E-05 2.8E-04 1.4E-03 4.8E-03 1.1E-02 1.9E-02 2.8E-02 3.8E-02 4.8E-02 1.5E-01 
p64 0 1.0E-09 3.4E-05 1.7E-04 4.8E-04 9.9E-04 1.7E-03 2.8E-03 4.3E-03 6.3E-03 8.4E-03 2.5E-02 
p61-p64 0 1.0E-09 6.6E-05 4.6E-04 2.0E-03 6.2E-03 1.5E-02 2.7E-02 4.4E-02 6.5E-02 8.9E-02 2.5E-01 
Mutational scenario: 0 → 2 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p65 0 0 0 0 0 0 0 0 1.1E-05 4.2E-04 3.3E-03 3.7E-03 
p66 0 0 0 0 0 0 0 7.3E-06 1.2E-03 1.3E-02 3.6E-02 5.0E-02 
p67 0 0 0 0 0 1.2E-05 5.0E-04 5.4E-03 2.0E-02 3.2E-02 3.7E-02 9.4E-02 
p68 0 0 0 0 9.1E-06 4.5E-04 5.0E-03 1.7E-02 2.9E-02 4.1E-02 5.4E-02 1.5E-01 
p69 0 0 3.6E-07 7.0E-06 2.2E-04 2.0E-03 6.8E-03 1.0E-02 1.1E-02 1.2E-02 1.3E-02 5.5E-02 
p70 0 0 1.0E-06 1.9E-05 4.3E-04 3.4E-03 1.1E-02 2.1E-02 3.1E-02 4.4E-02 5.9E-02 1.7E-01 
p65-p70 0 0 1.4E-06 2.6E-05 6.6E-04 5.9E-03 2.3E-02 5.3E-02 9.2E-02 1.4E-01 2.0E-01 5.2E-01 


















Table 2.12. continued 
Mutational scenario: 0 → 3 → 4 
Pathway a = 0 a = 0.1 a = 0.2 a = 0.3 a = 0.4 a = 0.5 a = 0.6 a = 0.7 a = 0.8 a = 0.9 a = 1.0 Total 
p71 0 0 0 0 1.2E-04 5.0E-03 2.0E-02 4.0E-02 6.4E-02 9.3E-02 1.3E-01 3.5E-01 
p72 0 0 0 1.5E-06 5.9E-04 4.8E-03 9.7E-03 1.5E-02 2.1E-02 2.8E-02 3.6E-02 1.1E-01 
p73 0 0 0 1.6E-05 6.0E-03 2.3E-02 4.2E-02 6.4E-02 9.1E-02 1.2E-01 1.6E-01 5.1E-01 
p74 0 0 0 1.5E-05 7.1E-04 3.0E-03 7.6E-03 1.4E-02 2.2E-02 3.2E-02 4.4E-02 1.2E-01 
p71-p74 0 0 0 3.3E-05 7.4E-03 3.6E-02 7.9E-02 1.3E-01 2.0E-01 2.7E-01 3.7E-01 1.1E+00 
 
aAdaptive landscapes were generated for seven distinct mutational scenarios and subjected to evolutionary excursions to determine the 
realization probability for a given mutational pathway (p). Excursions were performed for a range of drug pressure scenarios, with the drug 
pressure coefficient (a) varying from 0 (no pressure) to 1 (full pressure). For each mutational pathway, we report individual realization 
probabilities for each a value, as well as the total pathway realization probability for all a values. The highest total realization probabilities 
(top three probabilities for four-step and three-step mutational scenarios and top two probabilities for two-step scenarios) are underlined. We 
also report the sum of realization probabilities for the full set of pathways comprising a mutational scenario, shown in bolded italics. 








Table 2.13. Representative pfcrt mutational trajectories accessible to quinoline drug resistance evolution.a 
 Mutational intermediates Total realization probability 
Pathway 0 1 2 3 4 CQ md-CQ md-AQ 
p20 WT D AD ACD ABCD 2.8 × 10-6 3.8 × 10-5 1.1 × 10-4 
p23 WT D CD ACD ABCD 8.8 × 10-7 3.2 × 10-6 1.5 × 10-4 
p47 WT D – ACD ABCD 2.3 × 10-3 7.9 × 10-3 3.9 × 10-3 
p73 WT – – ACD ABCD 2.3 × 10-1 5.4 × 10-1 5.1 × 10-1 
 
aTotal realization probabilities for the collectively most accessible mutational pathways (p) identified in 
modeling of CQ, md-CQ, and md-AQ resistance evolution (see Tables 2.10–2.12). Shown are the two 
most accessible pathways for the 0→1→2→3→4 mutational scenario, as well as the most accessible 
pathways for the 0→1→3→4 and 0→3→4 scenarios. PfCRT haplotypes are listed in Table 2.3. 0-4, 
number of mutations comprising the given PfCRT haplotype; –, skipped mutational intermediate; CQ, 
chloroquine; md-CQ, monodesethyl-chloroquine; md-AQ, monodesethyl-amodiaquine; WT, wild-type 













evolution may be used to draw inferences about the evolution of the highly prevalent 
7G8 allele. Collectively, our data indicate that, in the 7G8 genetic background, PfCRT 
C72S confers increased parasite resistance to the quinoline compounds CQ, md-CQ, 
and md-AQ, while simultaneously enhancing parasite growth. Thus, we postulate that 
the top mutational pathways identified for the evolution of Ecu1110 pfcrt also 






















In this study, we harnessed ZFN-based combinatorial genetics and computational 
evolutionary modeling to probe the evolutionary trajectories accessible to parasites as 
they acquire mutations in the pfcrt gene, the primary determinant of CQR and a key 
modulator of susceptibility to several currently deployed antimalarials.114 Our 
simulations revealed pronounced biological constraints associated with the evolution 
of Ecu1110 pfcrt, a prototypical CQ-resistant allele comprised of four mutations, the 
smallest number required for resistance.186 Among the pathways based on the 
sequential accumulation of single mutations leading to the Ecu1110 allele, the 
maximum realization probabilities for CQ and md-CQ resistance were, respectively, 
~5×10-7 and ~10-6 (see Tables 2.10–2.11). In comparison, earlier modeling of 
pyrimethamine resistance evolution mediated by the sequential gain of up to four 
mutations in the pfdhfr gene (Table 2.14) showed a maximum realization probability 
of ~3×10-4.302 These findings are consistent with historical records showing that the 
evolution of drug-resistant forms of pfcrt in natural parasite populations occurred 
more rarely than for mutant pfdhfr.304  
  Our modeling of pfcrt evolution uncovered multiple adaptive valleys (see 
Figure 2.7D and Figure 2.7E) associated with the sequential acquisition of single 
mutations, such that the gain of a subsequent mutation generally constrained 
resistance evolution by reducing the total parasite fitness (fT). We consequently 
examined scenarios in which two or more mutations were acquired simultaneously. 
This analysis revealed pathways with vast increases in accessibility (up to a 
maximum total realization probability of ~2×10-1 and ~5×10-1 for CQ and md-CQ, 




Table 2.14. Comparison of combinatorial genetic studies modeling Plasmodium drug resistance gene evolution. 
 Lozovsky et al.  
(PNAS, 2009) 
Brown et al.  
(Mol Biol Evol, 2010) 
Kümpornsin,  
Modchang et al.  
(Mol Biol Evol, 2014) 
This study 
Gene (mutations) pfdhfr (4 mutations) pfdhfr (4 mutations) 
pfdhfr (4 mutations);  
pfgch1 (gene amplification)d 
pfcrt (4 mutations) 






E. coli S. cerevisiae E. coli P. falciparum 
Evolutionary 
excursions 
107 109 106 109 
Range of realization 
probabilities of top 
three pathways 
0.11 – 0.55a 
(i.) 0.13 – 0.27b,c 
(ii.) 0.19 – 0.40a,c 
0 – 1.5E-05 
CQ: 1.7E-07 – 5.0E-07f 
md-CQ: 1.5E-07 – 1.1E-06f 
md-AQ: 5.5E-05 – 9.3E-05f 
Sum of realization 










aBased on correlated fixation probability model, which assumes that the probability of fixation of a beneficial mutation is positively correlated 
with the magnitude of its effect. 
 
bBased on equal fixation probability model, which assumes that all beneficial mutations (mutations that increase IC50) fix with equal probability. 
 
cNote that the top three pathways identified in this study differed depending on the choice of probability model. 
 
dThis study employed an evolutionary model modified from Lozovsky et al. (PNAS, 2009) to explore the interplay of pfdhfr1 and pfgch1 in 
directing pyrimethamine resistance evolution. To assess the effect of pfgch1 amplification, the authors calculated absolute probabilities. 
 
eMaximum absolute probabilities observed for mutational scenario of pfgch1 amplification. 
 









three mutations has not been documented in the field, we hypothesize that pfcrt-
mediated CQR arose through mutational bursts with brief periods of intervening 
growth, whereby one or more mutations were acquired and expanded during a short 
time window prior to the acquisition of additional mutations. Based on our combined 
IC50 and growth data, the most likely scenario would be the near-simultaneous 
emergence of three to four mutations. While this would be an exceptionally infrequent 
event, we note that several months of intermittent in vitro pressure of a CQ-resistant 
P. falciparum strain (K1) with the antimalarial halofantrine selected for a pfcrt 
variant with three additional point mutations.305  
Mathematical modeling of the acquisition of multiple mutations in response to 
selective pressure has previously shown that the temporality of mutational events, 
population size, and duration of evolution might jointly facilitate the emergence of 
mutations with a frequency significantly greater than the cumulative product of 
single-mutation rates,306 previously estimated to be ~10-9 for P. falciparum.307,308 In 
the absence of evidence for hypermutator P. falciparum lineages,307,309 the emergence 
of Ecu1110 pfcrt in the low-transmission setting of South America can be attributed 
to the convergence of multiple factors, including the extent of drug pressure on 
parasite populations, monoclonality of infections, rate of genetic exchange between 
strains during sexual stage development in the mosquito vector, and host 
immunity.240 Of note, our model did not specifically investigate mutational reversion 
and conversion events,310 which could overcome suboptimal peaks in the pfcrt 
adaptive landscape. Additional pfcrt mutations might also have been acquired via 
meiotic recombination between intermediate alleles in P. falciparum sexual stages. 




on the evolution of the Dd2 allele, which carries eight point mutations and dominates 
in Southeast Asia. This allele, or a similar isoform, earlier spread from Asia into 
Africa, resulting in the widespread loss of CQ efficacy.311 We postulate that the Dd2 
allele occurred via one or more major bursts of multiple mutations in a very limited 
number of parasites that spread under selective CQ pressure. Resultant population 
bottlenecks would have consequently diminished the effective population size, 
reduced competition with fitter wild-type parasites, and enabled mutant parasites to 
traverse fitness valleys toward high-level resistance.246 We note that the Dd2 allele, 
while more CQ-resistant than the 7G8 allele, demonstrates a significant fitness 
cost.232,243 Evidence of ongoing selection is provided by the emergence in Cambodia of 
the Cam734 pfcrt allele that harbors nine mutations (of which five are not found in 
Dd2) and that, while less CQ-resistant than Dd2, confers a level of parasite fitness 
comparable to the wild-type allele.243  
  Prior combinatorial modeling of pfdhfr evolution in yeast has shown that in 
vitro growth rates can serve as a robust assessment of organismal fitness.248 In the 
absence of a comprehensive way to account for all biological characteristics that 
impact fitness during the complex Plasmodium life cycle, we quantified the parasite 
growth index (fG) associated with specific pfcrt mutations. Our analysis was performed 
within the pathogenically relevant setting of asexual blood stage infection, during 
which parasite numbers can rapidly increase and be exposed to drug pressure. The 
critical role of the fG parameter and its interplay with parasite drug resistance (fD) is 
demonstrated by the modulation of evolutionary pathway accessibilities by the drug 
pressure coefficient a, which governed the relative influence of fG and fD in dictating 




asexual blood-stage parasite fitness. Most notably, EcuD I356L consistently 
contributed to enhanced in vitro parasite growth and was the most accessible primary 
mutational step in our CQ and md-CQ evolutionary excursions. Interestingly, this 
mutation also increased AS IC50 values (see Figure 2.3C), evoking the recent 
association of the I356T mutation in Southeast Asia with k13-mutant artemisinin-
resistant parasite populations.159 
  Recent studies with P. falciparum parasites differing in their pfcrt allele have 
found that CQR-conferring PfCRT isoforms cause the accumulation of high levels of 
hemoglobin-derived peptides in the parasite DV, which was associated with a 
deleterious impact on parasite growth.232 Future studies with our combinatorial pfcrt 
variants can be used to address the impact of specific mutations on hemoglobin 
digestion. Given that the evolution of pfcrt-mediated CQR also required successful 
transmission of variant PfCRT isoforms to the mosquito vector, examining the effect 
of specific pfcrt mutations on transmission is equally merited. This is of interest in 
light of rodent malaria studies that demonstrated a transmission advantage 
associated with the expression of the 7G8 pfcrt allele in CQ-treated gametocytes.268 
  Our genetic dissection recalls important insights from recent studies of CQ 
transport mediated by PfCRT isoforms heterologously expressed in either X. laevis or 
S. cerevisiae.208,312 In agreement with both studies, we observed EcuA K76T to be 
insufficient for CQR and uncovered direct contributions to CQR by additional PfCRT 
mutations, in particular EcuC N326D. Crystallographic insights, presently lacking for 
PfCRT or its homologs, indicate that even seemingly conservative substitutions (e.g. 
isoleucine to leucine, as in I356L) can significantly impact a protein’s structure and 




of basic, polar, and acidic side chains at residues 76, 220, and 326, respectively, 
suggests specific electrostatic and conformational requirements for PfCRT-mediated 
CQR. Our findings clarify previous discussions about the role of non-K76T mutations, 
which have been surmised to solely compensate for a loss of native PfCRT 
function.170,314,315 Of note, in vitro and field-based studies have also observed that 
parasites harboring the conventional CQR marker K76T can acquire novel PfCRT 
mutations (e.g. C101F or C350R) that abolish resistance to CQ (Eastman et al. 2011; 
Pelleau et al. 2015),137,218 emphasizing the need for caution in interpreting the CQ 
susceptibility status of isolates based on incomplete pfcrt genotypes. 
 Interestingly, as compared to Ecu1110 PfCRT, which lacks the C72S mutation, 
7G8 PfCRT conferred decreased rates of CQ transport,208,312 yet increased the degrees 
of CQR and in vitro growth in P. falciparum. It is noteworthy that, in studies of 
isogenic parasite lines encoding variant PfCRT haplotypes from the Philippines (PH1 
and PH2) that likewise only differ at residue 72, C72S conferred increased parasite 
CQR, yet in that case reduced parasite growth.243 Collectively, these findings 
underscore the impact of the overall mutational milieu on the roles of specific pfcrt 
mutations. Furthermore, they raise the prospect that certain mutations may alleviate 
CQ-mediated inhibition of native PfCRT function without having a direct impact on 
drug transport. 
  In selecting the geographically related 7G8 parasite genetic background303 for 
our combinatorial analysis, we aimed to single out the specific contributions of and 
interactions between pfcrt mutations in the evolution of the quintuple-SNP 7G8 pfcrt 
allele that is widespread throughout South America. Of note, we did not observe 




(namely EcuA and EcuABCD) in GC03 (CQ-sensitive) parasites, which were derived from 
an earlier genetic cross between HB3 (CQ-sensitive) and Dd2 (CQ-resistant) 
parasites.316 Consistent with this, previous allelic exchange studies have unmasked 
the incompatibility of pfcrt alleles with certain genetic backgrounds.217 As point 
mutations in the gene encoding the DV-resident P. falciparum multidrug resistance 1 
(PfMDR1) transporter have previously been found to modulate pfcrt-mediated CQR 
in some parasite strains,317 we speculate that pfmdr1 may serve as a secondary genetic 
determinant of CQR evolution. It is conceivable that pfmdr1 mutations might 
modulate the accessibility of pfcrt mutational trajectories, akin to the recently 
documented capacity of the GTP cyclohydrolase 1 (gch1) gene to enhance the 
accessibility of pfdhfr mutational trajectories in the evolution of pyrimethamine 
resistance.302 It remains to be determined whether PfMDR1 mutations S1034C and 
D1246Y,318 present in 7G8 but not Ecu1110 parasites, might partly account for the 
different in vitro growth rates observed between parasites encoding identical 
(Ecu1110) pfcrt alleles in these two genetic backgrounds. With the availability of 
validated genetic engineering strategies targeting both pfmdr1143 and pfcrt, further 
exploration of the epistatic interactions between these two critical drug resistance loci 
is now possible. 
  In our analysis, the Ecu1110 PfCRT haplotype was identified as an accessible 
mutational precursor of the quintuple-SNP 7G8 haplotype, which was relatively more 
CQ-resistant and less deleterious to parasite growth. Our data support the rise of the 
7G8 PfCRT haplotype in multiple geographical loci, where the Ecu1110-type 
haplotype has also been documented albeit at far lower frequencies,257,319 as well as 




the malaria-endemic world.259 To date, 7G8 pfcrt is at or near fixation in South 
America256,257 and the Western Pacific320 and has been identified in some surveys of 
parasites from Africa, the Indian subcontinent, and Southeast Asia.260,287,321,322 
Notably, prior CQ and AQ use has been documented in each of these geographical 
regions, leading to the earlier conjecture that AQ might have driven the selection for 
7G8 pfcrt.133,323 Considering inter-individual variability in peak blood CQ 
concentration achieved in response to the standard CQ dose of 25 mg/kg,105 the long 
terminal elimination half-life of CQ,324 as well as the deployment of prophylactic 
chloroquinated and/or amodiaquinated salts,130 we posit that the evolution of mutant 
pfcrt was likely facilitated by sustained sub-therapeutic drug concentrations in these 
populations. It is notable that in our delineation of pfcrt mutational pathways, md-
CQ, the active metabolite of CQ, was associated with a higher pathway predictive 
ability. A comparison of the pharmacology of CQ and md-CQ in the setting of the 
parasite DV will be essential to contextualizing these differences. To our knowledge, 
the accumulation of md-CQ in the parasite DV of CQ-resistant versus CQ-sensitive 
strains has yet to be explored. 
  Beyond CQR, our results also corroborate the pleiotropic role of PfCRT in 
modulating responses to critical first-line ACT component drugs and shed light on 
opposing selective pressures exerted by these compounds. Notably, parasites encoding 
7G8 pfcrt exhibited high-level cross-resistance between CQ and md-AQ (the active 
metabolite of AQ), whereas their susceptibility to both AS and LUM was significantly 
increased as compared to wild-type pfcrt-expressing parasites. Accordingly, sole use 
of the ACT formulation AS-AQ in geographical regions where the 7G8 PfCRT 




pfcrt evolution of the drug-resistant Ecu1110 and 7G8 alleles is further supported by 
the shared subset of mutational trajectories that were favored by CQ and AQ in our 
analysis.  
  Our combinatorial evolutionary modeling sheds light on the capacity of P. 
falciparum parasites to produce and sustain rare bursts of mutational events. In part 
due to selective pressures from one or more antimalarial agents acting upon an 
immutable host factor (e.g. heme), such mutational events were likely responsible for 
generating stably persisting drug-resistant pfcrt alleles that ultimately caused the 
global loss of CQ efficacy. Of particular concern is the recent emergence of artemisinin 
resistance in Southeast Asia, driven largely by k13 gene point mutations that arose 
in genetically distinct parasite subpopulations.158,160,161,325 Clonal expansions of k13-
mutant parasites suggest the selection of several favorable genetic backgrounds, 
resulting in population bottlenecks that might have facilitated parasite progression 
via fitness valleys.159 More recently, PPQ resistance in Southeast Asia is now leading 
to treatment failures with the first-line regimen DHA-PPQ.135,138,139 The genetic basis 
of PPQ resistance is presently elusive, partly because of clonal subpopulation 
structures that hinder initial genome-wide association studies to pinpoint causal 
resistance determinants. Genetic and drug susceptibility profiling of newly resistant 
strains can also inform the selection of drug regimens that exert opposing selective 
pressures as a means to constrain the evolution of multidrug-resistant parasites. 
Given the central role of chemotherapy in alleviating the worldwide burden of 
malaria, leveraging genomic surveillance of malarial parasites with evolutionary and 
population genetic principles will facilitate detection of selection signatures that could 
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Southeast Asia is an epicenter of multidrug-resistant Plasmodium falciparum strains. 
Selective pressures on the subcontinent have recurrently produced several allelic 
variants of parasite drug resistance genes, including the P. falciparum chloroquine 
resistance transporter (pfcrt). Despite significant reductions in the deployment of the 
4-aminoquinoline drug chloroquine (CQ), which selected for the mutant pfcrt alleles 
that halted CQ efficacy decades ago, the parasite pfcrt locus is continuously evolving. 
This is highlighted by the emergence and expansion of a highly mutated allele, 
Cam734 pfcrt, which has evolved the unique ability to confer parasite CQ resistance 
without an associated fitness cost. In the present study, we used pfcrt-specific zinc 
finger nucleases to genetically dissect this allele in the pathogenic setting of asexual 
blood-stage infection. Comparative analysis of the drug resistance and growth profiles 
of isogenic parasites encoding full-length or partial Cam734, Dd2 (the most common 
Southeast Asian variant), and wild-type pfcrt alleles revealed previously unknown 
roles of PfCRT mutations in modulating parasite susceptibility to multiple 
antimalarial therapeutic agents, including the rare A144F mutation that has not been 
observed beyond Southeast Asia and that proved essential for Cam734-mediated CQ 
resistance. These studies were leveraged with biochemical approaches that 
collectively uncovered distinct effects of mutant Cam734 and Dd2 PfCRT isoforms on 
parasite CQ transport and cellular metabolism, including hemoglobin catabolism and 
disposition of heme. Our studies provide important insights into the complex 
molecular basis of PfCRT-mediated antimalarial drug resistance, of relevance to 
global health efforts aiming to characterize novel alleles that may undermine the 





Human malaria remains a leading global health scourge in part due to multidrug 
resistance mechanisms evolved by Plasmodium falciparum, the protozoan species 
responsible for the most severe forms of disease.15 Artemisinin-based combination 
therapies (ACTs) are the current first-line means of controlling malarial infections, 
including ones dominated with drug-resistant strains that arose during previous 
selective sweeps resulting from the global use of chloroquine (CQ) and sulfadoxine-
pyrimethamine.181,249,326 The 4-aminoquinoline compound CQ was especially pivotal 
earlier in reducing mortality rates.327 However, the multi-focal emergence and spread 
of CQ resistance (CQR) contributed to stalled control measures and substantial 
increases in malaria-associated hospitalizations and deaths.270 Nevertheless, owing to 
its safety, affordability, and established efficacy against non-resistant parasites, CQ 
continues to be deployed in regions that are free of CQR or harbor CQ-sensitive P. 
vivax.114 Interestingly, studies of infections with CQ-resistant P. falciparum strains 
in Guinea-Bissau recently revealed a ~5-fold increase in CQ efficacy upon doubling 
the standard dose in children aged <5 years, the age demographic at highest risk for 
malaria mortality.115 These findings coincide with a reprise in efforts to delineate the 
molecular basis of resistance to antimalarials bearing the hallmark CQ-type quinoline 
moiety.328  
Genetic linkage and allelic replacement studies have previously identified pfcrt 
variants as the primary determinant of CQR.120,186 These findings are supported by 
evidence of directional selection for mutant pfcrt alleles in P. falciparum parasite 
populations exposed to extensive CQ pressure.329 A secondary, strain-dependent 




(pfmdr1) gene.128,143,330 Among CQ-resistant field isolates, PfCRT isoforms are 
comprised of geographically distinct clusters of single-nucleotide polymorphisms 
(SNPs), namely K76T and 3 to 8 additional point mutations. PfCRT K76T is a critical, 
albeit insufficient, determinant of parasite in vitro CQR.242 This mutation also 
predicts in vivo CQ treatment failure with high sensitivity but lower specificity.198 At 
the cellular level, PfCRT is a multi-pass transporter embedded in the parasite 
digestive vacuole (DV) membrane, with enigmatic functions that may include 
transport of ions and/or peptides.188,201,209,235 In the absence of PfCRT structural 
information, mutational approaches have led studies into the effect of specific PfCRT 
mutations on drug transport and parasite growth.208,242,312 
Point mutations in PfCRT have also been associated with altered parasite 
susceptibility to ACT component drugs, namely artemisinins and their partner drugs 
(including amodiaquine, lumefantrine, and piperaquine).149,159,213,218,323 This is of 
particular relevance given reports of emerging clinical resistance to these first-line 
agents.135,331 To various degrees, these compounds interfere with or are otherwise 
impacted by parasite-mediated catabolism of host hemoglobin (Hb), which supplies 
parasites with amino acids and helps maintain intracellular osmolarity.49,54,55,100 This 
catabolic process produces ferriprotoporphyrin IX heme, which in its reactive free 
form can exert lethal oxidative damage to the parasite.59 For quinoline-based 
antimalarials, drug-heme interactions in the DV cause toxicity by preventing 
incorporation of ferriprotoporphyrin IX heme dimers (β-hematin) into the non-reactive 
hemozoin (Hz) crystals that account for >95% of total heme.58,61 Consistent with this 
inhibition of β-hematin mineralization, CQ treatment of drug-sensitive D10 parasites 




ordered fringe pattern of Hz crystals.55 
Cell fractionation methods in P. falciparum have further demonstrated that, 
upon CQ treatment, the proportion of total heme present as Hz significantly 
diminishes, whereas the proportion corresponding to free heme increases.55 These 
responses are dose-dependent and inversely proportional to parasite survival.55 Prior 
to accessing its heme target, the weak base and lipophilic drug CQ traverses multiple 
lipid bilayers and accumulates in the acidic DV via weak-base trapping.203 CQR-
promoting PfCRT isoforms transport CQ out of the DV, consequently restricting CQ-
heme contacts and allowing Hz formation to proceed.114,188 Of note, the mutational 
status of pfcrt impacts DV volume and pH, both of which influence Hz formation 
kinetics.195 Interestingly, recent metabolomic analyses of CQ-resistant versus CQ-
sensitive P. falciparum strains detected a link between mutant pfcrt-mediated CQR 
and the elevated accumulation of peptides derived from Hb digestion.232 Given the 
reduced growth of CQ-resistant parasites (expressing the Dd2 or 7G8 mutant pfcrt 
alleles) relative to isogenic parasites encoding wild-type pfcrt, defective Hb 
degradation was postulated as a cellular basis for the reduced fitness associated with 
mutant pfcrt.232 Reduced fitness of these mutant alleles was confirmed in in vitro 
studies.232,243 and was observed at a population level in Africa, whereby removal of CQ 
pressure led to the attrition of mutant pfcrt-expressing parasites in favor of wild-type, 
CQ-sensitive strains.263,332 
A pathogen’s fitness refers to its capacity to support infection and generate new 
progeny. For P. falciparum parasites, fitness is influenced in part by growth of 
pathogenic asexual blood-stage parasites, selection, mosquito-human transmission, 




impaired in parasites expressing mutant, CQR-associated PfCRT isoforms.114,241 To 
date, over 50 distinct PfCRT haplotypes have been recorded.208 Of these, the Asian 
haplotype Dd2 (M74I/N75E/K76T/A220S/Q271E/N326S/I356T/R371I, thought to 
have disseminated throughout Africa) and the South American/Oceanian haplotype 
7G8 (C72S/K76T/A220S/N326D/I356L) account for the vast majority of global 
mutational patterns, with additional isoforms harboring four or more SNPs and 
resembling either the Dd2 (e.g. the six-SNP African variant GB4) or 7G8 (e.g. the four-
SNP South American variant Ecu1110) PfCRT haplotype.114 Recent modeling in P. 
falciparum suggests that pfcrt evolution occurred via punctuated periods of mutation 
too brief to allow fixation of partial (i.e. bearing 1-3 SNPs) resistance alleles, shedding 
light on physiologic constraints that explain the rarity of mutant pfcrt emergence in 
the field.242 Intriguingly, studies from Cambodia, an epicenter of multidrug resistance 
in P. falciparum, also revealed a highly polymorphic CQR-conferring pfcrt allele, 
Cam734.262 Cam734 pfcrt encodes nine mutations (see Table 3.1), five of which (N75D, 
A144F, L148I, I194T, T333S) are not found in the predominant Southeast Asian CQ-
resistant allele, Dd2 pfcrt.208 After Dd2, Cam734 pfcrt represents the second most 
common allele in Southeast Asia159 and, unlike other CQR-associated isoforms, 
supports parasite growth comparable to isogenic parasites encoding the CQ-sensitive, 
wild-type pfcrt allele.243 
The emerging Cam734 PfCRT isoform presents an opportunity to explore P. 
falciparum genetic determinants that concurrently confer drug resistance and fully 
neutralize fitness costs, a unique feature not associated with other mutant PfCRT 
variants. Herein, we leveraged drug resistance versus growth profiling of isogenic, 




biochemical approaches – including metabolomic, heme fractionation, and drug 
transport studies – in order to address the following questions:  (1) To what extent do 
the rare mutations present in Cam734 PfCRT directly impact parasite resistance to 
clinically employed antimalarials? (2) Which mutations are compensatory and thus 
serve to preserve PfCRT function? (3) Mechanistically, how does mutant Cam734 
PfCRT confer CQR without an accompanying fitness cost? Results provided herein 
broaden our present understanding of the mechanistic basis of CQR and inform field 
efforts that evaluate pfcrt genotypes as a tool to predict the drug susceptibility status 

























aMutations distinct from the GC03 (wild-type) PfCRT haplotype are shaded, with Cam734 PfCRT-specific mutations indicated in dark gray 
and all other mutations indicated in light gray. DNA substitutions encoding each PfCRT mutation are as follows: M74I: ATG→ATT; N75D: 
AAT→GAT; N75E: AAT→GAA; K76T: AAA→ACA; A144F: GCC→TTC; L148I: CTT→ATT; I194T: ATA→ACA; A2220S: GCC→TCC; Q271E: 
CAA→GAA; N326S: AAC→AGC; T333S: ACC→AGC; I356T: ATA→ACA; R371I: AGA→ATA. 
Table 3.1. Summary of PfCRT haplotypes.a 
 PfCRT residue 
PfCRT haplotype 74 75 76 144 148 194 220 271 326 333 356 371 
GC03 (wild-type) M N K A L I A Q N T I R 
Dd2 I E T A L I S E S T T I 
Cam734 I D T F I T S E N S I R 
Cam734 D75N I N T F I T S E N S I R 
Cam734 F144A I D T A I T S E N S I R 
Cam734 I148L I D T F L T S E N S I R 
Cam734 T194I I D T F I I S E N S I R 










Human RBCs (Interstate Blood Bank) harboring P. falciparum asexual blood-stage 
parasites were cultured at 2-4% hematocrit in RPMI-1640-based malaria cell culture 
medium supplemented with 0.5% Albumax II (Invitrogen).167 Cultures were incubated 
at 37°C, 5% O2 / 5% CO2 / 90% N2. 
 
Genetic modification of the parasite pfcrt locus 
Previously generated plasmids collectively encoding a set of full-length (e.g. Cam734) 
or back-mutated (e.g. Cam734 F144A) pfcrt alleles were used as templates for PCR 
amplification of pfcrt exons 2 through 13 with primers p1 + p2 (see Table 3.2 for all 
primer details). To generate pfcrt donor plasmids, these amplicons were cloned into 
the pcrtDd2-hdhfr donor plasmid backbone295 using NcoI and SalI restriction sites.  
 A schematic of our genetic engineering strategy is shown in Figure 3.1A. 
Briefly, GC03 parasites were transfected with 40 μg donor plasmid (pcrt-hdhfr) and 
subjected to pressure with 2.5 nM WR99210 (Jacobus Pharmaceuticals). Donor 
plasmid-enriched parasites were subsequently transfected with 40 μg pZFNcrt-bsd and 
pressured with 2.5 nM WR99210 and 2 μg/ml Blasticidin HCl (Invitrogen) for six days, 
followed by prolonged pressure with 2.5 nM WR99210. To screen for desired genetic 
modification events (see Figure 3.1B), recombinant parasites were analyzed by direct 
blood PCR (KAPA Biosystems), as earlier described.242 Bulk cultures demonstrating 
evidence of genetic editing were cloned by limiting dilution333 and two parasite clones 


























aNucleotides corresponding to restriction sites are underlined. F, forward; R, reverse; gDNA, genomic DNA; pbcrt, P. berghei chloroquine 
resistance transporter; UTR, untranslated region. 
Table 3.2. Primers used in this study.a 
Primer Oligonucleotide sequence (5’ → 3’) Description Lab name 
p1 AACCATGGATTTATTGTGTAATAATTGAATCGACG NcoI-pfcrt exon 13 R p1640 
p2 CCCTTGTCGACCTTAACAGATGGCTC SalI-pfcrt intron1-exon 2 F p3519 
p3 TCAAACATGACAAGGGAAATAGT pfcrt exon 5 F p2427 
p4 CCAAGAATAAACATGCGAAACC pfcrt exon 7 R p3806 
p5 CTTGAATTCGACCTTAACAGATGGCTCAC pfcrt exon 2 F p3264 
p6 CTTATCGATAAGCAGAAGAACATATTAATAGGAATACTTAATTG pfcrt exon 3 R p3265 
p7 CTTGGGCCCAAGTTGTACTGCTTCTAAGC pfcrt gDNA 5′ UTR F p3404 
p8 CTCGAGATGGTTGGTTCGCTAAACTGC hDHFR F p3315 
p9 TTGACCCTTATATATTCCACCCA pfcrt gDNA 3′ UTR R p3403 











Figure 3.1. Genetic modification of the pfcrt locus via zinc finger nucleases (ZFNs).  
(A) Genetic engineering strategy. Briefly, parasites were transfected with a donor template 
plasmid (pcrt-hdhfr) with the coding region corresponding to exons 2 to 13 (e2-13) of a pfcrt 
allele of interest (indicated in purple; see Table 3.1 for full list of pfcrt alleles). Donor plasmids 
also include the following: a P. berghei crt (pbcrt) 3′ UTR sequence, a human dhfr (hdhfr) 
selection cassette, and flanking left (~0.4 kb upstream of the intron 1-exon 2 boundary) and 
right (~1 kb native 3′ UTR) homology regions.295 Donor plasmid-enriched parasites were 
transfected with pZFNcrt-bsd, which encodes a pair of pfcrt-specific ZFNs (ZFNL and ZFNR) via 
the calmodulin (cam) promoter and includes the blasticidin S deaminase (bsd) selection 
cassette. Operating as an obligate heterodimer, ZFNL and ZFNR catalyze a double-stranded 
DNA break in the pfcrt intron 1-exon 2 region (indicated with a red bolt). Recombinant parasites 
that were successfully generated via DNA repair mechanisms encode pfcrt e2-13 bearing 
mutations of interest. Recombinant parasites were cloned by limiting dilution, genetic editing 
was verified by diagnostic PCR (see Figure 3.1B), and sequence integrity was verified at the 
DNA and RNA levels. (B) Diagnostic PCRs of representative recombinant parasites encoding 
full-length (GC03Cam734) and back-mutated (GC03Cam734 F144A) pfcrt alleles. Controls include 
genetically unedited parental parasites (GC03), unedited donor plasmid-enriched parasites 
(GC03 + either pcrtCam734-hdhfr or pcrtCam734 F144A-hdhfr) and donor plasmids alone (pcrtCam734-
hdhfr or pcrtCam734 F144A-hdhfr). Primer (p) locations are illustrated in Figure 3.1A. PCR 
amplicons for ZFN-edited lines demonstrated the expected sizes of 0.4 kb (p5+p6), 1.2 kb 







To verify sequence integrity of parasite clones, the pfcrt locus was PCR-amplified 
using primers p10 + p7 and subsequently sequenced with primers p3 and p4. Sequence 
integrity was also verified at the transcript level by RT-PCR, as previously 
described.242 The previously generated295 GC03GC03 and GC03Dd2 lines as well as the 
unedited GC03 parental line were also included in subsequent analyses.  
 
Drug susceptibility assays 
Drug inhibitory concentrations that result in 50% (IC50) or 90% (IC90) growth 
inhibition were determined for a panel of drugs (CQ ± 0.8 μM verapamil [VP], 
monodesethyl-CQ, monodesethyl-amodiaquine, quinine, piperaquine, lumefantrine, 
artesunate, and pyronaridine), as previously described.217 Using an Accuri C6 flow 
cytometer, growth of parasites after 72 h exposure to drug was quantified via SYBR 
Green I and MitoTracker Deep Red staining. Reversibility of CQR by 0.8 μM VP was 
expressed as the CQ response modification index (RMI), equivalent to the quotient of 
the CQ+VP IC50 divided by the CQ IC50.298 Statistical significance was determined via 
non-parametric Mann-Whitney U tests using GraphPad Prism 6 software. 
 
In vitro growth assays and derivation of growth selection coefficients 
As a proxy for in vitro fitness, growth of parasite lines was assessed in 1:1 co-culture 
assays with the fluorescent reporter line NF54eGFP, using previously described 
methods.242 Briefly, 1:1 co-cultures consisting of the reporter line (GFP+) and a single 
pfcrt-modified test line (GFP–) were grown for 10 generations, and parasitemias were 
maintained between 0.3% and 8%. The GFP– proportion of parasites was determined 




SYTO61, which identifies infected RBCs (iRBCs). 
The ratio of the frequencies of the GFP– test strain (pt) and the GFP+ reporter 
strain (qt) at time t was natural log-transformed and used to calculate the fitness (ω) 
of the test allele as per ln (
𝑝𝑡
𝑞𝑡
) = ln (
𝑝0
𝑞0
) + 𝑡ln(𝜔).242 The relative fitness for each test 
strain was normalized to that of the GC03Cam734 parasite line, which encodes the full-
length Cam734 pfcrt allele, and was expressed as the normalized relative fitness (ω′). 
The per-generation selection coefficient (s) for each test strain was subsequently 
computed as per the relationship s = ω′ – 1.247 Statistical significance was assessed via 
two-way ANOVA with Sidak’s post-hoc test using GraphPad Prism 6 software. 
 
Metabolite extraction and mass spectrometric analysis 
All parasite culturing, metabolite extraction, mass spectrometry data acquisition, and 
data analyses were conducted using previously established methods.232 Briefly, after 
double synchronization with 5% sorbitol, late-stage (~36-42 h) P. falciparum 
trophozoites were magnetically purified using CS columns and a SuperMACS 
magnetic separator (Miltneyi Biotec). Eluted iRBCs were resuspended at 0.4% 
hematocrit and allowed to recover for 2 h at 37°C in a tissue culture incubator. 
Following recovery, cells were rapidly cooled to 4°C and pelleted by centrifugation at 
2,000×g for 5 min. Media was then aspirated away from the iRBC pellets, and 
metabolites were extracted by resuspending cells in cold (4°C) 90% methanol, 
homogenized by vortexing, and centrifuged at 10,000×g for 5 min at 4°C. The 
supernatant metabolite extracts were harvested and stored at -80°C until 
metabolomic analysis. Just prior to analysis, samples were dried under a stream of N2 




in HPLC-grade water. High-resolution mass spectrometry data were acquired on a 
Thermo Fisher Exactive Mass spectrometer in negative mode using 25 min reverse 
phase gradients using ion-pairing chromatography.232 Metabolites were identified 
using the known chromatographic retention times of standards, and metabolite 
signals were quantified using MAVEN.232 To allow for more direct metabolite-to-
metabolite comparison of phenotypes, raw mass spectrometry signals were expressed 
as z-scores. Briefly, for each metabolite, the mean expected signal (x̅ ) was defined as 
the mean intensity observed in the control line (GC03Dd2). Likewise, the standard 
deviation (s) for each metabolite signal was calculated from signals observed in the 
GC03Dd2 line (deduced from 4 replicates acquired from 3 independent harvests). The 
z-score (zi) for each observed signal (xi) was then computed as per the relationship zi 
= [xi – x̅ ]/s and plotted according to metabolite class. For summary statistics, z-scores 
were calculated from the signals observed for each compound class. These classes were 
comprised of metabolites that are directly associated with a metabolic pathway (e.g. 
TCA metabolism included TCA intermediates as well as the TCA-associated amino 
acid glutamate). P values were computed by one-way ANOVA. All data analyses and 
statistical test were conducted using custom in-house software written in the R 
statistical software environment. 
 
Heme fractionation experiments 
The heme fraction profiles of pfcrt-modified GC03GC03, GC03Dd2, and GC03Cam734 
parasites were determined following recently published protocols.334 First, parasite 
growth in response to CQ was determined using the lactate dehydrogenase assay.335 




early ring-stage parasites in the absence or presence of CQ in multiples (0.5×, 1×, 2×, 
2.5×, and 3×) of the biological CQ IC50. After 32 h, iRBCs were treated with 1% saponin 
to release mature trophozoites, followed by hypotonic lysis and centrifugation. 
Supernatants were treated with 2% SDS and 2.5% pyridine, yielding the Hb fraction. 
Pellets were treated with 2% SDS and 2.5% pyridine, sonicated, and centrifuged, and 
supernatants were removed to isolate the free heme fraction. The remaining pellets 
were solubilized in 2% SDS and 0.1 M NaOH, sonicated, neutralized with HCl, and 
treated with 2% SDS and 2.5% pyridine to generate the Hz fraction. For each fraction, 
the UV-visible spectrum of heme present as a heme-pyridine complex was measured 
with a multi-well plate reader (Spectramax 340 PC, Molecular Devices). The 
abundance of Hb, free heme, and Hz species was reported as a percent and as an 
absolute amount of heme Fe per cell. Cells were quantified using flow cytometry, as 
previously described.334 Statistical significance was assessed via unpaired t tests with 
Welch’s correction using GraphPad Prism 6 software. 
 
Yeast drug transport assays 
Cultivation, transfection, and quantitative growth rate analysis of Saccharomyces 
cerevisiae yeast strains was performed following previously detailed protocols.208,281 
Briefly, CH1305 yeast strains were transfected with either pYES2 (blank vector) or 
pYES2-derived plasmids encoding galactose/raffinose-inducible, codon-optimized 
PfCRT isoforms GC03 (HB3; wild-type), Cam734, Cam738, or Dd2. Quantitative 
assessment of yeast growth, a validated proxy for CQ transport,336 was done in PfCRT-
inducing (galactose/raffinose) or PfCRT-noninducing (glucose) conditions, with a 




triplicate with a Tecan GENios microplate reader following established parameters.208 
PfCRT protein expression of yeast lines was evaluated using Western blot analysis. 
 
Comparison of protein levels of yeast-expressed PfCRT isoforms 
Protein extracts from yeast strains harboring V5-tagged PfCRT isoforms or empty 
vector were prepared and subjected to Western blot analysis, as in previous studies.336 
Briefly, total protein in the yeast crude membrane fraction was quantified using the 
amido black assay. 7 µg total protein was subsequently incubated at 65°C for 5 min, 
electrophoretically separated on a 12% SDS-PAGE gel, and transferred onto a PVDF 
membrane. Membranes were incubated with horseradish peroxidase-conjugated anti-
V5-antibodies, and the 51.8-kDa PfCRT-V5 protein was detected by 
chemiluminescence using Amersham Hyperfilm ECL. 
 
Spinning disk confocal microscopy (SDCM) 
Measurements of parasite digestive vacuole (DV) volumes, data acquisition, 
deconvolution, and 3D restoration were performed as previously described191,195,337 
using a customized Perkin-Elmer spinning disk confocal microscope. Images were 
acquired with a 491 nm laser line at 200 ms exposure and 35% laser power. For CQ 
treatment, cultures were treated for 30 min in malaria culture media with 0.5% 
Albumax containing two times the 50% lethal dose of CQ (2× CQ LD50, corresponding 
to 200 nM for GC03GC03 and GC03Cam734 F144A; 1.2 μM for GC03Cam734; and 2.2 μM for 
GC03Dd2, as determined using established protocols.338 These concentrations 
collectively span the range of 12×–18× CQ IC50). Cells were mounted onto a coverslip 




Single-cell photometry (SCP) 
SCP experiments were done as previously detailed197,339 using a custom system 
comprised of a Nikon Diaphot microscope, a Photometrics Sensys 12-bit CCD camera, 
associated optics, custom perfusion cells, and custom dynamic thresholding software. 
Parasite cultures were treated for 30 min with media with 0.5% Albumax and a 
concentration of CQ corresponding to 2× CQ LD50 of each line (as detailed for SDCM 
experiments above). To measure pH, parasites were perfused with Hanks’ balanced 




































Generation of isogenic parasites encoding full-length or back-mutated 
Cam734 pfcrt alleles 
To dissect the contributions of the rare mutations comprising Cam734 PfCRT to 
parasite drug resistance and fitness, we utilized a recently established295 gene editing 
approach (Figure 3.1) with pfcrt-specific zinc finger nucleases (ZFNs). Starting with 
the GC03 strain, a CQ-sensitive progeny of the HB3×Dd2 genetic cross,184 we 
engineered isogenic parasites encoding full-length Cam734 pfcrt (GC03Cam734; PfCRT 
haplotype of recombinant lines listed in superscript) as well as partial Cam734-like 
isoforms containing “back-to-wild-type” mutations at PfCRT residues 75, 144, 148, 
194, and 333 (see Table 3.1). Our parasite panel also included the GC03GC03 and 
GC03Dd2 lines, which encode the wild-type GC03 (CQ-sensitive) and mutant Dd2 (CQ-
resistant) haplotypes, respectively (see Table 3.1). For each recombinant line, two 
independent clones were selected, and pfcrt sequence integrity was verified using 
sequencing primers listed in Table 3.2. Recombinant parasite design and validation 
is further detailed in Figure 3.1 and Methods.  
 
Cam734 pfcrt-defining mutations impact parasite responses to CQ 
We examined the roles of Cam734 PfCRT-constituent mutations in mediating CQR by 
assessing the responses of recombinant, pfcrt-modified parasites, along with 
genetically unmodified GC03 and Dd2 strains (see Table 3.1), to CQ and its clinically 
relevant metabolite, monodesethyl-CQ (md-CQ). The latter compound was included 




resistant lines and may have been the primary evolutionary selective agent.120,242 
Using 72 h flow cytometry-based drug susceptibility assays, we determined 
antimalarial drug concentrations that result in 50% (IC50) and 90% (IC90) inhibition 
of parasite proliferation (Table 3.3). For all drug susceptibility results, statistical 
comparisons were performed against GC03Cam734 parasites, which encode full-length 
Cam734 pfcrt. We note that, in our analysis, recombinant GC03 parasites encoding 
the major Southeast Asian pfcrt variants Cam734 and Dd2 conferred moderate (~5-
fold and ~14-fold) and high-level (~26-fold and ~43-fold) increases in CQ and md-CQ 
IC50 values, respectively, when compared to CQ-sensitive GC03GC03 parasites (Table 
3.3). This is consistent with earlier P. falciparum drug susceptibility studies.243 
CQ (Figure 3.2A; Table 3.3) and md-CQ (Figure 3.2B; Table 3.3) susceptibility 
profiles revealed direct roles for multiple Cam734 PfCRT-defining mutations in 
conferring CQR. Among these, PfCRT A144F was indispensable for CQ and md-CQ 
resistance (compare GC03Cam734 with the GC03Cam734 F144A line). The Cam734 F144A 
PfCRT haplotype (see Table 3.1) is equivalent to Cam738 PfCRT, which, like Cam734, 
was initially documented in Cambodia but, in contrast, did not achieve wide regional 
spread.262 Notably, although this haplotype harbors K76T and ≥3 additional 
mutations, its mutational configuration is nevertheless insufficient for CQR (see 
Figure 3.2A and Table 3.3). This underscores the notion of K76T as an insufficient 
predictor of CQR status and supports the fact that CQR can be abolished through the 
acquisition of additional PfCRT substitutions (e.g. C101F, L272F, C350R), even when 
K76T is present.137,196,199,208 
Our analysis also found contributory roles for PfCRT mutations N75D, L148I, 








Table 3.3. Antimalarial IC50 and IC90 values of pfcrt-modified and reference parasite lines.a 
  GC03Cam734 back-mutants     
 GC03Cam734 D75N F144A I148L T194I S333T GC03GC03 GC03Dd2 GC03 Dd2 
CQ IC50 73.4 ± 5.2 42.8 ± 4.7 11.4 ± 1.1 34.2 ± 3.3 56.1 ± 3.7 38.4 ± 4.5 14.0 ± 1.6 189 ± 19.2 11.8 ± 0.7 217 ± 16.7 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.002 0.0001 0.0006 0.06 0.0008 < 0.0001 < 0.0001 0.0003 0.0003 
CQ IC90 148 ± 10.1 91.4 ± 9.0 27.8 ± 2.2 87.2 ± 3.9 114 ± 7.1 81 ± 9.3 23.1 ± 2.1 329 ± 25.6 20.9 ± 2.2 412 ± 30 
n 12 6 6 5 5 6 10 9 5 5 
P – 0.002 0.0001 0.0003 0.08 0.0004 < 0.0001 < 0.0001 0.0003 0.0003 
CQ+VP IC50 40.5 ± 4.0 41.1 ± 8.4 10.8 ± 2.6 31.2 ± 1.9 33.2 ± 3.0 23.4 ± 6.0 18.0 ± 2.1 29.2 ± 4.6 14.8 ± 2.9 68.7 ± 10.2 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.75 0.002 0.08 0.15 0.024 0.0011 0.05 0.006 0.027 
CQ+VP IC90 103 ± 9.2 86.4 ± 16.5 30.8 ± 7.8 89.8 ± 9.7 88.3 ± 7.9 63.6 ± 15.7 31.9 ± 4.5 110 ± 13.7 23.2 ± 4.5 156 ± 14.1 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.58 0.0013 0.15 0.12 0.032 0.0002 0.67 0.002 0.020 
md-CQ IC50 489 ± 36.1 320 ± 26.5 31.9 ± 3.5 131 ± 17.7 404 ± 15.2 317 ± 27.2 18.6 ± 0.8 804 ± 60.2 20.4 ± 1.6 948 ± 83.2 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.003 0.0001 0.0003 0.10 0.007 < 0.0001 < 0.0001 0.0003 0.0003 
md-CQ IC90 925 ± 66.7 653 ± 74.5 104 ± 4.6 301 ± 34.6 823 ± 38.1 650 ± 68.1 34.6 ± 1.6 1582 ± 94 36.9 ± 4.0 1522 ± 100 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.007 0.0001 0.0003 0.18 0.007 < 0.0001 < 0.0001 0.0003 0.002 
md-AQ IC50 61.1 ± 3.1 40.9 ± 2.1 15.2 ± 1.6 27.0 ± 1.0 50.9 ± 3.1 42.5 ± 3.8 14.6 ± 1.3 58.8 ± 3.7 13.8 ± 1.5 66.9 ± 7.4 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.0004 0.0001 0.0003 0.08 0.003 < 0.0001 0.75 0.0003 0.57 
md-AQ IC90 107 ± 4.4 67.9 ± 6.0 24.8 ± 2.3 52.4 ± 2.4 92.0 ± 9.0 72.9 ± 8.2 21.4 ± 2.2 105 ± 7.1 20.1 ± 3.3 111 ± 5.5 
n 12 6 6 5 5 6 10 10 5 5 
P – 0.0008 0.0001 0.0003 0.08 0.003 < 0.0001 0.53 0.0003 0.57 














Table 3.3. continued 
  GC03Cam734 back-mutants     
 GC03Cam734 D75N F144A I148L T194I S333T GC03GC03 GC03Dd2 GC03 Dd2 
QN IC50 37.2 ± 4.2 39.7 ± 5.8 23.9 ± 2.3 26.8 ± 3.4 36.4 ± 1.8 37.4 ± 4.8 55.1 ± 4.6 39.3 ± 4.2 65.4 ± 11.5 91.7 ± 11.7 
n 10 6 6 5 3 6 10 10 3 3 
P – 0.71 0.011 0.10 0.81 0.86 0.0052 0.52 0.028 0.007 
QN IC90 144 ±11.0 114 ± 13.1 77.9 ± 6.7 120 ±15.8 114 ± 12.4 108 ± 10.0 171 ± 6.5 157 ± 11.6 173 ± 6.3 290 ± 52.5 
n 10 6 6 5 3 6 10 10 3 3 
P – 0.11 0.001 0.20 0.24 0.07 0.09 0.43 0.16 0.014 
PPQ IC50 9.1 ± 0.6 11.9 ±1.2 11.1 ± 0.6 14.1 ± 1.5 9.8 ± 1.2 9.8 ± 0.5 11.1 ± 0.5 13.3 ± 1.1 10.4 ± 0.6 12.2 ± 0.7 
n 8 6 6 3 3 6 8 8 3 3 
P – 0.11 0.08 0.049 0.38 0.49 0.10 0.007 0.50 0.049 
PPQ IC90 21.4 ± 1.9 25.0 ± 1.2 26.6 ± 0.6 28.6 ± 1.2 21.3 ± 3.2 22.0 ± 1.7 20.4 ± 1.8 27.9 ± 2.7 17.1 ± 2.2 25.9 ± 1.2 
n 8 6 6 3 3 6 8 8 3 3 
P – 0.28 0.08 0.049 0.67 > 0.99 0.70 0.07 0.17 0.28 
LUM IC50 1.03 ± 0.07 1.30 ± 0.14 1.07 ± 0.04 1.09 ± 0.07 1.37 ± 0.21 1.32 ± 0.10 2.13 ± 0.13 1.08 ± 0.10 2.08 ± 0.07 1.07 ± 0.03 
n 6 5 5 2 2 5 6 6 3 2 
P – 0.13 0.65 0.64 0.14 0.052 0.002 0.91 0.024 0.86 
LUM IC90 4.63 ± 0.37 4.94 ± 0.41 4.42 ± 0.21 4.60 ± 0.05 4.98 ± 0.56 5.40 ± 0.58 7.56 ± 0.47 5.73 ± 0.81 8.33 ± 0.31 6.52 ± 0.57 
n 6 5 5 2 2 5 6 6 3 2 
P – 0.77 0.87 0.64 0.43 0.42 0.004 0.42 0.024 0.14 
AS IC50 0.67 ± 0.08 0.84 ± 0.12 0.52 ± 0.07 0.86 ± 0.05 0.83 ± 0.16 0.73 ± 0.08 1.17 ± 0.13 0.73 ± 0.11 0.90 ± 0.01 1.83 ± 0.21 
n 7 5 5 7 2 5 7 7 3 6 
P – 0.29 0.20 0.18 0.39 0.56 0.007 0.56 0.18 0.0012 
AS IC90 2.31 ± 0.36 2.33 ± 0.29 1.94 ± 0.08 3.37 ± 0.33 2.24 ± 0.03 2.31 ± 0.11 3.57 ± 0.35 2.53 ± 0.45 2.83 ± 0.29 4.03 ± 0.41 
n 7 5 5 7 2 5 7 7 3 6 
P – 0.55 0.50 0.053 0.50 0.36 0.018 0.31 0.18 0.022 














aIC50 and IC90 values (nM) indicate the mean ± SEM, as determined in 2 to 12 independent assays performed in duplicate. CQ + VP assays 
were performed with 0.8 μM VP. CQ, chloroquine; VP, verapamil; md-CQ, monodesethyl-chloroquine; md-AQ, monodesethyl-amodiaquine; 
QN, quinine; PPQ, piperaquine; LUM, lumefantrine; AS, artesunate; PND, pyronaridine; n, number of assays; P values were determined in a 
non-parametric Mann-Whitney U test versus the parasite line GC03Cam734. P values <0.05 are indicated in bold and shaded in gray. 
Table 3.3. continued 
  GC03Cam734 back-mutants     
 GC03Cam734 D75N F144A I148L T194I S333T GC03GC03 GC03Dd2 GC03 Dd2 
PND IC50 5.0 ± 0.3 6.2 ± 0.3 5.9 ± 0.3 5.0 ± 0.4 5.6 ± 0.8 5.9 ± 0.3 6.5 ± 0.2 5.3 ± 0.5 5.8 ± 0.4 5.7 ± 0.7 
n 8 4 4 3 3 4 6 6 5 3 
P – 0.073 0.15 0.78 0.50 0.15 0.008 0.41 0.17 0.19 
PND IC90 7.9 ± 0.4 8.7 ± 0.1 8.7 ± 0.1 8.4 ± 0.6 8.8 ± 0.3 8.7 ± 0.1 9.7 ± 0.6 9.1 ± 0.6 8.7 ± 0.1 8.7 ± 0.1 
n 8 4 4 3 3 4 6 6 5 3 
















Figure 3.2. Drug resistance profiles of pfcrt-modified and reference parasite lines. (A) Parasite 
chloroquine (CQ) responses and verapamil (VP) reversibility of CQ resistance. Briefly, flow 
cytometry was used to assess growth of parasites following 72 h exposure to the indicated 
antimalarial drugs. Bar graphs correspond to mean ± SEM IC50 or response modification index 
(RMI) values. The RMI of CQ IC50 is equivalent to (IC50 for CQ + VP) ÷ (IC50 for CQ only), as 
detailed in Methods. (B) Parasite responses to monodesethyl (md)-chloroquine, md-
amodiaquine, quinine, and piperaquine. Bar graphs indicate mean ± SEM IC50 values. Results 
encompass 3 to 12 independent assays conducted in duplicate. Statistical differences were 
determined via non-parametric Mann-Whitney U tests, using the mean IC50 value of Cam734 
pfcrt-expressing GC03Cam734 parasites as the comparator. Antimalarial drug susceptibility and 
CQ RMI data are summarized along with corresponding statistical tests in Table 3.3 and Table 












































md-CQ (Figure 3.2B; Table 3.3), as parasite lines encoding back-mutations at each of 
the corresponding PfCRT residues demonstrated significant reductions in resistance 
(range of 1.5 to 3.7-fold reductions in CQ or md-CQ IC50 values for GC03Cam734 D75N, 
GC03Cam734 I148L, and GC03Cam734 S333T as compared to GC03Cam734 parasites). Thus, to 
various degrees, N75D, A144F, L148I, and T333S directly contribute to CQR and are 
not merely compensatory in terms of restoring function or fitness to mutant PfCRT 
isoforms. Only the I194T mutation was found to not significantly contribute to CQR. 
A defining molecular feature of P. falciparum CQR is resistance reversal by the 
calcium channel blocker verapamil (VP).126 The extent to which VP modifies CQR, 
referred to as the CQ response modification index (RMI), is PfCRT isoform-specific 
and is calculated by dividing the IC50 value for CQ in the presence of 0.8 µM VP by 
the IC50 value for CQ alone.298 Our CQR reversibility results are depicted in Figure 
3.2A and Table 3.4. Consistent with previous studies,243 isogenic parasites expressing 
PfCRT variants Cam734 (GC03Cam734) and Dd2 (GC03Dd2) exhibited moderate and 
high-level CQR reversibility (2.4-fold and 8.1-fold reductions in the CQ RMI, 
respectively, versus the GC03GC03 line that showed no CQR reversibility). Among the 
recombinant lines encoding partial, back-to-wild-type Cam734 PfCRT haplotypes, 
GC03Cam734 D75N and GC03Cam734 I148L parasites exhibited statistically significant 
increases in CQ RMI values as compared to GC03Cam734 parasites, highlighting critical 
roles for mutations N75D and L148I in the VP reversibility effect. These findings 
uncover a novel role for PfCRT residue 148 in mediating VP reversal of CQR and align 







Table 3.4. Verapamil-mediated CQ resistance reversibility of pfcrt-modified and reference parasite lines.a 
Line    Line    Line   
GC03Cam734 
RMI 0.54 ± 0.04  
GC03Cam734 T194I 
RMI 0.59 ± 0.03  
GC03 
RMI 1.2 ± 0.21 
n 12  n 5  n 5 
P –  P 0.63  P 0.025 
GC03Cam734 D75N 
RMI 0.92 ± 0.15  
GC03Cam734 S333T 
RMI 0.57 ± 0.11  
Dd2 
RMI 0.31 ± 0.04 
n 6  n 6  n 5 
P 0.020  P 0.84  P 0.0048 
GC03Cam734 F144A 
RMI 0.90 ± 0.17  
GC03GC03 
RMI 1.3 ± 0.15  
 
  
n 6  n 10    
P 0.13  P < 0.0001    
GC03Cam734 I148L 
RMI 0.93 ± 0.07  
GC03Dd2 
RMI 0.16 ± 0.03     
n 5  n 10  
 
  
P 0.0002  P < 0.0001    
 
aReversibility of chloroquine (CQ) resistance by 0.8 µM verapamil (VP) is indicated as the CQ response modification index (RMI), 
equivalent to (IC50 for CQ+VP) ÷ (IC50 for CQ only). Shown are mean RMI ± SEM values, as determined in 5 to 12 independent 
assays. n, number of assays. P values were determined in a non-parametric Mann-Whitney U test versus the parasite line 


















Cam734 pfcrt-defining mutations impact parasite responses to clinically 
important antimalarials  
As PfCRT variants can modulate parasite susceptibility to a host of antimalarials,114 
we also assessed the effects of Cam734 PfCRT-constituent mutations on parasite 
responses to clinically employed antimalarials beyond CQ (Figure 3.2 and Figure 3.3). 
We explored the following: (1) ACT partner drugs, including monodesethyl-
amodiaquine (md-AQ, the active metabolite of AQ), lumefantrine (LUM), piperaquine 
(PPQ), and pyronaridine (PND); (2) the ACT artemisinin derivative artesunate (AS); 
and (3) quinine (QN), a second-line agent used to treat severe malaria. In keeping 
with known cross-resistance relationships between CQ and AQ,114 we observed 
significant reductions in md-AQ resistance (Figure 3.2B; Table 3.3) among parasites 
harboring reversions of mutations N75D, A144F, L148I, and T333S (range of 1.4 to 
4.0-fold reductions in md-AQ IC50 values for GC03Cam734 D75N, GC03Cam734 F144A, 
GC03Cam734 I148L, and GC03Cam734 S333T as compared to GC03Cam734 parasites). Reversion 
of PfCRT mutation A144F back to wild-type (compare GC03Cam734 F144A with 
GC03Cam734) was likewise associated with a significant (~1.6-fold) reduction in QN IC50 
(Figure 3.2B; Table 3.3), emphasizing A144F as a critical determinant of parasite 
resistance to multiple quinoline-type antimalarials. We further detected a modest 
(~1.5-fold), statistically significant increase in PPQ IC50 for the GC03Cam734 I148L line, 
as compared to GC03Cam734. This highlights the capacity of pfcrt mutations to impact 
parasite PPQ resistance, a rising problem in Southeast Asia with a presently unclear 
genetic basis.135,136,138 As compared to wild-type (GC03) pfcrt, full-length Cam734 
sensitized parasites to LUM, AS, and PND, and this phenotype was not modulated by 










Figure 3.3. Parasite responses to lumefantrine, artesunate, and pyronaridine. Following 72 h 
exposure of parasites to the indicated antimalarial drugs, parasite growth was assessed using 
flow cytometry. Bar graphs correspond to mean ± SEM IC50 values. Results encompass 2 to 
12 independent assays conducted in duplicate. Statistical differences were determined via 
non-parametric Mann-Whitney U tests, using the mean IC50 value of Cam734 pfcrt-expressing 
GC03Cam734 parasites as the comparator. IC50 and IC90 values are summarized along with 

















































Cam734 pfcrt-defining mutations offset parasite fitness costs in vitro  
Previous efforts to disrupt the pfcrt gene demonstrated that it is essential for survival 
of blood-stage P. falciparum parasites.229 Furthermore, pfcrt mutations can be 
deleterious to parasite growth,242,243 a measurable phenotype that serves as a proxy 
for fitness and reflects parasite functional requirements.239 To evaluate the 
contributions of Cam734 pfcrt-constituent SNPs to parasite growth, we used 
previously established co-culture methods242,299 to determine the relative growth rates 
of our isogenic, pfcrt-modified parasites. Briefly, this entailed setting up 1:1 co-
cultures consisting of equal proportions of a CQ-sensitive, wild-type pfcrt-expressing 
GFP-positive (GFP+) reporter line and a pfcrt-modified GFP-negative (GFP–) test line 
(see Methods). To assess the impact of a sub-therapeutic dose of CQ on parasite 
growth, experiments were performed in the absence or presence of 7.5 nM CQ (~0.5× 
CQ IC50 of CQ-sensitive GC03GC03 parasites). These co-cultures were monitored for 10 
generations, with the GFP– proportion of co-culture determined every third day by 
flow cytometry (Figure 3.4). As detailed in Methods, these data were used to derive 
the per-generation selection coefficient (s) of each test line (Figure 3.5; Table 3.5). The 
s parameter serves as a proxy for the degree of fitness of a given parasite line, as 
compared to GC03Cam734 parasites, which encode the full-length Cam734 pfcrt allele 
(s=0, s>0, and s<0 indicate fitness levels equal, greater than, or less than that of 
GC03Cam734 parasites). 
  As determined in our in vitro growth assays (Figure 3.5; Table 3.5), the growth 
rate of parasites encoding Cam734 pfcrt was markedly increased relative to isogenic 
parasites encoding mutant Dd2 pfcrt (s=-0.25 for GC03Dd2 versus GC03Cam734) and was 













Figure 3.4. In vitro growth plots of pfcrt-modified and reference parasites. Co-cultures 
consisting of 1:1 proportions of a single GFP-negative (GFP–) test line and a GFP-positive 
(GFP+) reporter line were seeded at day 0 and regularly monitored by flow cytometry for 10 
parasite generations (see Methods). Three independent assays were conducted in duplicate 
in the absence or presence of a sub-lethal dose of chloroquine (CQ; 7.5 nM, equivalent to 
~0.5× CQ IC50 of the CQ-sensitive line GC03GC03). (A) Plots of the mean ± SEM proportion of 
GFP– test lines (p) as a function of number of parasite generations (t). GFP+ (reporter line only) 
and GFP– (GC03GC03 only) control (ctrl) lines exhibited steady fluorescence levels over the 
duration of the experiment. (B) Plots of mean ± SEM natural log (ln)-transformed ratios of the 
proportion of a GFP– test line to the GFP+ reporter line at time t (pt/qt). This parameter was 



















Figure 3.5. In vitro growth profiles of pfcrt-modified and reference parasite lines. Briefly, co-
cultures initially consisting of a 1:1 ratio of a GFP– test strain and a GFP+ reporter strain were 
monitored by flow cytometry for 10 generations (see Methods and Figure 3.4), and the per-
generation selection coefficient (s) for each test strain was derived from parasite growth 
curves. Bar graphs correspond to mean ± SEM s values for parasites subjected to no drug or 
7.5 nM chloroquine (CQ). A summary of s values and inter-strain and intra-strain statistical 








Table 3.5. In vitro growth selection coefficients of pfcrt-modified and reference parasite lines.a 
Line  No drug 7.5 nM CQ  Line  No drug 7.5 nM CQ 
GC03Cam734 
s 0.00 ± 0.008 0.18 ± 0.026  
GC03Cam734 S333T 
s -0.17 ± 0.008 -0.19 ± 0.009 
P1 – –  P1 < 0.0001 < 0.0001 
P2 < 0.0001  P2 0.69 
GC03Cam734 D75N 
s -0.11 ± 0.009 -0.11 ± 0.011  
GC03GC03 
s 0.06 ± 0.007 0.03 ± 0.008 
P1 < 0.0001 < 0.0001  P1 0.002 < 0.0001 
P2 > 0.99  P2 0.71 
GC03Cam734 F144A 
s -0.07 ± 0.009 -0.14 ± 0.010  
GC03Dd2 
s -0.25 ± 0.006 -0.25 ± 0.007 
P1 < 0.0001 < 0.0001  P1 < 0.0001 < 0.0001 
P2 < 0.0001  P2 > 0.99 
GC03Cam734 I148L 
s -0.26 ± 0.006 -0.30 ± 0.007  
GC03 
s -0.05 ± 0.009 -0.06 ± 0.009 
P1 < 0.0001 < 0.0001  P1  0.0047 < 0.0001 
P2 0.15  P2 0.99 
GC03Cam734 T194I 
s -0.14 ± 0.009 -0.15 ± 0.009  
 
   
P1 < 0.0001 < 0.0001     
P2 0.99    
 
aParasite in vitro growth was evaluated in the absence or presence of a sub-lethal dose of CQ (7.5 nM; ~0.5×CQ IC50 of the CQ-
sensitive line GC03GC03) and normalized against GC03Cam734 in the absence of drug pressure (6 replicates per condition). The per-
generation selection coefficient (indicated above as s ± SEM) was derived from the relative fitness index (ω') as per the relationship s 
= ω' – 1, such that s<0 and s>0 respectively indicate growth inferior or superior to that of the GC03Cam734 parasite line, which encodes 
the full-length Cam734 pfcrt allele. CQ, chloroquine; P1, P value for inter-strain comparisons, determined versus the parasite line 
GC03Cam734 using two-way ANOVA with Sidak’s post-hoc test; P2, P value for intra-strain comparisons, determined for a given parasite 
strain in the absence versus presence of 7.5 nM CQ using two-way ANOVA with Sidak’s post-hoc test. P values <0.05 are indicated 















GC03GC03 versus GC03Cam734). These findings agree with earlier studies of isogenic, 
pfcrt-modified lines constructed via an independent allelic exchange strategy.243 
Remarkably, growth of GC03Cam734 parasites was significantly enhanced (~1.2-fold; 
Figure 3.5; Table 3.5) by the presence of a sub-lethal dose of CQ (7.5 nM), surpassing 
the growth rates of all other parasite lines, including those expressing GC03 pfcrt. 
Our results further demonstrate that the Cam734 PfCRT-constituent mutations 
N75D, A144F, L148I, I194T, and T333S distinctly contribute to the growth of asexual 
blood-stage parasites expressing full-length Cam734 PfCRT, as the corresponding 
partial, back-mutant haplotypes conferred significantly decreased relative growth 
rates (s value range of -0.07 to -0.30 for GC03Cam734 D75N, GC03Cam734 F144A, GC03Cam734 
I148L, GC03Cam734 T194I, and GC03Cam734 S333T; see Table 3.5). 
Among the back-mutant parasites, the most deleterious growth was observed 
for parasites expressing Cam734 I148L PfCRT, which was reminiscent of the growth 
phenotype of the Dd2 PfCRT isoform that is known to substantially impair parasite 
fitness (compare GC03Cam734 I148L versus GC03Dd2; Figure 3.5; Table 3.5). Considering 
our dissection of the roles of Cam734 PfCRT mutations in parasite CQ susceptibility 
and growth, our results suggest that PfCRT I194T is a critical compensatory 
mutation, while mutations N75D, A144F, I148L, and S333T play dual roles, directly 
contributing to CQR and compensating for associated fitness costs. 
  
Cam734 pfcrt affects parasite hemoglobin processing and central carbon 
metabolism 
The catabolism of host-derived Hb is an essential parasite process that liberates two 




and (2) free Hb-derived peptides that ultimately contribute to the parasite’s nutrient 
pool.340 Recent studies have shown that peptides derived from either α or β chains of 
Hb can accumulate up to 32-fold within isogenic parasites expressing CQ-resistant 
(Dd2 and 7G8) pfcrt alleles as compared to CQ-sensitive (wild-type) pfcrt-expressing 
parasites.232 The accumulation of Hb-derived peptides in parasites expressing PfCRT 
variants was subsequently linked to impaired Hb catabolism and a consequent defect 
in their in vitro fitness, as measured by growth rate analysis.232 Given the unique 
capacity of mutant Cam734 PfCRT to neutralize fitness costs that are typically 
associated with CQ-resistant PfCRT isoforms, we proceeded to examine whether 
Cam734 PfCRT mitigates the accumulation of Hb-derived peptides.  
To test this, we measured endogenous metabolite levels in isogenic lines 
encoding the CQ-resistant pfcrt alleles Cam734 and Dd2 (GC03Cam734 and GC03Dd2). 
Briefly, red blood cells (RBCs) harboring late-stage (~36-42 h) trophozoites were 
magnetically purified, metabolites were extracted, and extracts were analyzed using 
established mass spectrometry-based metabolomic methods.232 Results of our 
metabolomic analysis are depicted in Figure 3.6 for individual metabolites and Figure 
3.7 for compound classes. Metabolite signal intensities and z-scores are reported in 
Table 3.6 and Table 3.7, respectively. Our results show that the CQ-resistant pfcrt 
alleles Cam734 and Dd2 conferred comparably accumulated levels of Hb-derived 
peptides (P=0.33; see Figure 3.7 and Table 3.7), which have previously been shown to 
accumulate in the GC03Dd2 line.232 As perturbations in Hb metabolism are generally 
associated with a fitness cost, the similarity in peptide levels between GC03Cam734 and 
GC03Dd2 parasites indicates that Cam734 PfCRT promotes parasite growth through 






Figure 3.6. Individual metabolite profiles of isogenic, mutant pfcrt-expressing parasites. Metabolite extracts derived from tightly-synchronized 
trophozoite-stage isogenic (GC03) parasites encoding either Dd2 or Cam734 pfcrt were analyzed by mass spectrometry. Metabolite signals 
were converted to z-scores. Each bar shows the z-score for an experimental replicate obtained for GC03Dd2 (black) or GC03Cam734 (red) 
parasites. Dashed lines represent lower (5%) and upper (95%) boundaries for the normal distribution, as defined for GC03Dd2 parasites. 
Values outside this range in the GC03Cam734 samples differ significantly from the isogenic GC03Dd2 line. Metabolites were harvested on three 
independent occasions (n=4 to 6 total replicates per parasite strain). Metabolite z-scores, P values, and full names of individual metabolites 
are detailed in Table 3.7. TCA, tricarboxylic acid; PPP, pentose phosphate pathway; Nt, nucleotide; AA, amino acid; NAc, N-Acetylated. 


















Figure 3.7. Metabolomic profiles of isogenic, mutant pfcrt-expressing parasites. Metabolite 
extracts derived from tightly-synchronized trophozoite-stage isogenic (GC03) parasites 
encoding either Dd2 or Cam734 pfcrt were analyzed by mass spectrometry. For each 
metabolite class, individual metabolite signals were averaged and expressed as z-scores 
(detailed in Methods), allowing for comparisons across distinct metabolite classes. Dashed 
lines represent lower (5%) and upper (95%) boundaries for the normal distribution, as defined 
for GC03Dd2 (black) parasites. Values outside this range in the GC03Cam734 (red) samples 
differ significantly from the isogenic GC03Dd2 line. Metabolites were harvested on three 
independent occasions (n=4-6 total replicates per parasite strain). Compound class 
abbreviations, z-scores, and P values are presented in Table 3.7. Mass spectrometric 







Table 3.6. Metabolite mass spectrometry signal intensities.a 
   GC03Dd2  GC03Cam734 
Class Compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6 





1.82         
E+06 
2.04         
E+06 
1.75         
E+06 
2.13         
E+06 
 
2.62         
E+06 
2.61         
E+06 
2.55         
E+06 
2.31         
E+06 
3.38         
E+06 
3.70         
E+06 
 3-phosphoglycerate (3-PG)  
1.67         
E+05 
3.27         
E+05 
1.75         
E+05 
2.56         
E+05 
 
2.62         
E+05 
2.74         
E+05 
3.33         
E+05 
3.31         
E+05 
4.95         
E+05 






9.98         
E+03 
1.38         
E+04 
1.04         
E+04 
1.26         
E+04 
 
1.24         
E+04 
1.19         
E+04 
1.28         
E+04 
1.20         
E+04 
1.18         
E+04 






3.30         
E+03 
4.87         
E+03 
2.88         
E+03 
3.99         
E+03 
 
3.96         
E+03 
4.62         
E+03 
4.20         
E+03 
5.30         
E+03 
7.42         
E+03 






6.46         
E+05 
6.81         
E+05 
5.40         
E+05 
7.63         
E+05 
 
8.52         
E+05 
8.30         
E+05 
8.48         
E+05 
9.27         
E+05 
1.47         
E+06 
1.49         
E+06 
 Glucose-6-phosphate (G-6-P)  
1.48         
E+06 
2.01         
E+06 
1.42         
E+06 
1.73         
E+06 
 
1.87         
E+06 
1.94         
E+06 
1.95         
E+06 
2.07         
E+06 
1.90         
E+06 
2.14         
E+06 
 Phosphoenolpyruvate (PEP)  
2.78         
E+06 
3.13         
E+06 
2.65         
E+06 
3.13         
E+06 
 
4.16         
E+06 
3.90         
E+06 
3.72         
E+06 
3.55         
E+06 
4.64         
E+06 






6.77         
E+05 
8.99         
E+05 
5.45         
E+05 
8.09         
E+05 
  
9.08         
E+05 
7.81         
E+05 
7.50         
E+05 
8.00         
E+05 
8.03         
E+05 
8.55         
E+05 
TCA 4-aminobutyrate (GABA)  
3.98         
E+05 
4.30         
E+05 
3.86         
E+05 
4.21         
E+05 
 
4.91         
E+05 
4.73         
E+05 
5.27         
E+05 
5.00         
E+05 
4.53         
E+05 
4.89         
E+05 
 α-ketoglutarate (α-KG)  
1.72         
E+04 
2.05         
E+04 
1.87         
E+04 
2.34         
E+04 
 
2.61         
E+04 
2.77         
E+04 
2.28         
E+04 
2.20         
E+04 
3.01         
E+04 
2.89         
E+04 
 Citrate  
6.36         
E+04 
9.01         
E+04 
6.86         
E+04 
7.32         
E+04 
 
8.77         
E+04 
9.69         
E+04 
9.31         
E+04 
1.00         
E+05 
1.00         
E+05 
9.19         
E+04 
 Fumarate  
4.23         
E+04 
9.85         
E+04 
3.08         
E+04 
5.83         
E+04 
 
5.64         
E+04 
4.94         
E+04 
5.91         
E+04 
6.24         
E+04 
5.72         
E+04 
8.04         
E+04 
 Glutamate  
7.30         
E+05 
8.25         
E+05 
6.94         
E+05 
6.87         
E+05 
 
9.04         
E+05 
8.27         
E+05 
9.95         
E+05 
9.45         
E+05 
8.82         
E+05 
1.03         
E+06 
 Malate  
5.87         
E+04 
9.15         
E+04 
4.88         
E+04 
7.68         
E+04 
 
8.26         
E+04 
8.11         
E+04 
6.91         
E+04 
8.13         
E+04 
7.29         
E+04 
8.99         
E+04 
  Succinate   
6.76         
E+04 
1.03         
E+05 
6.78         
E+04 
9.28         
E+04 
  
7.99         
E+04 
7.95         
E+04 
1.06         
E+05 
9.64         
E+04 
1.07         
E+05 














Table 3.6. continued 
   GC03Dd2  GC03Cam734 
Class Compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6 





1.46         
E+05 
2.80         
E+05 
1.47         
E+05 
2.30         
E+05 
 
2.10         
E+05 
2.12         
E+05 
2.23         
E+05 
2.54         
E+05 
2.32         
E+05 






4.78         
E+04 
7.30         
E+04 
4.80         
E+04 
6.41         
E+04 
 
6.14         
E+04 
6.36         
E+04 
6.20         
E+04 
6.00         
E+04 
5.58         
E+04 
7.20         
E+04 
 D-gluconate  
2.65         
E+05 
3.07         
E+05 
1.90         
E+05 
2.48         
E+05 
 
2.44         
E+05 
2.07         
E+05 
2.14         
E+05 
2.40         
E+05 
2.54         
E+05 






6.23         
E+04 
9.54         
E+04 
4.92         
E+04 
6.47         
E+04 
 
9.70         
E+04 
8.47         
E+04 
8.54         
E+04 
8.48         
E+04 
5.83         
E+04 






1.02         
E+04 
1.34         
E+04 
7.49         
E+03 
9.22         
E+03 
 
1.06         
E+04 
9.54         
E+03 
1.11         
E+04 
1.03         
E+04 
1.19         
E+04 






3.34         
E+04 
4.81         
E+04 
3.08         
E+04 
3.72         
E+04 
 
4.07         
E+04 
3.80         
E+04 
4.37         
E+04 
4.25         
E+04 
4.51         
E+04 
4.78         
E+04 
 Ribose-5-phosphate (Rib-5-P)  
2.74         
E+04 
4.79         
E+04 
2.67         
E+04 
3.69         
E+04 
 
4.07         
E+04 
3.86         
E+04 
4.67         
E+04 
4.33         
E+04 
3.49         
E+04 
4.01         
E+04 
 
Sedoheptulose bisphosphate  
(S-BP) 
 
6.62         
E+04 
9.16         
E+04 
4.98         
E+04 
7.45         
E+04 
 
8.28         
E+04 
8.33         
E+04 
8.28         
E+04 
8.96         
E+04 
9.74         
E+04 
1.20         
E+05 
  Xylulose-5-phosphate (Xyl-5-P)   
2.20         
E+04 
4.06         
E+04 
2.06         
E+04 
2.73         
E+04 
  
2.71         
E+04 
2.61         
E+04 
3.25         
E+04 
3.09         
E+04 
2.96         
E+04 






5.73         
E+04 
5.37         
E+04 
2.96         
E+04 
3.14         
E+04 
 
8.55         
E+04 
7.80         
E+04 
3.66         
E+04 
4.09         
E+04 
4.10         
E+04 
4.83         
E+04 
 ATP  
1.22         
E+07 
1.59         
E+07 
1.41         
E+07 
1.56         
E+07 
 
1.97         
E+07 
1.82         
E+07 
2.16         
E+07 
2.08         
E+07 
1.84         
E+07 
2.01         
E+07 
 ADP  
1.68         
E+06 
2.50         
E+06 
1.90         
E+06 
2.01         
E+06 
 
1.81         
E+06 
1.57         
E+06 
1.85         
E+06 
1.95         
E+06 
2.04         
E+06 
1.79         
E+06 
 AMP  
1.72         
E+05 
3.21         
E+05 
2.22         
E+05 
2.07         
E+05 
 
1.68         
E+05 
1.44         
E+05 
1.81         
E+05 
1.90         
E+05 
2.22         
E+05 
1.94         
E+05 
 dATP  
1.44               
E+05 
3.31               
E+05 
2.32         
E+05 
2.50         
E+05 
 
3.47         
E+05 
3.22         
E+05 
3.70         
E+05 
3.74         
E+05 
3.35         
E+05 
3.84         
E+05 
 dAMP  
1.95         
E+03 
5.41         
E+03 
3.71         
E+03 
2.51         
E+03 
 
2.24         
E+03 
1.98         
E+03 
2.32         
E+03 
2.35         
E+03 
2.92         
E+03 
2.20         
E+03 
 CTP  
1.09         
E+05 
1.83         
E+05 
1.35         
E+05 
1.33         
E+05 
 
2.13         
E+05 
1.96         
E+05 
1.95         
E+05 
2.01         
E+05 
1.93         
E+05 
1.74         
E+05 











Table 3.6. continued 
   GC03Dd2  GC03Cam734 
Class Compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6 




4.06         
E+04 
7.67         
E+04 
4.83         
E+04 
4.56         
E+04 
 
4.38         
E+04 
3.75         
E+04 
4.40         
E+04 
4.54         
E+04 
4.55         
E+04 
3.88         
E+04 
 CMP  
4.37         
E+04 
6.70         
E+04 
3.97         
E+04 
4.71         
E+04 
 
2.90         
E+04 
2.70         
E+04 
3.51         
E+04 
3.24         
E+04 
3.03         
E+04 
2.76         
E+04 
 dCTP  
1.75         
E+04 
3.40         
E+04 
2.53         
E+04 
2.50         
E+04 
 
2.53         
E+04 
2.28         
E+04 
3.07         
E+04 
3.25         
E+04 
2.43         
E+04 
2.41         
E+04 
 dTTP  
4.43         
E+05 
1.01         
E+06 
7.09         
E+05 
8.56         
E+05 
 
1.09         
E+06 
9.90         
E+05 
1.32         
E+06 
1.20         
E+06 
9.74         
E+05 
1.15         
E+06 
 dTDP  
3.23         
E+04 
6.07         
E+04 
3.78         
E+04 
4.20         
E+04 
 
3.10         
E+04 
2.46         
E+04 
3.38         
E+04 
3.50         
E+04 
3.47         
E+04 
3.06         
E+04 
 GTP  
1.16         
E+05 
2.40         
E+05 
1.92         
E+05 
1.87         
E+05 
 
3.23         
E+05 
2.85         
E+05 
3.44         
E+05 
3.24         
E+05 
3.20         
E+05 
3.07         
E+05 
 GDP  
7.44         
E+04 
1.10         
E+05 
9.48         
E+04 
8.41         
E+04 
 
8.00         
E+04 
6.98         
E+04 
8.76         
E+04 
7.98         
E+04 
8.16         
E+04 
6.07         
E+04 
 GMP  
2.37         
E+05 
4.22         
E+05 
2.86         
E+05 
3.53         
E+05 
 
1.45         
E+05 
1.47         
E+05 
2.81         
E+05 
2.86         
E+05 
1.88         
E+05 
1.82         
E+05 
 UTP  
1.16         
E+06 
2.39         
E+06 
1.77         
E+06 
1.88         
E+06 
 
2.83         
E+06 
2.54         
E+06 
2.83         
E+06 
2.77         
E+06 
3.04         
E+06 
3.21         
E+06 
 UDP  
2.62         
E+05 
4.42         
E+05 
3.24         
E+05 
3.36         
E+05 
 
2.47         
E+05 
2.05         
E+05 
2.57         
E+05 
2.55         
E+05 
3.16         
E+05 
2.78         
E+05 
 UMP  
2.41         
E+05 
3.93         
E+05 
2.74         
E+05 
3.40         
E+05 
 
1.24         
E+05 
1.36         
E+05 
1.93         
E+05 
1.98         
E+05 
1.83         
E+05 
1.87         
E+05 
 IMP  
6.69         
E+05 
9.34         
E+05 
5.66         
E+05 
7.57         
E+05 
 
7.91         
E+05 
8.31         
E+05 
8.19         
E+05 
8.59         
E+05 
8.38         
E+05 
1.04         
E+06 
 Inosine (I)  
1.60         
E+04 
3.52         
E+04 
1.72         
E+04 
2.36         
E+04 
 
2.22         
E+04 
2.29         
E+04 
2.22         
E+04 
2.33         
E+04 
2.33         
E+04 
3.00         
E+04 
  Thymidine (dT)   
9.60         
E+02 
5.27         
E+03 
2.09         
E+03 
2.54         
E+03 
  
2.72         
E+03 
4.74         
E+03 
2.56         
E+03 
2.85         
E+03 
3.11         
E+03 
4.20         
E+03 










Table 3.6. continued 
   GC03Dd2  GC03Cam734 
Class Compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6 
              
Nt conj ADP-D-glucose  
8.51         
E+04 
1.08         
E+05 
8.00         
E+04 
9.81         
E+04 
 
1.00         
E+05 
9.73         
E+04 
1.00         
E+05 
1.06         
E+05 
1.05         
E+05 
1.23         
E+05 
 CDP-choline  
1.33         
E+04 
1.54         
E+04 
1.11         
E+04 
1.43         
E+04 
 
1.24         
E+04 
1.22         
E+04 
1.15         
E+04 
1.16         
E+04 
1.14         
E+04 
1.44         
E+04 
 CDP-ethanolamine (CDP-ETA)  
7.43         
E+05 
7.81         
E+05 
6.27         
E+05 
8.07         
E+05 
 
6.29         
E+05 
6.41         
E+05 
5.98         
E+05 
6.17         
E+05 
6.30         
E+05 






9.54         
E+04 
2.36         
E+05 
1.12         
E+05 
1.67         
E+05 
 
1.24         
E+05 
1.09         
E+05 
1.51         
E+05 
1.56         
E+05 
1.07         
E+05 
1.63         
E+05 
 UDP-D-glucose  
1.18         
E+07 
5.44         
E+06 
5.20         
E+06 
7.17         
E+06 
 
5.91         
E+06 
5.17         
E+06 
4.32         
E+06 
4.66         
E+06 
4.87         
E+06 
5.53         
E+06 
 UDP-D-glucuronate  
2.04         
E+05 
3.00         
E+05 
2.02         
E+05 
2.46         
E+05 
 
3.44         
E+05 
3.02         
E+05 
3.83         
E+05 
3.47         
E+05 
3.47         
E+05 






3.57         
E+06 
3.69         
E+06 
2.43         
E+06 
3.40         
E+06 
  
3.04         
E+06 
2.78         
E+06 
2.96         
E+06 
3.26         
E+06 
2.70         
E+06 
3.37         
E+06 
Redox Glutathione (GSH)  
2.44         
E+04 
5.43         
E+04 
1.94         
E+04 
5.07         
E+04 
 
1.15         
E+04 
9.87         
E+03 
1.95         
E+04 
2.45         
E+04 
2.46         
E+04 
3.73         
E+04 
 Glutathione disulfide (GSSG)  
9.60         
E+06 
1.25         
E+07 
7.12         
E+06 
1.15         
E+07 
 
9.26         
E+06 
9.20         
E+06 
1.07         
E+07 
1.09         
E+07 
1.04         
E+07 
1.23         
E+07 
 NAD+  
1.82         
E+06 
2.73         
E+06 
1.65         
E+06 
2.26         
E+06 
 
1.99         
E+06 
1.72         
E+06 
2.00         
E+06 
2.10         
E+06 
1.95         
E+06 
2.69         
E+06 
 NADH  
8.08         
E+03 
8.09         
E+03 
8.75         
E+03 
1.11         
E+04 
 
8.23         
E+03 
6.73         
E+03 
7.56         
E+03 
9.86         
E+03 
1.21         
E+04 
1.37         
E+04 
  NADP+   
3.54         
E+05 
5.18         
E+05 
3.23         
E+05 
3.64         
E+05 
  
4.20         
E+05 
4.30         
E+05 
4.63         
E+05 
4.63         
E+05 
4.29         
E+05 
4.60         
E+05 
AA Phenylalanine (Phe)  
3.91         
E+05 
5.10         
E+05 
4.07         
E+05 
4.15         
E+05 
 
4.92         
E+05 
4.91         
E+05 
5.34         
E+05 
4.81         
E+05 
4.89         
E+05 
4.91         
E+05 
  Tryptophan (Trp)   
4.22         
E+05 
5.14         
E+05 
4.45         
E+05 
4.52         
E+05 
  
5.19         
E+05 
5.56         
E+05 
4.85         
E+05 
5.29         
E+05 
5.53         
E+05 






1.65         
E+04 
2.80         
E+04 
1.64         
E+04 
2.45         
E+04 
 
1.92         
E+04 
1.71         
E+04 
1.88         
E+04 
2.33         
E+04 
2.50         
E+04 
2.81         
E+04 
 N-Acetyl-glutamate (NAc-Glu)  
8.99         
E+03 
1.54         
E+04 
6.17         
E+03 
1.22         
E+04 
 
1.27         
E+04 
1.57         
E+04 
1.14         
E+04 
1.47         
E+04 
1.41         
E+04 
1.68         
E+04 










Table 3.6. continued 
   GC03Dd2  GC03Cam734 
Class Compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6 
              
NAc AA 
(cont.) 
N-Acetyl-glutamine (NAc-Gln)  
2.18         
E+04 
3.39         
E+04 
2.32         
E+04 
3.24         
E+04 
 
3.38         
E+04 
3.32         
E+04 
3.83         
E+04 
4.21         
E+04 
4.23         
E+04 
5.00         
E+04 
  N-Acetyl-L-alanine (NAc-L-Ala)   
3.03         
E+03 
4.01         
E+03 
2.76         
E+03 
4.60         
E+03 
  
4.15         
E+03 
3.77         
E+03 
3.91         
E+03 
4.16         
E+03 
2.88         
E+03 
4.05         
E+03 
Peptide DLH  
2.28         
E+06 
4.34         
E+06 
2.60         
E+06 
3.34         
E+06 
 
1.77         
E+06 
1.69         
E+06 
1.87         
E+06 
1.99         
E+06 
1.38         
E+06 
1.64         
E+06 
 DLS  
1.35         
E+06 
2.26         
E+06 
1.62         
E+06 
2.27         
E+06 
 
1.88         
E+06 
1.81         
E+06 
1.70         
E+06 
1.86         
E+06 
1.81         
E+06 
2.09         
E+06 
 HVDD  
2.31         
E+06 
3.48         
E+06 
2.30         
E+06 
3.21         
E+06 
 
2.61         
E+06 
2.57         
E+06 
2.09         
E+06 
2.24         
E+06 
2.12         
E+06 
2.40         
E+06 
 LD  
2.63         
E+05 
4.32         
E+05 
1.57         
E+05 
2.30         
E+05 
 
3.74         
E+05 
3.74         
E+05 
3.38         
E+05 
3.54         
E+05 
2.43         
E+05 
3.35         
E+05 
 PD  
2.60         
E+06 
3.21         
E+06 
2.52         
E+06 
3.49         
E+06 
 
2.58         
E+06 
2.71         
E+06 
2.66         
E+06 
2.85         
E+06 
2.87         
E+06 
3.70         
E+06 
 PE  
3.30         
E+06 
4.02         
E+06 
3.11         
E+06 
4.02         
E+06 
 
3.95         
E+06 
3.44         
E+06 
3.80         
E+06 
3.86         
E+06 
3.27         
E+06 
4.15         
E+06 
 PEE  
1.87         
E+06 
2.74         
E+06 
1.80         
E+06 
2.54         
E+06 
 
2.42         
E+06 
2.36         
E+06 
2.48         
E+06 
2.76         
E+06 
1.98         
E+06 
2.50         
E+06 
 PEEK  
1.89         
E+05 
2.21         
E+05 
1.88         
E+05 
2.37         
E+05 
 
2.64         
E+05 
2.57         
E+05 
2.40         
E+05 
2.55         
E+05 
2.34         
E+05 
3.12         
E+05 
 PVNF  
1.36         
E+06 
2.34         
E+06 
1.49         
E+06 
1.88         
E+06 
 
1.70         
E+06 
1.72         
E+06 
1.73         
E+06 
1.75         
E+06 
1.31         
E+06 
1.42         
E+06 
 SD  
1.72         
E+05 
2.40         
E+05 
1.60         
E+05 
2.20         
E+05 
 
1.96         
E+05 
1.95         
E+05 
2.04         
E+05 
2.19         
E+05 
1.92         
E+05 
2.30         
E+05 
  VD   
4.51         
E+04 
5.93         
E+04 
3.87         
E+04 
5.45         
E+04 
  
5.74         
E+04 
5.26         
E+04 
5.47         
E+04 
5.10         
E+04 
4.74         
E+04 
6.32         
E+04 
Cofactor Biotin  
2.58         
E+04 
3.93         
E+04 
3.06         
E+04 
2.57         
E+04 
 
3.96         
E+04 
4.60         
E+04 
3.88         
E+04 
3.96         
E+04 
3.80         
E+04 
3.61         
E+04 
 Folate  
1.27              
E+05 
1.23         
E+05 
1.49         
E+05 
1.29         
E+05 
 
1.60         
E+05 
1.61         
E+05 
1.83         
E+05 
1.94         
E+05 
1.91         
E+05 
1.70         
E+05 
  Pantothenate   
8.66         
E+04 
1.65         
E+05 
9.53         
E+04 
1.03         
E+05 
  
1.66         
E+05 
1.57         
E+05 
1.31         
E+05 
1.46         
E+05 
1.24         
E+05 










aMass spectrometric signal intensities for metabolites derived from trophozoite-stage isogenic (GC03) parasites encoding either Dd2 
or Cam734 pfcrt. Metabolites were harvested on three independent occasions, yielding 4 and 6 individual replicates (r) for the GC03Dd2 
and GC03Cam734 strains, respectively. Glyc, glycolysis; TCA, tricarboxylic acid cycle; PPP, pentose phosphate pathway; Nt met, 









































Table 3.7. Metabolite z-scores and P values.a 
  GC03Dd2  GC03Cam734   
Compound class or compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6   P 
               
Compound classes               
ATP/ADP  0.12 -1.40 0.34 0.95  6.14 7.38 7.47 5.77 3.02 6.70  0.0002 
ATP/AMP  0.53 -1.36 -0.11 0.93  4.63 5.48 4.80 3.92 1.61 3.41  0.0011 
Glycolysis  -0.59 0.99 -1.09 0.70  2.62 2.26 2.08 1.90 4.71 6.79  0.0133 
Pentose phosphate pathway (PPP)  -0.44 1.30 -1.04 0.18  0.30 0.02 0.23 0.53 0.32 1.07  0.3740 
Tricarboxylic acid (TCA) cycle  -0.46 1.42 -0.87 -0.09  1.89 1.26 2.84 2.42 1.71 3.16  0.0035 
Nucleotide biosynthesis  0.27 1.28 -0.99 -0.56  2.09 1.85 -0.37 -0.08 -0.07 0.69  0.3360 
Redox  -0.32 1.06 -1.24 0.50  -0.36 -0.47 0.16 0.26 0.03 0.95  0.8439 
Cofactors  -0.93 1.39 0.00 -0.46  2.38 2.35 2.06 2.76 2.04 1.32  0.0017 
Nucleoside triphosphates (nTPs)  -1.33 0.95 -0.17 0.55  2.88 2.06 3.73 3.34 2.39 3.21  0.0004 
Nucleoside diphosphates (nDPs)  -1.00 1.38 -0.30 -0.08  -0.72 -1.39 -0.59 -0.39 -0.05 -0.75  0.1939 
Nucleoside monophosphates (nMPs)  -0.79 1.35 -0.72 0.15  -1.08 -1.00 -0.38 -0.23 -0.51 -0.06  0.2602 
Deoxynucleoside triphosphates (dnTPs)  -1.28 1.10 -0.16 0.35  1.38 0.97 2.16 1.82 0.97 1.67  0.0123 
Deoxynucleoside diphosphates (dnDPs)  -0.89 1.42 -0.44 -0.10  -0.99 -1.51 -0.76 -0.67 -0.69 -1.02  0.0586 
Deoxynucleoside monophosphates (dnMPs)  -0.94 1.32 0.21 -0.58  -0.76 -0.92 -0.70 -0.68 -0.31 -0.78  0.1290 
Nucleotide conjugates  1.38 -0.40 -0.97 0.00  -0.53 -0.84 -1.01 -0.82 -0.94 -0.45  0.1006 
N-Acetyl (NAc)-Amino Acids  -0.79 1.08 -0.90 0.62  0.39 0.38 0.54 1.26 1.27 2.16  0.0974 
Aromatic amino acids  -0.82 1.45 -0.40 -0.24  1.31 1.69 1.38 1.29 1.64 1.23  0.0081 
Peptides  -0.88 1.09 -0.82 0.61  -0.34 -0.51 -0.51 -0.24 -0.95 -0.07  0.3296 
               
Individual compounds               
2,3-bisphosphoglycerate (2,3-BPG)  -0.66 0.60 -1.02 1.08  3.89 3.81 3.49 2.11 8.19 10.0  0.0123 
3-phosphoglycerate (3-PG)  -0.85 1.27 -0.75 0.33  0.41 0.57 1.35 1.33 3.50 4.39  0.0708 
D-glyceraldehdye-3-phosphate (PGAL)  -0.95 1.16 -0.71 0.50  0.38 0.11 0.61 0.16 0.08 2.08  0.3372 
Dihydroxy-acetone-phosphate (DHAP)  -0.53 1.28 -1.01 0.26  0.23 0.99 0.50 1.77 4.22 4.42  0.0844 
Fructose-1,6-bisphosphate (F-1,6-BP)  -0.13 0.25 -1.27 1.14  2.11 1.87 2.07 2.92 8.77 9.04  0.0389 
Glucose-6-phosphate (G-6-P)  -0.68 1.30 -0.88 0.25  0.78 1.03 1.07 1.50 0.91 1.77  0.0279 
Phosphoenolpyruvate (PEP)  -0.57 0.85 -1.12 0.84  4.99 3.95 3.23 2.54 6.95 12.3  0.0168 
sn-Glycerol-3-phosphate (sn-Glycerol-3-P)  -0.36 1.08 -1.21 0.50  1.14 0.31 0.12 0.44 0.46 0.79  0.2500 
4-aminobutyrate (GABA)  -0.53 1.04 -1.12 0.61  4.08 3.15 5.84 4.52 2.20 3.97  0.0007 










Table 3.7. continued 
  GC03Dd2  GC03Cam734   
Compound class or compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6   P 
               
Individual compounds (cont.)               
α-ketoglutarate (α-KG)  -1.03 0.20 -0.46 1.30  2.29 2.87 1.07 0.76 3.76 3.32  0.0128 
Citrate  -0.90 1.41 -0.46 -0.06  1.20 2.00 1.67 2.28 2.30 1.56  0.0037 
Fumarate  -0.51 1.39 -0.90 0.03  -0.04 -0.27 0.05 0.17 -0.01 0.77  0.8015 
Glutamate  -0.06 1.43 -0.62 -0.75  2.69 1.47 4.11 3.34 2.33 4.68  0.0026 
Malate  -0.54 1.19 -1.06 0.42  0.72 0.64 0.01 0.65 0.21 1.10  0.2466 
Succinate  -0.85 1.13 -0.84 0.55  -0.16 -0.19 1.28 0.75 1.31 1.41  0.2177 
6-phospho-D-gluconate (6-P-D-gluconate)  -0.84 1.20 -0.81 0.44  0.14 0.17 0.34 0.81 0.47 1.48  0.2634 
D-erythrose-4-phosphate (D-erythrose-4-P)  -0.84 1.18 -0.82 0.47  0.25 0.43 0.30 0.14 -0.19 1.10  0.4755 
D-gluconate  0.25 1.12 -1.29 -0.08  -0.17 -0.94 -0.79 -0.25 0.04 0.25  0.5188 
D-sedoheptulose-7-phosphate (D-S-7-P)  -0.29 1.41 -0.96 -0.16  1.49 0.86 0.90 0.87 -0.49 0.25  0.2548 
Octulose-1-phosphate (Octulose-1-P)  0.06 1.34 -1.04 -0.35  0.22 -0.22 0.39 0.08 0.71 0.94  0.4555 
Octulose-bisphosphate (Octulose-BP)  -0.52 1.41 -0.87 -0.02  0.44 0.08 0.83 0.67 1.01 1.36  0.1475 
Ribose-5-phosphate (Rib-5-P)  -0.74 1.32 -0.81 0.22  0.60 0.39 1.20 0.86 0.01 0.54  0.2147 
Sedoheptulose bisphosphate (S-BP)  -0.25 1.21 -1.19 0.23  0.70 0.73 0.71 1.09 1.54 2.87  0.0611 
Xylulose-5-phosphate (Xyl-5-P)  -0.62 1.42 -0.77 -0.03  -0.06 -0.17 0.53 0.35 0.22 -0.06  0.7547 
N-Carbamoyl-L-aspartate (N-carb-L-Asp)  0.98 0.74 -0.92 -0.80  2.93 2.41 -0.44 -0.14 -0.14 0.37  0.3538 
ATP  -1.33 0.86 -0.21 0.68  3.10 2.21 4.22 3.75 2.33 3.34  0.0005 
ADP  -0.99 1.38 -0.34 -0.04  -0.61 -1.32 -0.50 -0.20 0.06 -0.66  0.2779 
AMP  -0.91 1.42 -0.14 -0.37  -0.98 -1.36 -0.77 -0.63 -0.14 -0.57  0.1374 
dATP  -1.24 1.19 -0.09 0.14  1.40 1.07 1.70 1.75 1.25 1.88  0.0077 
dAMP  -0.94 1.32 0.21 -0.58  -0.76 -0.92 -0.70 -0.68 -0.31 -0.78  0.1290 
CTP  -1.01 1.38 -0.15 -0.22  2.34 1.80 1.77 1.95 1.69 1.09  0.0041 
CDP  -0.75 1.47 -0.28 -0.44  -0.55 -0.94 -0.54 -0.46 -0.45 -0.86  0.1603 
CMP  -0.47 1.45 -0.80 -0.19  -1.67 -1.84 -1.17 -1.40 -1.57 -1.80  0.0053 
dCTP  -1.17 1.27 -0.03 -0.07  -0.02 -0.40 0.77 1.05 -0.17 -0.20  0.7377 
dTTP  -1.29 1.06 -0.19 0.42  1.40 0.97 2.34 1.85 0.91 1.64  0.0137 
dTDP  -0.89 1.42 -0.44 -0.10  -0.99 -1.51 -0.76 -0.67 -0.69 -1.02  0.0586 
GTP  -1.33 1.10 0.16 0.07  2.70 1.97 3.12 2.74 2.65 2.40  0.0004 
GDP  -1.07 1.26 0.25 -0.44  -0.71 -1.37 -0.21 -0.72 -0.60 -1.97  0.1049 










Table 3.7. continued 
  GC03Dd2  GC03Cam734   
Compound class or compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6   P 
               
Individual compounds (cont.)               
GMP  -1.09 1.21 -0.47 0.35  -2.22 -2.20 -0.54 -0.47 -1.69 -1.76  0.0302 
UTP  -1.27 1.17 -0.07 0.16  2.02 1.45 2.02 1.91 2.45 2.78  0.0018 
UDP  -1.06 1.35 -0.22 -0.07  -1.26 -1.82 -1.11 -1.15 -0.33 -0.83  0.0493 
UMP  -1.05 1.19 -0.56 0.41  -2.76 -2.60 -1.75 -1.67 -1.89 -1.84  0.0020 
IMP  -0.40 1.30 -1.06 0.16  0.38 0.64 0.56 0.82 0.68 1.96  0.1246 
Inosine (I)  -0.80 1.39 -0.66 0.07  -0.09 0.00 -0.09 0.03 0.03 0.80  0.7990 
Thymidine (dT)  -0.96 1.40 -0.34 -0.09  0.00 1.11 -0.09 0.08 0.22 0.81  0.4704 
ADP-D-glucose  -0.61 1.19 -1.01 0.43  0.59 0.37 0.62 1.03 1.02 2.44  0.1028 
CDP-choline  -0.12 1.03 -1.33 0.41  -0.62 -0.70 -1.07 -1.04 -1.17 0.48  0.2084 
CDP-ethanolamine (CDP-ETA)  0.04 0.53 -1.42 0.85  -1.39 -1.25 -1.78 -1.55 -1.38 1.19  0.1743 
S-Adenosyl-L-homocysteine (SAH)  -0.90 1.32 -0.64 0.22  -0.45 -0.69 -0.03 0.06 -0.72 0.17  0.5489 
UDP-D-glucose  1.44 -0.64 -0.72 -0.08  -0.49 -0.73 -1.01 -0.90 -0.83 -0.61  0.0988 
UDP-D-glucuronate  -0.74 1.35 -0.78 0.17  2.31 1.38 3.14 2.36 2.36 3.04  0.0014 
UDP-N-acetyl-glucosamine (UDP-NAG)  0.52 0.72 -1.47 0.22  -0.42 -0.85 -0.55 -0.02 -1.00 0.18  0.3623 
Glutathione (GSH)  -0.72 0.96 -1.00 0.76  -1.44 -1.53 -0.99 -0.71 -0.71 0.01  0.1044 
Glutathione disulfide (GSSG)  -0.24 0.98 -1.29 0.56  -0.39 -0.41 0.22 0.30 0.09 0.90  0.8073 
NAD+  -0.61 1.27 -0.97 0.30  -0.26 -0.81 -0.23 -0.04 -0.33 1.20  0.8858 
NADH  -0.65 -0.64 -0.18 1.46  -0.54 -1.59 -1.01 0.59 2.14 3.28  0.6599 
NADP+  -0.41 1.47 -0.76 -0.30  0.35 0.46 0.84 0.84 0.45 0.81  0.1675 
Phenylalanine (Phe)  -0.74 1.47 -0.44 -0.29  1.14 1.10 1.90 0.92 1.08 1.11  0.0237 
Tryptophan (Trp)  -0.92 1.42 -0.34 -0.15  1.54 2.47 0.67 1.79 2.39 1.39  0.0115 
N-Acetyl-glucosamine-1,6-bisphosphate 
(NAG-1,6-BP) 
 -0.83 1.14 -0.85 0.54  -0.37 -0.74 -0.43 0.33 0.63 1.16  0.8618 
N-Acetyl-glutamate (NAc-Glu)  -0.42 1.18 -1.13 0.38  0.52 1.28 0.18 1.01 0.87 1.56  0.0913 
N-Acetyl-glutamine (NAc-Gln)  -0.97 0.98 -0.75 0.73  0.96 0.86 1.69 2.30 2.34 3.57  0.0172 
N-Acetyl-L-alanine (NAc-L-Ala)  -0.67 0.48 -0.98 1.17  0.65 0.20 0.36 0.66 -0.84 0.53  0.6121 
DLH  -0.94 1.31 -0.59 0.22  -1.50 -1.59 -1.40 -1.26 -1.93 -1.64  0.0055 
DLS  -1.13 0.83 -0.56 0.86  0.02 -0.15 -0.37 -0.03 -0.14 0.47  0.9380 
HVDD  -0.84 1.07 -0.86 0.63  -0.35 -0.43 -1.22 -0.96 -1.15 -0.70  0.1046 














Table 3.7. continued 
  GC03Dd2  GC03Cam734   
Compound class or compound   r1 r2 r3 r4   r1 r2 r3 r4 r5 r6   P 
               
Individual compounds (cont.)               
LD  -0.07 1.39 -0.97 -0.35  0.89 0.89 0.57 0.72 -0.24 0.55  0.2448 
PD  -0.75 0.54 -0.92 1.13  -0.80 -0.52 -0.63 -0.22 -0.19 1.58  0.8335 
PE  -0.65 0.86 -1.06 0.85  0.70 -0.37 0.39 0.52 -0.71 1.13  0.6127 
PEE  -0.78 1.07 -0.92 0.63  0.39 0.25 0.51 1.10 -0.54 0.56  0.4524 
PEEK  -0.81 0.51 -0.85 1.16  2.28 1.98 1.26 1.90 1.03 4.23  0.0169 
PVNF  -0.92 1.29 -0.63 0.26  -0.15 -0.12 -0.09 -0.03 -1.04 -0.78  0.4389 
SD  -0.69 1.10 -0.99 0.58  -0.05 -0.08 0.16 0.54 -0.14 0.84  0.6428 
VD  -0.46 1.07 -1.16 0.55  0.87 0.35 0.57 0.17 -0.22 1.50  0.3111 
Biotin  -0.71 1.40 0.03 -0.73  1.46 2.46 1.32 1.46 1.20 0.90  0.0156 
Folate  -0.42 -0.77 1.47 -0.27  2.43 2.49 4.42 5.36 5.07 3.25  0.0011 
Pantothenate   -0.72 1.47 -0.48 -0.27   1.48 1.25 0.53 0.94 0.32 0.20   0.1372 
 
aMetabolite compound classes and individual metabolite z-scores (see Methods for z-score derivation). P values were determined 
using one-way ANOVA. Corresponding metabolite signal intensities are reported in Table 3.6. Metabolites were harvested on 
three independent occasions, yielding 4 and 6 individual replicates (r) for the GC03Dd2 and GC03Cam734 strains, respectively. P 








Intriguingly, a survey of the metabolomes of GC03Cam734 and GC03Dd2 parasites 
revealed several distinguishing metabolic phenotypes. Most significantly, ATP/ADP 
and ATP/AMP ratios were significantly higher in GC03Cam734 parasites than in 
GC03Dd2 parasites (P=0.0002 and P=0.0001, respectively; see Figure 3.7 and Table 
3.7). Low ATP/AMP ratios are a classic marker of metabolic stress341 and the relatively 
higher ratios seen in GC03Cam734 parasites are consistent with their increased in vitro 
growth rate as compared with GC03Dd2 (see Figure 3.5). GC03Cam734 parasites also 
exhibited significantly increased levels of glycolytic and tricarboxylic acid (TCA) cycle-
associated metabolites (P=0.003 and P=0.01, respectively; see Figure 3.7 and Table 
3.7), suggesting differences in central carbon processing as a metabolic compensatory 
mechanism associated with the Cam734 pfcrt allele.342 Collectively, these findings 
indicate that parasites encoding Cam734 and Dd2 PfCRT both suffer from impaired 
parasite Hb catabolism, but that the metabolic impact of these changes is more severe 
for lines encoding Dd2 PfCRT. 
 
Distribution of heme species in isogenic pfcrt-modified parasites  
CQ treatment of P. falciparum parasites affects their disposition of heme species, 
namely free heme, Hz, and Hb. In a dose-dependent manner, CQ causes a decrease in 
the formation of non-toxic Hz crystals, an increase in toxic free heme, and an 
accompanying reduction in parasite survival.55 To date, the profiles of heme fractions 
had only been explored in CQ-sensitive (D10, NF54, D6) parasites.334,343 Given the 
central role of pfcrt in dictating parasite responses to CQ, we examined the 
composition of heme species in CQ-treated and untreated isogenic parasites encoding 




alleles Cam734 and Dd2. Our heme fractionation assay entailed treatment of 
synchronous, early ring-stage parasites with CQ in multiples (range of 0× to 3×) of 
parasite line-specific CQ IC50 values. After 32 h, trophozoite-stage parasites were 
subjected to a series of cellular fractionation steps. The abundance of heme present as 
Hb, free heme, or Hz was subsequently determined spectrophotometrically and 
reported both as a percentage of total heme (Figure 3.8) and as an amount of heme 
iron (Fe) per cell (Figure 3.9).  
Our results demonstrate that parasite exposure to CQ caused a dose-
dependent increase in free heme for all pfcrt-modified parasite lines (Figure 3.8A and 
Figure 3.9A). Considering all CQ treatments, maximal mean free heme Fe 
concentrations of 10.5, 12.6, and 19.3 femtograms (fg) per cell were observed in 
GC03Cam734, GC03Dd2, and GC03GC03 parasites (Figure 3.9A), respectively. The 
difference between GC03Cam734 and GC03GC03 parasites achieved statistical 
significance (P=0.02 by unpaired t test with Welch’s correction). Inversely correlating 
with free heme profiles, Hz profiles of pfcrt-modified parasites showed comparable, 
CQ dose-dependent decreases in Hz (Figure 3.8B and Figure 3.9B).  
We note that GC03GC03 parasites showed a higher, statistically significant level 
of heme at baseline (i.e. in the absence of CQ) as compared to GC03Dd2 and GC03Cam734 
parasites (P=0.004 and P=0.0012, respectively, by unpaired t tests with Welch’s 
correction), although the lowest level of Hz achieved in all three CQ-treated strains 
was comparable (Figure 3.8B). The reason for this difference in baseline free heme is 
not yet known. We hypothesize that free heme in untreated parasites is sequestered, 
possibly through association with neutral lipids in the DV.65 The baseline difference 













Figure 3.8. Distribution of heme species in control and chloroquine (CQ)-treated pfcrt-
modified parasite lines. The percent of total heme present as (A) free heme, (B) hemozoin 
(Hz), and (C) hemoglobin (Hb) was measured spectrophotometrically in isogenic parasites 
expressing the wild-type (CQ-sensitive) GC03 pfcrt allele or mutant (CQ-resistant) Dd2 and 
Cam734 pfcrt alleles. Prior to heme fractionation, synchronous parasites were exposed for 
32 h to multiples of line-specific CQ IC50 values (1× CQ IC50 of 19.5 nM, 187 nM, and 90.9 
nM for GC03GC03, GC03Dd2, and GC03Cam734, respectively). Bar graphs indicate mean ± SEM 
percentage values for 5 to 10 independent replicates. For each parasite line, values obtained 
for CQ-treated samples (gray bars) were compared against the untreated control (black bars), 
and statistical significance was determined via unpaired t tests with Welch’s correction. 
Absolute concentrations of heme species are depicted in Figure 3.9. *P<0.05; **P<0.01; 
























































Figure 3.9. Absolute concentrations of heme species in control and chloroquine (CQ)-treated 
pfcrt-modified parasite lines. The amount (in femtograms, fg) of heme Fe per cell present as 
(A) free heme, (B) hemozoin (Hz), or (C) hemoglobin (Hb) was measured 
spectrophotometrically in isogenic parasites expressing the wild-type (CQ-sensitive) GC03 
pfcrt allele or mutant (CQ-resistant) Dd2 and Cam734 pfcrt alleles. Prior to heme 
fractionation, synchronous parasites were exposed for 32 h to CQ concentrations 
corresponding to line-specific CQ IC50 folds (1× CQ IC50 values of 19.5 nM, 187 nM, and 90.9 
nM for GC03GC03, GC03Dd2, and GC03Cam734, respectively. In absolute values, 0.5× CQ IC50 
for GC03Cam734 is equivalent to 2.3× the CQ IC50 for GC03GC03 and 0.25× the CQ IC50 for 
GC03Dd2). Bar graphs indicate mean ± SEM percentage values for 5 to 8 technically 
independent replicates. For each parasite line, values obtained for CQ-treated samples (gray 
bars) were compared against the untreated control (black bars), and statistical significance 
was determined via unpaired t tests with Welch’s correction. *P<0.05; **P<0.01; ***P<0.001; 























larger DV of GC03Dd2 and GC03Cam734 lines, as compared to GC03GC03 parasites (see 
Table 3.8), resulting in a lower lipid to aqueous volume ratio. A fixed lipid-aqueous 
portioning coefficient and consequent fixed ratio of lipid to aqueous heme 
concentration would yield an increased quantity of aqueous free heme (volume × 
concentration), which in turn is mostly incorporated into Hz. 
Several notable differences were observed among the Hb profiles of pfcrt-
modified lines (Figure 3.8C and Figure 3.9C). First, isogenic parasites encoding 
mutant pfcrt alleles Cam734 and Dd2 exhibited higher concentrations of Hb as 
compared to wild-type (GC03) pfcrt-expressing parasites (mean Hb-specific heme Fe 
concentrations of 6.3, 3.7, and 2.3 fg per cell, respectively; Figure 3.9C), with the 
difference between GC03GC03 and GC03Cam734 lines achieving statistical significance 
(P=0.006 by unpaired t test with Welch’s correction). Consistent with previous 
findings,55 CQ-sensitive GC03GC03 parasites (Figure 3.8C and Figure 3.9C) showed a 
significant elevation in Hb species that did not occur until 2.5× CQ IC50. A comparable 
delay in Hb digestion until 2.5× CQ IC50 was observed for Cam734 pfcrt-expressing 
GC03Cam734 parasites, contrasting with the profile of Dd2 pfcrt-expressing GC03Dd2 
parasites, which showed elevations in Hb species at a lower (1×) CQ IC50 fold (Figure 
3.8C and Figure 3.9C). The increase in Hb observed for GC03Dd2 parasites coincided 
with a statistically significant increase in free heme at 1× CQ IC50 (see Figure 3.8A). 
This is consistent with previous studies of CQ-treated parasites, in which increases in 
undigested Hb were found to follow significant increases in free heme.55 This suggests 
a secondary mechanism of CQ action, whereby Hb degradation at higher CQ 
concentrations is inhibited, possibly through a physiologic effect of elevated CQ on the 




heme in aqueous environments have been shown to form heme aggregates capable of 
disrupting lipid bilayers and triggering membrane disorder, which in turn could 
disrupt Hb transport and metabolism.344 
For each pfcrt-modified line, we also compared the CQ dose dependence of 
parasite free heme fractions versus parasite growth (Figure 3.10). Interestingly, for 
each line, the free heme concentration curve crossed the parasite growth curve at 
approximately the same mid-point (IC50 value), indicating that the inverse 
relationship between CQ action on free heme levels and growth inhibition that was 
previously established for parasite lines encoding wild-type pfcrt334 is preserved 
among lines encoding CQ-resistant pfcrt alleles. These data reinforce the conception 
that CQ-mediated growth inhibition results from this drug’s inhibition of parasite-
mediated inactivation of reactive heme via its incorporation into chemically inert Hz. 
 
Cam734 PfCRT confers membrane potential-sensitive CQ transport 
A key feature of CQR in P. falciparum parasites is the ability of mutant PfCRT to 
efflux CQ from the parasite DV, in turn reducing CQ access to heme. Measurement of 
drug transport is experimentally challenging in Plasmodium parasites due to the 
presence of multiple membrane-bound intracellular compartments. Accordingly, we 
evaluated CQ transport mediated by Cam734 PfCRT using a recently optimized S. 
cerevisiae galactose-inducible PfCRT expression system.208 Yeast-expressed PfCRT 
isoforms localize largely to the cell membrane and mediate transport of CQ from the 
external medium (low pH, positive membrane potential [Ψ]) to the yeast cytosol (high 
pH, negative Ψ), recapitulating the electrochemical gradient-driven transport of CQ 













Figure 3.10. Survival and percentage free heme as a function of chloroquine (CQ) concentration for pfcrt-modified parasites. Shown are 
curves of parasite growth (black curve) and of the percentage of heme species present as free heme (gray curve), graphed as a function of 
the log10-transformed CQ concentration (in nM). Plotted points and error bars correspond to mean ± SEM measurements made in parasite 








cytosol (high pH, negative Ψ).336 Of note, at baseline, the yeast cell membrane 
possesses a high ∆pH and a low ∆ψ. By increasing the pH of the external medium 
(pHexternal), the cell membrane ∆pH can be experimentally lowered, yielding a 
compensatory potassium channel-dependent increase in ∆ψ.336 In this system, at 
higher ∆ψ, CQ transport by CQ-resistant PfCRT isoforms is more pronounced as 
compared to the basal level of transport mediated by the CQ-sensitive GC03 (wild-
type; equivalent to HB3) PfCRT isoform.208,281 Earlier studies have validated that 
growth rates of PfCRT-expressing yeast serve as a proxy for CQ transport.281  
Using quantitative growth rate analyses, we examined the effect of varying 
external pH (and hence the ∆ψ) in yeast strains expressing PfCRT isoforms GC03, 
Cam734, Cam738 (Cam734 F144A), or Dd2 (see Table 3.1 for haplotypes). Growth was 
assessed in the presence of 5 mM CQ, a concentration required for this drug to exert 
differential growth inhibitory activity on yeast strains expressing various PfCRT 
isoforms.208 As a negative control, we also included yeast harboring no PfCRT (vector 
control). To examine the effect of ∆ψ on transport, we assessed growth over a range of 
pHexternal values (range of 7.20 [low ∆ψ] to 7.45 [high ∆ψ]; Figure 3.11A). Intriguingly, 
in low ∆ψ conditions, growth of yeast expressing Cam734 PfCRT was comparable to 
that of yeast expressing the CQ-sensitive GC03 PfCRT isoform (Figure 3.12). 
However, when the ∆ψ was clamped to higher values, Cam734 PfCRT conferred a 
CQR-associated delayed growth phenotype that was intermediate to that of GC03 
(wild-type) and Dd2 PfCRT (Figure 3.12). Of note, the growth phenotype associated 
with the Cam738 isoform (lacking the Cam734 mutation A144F) was intermediate to 


















Figure 3.11. Membrane potential (∆ψ) dependence of PfCRT-mediated yeast growth delay 
and PfCRT isoform expression. (A) Growth delay of yeast lines encoding wild-type (gray 
diamonds), Dd2 (black squares), Cam734 (blue triangles), or Cam738 (Cam734 F144A; red 
triangles) PfCRT (tagged to a V5 epitope at its C terminus281) was measured in the presence 
of 5 mM CQ and normalized to growth of yeast harboring empty vector (see Methods). Growth 
was examined for a range (7.20 to 7.45) of pHexternal values. Through compensatory 
mechanisms, the yeast ∆ψ increases with increased pHexternal. CQ transport rates were 
calculated as previously described.281 Error bars indicate the SEM for at least three 
independent yeast clones analyzed in triplicate. (B) Yeast protein extracts were subjected to 
Western blot analysis with anti-V5 antibodies, as described in Methods. Briefly, total protein 
concentrations in the yeast crude membrane fractions were quantified using an amido black 
assay and 7.0 µg protein was electrophoretically separated and transferred onto a PVDF 
membrane. Levels of the 51.8-kDa PfCRT-V5 protein were comparable for all PfCRT isoforms 
(GC03, Dd2, Cam734, Cam738). A yeast strain harboring an empty vector was included in the 





































Figure 3.12. Effect of membrane potential (∆ψ) on chloroquine (CQ)-induced growth inhibition of yeast expressing PfCRT isoforms. Growth 
(measured as OD600) of yeast harboring no (empty vector; solid black line), wild-type (WT; GC03/HB3; gray line), Cam734 (blue line), Cam738 
(Cam734 F144A; red line) or Dd2 (dashed black line) PfCRT was assessed in the presence of 5 mM CQ in low-∆ψ (left panel; pHexternal 7.20) 
or high-∆ψ (right panel; pHexternal 7.45) conditions, as detailed in Methods. Increased growth inhibition correlates with increased CQ 
accumulation in the yeast cytosol and reflects increased CQ resistance.281 ∆ψ increases with increased pHexternal due to compensatory 
mechanisms that maintain the cell membrane electrochemical gradient. Growth of yeast lines over the pHexternal range of 7.20 – 7.45 is 








mutation is critical for drug transport mediated by the Cam734 isoform and is 
consistent with our drug assay data that showed a CQR phenotype for parasites 
expressing Cam734 pfcrt, but not Cam738 pfcrt (see Figure 3.2A). These PfCRT-
specific phenotypes were not attributable to differences in protein expression, as 
comparable protein expression of PfCRT variants was observed upon galactose 
induction of yeast (Figure 3.11B).  
We have observed that Cam734 is significantly potentiated by ∆ψ, resembling 
a CQ-sensitive PfCRT isoform at low ∆ψ and a mutant, CQ-resistant PfCRT isoform 
at high ∆ψ. This unique plasticity in mediating drug transport may underlie the 
improved asexual blood-stage fitness associated with the Cam734 PfCRT isoform, as 
compared with Dd2 (see Figure 3.5), whereby Cam734-defining mutations confer drug 
transport only in certain ∆ψ DV conditions. We also note that CQ transport, as 
assessed in heterologous expression systems, may only partially account for in vitro 
parasite CQR. This is highlighted by the earlier observation that the CQ-resistant 
Ecu1110 PfCRT variant confers lower parasite CQR, but higher CQ transport, than 
the related 7G8 PfCRT variant.242,312,345 Thus, the possibility also exists that Cam734 
facilitates CQR in part by alleviating CQ-mediated inhibition of an endogenous PfCRT 
function. Continued elucidation of the elusive function of PfCRT will assist in 
clarifying these distinctions. 
 
Differential effects of PfCRT isoforms on parasite digestive vacuole pH 
and volume 
Investigations utilizing the entrapment of a dextran-conjugated NERF to probe the 




mutations to alter DV physiology.195,197,345 Using similar methods (see Methods), we 
determined the DV pH and volume in isogenic parasites encoding GC03, Dd2, 
Cam734, and Cam738 (Cam734 F144A) PfCRT, in the presence or absence of CQ 
concentrations corresponding to 2× CQ 50% lethal dose (LD50; see Methods). From 
smallest to largest DV volume as well as from most alkaline to most acidic DV pH, the 
order of parasite lines was found to be as follows: GC03GC03, GC03Cam734 F144A, 
GC03Cam734, and GC03Dd2 (Table 3.8). This order was preserved upon a brief (30 min) 
addition of CQ, which consistently increased DV volume (by 13% to 33%). As the 
composition of the DV environment governs the degree of heme-to-Hz conversion,58 
one might envisage that, compared to Dd2 PfCRT, the reduced DV size and more wild-
type (GC03) PfCRT-like like DV pH associated with the Cam734 isoform may play a 






























Table 3.8. Digestive vacuole volume size and pH of pfcrt-modified lines.a 
 DV volume size ± SEM (μm3)  pH ± SEM 
Line No drug CQ % increase  No drug CQ 
GC03
GC03
 1.92 ± 0.04 2.16 ± 0.72 13%  5.74 ± 0.01 5.70 ± 0.01 
GC03
Cam734
 2.52 ± 0.03 3.10 ± 0.17 23%  5.55 ± 0.02 5.54 ± 0.01 
GC03
Cam734 F144A
 2.34 ± 0.02 2.75 ± 0.21 17%  5.61 ± 0.02 5.61 ± 0.01 
GC03
Dd2
 2.79 ± 0.05 3.72 ± 0.13 33%  5.24 ± 0.01 5.28 ± 0.02 
 
aFor the indicated isogenic, pfcrt-modified lines, digestive vacuole (DV) volume size and pH were determined using spinning 
disk confocal microscopy and single-cell photometry, respectively. Measurements were made following 30 min exposure to no 
drug or 2× CQ LD50. Results are reported as mean ± SEM DV volume size (μm3) or pH, as determined for ≥20 parasites, 
beginning in each case with tightly synchronized young trophozoites. DV volume values for CQ-treated parasites were compared 





























To ensure successful progression through their life cycle, drug-resistant P. falciparum 
parasites must balance the acquisition of drug resistance with the maintenance of 
essential physiological processes. Focusing on the pathogenic intraerythrocytic stages 
of parasite growth, we explored herein how novel mutations comprising the unusually 
polymorphic Cam734 PfCRT variant contribute to this complex relationship. Our 
analysis of the drug responses and growth rates of isogenic, pfcrt-modified lines 
reveals that multiple PfCRT mutations possess dual roles, contributing to both 
quinoline resistance and parasite proliferation. This was most notable for the A144F 
mutation that is unique to Cam734 PfCRT, which proved to be indispensable for 
parasite resistance to multiple quinoline-type compounds, including CQ, QN, and the 
first-line ACT partner drug AQ. This phenotype is reminiscent of earlier work, in 
which back-mutation of K76T ablated CQ resistance and nearly halved the degree of 
parasite resistance to QN.126 Of note, CQ-sensitive parasites encoding Cam734 F144A 
PfCRT (i.e. Cam738; see Table 3.1) retained K76T as well as 7 other mutations, thus 
meeting the canonical mutational criteria for a CQ-resistant haplotype.114 A clinical 
correlation that agrees with the notion that mutations beyond K76T can profoundly 
alter parasite drug responses is the fact that K76T predicts clinical CQR with good 
sensitivity, but only moderate specificity.198,199 
In light of the previously documented impacts of CQ on parasite heme 
disposition (reduced Hz, increased free heme) and the ability of PfCRT mutations to 
regulate the access of CQ to its heme target in the DV,55,58,126 we used our isogenic 
parasite lines to explore the role of PfCRT in the critical process of heme 




Cam734 and Dd2 PfCRT was the wild-type (GC03)-like propensity of Cam734 PfCRT 
to delay Hb digestion until higher CQ IC50 folds, as compared to Dd2 (see Figure 3.8C). 
Our observed elevation of Hb species with increased CQ dose recalls prior studies that 
showed an increase in undigested Hb following CQ treatment, in part by inhibiting 
vesicular trafficking of host RBC Hb to the DV.346,347 We predict that future PfCRT-
focused experiments will provide important insights into the mechanisms by which 
various clinically important antimalarials (e.g. AQ, LUM, AS) induce increased heme 
levels,55 akin to CQ, and yet retain potency against both CQ-sensitive and CQ-
resistant strains. 
Our metabolomics analysis (see Figure 3.7) and total hemoglobin 
quantification (see Figure 3.8C and Figure 3.9C) clearly show that GC03Cam734 
parasites exhibit major changes in the Hb digestion pathway. Given that these 
changes are normally associated with impaired fitness,232 our results raise an obvious 
question: does Cam734 PfCRT impart a metabolic compensatory mechanism that 
allows these parasites to circumvent the normally deleterious effects of altered Hb 
digestion? Previous heterologous expression studies using Xenopus laevis oocytes 
have reported the ability of PfCRT mutations to selectively confer transport of the 
tripeptide glutathione.234 However, we saw no significant differences in glutathione or 
any other redox-associated metabolites (see Figure 3.6 and Table 3.7) between 
isogenic lines encoding Cam734 or Dd2 PfCRT, suggesting that major redox-related 
metabolic changes are unlikely to account for the improved fitness associated with the 
Cam734 pfcrt allele. In contrast, we observed striking differences in ATP/AMP ratios 
and central carbon metabolism between lines encoding Cam734 and Dd2 PfCRT (see 





Recent evolutionary genetic studies of the adaptive landscapes (i.e. mutational 
paths and their accompanying fitness costs) associated with drug resistance-
conferring mutations in parasite dihydrofolate reductase (dhfr) and pfcrt genes 
highlight key points that can be used to hypothesize how Cam734 pfcrt evolved: (1) 
forward pfcrt evolution is a physiologically constrained process that is consistent with 
the rarity of pfcrt alleles bearing three or fewer polymorphisms; (2) forward and 
reverse gene evolution are associated with distinct adaptive landscapes; and (3) 
adaptive landscapes can be substantially modified by their drug 
environment.242,245,348,349 The spread of CQR in Asia as well as in Africa has long been 
attributed to a single (Dd2 or Dd2-like) pfcrt allele.249 Of note, Cam734 shares four of 
the eight mutations comprising both the eight-amino acid Dd2 variant (see Table 3.1) 
and the related 6-amino acid variant GB4 (equivalent to Dd2 S326N T356I) that is 
also seen in Southeast Asia (Gabryszewski et al., manuscript in preparation). We posit 
that, faced with high CQ pressure, parasites underwent mutational bursts (as 
previously suggested242) that led to the evolution of Dd2 pfcrt. With reduced CQ 
pressure, a “reverse” evolutionary process might have led to the loss of some 
mutations and eventual acquisition of novel ones, as in the case of Cam734 pfcrt.  
In their report documenting Cam734 pfcrt in Cambodia, Durrand et al. also 
reported the related allele Cam738 (Cam734 F144A).262 We posit that Cam738 served 
as a mutational precursor of the more evolutionarily successful Cam734 allele. This 
is supported by the inferior growth of isogenic parasites expressing Cam738 pfcrt as 
compared with Cam734 pfcrt, in the absence or presence of CQ or other quinoline 




PfCRT residue 144 are apparent in Asia, in some cases requiring two nucleotide 
substitutions. For example, in the Philippines and in China, PfCRT haplotypes have 
been detected that, respectively, harbor the mutations A144T and A144Y.350,351 
Interestingly, addition of A144Y to the CQ-resistant Dd2 PfCRT isoform was 
previously found to abrogate CQ transport in S. cerevisiae.208 
With sustained exposure to drug selective forces, parasites may evolve 
intergenic and/or intragenic compensatory changes that allow them to persist even in 
the absence of drug pressure.240 The Cam734-defining compensatory mutations 
identified in our analysis reveal an intragenic basis for the enhanced fitness of this 
CQ-resistant allele, which could explain its continued presence in Southeast Asia 
despite the lack of CQ use for several decades to treat P. falciparum malaria. The 
degree to which secondary genetic factors also play a role is presently unclear. We 
note that our pfcrt-modified lines were generated in GC03 parasites, a clone of the 
HB3 (Central America) × Dd2 (Asia) genetic cross.185 These parasites encode the HB3 
pfmdr1 haplotype, which differs from Dd2 PfMDR1 at three distinct residues (86, 184, 
1042).142 A recent study has shown that the PfMDR1 N86Y mutation (present in Dd2 
parasites) augments the degree of CQR imparted by mutant Dd2 PfCRT.143 We have 
recently observed that, as compared to GC03 parasites (see Figure 3.2A), expression 
of Cam734 pfcrt in the Dd2 genetic background results in higher, Dd2-like levels of 
CQR (unpublished data). This is consistent with a prior transfection-based study that 
highlighted the importance of parasite genetic background in dictating the level to 
which mutant pfcrt alleles can mediate CQR.217 
The notion that additional genetic changes are required to produce high-level 




PfCRT-encoding parasites exhibit increased expression of proteins involved in pH 
regulation, including a V-type H+ pyrophosphatase.352 Our observation that, compared 
with Dd2, Cam734 PfCRT required a higher ∆ψ to manifest increased growth in the 
presence of CQ (consistent with elevated drug transport; see Figure 3.12) suggests 
that high-level Cam734 PfCRT-mediated drug resistance may be potentiated by 
parasite proteins that govern the ∆ψ across the DV membrane. We speculate that this 
plasticity in drug transport might be a reflection of the balance that Cam734 PfCRT 
has achieved in mediating resistance while also avoiding fitness costs. Future genetic 
dissections of pfcrt alleles, as well as candidate secondary genetic modulators (e.g. 
pfmdr1), are possible with the recent advent of efficient parasite genome editing 
tools.143,353 Leveraging these approaches with analysis of parasite whole-genome 
sequences will aid in deciphering the genetic complexities that underlie new and 
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Just a few geographical origins fully account for the historic emergence of chloroquine 
(CQ) resistance (CQR)-conferring variants of the Plasmodium falciparum Chloroquine 
Resistance Transporter (PfCRT), whose spread undermined the global gold-standard 
status of CQ. One of these variants evolved in Southeast Asia and eventually spread 
into and throughout Africa, where it contributed to stalled control efforts and a 
resurgence in malarial mortality. This PfCRT variant has been widely assumed to be 
the eight-amino acid Dd2 isoform (M74I/N75E/K76T/A220S/Q271E/N326S/ 
I356T/R371I), which spread widely throughout Southeast Asia. In the context of 
higher parasite transmission and declining CQ use, wild-type PfCRT has re-emerged 
to become the most common PfCRT haplotype in Africa, followed by the six-amino acid 
GB4 variant (Dd2 S326N T356I) that was either the original haplotype that arrived 
from Asia or that has since emerged in Africa as pfcrt mutations were divested. To 
better understand these regional differences in allele prevalence, we genetically 
modified the pfcrt locus of asexual blood-stage P. falciparum parasites using zinc 
finger nucleases and generated a panel of isogenic parasites encoding all PfCRT 
haplotypes spanning the mutational interval between GB4 and Dd2, which differ at 
PfCRT residues 326 and/or 356. We explored the recent association of PfCRT 
mutations N326S and I356T with artemisinin resistance by generating our allelic 
panel in parasites either sensitive (wild-type K13) or resistant (R539T K13) to 
artemisinin. Phenotypic analysis of the drug susceptibility profile, degree of stage-
specific survival following brief exposure to drug pulses, and growth kinetics of these 
lines revealed unique and complex impacts of PfCRT mutations on both drug 




confer the properties of a multidrug resistance transporter, constrained by fitness 
costs imposed by its essential role in regulating digestive vacuole physiology. 
Comprehensive characterization of PfCRT variants that arose in response to global 
CQ pressure and that are now subjected to complex, region-specific selective forces 
are of direct relevance to the regional recommendations of antimalarials, whose 
























The pathogenesis of human malaria is initiated by intraerythrocytic Plasmodium 
parasites, with Plasmodium falciparum causing the most severe and lethal disease. 
Recent reductions in the global incidence of malaria can be attributed in large part to 
the global deployment of artemisinin-based combination therapies (ACTs) to treat 
asexual blood stage infections, combined with vector control strategies.13 ACTs consist 
of a fast-acting, albeit rapidly eliminated, artemisinin (ART) compound paired with a 
long-lived partner drug that is required to clear residual parasite biomass. 
Worryingly, emerging resistance to ACTs is now a reality, in part due to mismatched 
pharmacokinetic profiles of ACT components and parasite evolution of multidrug 
resistance.123 The untimely rise and dispersal of chloroquine (CQ) and sulfadoxine-
pyrimethamine resistance during past malaria control campaigns underscores the 
pressing need to identify and characterize novel drug resistance mechanisms before 
they render current drugs widely ineffective.17  
Artemether-lumefantrine (ATM-LUM), artesunate-amodiaquine (AS-AQ), and 
dihydroartemisinin-piperaquine (DHA-PPQ) are the three most widely used ACTs 
worldwide. The structural hallmark of the core ART component (ATM, AS, DHA) is 
an endoperoxide bridge that, upon cleavage by heme, provokes oxidative stress.100 
First reported in Western Cambodia and now increasingly observed in neighboring 
countries,181,354 the clinical indicator of waning ART efficacy is delayed parasite 
clearance from patient blood.354 This phenotype tracks with mutations in the parasite 
kelch13 (k13) gene158 that are sufficient to confer parasite ART resistance in vitro,160 
which manifests as an increase in survival of ring-stage parasites to a brief, 




are widely used beyond Asia and k13 mutations are infrequently detected among 
African parasite isolates,356,357 so far only Southeast Asian parasites have experienced 
demonstrable selective pressures on the k13 locus.164 The spread of ART resistance in 
Southeast Asia has been attributed in part to the acquisition of secondary resistance 
determinants, including mutations in parasite genes encoding Apicoplast ribosomal 
protein S10 (ArpS10), Ferredoxin (Fd), P. falciparum Multidrug Resistance 2 
Transporter (PfMDR2), and P. falciparum Chloroquine Resistance Transporter 
(PfCRT).159 Of these, pfcrt mutations are known to modulate parasite ART 
susceptibility in vitro.120,242 However, their effects on parasite DHA survival, the in 
vitro correlate of clinical ART resistance, had not been explored. Interestingly, Miotto 
et al. recently identified PfCRT N326S and I356T as mutations common among ART-
resistant founder parasite populations.159 
The recent evolution of resistance to first-line ACT partner drugs poses an 
additional layer of urgency. Reports from Southeast Asia now indicate rapidly 
emerging resistance to the bisquinoline compound PPQ.135,136,138,358 Analogous to the 
ring-stage survival assay (RSA) for in vitro detection of ART resistance, a PPQ 
survival assay (PSA) was recently developed, whereby parasite survival is evaluated 
following two days of exposure to a pharmacologically relevant PPQ dose.139 The 
genetic basis of resistance to PPQ has yet to be elucidated, although variations in 
genes affecting parasite digestive vacuole (DV) physiology and hemoglobin (Hb) 
processing, including pfcrt and the gene encoding the P. falciparum Multidrug 
Resistance 1 Transporter (PfMDR1), are speculated to be of importance.139,223 
Modulation of blood-stage parasite PPQ susceptibility by PfCRT mutations in certain 




studies.137,196,217,218 As well, the mutational status of pfcrt and pfmdr1 is known to 
impact the efficacy of the aryl-aminoalcohol compound LUM143,148,213,359 and the 
quinoline compound AQ.133,143,149 In the case of pfcrt, ATM-LUM and AS-AQ select for 
wild-type and mutant pfcrt alleles, respectively.149 Selection of wild-type pfcrt was also 
previously reported for DHA-PPQ,360 although the precise impact of PPQ on the pfcrt 
locus is less clear.183 Evidence for ACT regimen-dependent selection of PfCRT variants 
corroborates recent descriptions of PfCRT as a pleiotropic mediator of multidrug 
resistance.114,220,242 
As its name suggests, PfCRT was initially designated as the primary mediator 
of resistance to chloroquine (CQ). Following its historic contribution to malaria control 
efforts, CQ ultimately lost its status as a gold-standard antimalarial during the second 
half of the 20th century due to the multi-focal emergence and spread of chloroquine 
resistance (CQR).249,271 Despite this, CQ continues to be used to treat P. falciparum 
infections in resistance-free regions and remains a first-line treatment of non-
falciparum malaria.32 Upon accumulating in the parasite digestive vacuole (DV), CQ 
interferes with parasite detoxification of heme, a potentially toxic byproduct of Hb 
digestion.55 PfCRT mutations mediate CQR by conferring restricted access of CQ to 
its heme target,188 of relevance given the centrality of Hb catabolism and heme 
detoxification to the modes of action and/or resistance of a wide array of 
antimalarials.55,58,100,276 Consistently accompanied by ≥3 PfCRT single-nucleotide 
polymorphisms (SNPs), PfCRT K76T is necessary, but insufficient, for parasite CQR 
and serves as a sensitive, but not specific, marker of CQ treatment failure.114,198,242 
Recent studies have begun to uncover distinct roles for mutations beyond K76T in 




altering responses to other drugs.137,196,242,243 
In this study, we investigated the geographic distribution of pfcrt alleles and 
determined their impact on asexual blood-stage parasite drug resistance and fitness. 
Specifically, we explored the PfCRT haplotypes present in Asia (eight-SNP variant 
Dd2) and Africa (six-SNP variant GB4), which differ at PfCRT residues 326 and 356. 
Of note, Dd2 PfCRT harbors N326S and I356T, the ART resistance-associated PfCRT 
mutations reported by Miotto et al. that are common among Southeast Asian parasite 
isolates.159 We evaluated the impact of these mutations on parasite proliferation and 
antimalarial drug responses using isogenic blood-stage parasites encoding GB4 
PfCRT, Dd2 PfCRT, or intermediate PfCRT haplotypes encoding Dd2 S326N or Dd2 
T356I PfCRT. Our analysis included a k13-mutant genetic background (R539T K13) 
permissive for enhanced ring-stage parasite DHA survival, which was used to explore 
the capacity of PfCRT mutations to modulate this ART resistance phenotype. Our 
findings redefine the global distribution of pfcrt alleles and their historical 
dissemination and provide new insights into the contributions of PfCRT mutations to 













Parasite cultivation and genetic modification 
Unless stated otherwise, P. falciparum-infected human erythrocytes were cultured at 
4% hematocrit in RPMI-1640 culture medium supplemented with 0.5% Albumax II 
(Invitrogen). Cultures were incubated at 37°C, 5% O2 / 5% CO2 / 90% N2. 
To genetically modify the pfcrt locus of Dd2 or Dd2R539T parasites (Figure 4.1), 
a set of pcrt-hdhfr donor plasmids encoding variant pfcrt alleles was prepared. This 
set included the previously generated plasmids pcrtGC03-hdhfr and pcrtDd2-hdhfr (pfcrt 
allele listed in superscript; see Table 4.1). Site-directed mutagenesis (SDM)361 with 
PfuTurbo Polymerase (Agilent) and primer pairs p1+p2 and p3+p4 was used to 
introduce PfCRT back-to-wildtype S326N and/or T356I reversions into the donor 
template pcrtDd2-hdhfr, generating the additional donor plasmids pcrtDd2 S326N-hdhfr, 
pcrtDd2 T356I-hdhfr, and , pcrtGB4-hdhfr. 
 Briefly, Dd2 or Dd2R539T parasites (≥4% parasitemia, mostly ring-stage) were 
transformed with 40 μg donor plasmid (pcrt-hdhfr) and pressured with 2.5 nM 
WR99210 (Jacobus Pharmaceuticals). Parasites enriched with the pcrt-hdhfr plasmid 
were similarly transformed with pZFNcrt-bsd and pressured with 2.5 nM WR99210 + 
2 μg/ml Blasticidin HCl (Invitrogen) for six days, followed by continuous pressure with 
2.5 nM WR99210. As detailed elsewhere,242 blood PCR reactions (KAPA Biosystems) 
were used to assess for successful allelic replacement in bulk cultures and in cloned 
recombinant parasites. Parasites were cloned by limiting dilution following 
established protocols.296 The full-length pfcrt gene was PCR-amplified with primer 
pair p9+p12 and sequenced with primers p5 and p6 to verify sequence integrity (see 

























aThe mutational status of PfCRT and K13 is summarized for all recombinant parasite lines generated in this study. Mutations are 
shaded in gray. The PfCRT haplotype encoded by Dd2 (wild-type K13) and Dd2R539T (mutant R539T K13) parasites is indicated in 





Table 4.1. PfCRT and K13 haplotypes of recombinant isogenic parasite lines.a 
 PfCRT  K13 
Parasite line 74 75 76 220 271 326 356 371  539 
Dd2GC03 M N K A Q N I R  R 
Dd2Dd2 I E T S E S T I  R 
Dd2Dd2 S326N I E T S E N T I  R 
Dd2Dd2 T356I I E T S E S I I  R 
Dd2GB4 (Dd2Dd2 S326N T356I) I E T S E N I I  R 
Dd2R539TGC03 M N K A Q N I R  T 
Dd2R539TDd2 I E T S E S T I  T 
Dd2R539TDd2 S326N I E T S E N T I  T 
Dd2R539TDd2 T356I I E T S E S I I  T 









Figure 4.1. Parasite allelic modification of pfcrt and validation of genetic editing. (A) Zinc finger 
nuclease (ZFN)-based genetic engineering strategy. As detailed in Methods, parasites were 
first enriched with a donor plasmid (pcrt-hdhfr) that encodes pfcrt exons 2-13 (e2-13) and 
includes mutations of interest (indicated in purple). A comprehensive list of PfCRT haplotypes 
that were introduced into Dd2 or Dd2R539T parasites is found in Table 4.1. The pcrt-hdhfr 
plasmid also comprises the following elements: P. berghei crt (pbcrt) 3′ UTR, human dhfr 
(hdhfr) selection cassette, as well as pfcrt-hdhfr-flanking homology regions (~0.4 kb upstream 
of the intron 1-exon 2 boundary and ~1 kb native 3′ UTR downstream of hdhfr). Parasites were 
subsequently transfected with pZFNcrt-bsd. This plasmid facilitates calmodulin (cam) promoter-
driven expression of a pair of pfcrt-targeting ZFNs (ZFNL and ZFNR) and includes the 
blasticidin S deaminase (bsd) selection cassette. Following ZFN-catalyzed introduction of a 
double-stranded break in pfcrt (indicated with lightening bolt), parasites that employ the pcrt-
hdhfr plasmid as a donor template incorporate mutations of interest through homologous 
recombination-based mechanisms. (B) Blood PCR-based verification of pfcrt allelic exchange. 
Shown are representative results for Dd2 parasites into which the full-length GB4 pfcrt allele 
was introduced (Dd2GB4) as well as controls, namely genetically unedited parental parasites 
(Dd2), unedited donor plasmid-enriched parasites (Dd2 + pcrtGB4-hdhfr), and the sole donor 
plasmid (pcrtGB4-hdhfr). All appropriately edited lines showed the expected DNA band 
migration patterns: 0.4 kb (p7+p8), 1.2 kb (p9+p8), 2.5 kb (p10+p11), and 2.7 kb (p9+p12). 























aSDM, site-directed mutagenesis; F, forward; R, reverse; gDNA, genomic DNA; pbcrt, P. berghei chloroquine resistance transporter; UTR, 
untranslated region. 
Table 4.2. Primers used in this study.a 
Primer Oligonucleotide sequence (5’ → 3’) Description Lab name 
p1 CCTTCGCATTGTTTTCCTTCTTTAACATTTGTGATAATTTAATAACCAGC SDM PfCRT S326N F p1765 
p2 GCTGGTTATTAAATTATCACAAATGTTAAAGAAGGAAAACAATGCGAAGG SDM PfCRT S326N F p1766 
p3 GTTAGTTGTATACAAGGTCCAGCAATAGCAATTGCTTATTAC SDM PfCRT T356I F p5633 
p4 GTAATAAGCAATTGCTATTGCTGGACCTTGTATACAACTAAC SDM PfCRT T356I R p5634 
p5 TCAAACATGACAAGGGAAATAGT pfcrt exon 5 F p2427 
p6 CCAAGAATAAACATGCGAAACC pfcrt exon 7 R p3806 
p7 CTTGAATTCGACCTTAACAGATGGCTCAC pfcrt exon 2 F p3264 
p8 CTTATCGATAAGCAGAAGAACATATTAATAGGAATACTTAATTG pfcrt exon 3 R p3265 
p9 CTTGGGCCCAAGTTGTACTGCTTCTAAGC pfcrt gDNA 5′ UTR F p3404 
p10 CTCGAGATGGTTGGTTCGCTAAACTGC hDHFR F p3315 
p11 TTGACCCTTATATATTCCACCCA pfcrt gDNA 3′ UTR R p3403 








Drug susceptibility assays 
The concentrations of antimalarial drugs that were 50% and 90% growth-inhibitory 
(i.e. IC50 and IC90) to asexual blood-stage parasites were determined using a flow 
cytometry-based assay that detects parasite nuclei and mitochondria using SYBR 
Green I and MitoTracker Deep Red, respectively.242 Parasites were subjected to two-
fold serial dilutions of drug, and parasite growth was determined with an Accuri C6 
flow cytometer after 72 h. Our antimalarial drug panel included CQ ± 0.8 μM 
verapamil (VP), monodesethyl-CQ, monodesethyl-AQ, LUM, AS, PPQ, pyronaridine 
(PND), and quinine (QN). To determine verapamil (VP)-mediated reversibility of 
CQR, the CQ+VP IC50 value was divided by the CQ IC50 value, yielding the CQ 
response modification index (RMI).298 Statistical significance was determined via non-
parametric Mann-Whitney U tests using GraphPad Prism 6 software. 
 
In vitro growth assays 
Growth of asexual blood-stage parasites was assessed in vitro using a previously 
described method that employs flow cytometric detection of GFP and the far-red 
fluorescent dye SYTO61.242 Briefly, 1:1 co-cultures were established with a GFP-
positive (GFP+) fluorescent reporter line (RGFP) and a single GFP-negative (GFP–) 
pfcrt-modified test line. RGFP in these assays corresponds to the previously generated 
CQ-resistant Dd2BiP-eGFP line. This line uses a BiP promoter to drive enhanced GFP 
(eGFP) expression and has a genetic background comparable to that of our pfcrt-
modified test lines.299 Using flow cytometry, we determined the proportion of GFP– 
parasites (corresponding to the pfcrt-modified test line) every three days for 20 days 




that parasitemia never exceeded 8%. 
  The frequencies of the GFP– test line and the GFP+ reporter line at time t are 
referred to as pt and qt, respectively. As previously detailed, the fitness (ω) associated 
with a particular test line was derived from the natural log-transformed ratio pt/qt and 
normalized to isogenic parasites encoding the wild-type (GC03) pfcrt allele in the Dd2 
genetic background (Dd2GC03), yielding the relative fitness (ω′) metric. The in vitro 
growth selection coefficient (s) for each test strain was derived from the relationship 
s = ω′ – 1.242 Statistical significance was assessed via two-way ANOVA with Sidak’s 
post-hoc test using GraphPad Prism 6 software. 
 
DHA and PPQ survival assays 
Stage-specific survival assays were conducted following published protocols, with 
minor modifications.139,160,355 Briefly, 15 ml of parasite culture was synchronized with 
5% sorbitol and cultivated through the mature schizont stage (≥0.5% schizont 
parasitemia). Cultures were heparinized for 30 min at 37°C in RPMI-1640 medium 
containing 15 U/ml sodium heparin (Millipore), with occasional mild vortexing. 
Parasites were subsequently subjected to a gradient of 75% Percoll (Sigma-Aldrich) 
and centrifuged at 3400 rpm for 15 min. The schizont fraction was washed with RPMI-
1640 medium and incubated with human RBCs for 3 h to initiate a new asexual blood-
stage cycle, followed by synchronization with 5% sorbitol to eliminate non-ring 
parasite forms. Serial dilutions of DHA or PPQ were pre-aliquoted into 96-well plates 
using a BioTek Precision Pipetting System. Parasite cultures at early-ring (t=0–3 hpi) 
or mid-trophozoite (t=18–21 h post-invasion) stages were added to plates containing 




wells were included for each parasite line and drug concentration. Vehicle controls for 
DHA and PPQ survival assays were DMSO and 0.5% lactic acid, respectively. For 
DHA survival assays, parasites were incubated in drug for 3 h. For PPQ survival 
assays, parasites were incubated through the 48 hpi timepoint. Following drug 
incubation, parasites were washed three times with RPMI-1640 medium and grown 
in fresh medium until the assay endpoint of 72 h. Parasitemia was assessed by flow 
cytometry, which correlated with microscopic assessment of parasitemia. Parasite 
survival is equivalent to parasitemia in the presence of drug divided by the 




























RESULTS AND DISCUSSION 
Distribution of pfcrt alleles in Africa and Southeast Asia 
Together, Africa and Southeast Asia account for the vast majority of the global burden 
of malaria. Using the MalariaGEN Pf3k database of P. falciparum whole genome 
sequences that encompass these regions,159 we assessed the geographic distribution of 
allelic pfcrt variants (Figure 4.2). In Africa, wild-type (GC03) PfCRT comprised 75% 
of the total haplotypes. Of the mutant PfCRT haplotypes in this region, GB4 was the 
most common (47% of mutant haplotypes; 12% of total haplotypes), followed by Dd2 
S326N (28% of mutants; 7% of total). The remaining portion of mutant haplotypes 
(25% of mutants; 6% of total) was comprised of various, polymorphic haplotypes, with 
the GB4 S220A PfCRT variant being most common. In contrast, in Southeast Asia, 
the wild-type PfCRT haplotype comprised only 8% of the total haplotypes. Dd2 was 
the most common mutant haplotype (57% of mutants; 52% of total), followed by 
Cam734 (15% of mutants; 14% of total), GB4 (13% of mutants; 12% of total), and other 
mutant haplotypes (14% of mutants; 15% of total).  
Several striking features emerge from this data. First, the predominant pfcrt 
allele in Africa is not the 8-amino acid variant Dd2, the first mutant pfcrt allele that 
was discovered through the analysis of the HB3×Dd2 genetic cross.185 It is also not the 
7-amino acid variant Dd2 T356I, which lacks the I356T mutation. Both the Dd2 and 
Dd2 T356I alleles were originally observed in Asian and African parasites available 
at the time that pfcrt was reported (2000), and it has been frequently assumed that 
Dd2 was the original allele that spread from Asia to Africa, which caused a 
devastating loss of CQ efficacy and increase in malaria mortality.186,249,270 It is now 









Figure 4.2. Predominant pfcrt alleles are distinct in Africa and Asia. Pie charts illustrate the 
regional proportion of the indicated haplotypes, as estimated based on whole genome 
sequences present in the MalariaGEN Pf3k database.159 Pie chart sections correspond to the 
following haplotype proportions: Africa – WT 75%; GB4 12%; Dd2 S326N 7%; Others 6%; 
Southeast Asia – wild-type (WT) 8%; Dd2 52%; Cam734 14%; GB4 12%; Others 14%. The 
mutational composition of the WT (GC03), Dd2, GB4, and Dd2 S326N PfCRT haplotypes is 
shown in Table 4.1. Cam734 PfCRT consists of the following mutations: M74I, N75D, K76T, 














a 7-amino acid variant that has not yet been described in any culture-adapted strain 
(referred here to as Dd2 S326N) are the predominant mutant PfCRT variants in 
Africa. Interestingly, the GB4 variant is quite abundant in Southeast Asia. Further 
studies with isolates collected over time will be required to identify whether GB4 was 
the original allele that spread from Asia into Africa, or whether both continents have 
seen a progressive loss of PfCRT mutations, starting from the 8-amino acid or 7-amino 
acid variants. These observations were only made possible with the recent report of 
1,500 and 1,000 P. falciparum genomes from Africa and Asia, respectively, 
highlighting the value of large-scale genome studies.164 
 
Generation of isogenic parasites encoding variant pfcrt and k13 alleles 
Herein, we aimed to characterize the most prevalent mutant PfCRT haplotypes in 
Africa and Southeast Asia (GB4 and Dd2, respectively), in relation to wild-type (GC03) 
PfCRT. The mutational composition of these haplotypes is similar, with Dd2 PfCRT 
harboring two mutations (N326S and I356T) on top of the six mutations (M74I, N75E, 
K76T, A220S, Q271E, R371I) it shares with the GB4 isoform (Table 4.1). To define 
cellular features associated with the GB4 and Dd2 PfCRT haplotypes that may 
provide a basis for their regional distributions, and to dissect the roles of PfCRT 
S326N and T356I in parasite drug resistance versus fitness, we genetically modified 
the pfcrt locus of P. falciparum asexual blood-stage parasites. Using an established 
zinc finger nuclease (ZFN)-based approach (Figure 4.1), we generated isogenic 
parasites varying only by the pfcrt allele that they express. The pfcrt sequence of these 
parasite lines was verified using primers listed in Table 4.2. Our PfCRT haplotype 




intermediates spanning the mutational interval between GB4 and Dd2, namely Dd2 
S326N and Dd2 T356I PfCRT (see Table 4.1). Of note, inclusion of the Dd2 S326N 
PfCRT haplotype in our analysis allowed us to characterize the second most common 
mutant PfCRT haplotype in Africa (see Figure 4.2). To explore the recently reported 
association of PfCRT mutations N326S and I356T with ART-resistant founder 
parasite populations,159 we generated this panel of PfCRT haplotypes in two separate 
parasite backgrounds, namely Dd2 and Dd2R539T, which encode wild-type and mutant 
R539T K13, respectively (see Table 4.1). The latter strain is equivalent to Dd2R539T, a 
published k13-modified line that exhibited one of the highest levels of ART resistance 
in the Dd2 background.160 
 
CQ responses of pfcrt-modified lines 
Mutant forms of PfCRT are most extensively recognized for their ability to confer 
CQR. To assess whether variants in our panel of pfcrt alleles have an impact on 
parasite CQ responses, we subjected asexual blood-stage parasites to flow cytometry-
based drug susceptibility assays and determined 50% and 90% growth-inhibitory 
antimalarial drug concentrations (IC50 and IC90, respectively; Table 4.3). For CQ 
(Figure 4.3A) and its main in vivo metabolite, monodesethyl-CQ (md-CQ; Figure 
4.3B), mutant PfCRT isoforms Dd2, Dd2 S326N, Dd2 T356I, and GB4 each conferred 
statistically significant increases in drug IC50 values as compared with the GC03 
(wild-type) isoform (P<0.002 in all instances). Among the mutant isoforms, the highest 
and lowest levels of resistance to CQ and md-CQ were conferred, respectively, by Dd2 
and GB4 PfCRT (Figure 4.3; Table 4.3). The reduced level of resistance associated 





Table 4.3. Antimalarial IC50 and IC90 values of pfcrt-modified parasite lines.a 














CQ IC50 161 ± 10.1 134 ± 10.5 144 ± 10.1 102 ± 10.8 11.9 ± 0.4  152 ± 10.8 131 ± 14.6 132 ± 12.9 92.5 ± 8.8 12.9 ± 0.5 
n 7 7 5 4 8  7 6 5 4 7 
P –  0.53 0.97 0.009 <0.0001  0.99 0.43 0.57 0.0011 <0.0001 
CQ IC90 261 ± 12.0 231 ± 9.9 268 ± 27.6 204 ± 18.1 18.8 ± 1.7  277 ± 24.4 255 ± 17.8 263 ± 26.9 199 ± 13.3 24.9 ± 0.7 
n 7 7 5 4 8  7 6 5 4 7 
P –  0.92 >0.99 0.43 <0.0001  >0.99 >0.99 >0.99 0.32 <0.0001  
CQ+VP IC50 32.5 ± 4.1 26.6 ± 4.6 22.5 ± 5.8 30.7 ± 8.9 13.3 ± 0.8  23.8 ± 6.1 26.6 ± 4.7 19.0 ± 6.8 23.9 ± 4.7 13.2 ± 0.6 
n 6 6 5 3 7  6 5 5 3 6 
P –  0.99 0.88 >0.99 0.07  0.93 >0.99 0.57 0.98 0.09 
CQ+VP IC90 80.2 ± 7.2 62.3 ± 0.9 79.5 ± 8.7 66.6 ± 11.6 24.7 ± 1.7  78.8 ± 13.2 72.1 ± 12.8 71.7 ± 13.8 59.3 ± 8.11 26.4 ± 1.1 
n 6 5 5 3 7  6 5 5 3 6 
P –  0.90 >0.99 >0.99 0.0005  >0.99 >0.99 >0.99 0.90 0.0014 
md-CQ IC50 845 ± 44 703 ± 80 744 ± 69 537 ± 66 21.2 ± 0.8  720 ± 29 608 ± 56 602 ± 47 426 ± 53 21.0 ± 2.4 
n 7 7 5 4 7  7 6 5 4 6 
P –  0.48 0.92 0.006 <0.0001  0.65 0.03 0.04 <0.0001 <0.0001 
md-CQ IC90 1527 ± 68 1309 ±83 1428 ± 58 828 ± 74 48.3 ± 1.7  1334 ± 134 1144 ± 137 1186 ± 109 742 ± 103 48.1 ± 3.3 
n 7 7 5 4 7  7 6 5 4 6 
P –  0.69 >0.99 0.0002 <0.0001  0.82 0.08 0.22 <0.0001 <0.0001 
md-AQ IC50 90.7 ± 6.2 45.3 ± 2.9 71.5 ± 7.7 44.4 ± 6.8 23.7 ± 1.7  79.1 ± 3.8 46.5 ± 2.2 69.5 ± 2.2 43.5 ± 5.8 27.1 ± 1.9 
n 7 7 5 4 7  7 6 5 4 6 
P –  <0.0001 0.07 <0.0001 <0.0001  0.54 <0.0001 0.03 <0.0001 <0.0001 
md-AQ IC90 163 ± 8.7 88.9 ± 4.6 117 ± 13.8 79.7 ± 8.5 37.7 ± 2.7  131 ± 11.3 80.2 ± 6.6 122 ± 9.9 64.1 ± 12.3 36.7 ± 3.2 
n 7 6 5 3 6  7 6 5 3 6 
P –  <0.0001 0.013 <0.0001 <0.0001  0.13 <0.0001 0.04 <0.0001 <0.0001 












Table 4.3. continued 














QN IC50 139 ± 22.5 134 ± 21.1 118 ± 15.6 128 ± 19.7 96.9 ± 8.2  98.1 ± 16.2 120 ± 15.0 103 ± 8.6 126 ± 43.0 83.7 ± 6.6 
n 4 7 5 4 6  4 4 4 4 4 
P – >0.99 0.98 >0.99 0.85  0.92 >0.99 0.96 >0.99 0.67 
QN IC90 355 ± 19 393 ± 58 363 ± 4 587 ± 169 318 ± 68  390 ± 25 436 ± 50 408 ± 59 399 ± 96 296 ± 42 
n 4 7 5 4 6  4 4 4 4 4 
P – >0.99 >0.99 0.50 >0.99  >0.99 >0.99 >0.99 >0.99 >0.99 
PPQ IC50 1.3 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 1.0 ± 0.1  1.2 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 0.9 ± 0.1 
n 6 7 5 4 8  6 5 5 4 6 
P – >0.99 >0.99 >0.99 0.55  >0.99 0.51 0.66 >0.99 0.09 
PPQ IC90 3.0 ± 0.2 2.5 ± 0.3 3.0 ± 0.1 3.0 ± 0.5 2.3 ± 0.3  2.6 ± 0.2 2.0 ± 0.1 2.6 ± 0.3 2.5 ± 0.3 1.8 ± 0.1 
n 6 7 5 4 8  6 5 5 4 6 
P – 0.88 >0.99 >0.99 0.47  0.20 0.99 0.97 0.07 0.96 
LUM IC50 1.1 ± 0.1 1.2 ± 0.2 1.0 ± 0.04 1.6 ± 0.5 2.0 ± 0.2  1.0 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 1.1 ± 0.04 1.9 ± 0.4 
n 4 7 4 3 6  4 4 4 3 4 
P – >0.99 >0.99 0.91 0.12  >0.99 >0.99 >0.99 >0.99 0.40 
LUM IC90 11.2 ± 1.1 8.9 ± 1.1 13.2 ± 1.3 16.0 ± 5.6 12.2 ± 1.2  9.1 ± 1.4 8.7 ± 1.4 7.0 ± 0.6 12.0 ± 7.1 9.2 ± 0.7 
n 4 7 4 3 6  4 4 4 3 4 
P – >0.99 >0.99 0.92 >0.99  >0.99 >0.99 0.94 >0.99 >0.99 
AS IC50 2.3 ± 0.2  2.2 ± 0.3 2.5 ± 0.2 1.8 ± 0.2 2.3 ± 0.2  2.3 ± 0.3 2.5 ± 0.3 2.2 ± 0.2 1.7 ± 0.3 3.0 ± 0.2 
n 7 9 6 5 10  7 6 6 5 6 
P – >0.99 >0.99 0.93 >0.99  >0.99 >0.99 >0.99 0.83 0.77 
AS IC90 4.1 ± 0.3 4.7 ± 0.6 5.5 ± 0.7 4.2 ± 0.8 4.9 ± 0.5  4.6 ± 0.6 4.9 ± 0.6 5.0 ± 0.6 3.7 ± 1.0 5.7 ± 0.9 
n 7 7 6 3 8  7 6 6 3 7 
P – >0.99 0.86 >0.99 >0.99  >0.99 >0.99 >0.99 >0.99 0.65 
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PND IC50 11.7 ± 2.1 10.8 ± 1.0 12.6 ± 1.5 10.2 ± 1.1 9.3 ± 1.6  11.8 ± 1.5 14.2 ± 1.3 13.6 ± 1.8 8.2 ± 3.0 14.0 ± 1.9 
n 5 6 5 3 7  5 4 5 3 5 
P – >0.99 >0.99 >0.99 0.99  >0.99 >0.99 >0.99 0.96 >0.99 
PND IC90 19.5 ± 4.1 17.0 ± 0.5 21.7 ± 3.5 17.8 ± 0.7 13.9 ± 2.4  20.1 ± 3.1 21.7 ± 4.0 21.0 ± 3.3 14.5 ± 5.6 19.3 ± 3.2 
n 5 6 5 3 7  5 4 5 3 5 
P – >0.99 >0.99 >0.99 0.94  >0.99 >0.99 >0.99 >0.99 >0.99 
 
aIC50 and IC90 values (nM) indicate the mean ± SEM, as determined in 3 to 10 independent assays. CQ + VP assays were performed 
with 0.8 μM VP. CQ, chloroquine; VP, verapamil; md-CQ, monodesethyl-chloroquine; md-AQ, monodesethyl-amodiaquine; QN, quinine; 
PPQ, piperaquine; LUM, lumefantrine; AS, artesunate; PND, pyronaridine;  n, number of assays. Statistical significance was determined 
via one-way ANOVA with Tukey’s multiple comparisons test. P values (in bold and shaded in gray if <0.05) are reported for comparisons 









Figure 4.3. Chloroquine responses of pfcrt-modified lines. (A and B) Parasite susceptibilities 
to (A) chloroquine (CQ) and (B) monodesethyl (md)-CQ were assessed by flow cytometry 
following exposure to the indicated drug for 72 h. Bar graphs correspond to mean ± SEM IC50 
values. (C) Verapamil (VP)-mediated reversibility of CQ resistance. Parasite IC50 values for 
CQ + 800 nM VP and CQ alone were determined as described for CQ and md-CQ. The 
quotient of these values yielded the CQ response modification index (RMI). Bar graphs 
correspond to mean ± SEM RMI values. For all panels, results reflect 4 independent assays, 







reduction versus Dd2 PfCRT for CQ and md-CQ) was significant in both the Dd2 and 
Dd2R539T parasite genetic backgrounds (P<0.01). Additionally, PfCRT haplotypes Dd2 
S326N and Dd2 T356I conferred a slight reduction in parasite CQ and md-CQ 
resistance, as compared with Dd2 PfCRT, achieving statistical significance in the 
Dd2R539T background for md-CQ (P<0.05; Figure 4.3B; Table 4.3). 
  Laboratory studies of CQ-resistant parasites have previously identified 
chemosensitization by the calcium channel blocker verapamil (VP) as a defining 
feature of parasite CQR. VP reversibility of CQR is reported as the CQ response 
modification index (RMI), i.e. the IC50 value for CQ plus 800 nM VP divided by the 
IC50 value for CQ alone.298 Comparison of RMI values among our pfcrt-modified lines 
(Figure 4.3C; Table 4.4) showed that Dd2 PfCRT confers a significant degree of CQR 
reversibility, consistent with previous studies.120 RMI values associated with the Dd2, 
Dd2 S326N, Dd2 T356I, and GB4 isoforms (Figure 4.3C) were comparably reduced as 
compared to isogenic parasites expressing the wild-type (GC03) isoform, which did not 
confer chemosensitization. As anticipated, none of the CQ responses that were 
evaluated were altered by mutation of the k13 locus (P>0.05 for all pairwise 
comparisons of pfcrt-matched parasites in Dd2 versus Dd2R539T backgrounds).  
Given the similarity in mutational composition of GB4 and Dd2 PfCRT (see 
Table 4.1) and the physiological constraints known to be associated with de novo 
evolution of pfcrt alleles,242 it is plausible that these isoforms share a common 
mutational trajectory. Our CQ susceptibility findings suggest that GB4 PfCRT may 





Table 4.4. Verapamil-mediated CQ resistance reversibility of pfcrt-modified parasite lines.a 














RMI 0.17 ± 0.03 0.21 ± 0.04 0.16 ± 0.04 0.25 ± 0.05 1.2 ± 0.04  0.13 ± 0.03 0.19 ± 0.01 0.14 ± 0.09 0.24 ± 0.04 1.1 ± 0.04 
n 7 7 5 4 8  7 6 5 4 7 
P – >0.99 >0.99 0.92 <0.0001  >0.99 >0.99 >0.99 0.99 <0.0001 
 
aReversibility of chloroquine (CQ) resistance by 0.8 µM verapamil (VP) is indicated as the CQ response modification index (RMI), equivalent 
to (IC50 for CQ+VP) ÷ (IC50 for CQ only). Shown are mean RMI ± SEM values, as determined in 4 to 8 independent assays. n, number of 
assays. P values were determined in a non-parametric Mann-Whitney U test versus the parasite line GC03Cam734. P values <0.05 are 








Susceptibility of pfcrt-modified lines to clinically employed antimalarials 
PfCRT isoforms are increasingly noted to function as modulators of parasite 
susceptibility to multiple antimalarials beyond CQ, including first-line ACT 
components. We therefore examined the drug susceptibility profiles of our isogenic, 
pfcrt-modified lines to a panel of clinically important drugs (Figure 4.4; Table 4.3). 
Among these are the ACT artemisinin compound AS, various ACT partner drugs 
(LUM; PPQ; the AQ in vivo metabolite monodesethyl-AQ; and pyronaridine, PND), 
and the quinoline-type drug quinine (QN). Consistent with the known cross-resistance 
between CQ and AQ,114 all mutant pfcrt alleles heightened parasite resistance to md-
AQ, as compared with wild-type (GC03) pfcrt, with Dd2 pfcrt conferring the highest 
level of md-AQ resistance (Figure 4.4; Table 4.3). Interestingly, an important 
contributory role was identified for PfCRT mutation N326S; mutant PfCRT 
haplotypes bearing S326N reversions (i.e. Dd2 S326N and GB4; see Table 4.1) 
conferred a marked, statistically significant (P<0.0001) reduction in md-AQ resistance 
relative to the Dd2 isoform (Figure 4.4; Table 4.3). The notion that PfCRT residue 326 
is a key mediator of AQ resistance agrees with a recent report that described mutation 
N326D, found among South American and Western Pacific parasite isolates, as a 
direct contributor to md-AQ resistance.242 We note that no statistically significant 
differences were observed among parasite lines for the compounds LUM, AS, PPQ, 
PND, and QN (Figure 4.4; Table 4.3). 
Of note, AQ is the partner drug in the ACT regimen AS-AQ that is widely used 
for treatment and prevention of malaria in Africa. AQ also comprises the formulation 
AQ-sulfadoxine-pyrimethamine, which is administered prophylactically to young 





Figure 4.4. Responses of pfcrt-modified lines to various clinically employed antimalarial drugs. Parasite susceptibilities to monodesethyl 
(md)-amodiaquine, lumefantrine, artesunate, piperaquine, pyronaridine, and quinine were assessed by flow cytometry following exposure to 








Recent clinical studies by Yeka et al. documented a lower incidence of parasite 
recrudescence following treatment with AS-AQ as compared to ATM-LUM, the two 
most widely deployed regimens that are known to select for mutant and wild-type 
pfcrt-expressing parasites, respectively.149 Based on the wide prevalence of the wild-
type pfcrt allele in Africa and the paucity of pfcrt alleles that conferred a high degree 
of AQ resistance in our study, continued use of AQ-based regimens in Africa seems 
justified. A meta-analysis of worldwide AS-AQ efficacy sheds light on a distinct 
situation in Asia, where the Dd2 pfcrt allele is widely prevalent and where the risk of 
parasite recrudescence following AS-AQ treatment is significantly (7-fold) higher as 
compared to Africa.362  Given this data, it is possible that only certain AQ resistance-
conferring pfcrt alleles (e.g. Dd2) are able to confer the minimum degree of AQ 
resistance necessary to sustain resistant parasite populations, whereas other mutant 
pfcrt alleles (e.g. GB4, Dd2 S326N) are more rapidly cleared and, in the context of 
appropriate dosing, pose less of a threat.  
 
Survival of k13-mutant, pfcrt-modified lines exposed to DHA 
Although our drug susceptibility assays did not reveal significant shifts in AS IC50 
values among parasite lines, the utility of IC50-based studies for the detection of 
clinical ART resistance is limited. A more powerful metric is parasite survival 
following drug pulses that mimic its pharmacology in vivo. For ART compounds, 
reduced DHA susceptibility of early ring-stage (0-3 h) parasites in RSAs conducted in 
vitro correlates with ART resistance in the clinical setting, defined as slower rates of 
parasite clearance.162,355,363 This phenotype has been associated with mutations in the 




exposure to DHA in vitro in RSAs.158,160 
In the present study, we interrogated the effect of variant pfcrt allele 
expression on parasite DHA survival during the ring and trophozoite parasite 
intraerythrocytic stages. Our inquiry was motivated by several lines of evidence 
implicating a possible role for PfCRT in modulating parasite ART responses: (1) 
Disposition of heme, the putative ART activator, is affected by parasite pfcrt 
genotypes;55,232; (2) In addition to their activity against ring-stage parasites, ARTs are 
potent against trophozoites, during which both PfCRT and heme are highly 
abundant;114,157 (3) A multigenic basis of ART resistance was recently revealed by 
whole genome analyses, which identified an association between ART resistance and 
PfCRT mutations N326S and I356T;159 (4) In some genetic backgrounds, PfCRT 
mutations can modulate asexual blood-stage parasite susceptibility to ART 
compounds.120,242 To probe the capacity of PfCRT mutations to modulate the parasite’s 
ability to survive DHA pressure, we employed the k13-mutant Dd2R539T genetic 
background (see Table 4.1), which bears a R539T K13 mutation that confers in vitro 
RSA survival to DHA. 
While DHA-based survival assays are routinely performed on early-ring (0–3 
h) stage parasites with 700 nM DHA, we aimed to consider the possibility that PfCRT 
mutations may modulate ART resistance at sub-physiologic levels of DHA and that 
this effect may be restricted to a specific stage of the parasite intraerythrocytic life 
cycle. Accordingly, we evaluated the survival of early ring (0–3 h) and mid-trophozoite 
(28–31 h) P. falciparum blood-stage parasites following exposure to a wide range of 
DHA concentrations (1.4–700 nM). Results for ring-stage DHA survival assays 







Figure 4.5. Dihydroartemisinin (DHA) survival of k13-mutant, pfcrt-modified lines. Tightly 
synchronized parasites at the (A) early ring (0-3 hours post-invasion, hpi) or (B) mid-
trophozoite (28-31 hpi) developmental stage were exposed to a three-hour pulse of DHA at 
the indicated concentrations. Parasite viability was determined by flow cytometry at 72 hpi. 
Bar graphs correspond to the mean ± SEM percentage DHA survival, equivalent to the 
parasitemia of DHA-treated parasites divided by the parasitemia of vehicle control (DMSO)-






discernible effect on parasite survival for any concentration examined. In contrast, in 
trophozoite-stage DHA survival assays (Figure 4.5B), significant differences in 
parasite survival were observed at the sub-physiologic concentration of 5.5 nM DHA. 
Specifically, parasites encoding wild-type (GC03) PfCRT exhibited significantly 
increased protection from DHA toxicity as compared to parasites encoding either Dd2 
or Dd2 T356I PfCRT (P=0.004 and P=0.02, respectively, as determined by ANOVA 
with Sidak’s post-hoc comparison). Interestingly, PfCRT Dd2 S326N was associated 
with increased parasite survival as compared to the Dd2 haplotype, a difference that 
was significant at 2.7 nM DHA (P=0.005 by ANOVA with Sidak’s post-hoc 
comparison). We note that, compared to ring-stage parasites, all parasites at this 
stage were considerably more susceptible to DHA exposure (e.g. compare parasite 
survival for 700 nM DHA in Figure 4.5A and for 5.5–10.9 nM DHA in Figure 4.5B, 
which show comparable survival rates). This can be attributed to the higher levels of 
activating heme that results from increased Hb catabolism in trophozoites. Additional 
experiments are underway to explore the impact of the GB4 PfCRT isoform on 
parasite DHA survival. 
These findings contribute to our presently incomplete understanding of ART 
action and the possible involvement of PfCRT, particularly during the parasite 
trophozoite stage. An aspect of ART toxicity to Plasmodium parasites is thought to 
involve the induction of oxidative stress, as suggested by previous real-time studies of 
parasite glutathione (GSH)-dependent redox state.363 Given the prospect that GSH is 
potentially one of the substrates of PfCRT,209,364 it is plausible that variant forms of 
PfCRT may help the parasite avert oxidative damage, perhaps through PfCRT-




heme.59,154 Whether through this or a GSH-independent mechanism, PfCRT variants 
can influence parasite disposition of free heme (see Chapter 3), whose putative 
activation of ART activator is thought to account for >65% of the activity of ARTs 
during the trophozoite stage.100,157 
The trophozoite stage-specific findings that Dd2 S326N and Dd2 T356I PfCRT 
conferred either increased or no change in parasite DHA survival as compared to Dd2 
PfCRT (see Figure 4.5B) may appear counterintuitive in light of the recent association 
of mutations N326S and I356T with ART-resistant founder populations.159 An 
explanation for these results is that, rather than contributing directly to protection 
from ACT toxicity, the presence of PfCRT mutations N326S and/or I356T provides a 
parasite genetic background that is conducive to the acquisition of additional ART 
resistance-conferring mutations and that aids in minimizing associated fitness costs.  
 
Survival of k13-mutant, pfcrt-modified lines exposed to PPQ 
Similar to ART resistance, IC50-based drug susceptibility studies appear insufficient 
to reveal parasite resistance to the first-line ACT partner drug PPQ. This is apparent 
from ex vivo analyses of recrudescent parasites derived from DHA-PPQ treatment 
failures, which show a wide range of PPQ IC50 values that overlap with IC50 values of 
non-resistant isolates.139 The molecular basis of PPQ resistance is likely multigenic 
and is clinically paramount in the context of DHA-PPQ resistance that is spreading 
throughout Cambodia as well as surrounding regions in Southeast Asia.365 Recent 
studies of PPQ-resistant parasites have highlighted the effectiveness of in vitro PPQ-
based parasite survival assays in uncovering resistance phenotypes that correlate 




nM PPQ for 48 h. The basis for a much longer duration of drug exposure as compared 
to DHA-based assays is the relatively more prolonged half-life of PPQ in the blood 
following treatment.139,366 Parasite survival is then assessed at the 72 h endpoint. 
Similar to our DHA-based survival assays, we subjected pfcrt-modified 
Dd2R539T parasites to serial dilutions of PPQ. To probe for stage-specific effects, we 
first treated parasites with PPQ at either the early-ring stage (t=0–3 hours post-
invasion, hpi) or mid-trophozoite stage (t=28–31 hpi). Parasites were incubated with 
PPQ through the 48 hpi timepoint, and parasite viability was assessed by flow 
cytometry at 72 h. Results for PPQ survival assays initiated during the early ring 
stage (Figure 4.6A) showed comparable degrees of sensitivity of pfcrt-modified 
parasites to concentrations substantially lower than 200 nM PPQ, the physiologic dose 
used to detect clinically relevant PPQ resistance. Intriguingly, for PPQ survival 
assays initiated during the mid-trophozoite stage (Figure 4.6B), differential, pfcrt 
allele-specific PPQ responses were especially marked for parasites treated with 12.5 
nM PPQ. As compared to isogenic parasites encoding Dd2 PfCRT, parasites encoding 
Dd2 S326N, Dd2 T356I, and GC03 (wild-type) PfCRT haplotypes showed significant 
differences in parasite survival (P=0.003, P=0.04, and P<0.0001, respectively, as 
determined by ANOVA and Sidak’s post-hoc test). Of note, GC03 PfCRT did not 
protect against PPQ action, whereas PPQ mutant PfCRT haplotypes (especially Dd2 
T356I; see Figure 4.6B) provided protection. Additional experiments are underway to 
explore the impact of the GB4 PfCRT isoform on parasite PPQ survival. 
The apparent modulatory capacity of PfCRT residue 356 that we observed in 
our trophozoite-stage PPQ survival assays (see Figure 4.6B) adds to a growing body 





Figure 4.6. Piperaquine (PPQ) survival of k13-mutant, pfcrt-modified lines. Tightly 
synchronized parasites in the (A) early ring (0-3 hours post-invasion, hpi) or (B) mid-
trophozoite (28-31 hpi) developmental stage were incubated at the indicated doses of PPQ 
until 48 hpi, after which drug was washed out. Parasite viability was determined by flow 
cytometry at 72 hpi. Bar graphs correspond to the mean ± SEM percentage PPQ survival, 
equivalent to the parasitemia of PPQ-treated parasites divided by the parasitemia of vehicle 
control (5% lactic acid)-treated parasites. Data represent three independent experiments, 







PPQ.137,217,218 For example, Pellau et al. recently demonstrated that the novel French 
Guianese PfCRT mutation C350R conferred decreased parasite susceptibility to 
PPQ.137 Interestingly, based on bioinformatic analysis, residues 326-356 are predicted 
to span PfCRT residues present within the ninth transmembrane domain of PfCRT. 
This domain is thought to have roles in substrate binding and/or translocation.233 Of 
note is a recent report by Duru et al. of at least two distinct mutations spanning this 
region of PfCRT among PPQ-resistant clinical isolates from Southeast Asia.139 
Collectively, these observations suggest that PfCRT might be one factor involved in 
PPQ resistance, with probable contributions from additional genetic loci. 
Furthermore, they emphasize the need to swiftly delineate molecular markers that 
will aid in containing the spread of PPQ resistance in Southeast Asia. 
 
In vitro growth of pfcrt-modified lines 
Plasmodium fitness is a multifaceted property that reflects parasites’ reproductive 
success over multiple rounds of infection. A critical aspect of and proxy for parasite 
fitness is the growth of pathogenic asexual blood-stage parasites, which may reach a 
biomass as high as 1012 parasites per infected individual.239,367 Previous analyses of 
isogenic parasites expressing variant pfcrt alleles have shed light on their ability to 
influence parasite growth rates and have aided in inferring how they spread 
globally.242,243 Herein, we used an established242 flow cytometery-based co-culture 
assay that compares growth of GFP-negative (GFP–) pfcrt-modified test lines with 
that of a GFP-positive (GFP+) reporter line. The GFP– proportion of co-culture was 
regularly determined for a period of 10 parasite generations and used to derive the 




parameter was used as a reflection of asexual blood-stage fitness, with s=0, s>0, and 
s<0 indicating fitness equal, greater than, and less than that of Dd2GC03 parasites (i.e. 
parasites encoding wild-type alleles at both the pfcrt and k13 loci). 
Our results revealed key differences in the fitness costs associated with mutant 
pfcrt alleles (Figure 4.7; Table 4.5). In general, among pfcrt-matched lines, parasites 
harboring mutant K13 R539T (i.e. Dd2R539T) showed a more pronounced, statistically 
significant growth defect as compared to parasites with wild-type K13 (i.e. Dd2), with 
the exception of lines encoding either GB4 or Dd2 T356I PfCRT (no significant 
difference in Dd2 versus Dd2R539T backgrounds; Figure 4.7; Table 4.5). In both the Dd2 
and Dd2R539T genetic backgrounds, Dd2 and Dd2 T356I PfCRT isoforms conferred a 
notable fitness cost (range of mean s values: -0.16 to -0.24; Figure 4.7; Table 4.5). 
Interestingly, PfCRT isoforms Dd2 S326N and GB4, predominant in Africa (see 
Figure 4.2), were associated with a less severe fitness cost (range of mean s values: -
0.09 to -0.04; Table 4.5). Earlier studies with isogenic, pfcrt-modified parasites 
support the notion that Dd2 PfCRT confers a substantial fitness cost to parasites, as 
compared with other variant haplotypes.243 Our present observations hint at the 
prospect that parasite populations expressing a markedly unfit PfCRT haplotype are 
able to persist in Southeast Asia, but not Africa. These differences could be attributed 
to one or more of the following factors: (1) the specific drug regimens used, their 
pharmacokinetic disposition in local populations, and the selective forces that these 
drugs exert on the parasite pfcrt locus; (2) pfcrt allele-specific differences in parasite 
transmission to the mosquito vector; (3) a higher level of transmission in Africa than 
in Southeast Asia, which translates to increased immune protection as well as a 







Figure 4.7. In vitro growth characteristics of pfcrt-modified and reference parasite lines. Briefly, 
1:1 co-cultures consisting of a GFP– test strain and a GFP+ reporter strain were initiated at day 
0 and monitored by flow cytometry for 10 generations, as described in Methods. The per-
generation selection coefficient (s) for each test strain reflects parasite growth as compared to 
Dd2GC03 parasites, which encode the wild-type (GC03) pfcrt allele (i.e. s=0 for Dd2GC03). Bar 
graphs correspond to mean ± SEM s values (detailed in Table 4.5), as determined in three 


























Table 4.5. In vitro growth selection coefficients of pfcrt-modified and reference parasite lines.a 
 Dd2 parent  Dd2 recombinants 
pfcrt allele Dd2  Dd2 Dd2 S326N Dd2 T356I GB4 GC03 
s -0.12 ± 0.007  -0.16 ± 0.007 -0.04 ± 0.011 -0.20 ± 0.009 -0.08 ± 0.014 0.00 ± 0.012 
P1 <0.0001  <0.0001 0.03 <0.0001 <0.0001 – 
        
 Dd2R539T parent  Dd2R539T recombinants 
pfcrt allele Dd2  Dd2 Dd2 S326N Dd2 T356I GB4 GC03 
s -0.24 ± 0.007  -0.24 ± 0.006 -0.09 ± 0.010 -0.22 ± 0.006 -0.07 ± 0.011 -0.05 ± 0.010 
P1 <0.0001  <0.0001 0.01 <0.0001 0.54 – 
        
P2 <0.0001  <0.0001 0.002 0.57 0.96 <0.0001 
 
aGrowth selection coefficients (s) of recombinant and parental parasite lines were determined as detailed in Methods and normalized against 
the Dd2GC03 line, which encodes the wild-type (GC03) pfcrt allele. s<0 and s>0 indicate growth inferior or superior to that of the Dd2GC03 line, 
respectively. Listed are mean s ± SEM values, which encompass three independent experiments performed in duplicate (n=6 total replicates 
per line). Statistical comparisons were done using two-way ANOVA with Sidak’s post-hoc test. P1 indicates the statistical significance for pfcrt-
variant lines as compared to otherwise isogenic parasites encoding GC03 pfcrt (either Dd2GC03 or Dd2R539TGC03). P2 indicates the statistical 
significance observed between pfcrt-matched lines in the Dd2 (wild-type K13) versus Dd2R539T (mutant K13) genetic backgrounds. P values 









In this work, we studied the major PfCRT haplotypes in Africa and Southeast Asia 
(GB4 and Dd2, respectively) as a means of genetically dissecting the widely referred 
to “African/Asian” Dd2 PfCRT variant. Focusing on PfCRT mutations beyond the 
predominant and well-characterized molecular marker K76T, we investigated the 
pleiotropic roles of PfCRT amino acid positions 326 and 356, which define the majority 
of variant PfCRT haplotypes circulating in either Africa or Asia.  
Our findings illuminate the capacity of PfCRT mutations to alter parasite 
responses to distinct classes of antimalarials. Among these classes of compounds are 
several first-line ACTs, whose efficacy is compromised in select geographical regions. 
The observation that PfCRT mutations can modulate the cytocidal activity of DHA, 
albeit in a stage-specific manner and only at low nanomolar concentrations, should 
serve as a stimulus for further investigation of other candidate genetic determinants 
of ART resistance (e.g. fd, pfmdr2). It is conceivable that these may amplify pfcrt-
mediated reductions in parasite susceptibility.  
In light of our finding of PfCRT-mediated modulation of ART susceptibility, 
our data indicates that varying selective forces may be inherent to a single ACT 
formulation; for example, in our survival assays, DHA and PPQ selected for K76 and 
K76T, respectively. Likewise, opposing selective forces may be exerted by the long-
lived partner drugs comprising distinct ACT formulations. Consistent with this, we 
documented the ability of PfCRT mutations to modulate parasite AQ and PPQ 
susceptibility in pfcrt allele-specific ways. Our results support the practice of 
antimalarial regimen cycling and active monitoring of pfcrt genotypes. Of note, the 




attention to the mounting problem of resistance to this drug, and suggests that 
characterization of PfCRT mutations emerging in settings with PPQ resistance should 
be prioritized. Additional experiments, currently underway, will reveal whether the 
presence of PfCRT I356T in the GB4 haplotype likewise increases parasite PPQ 
resistance. 
Our work adds to a growing collection of studies of drug transport, drug 
susceptibility of isogenic parasite strains, and pfcrt allele prevalence in the field, 
which collectively support the notion of PfCRT as a pleiomorphic mediator of parasite 
multidrug resistance.120,137,208,213,220 As malaria control efforts intensify in the coming 
years, their success will depend, in part, on the precise definition and monitoring of 


















































DISSECTING THE POLYMORPHIC PFCRT GENE, ONE (OR MORE 
THAN ONE) SNP AT A TIME 
In 2012, Straimer et al. established a zinc finger nuclease (ZFN)-based gene editing 
system tailored to the parasite P. falciparum chloroquine resistance transporter 
(pfcrt) gene.295 This system has served as an incredibly powerful tool for ascertaining 
the effects of pfcrt single nucleotide polymorphisms (SNPs) on the biology and drug 
responses of pathogenic asexual blood-stage P. falciparum parasites. The ZFN 
strategy promotes targeted incorporation of mutations through the introduction of a 
double-stranded DNA (dsDNA) break at a defined site in the parasite genome.295 
Mutations are subsequently captured as parasites repair the dsDNA break through 
non-crossover-based pathways.353 In contrast, earlier pfcrt allelic exchange strategies 
relied on infrequent, stochastic crossover events that facilitated capture of entire 
episomes and led to concatamerization.120,217,243 These methods were associated with 
lower gene editing efficiency and required extended periods of drug selection. 
Great strides have been made in the four years since the establishment of a 
ZFN-based system for pfcrt genetic editing. Once a drawn-out process that took 
months and, in some cases, more than one year, parasite genetic editing can now be 
performed over the course of several weeks. Editing efficiencies approaching 100% 
were observed for a number of the pfcrt-modified recombinant lines described in this 
dissertation. At present, a large compendium of recombinant parasites is at our 
disposal, encompassing various partial and full-length pfcrt alleles expressed in one 
or more distinct genetic backgrounds. To date, at least 55 recombinant, pfcrt-modified 




communication), 35 of which are characterized in Chapters 2-4 of this dissertation. 
Of note, success of genetic editing was partly dependent on the genetic 
background of parasites. For example, in our initial attempt to engineer a panel of 
combinatorial PfCRT haplotypes based on the Ecuadorian Ecu1110 variant (see 
Chapter 2), the GC03 (CQ-sensitive) genetic background was not receptive to allelic 
exchange with certain haplotypes, such as EcuA (i.e. K76T; wild-type at all other 
residues). It is likely that some mutant pfcrt alleles are associated with physiological 
constraints that render them incompatible with particular genetic backgrounds. Such 
incompatibilities have been observed in previous allelic exchange experiments and 
may be attributable to complex interactions between pfcrt and secondary genetic loci, 
such as the P. falciparum multidrug resistance 1 (pfmdr1) gene.217 Consistent with 
this, recent transcriptome comparisons of P. falciparum lines bearing different 
variants and/or levels of pfcrt and pfmdr1 revealed tight associations in the levels of 
transcripts expressed by these genes.368 
Deployment of parasite pfcrt genetic editing approaches in future 
investigations will be key to delineating the putative roles of pfcrt mutations in 
driving resistance to our first-line antimalarials. A notable example is PPQ resistance, 
whose spread in Southeast Asia is coinciding with the rise of novel mutations in 
pfcrt.139 Additionally, as chloroquine (CQ) remains a first-line drug for the treatment 
of infection with P. vivax, elucidation of the presently unclear mechanisms of P. vivax 
CQ resistance (CQR) is warranted. Application of the ZFN-based system to probe the 
capacity of P. vivax chloroquine resistance transporter (pvcrt) gene mutations to 





Site-specific endonuclease-based genetic editing systems, including ZFNs and 
the more recently developed CRISPR-Cas9 system, have revolutionized our ability to 
manipulate multiple parasite genetic loci. This will allow for discernment of potential 
epistatic interactions between pfcrt and known (e.g. pfmdr1) as well as candidate (e.g. 
ferredoxin, fd; P. falciparum multidrug resistance 2, pfmdr2) genetic loci implicated 
in modulating parasite susceptibility to various antimalarial compounds.127,159 As 
Plasmodium parasites continue to evolve genetically complex resistance mechanisms, 
the efficacy of present and future antimalarials will hinge upon our ability to identify 
and characterize candidate drug resistance mutations. This will require leveraging 
data from large-scale genome-wide association studies (GWAS) with targeted 
dissections of gene-specific impacts on parasite drug resistance and fitness.  
 
DISTINCT ROLES OF PFCRT MUTATIONS IN P. FALCIPARUM 
DRUG RESISTANCE AND FITNESS  
The investigations described herein provide critical insights into the roles of PfCRT 
mutations in the fine balance between drug resistance and fitness maintained by P. 
falciparum parasites during their asexual blood stage (Table 5.1). Importantly, our 
results shed light on distinct contributions of PfCRT mutations beyond the well-
characterized CQR-associated mutation K76T. A popular dogma in earlier 
descriptions of PfCRT mutations has been that PfCRT K76T serves as the central 
mediator of CQR, with additional mutations playing compensatory roles (i.e. offsetting 





Table 5.1. Summary of effects of PfCRT mutations on drug resistance and fitness of asexual blood-stage P. falciparum.a 
PfCRT mutation Parent haplotype Background CQR Fitness Additional notes 
C72S 7G8 7G8 ↑ ↑ AQRCQR 
N75D Cam734 GC03 ↑ ↑ ↑ CQRVPR; ↑ AQR 
K76T Ecu1110 7G8 ↑ > ↓  ↓ >> ↑ ↑ CQRVPR; AQRCQR; ↓ ASR 
A144F Cam734 GC03 ↑ ↑ ↑ AQR; ↑ QNR 
L148I Cam734 GC03 ↑ ↑ ↑ CQRVPR; ↑ AQR; ↓ PPQR 
I194T Cam734 GC03 – ↑ – 
A220S Ecu1110 7G8 ↑ > ↓ ↓ or ↑ AQRCQR 
N326D Ecu1110 7G8 ↑ ↓ ↑ CQRVPR; AQRCQR; ↑ AQR 
N326S Dd2 Dd2 – ↓ ↑ AQR 
T333S Cam734 GC03 ↑ ↑ ↑ AQR 
I356L Ecu1110 7G8 ↑ >> ↓ ↑ >> ↓ AQRCQR 
I356T Dd2 Dd2 – – ↓ PPQR 
 
aThis table summarizes results presented in Chapters 2-4 of this dissertation. Future investigations, in mutational contexts and/or genetic 
backgrounds not examined herein, may ascribe additional phenotypes to PfCRT mutations. For each PfCRT mutation, the parent haplotype 
context and genetic background in which it was studied are indicated. Mutational composition of PfCRT haplotypes is detailed in Table 1.6. 
↑ and ↓ represent increases and decreases, respectively. The degree to which phenotypic changes were noted is indicated by > (i.e. more 
than) and >> (i.e. substantially more than), with – indicating absence of evidence. Resistance encompasses results from either cytostatic 
(IC50-based) or cytocidal (parasite survival-based) assays and indicates relative changes in resistance, which don’t necessarily correspond 
to clinical resistance. Fitness reflects parasite growth in vitro, in the absence of drug. CQR, chloroquine resistance; AQR, amodiaquine 
resistance; AQRCQR, AQR–CQR cross-resistance; CQRVPR verapamil reversibility (VPR) of CQR; ASR, artesunate resistance; QNR, quinine 








First, consistent with findings gleaned from heterologous drug transport studies,208,312 
we observed that PfCRT K76T is insufficient to confer CQR in asexual blood-stage 
parasites, the biological setting in which CQ is chiefly active against Plasmodium. In 
fact, certain non-K76T mutations (e.g. N326D) could confer statistically significant 
increases in parasite resistance to the active metabolite of CQ, monodesethyl-CQ (md-
CQ). Of note, mutation of PfCRT 326 (e.g. N326D, N326S) was associated with 
increased parasite drug resistance to quinoline-type drugs and consistently had a 
deleterious impact on asexual blood-stage parasite fitness (see Table 5.1), indicating 
that this non-K76T mutation is not compensatory. This is consistent with the recent 
report of reduced CQR and increased proliferation of recombinant parasites that 
initially encoded PH1 PfCRT (K76, A144T, L160Y, N326D) but lost the N326D 
mutation during long-term culture.243 In the genetic dissection of Cam734 pfcrt (see 
Chapter 3), of the five novel mutations examined, only PfCRT I194T was associated 
with a purely compensatory role (i.e. improved parasite growth), whereas the 
remaining four mutations improved parasite growth and directly contributed to 
parasite CQR (see Table 5.1). We also noted an exception to the rule of thumb that 
parasite CQR requires K76T in the presence of ≥3 additional mutations; removal of 
the A144F mutation from Cam734 PfCRT (i.e. Cam734 F144A) yielded CQ-sensitive 
parasites that nevertheless harbored K76T and seven additional PfCRT mutations.  
Our results indicate that the key CQR-associated mutation K76T confers CQR 
only in certain mutational contexts, with direct contributions from other mutations, 
some of which also offset fitness costs. How the various full-length and partial pfcrt 
alleles decribed herein impact parasite fitness is presently unclear, in large part due 




facilitated through functional characterizations of the recombinant lines harboring 
these alleles, using metabolomics and other approaches.232 While peak expression of 
mutant PfCRT occurs in hemozoin (Hz)-rich trophozoites, PfCRT is also found within 
rings and schizonts and, when mutated, is able to confer CQR at these stages.337 
Spinning disk confocal microscopy-based methods have been established that could 
evaluate whether any of the PfCRT isoforms studied herein have an impact on the 
various stages of the parasite blood-stage lifecycle, at baseline or in the presence of 
CQ.337  Interestingly, earlier work, in which a mutant (7G8) pfcrt allele was integrated 
into the genome of the rodent malaria species P. berghei, documented the ability of 
mutant PfCRT to enhance parasite infectivity to mosquitos in the presence of CQ.268 
Since transmission is an important element of parasite fitness, another critical 
question worth exploring is whether the various pfcrt alleles studied herein have 
discernable impacts on transmission of gametocytes to the mosquito vector. 
We note that, with the exception of parasite survival assays performed in 
Chapter 4, the 50% growth-inhibitory concentration (IC50) to a given drug was largely 
used as a metric of parasite resistance throughout our studies. In focusing on parasite 
growth inhibition in our analyses, we characterized the cytostatic effects of 
antimalarial drugs. While cytostatic, IC50-based assays are routinely performed to 
profile parasite drug response, cytocidal, 50% lethal dose (LD50)-based assays more 
exclusively reveal drug concentrations required to kill parasites. It is known that (1) 
PfCRT mediates both cytostatic and cytocidal CQR; (2) Cytocidal CQ concentrations 
can be up to 100× higher than concentrations required for a cytostatic effect; and (3) 
The fold-increase in CQR between a resistant and susceptible line is decreased for 




recapitulated in a preliminary analysis of the cytocidal effects of CQ on a subset of our 
isogenic, pfcrt-modified lines from the Ecu1110 pfcrt genetic dissection study (see 
Chapter 2). Our results collectively underscore the utility of relative drug resistance 
relationships in defining the impacts of pfcrt SNPs. Future work will be needed to 
delineate the complex pharmacology of these drugs and to define how exactly in vitro 
metrics of resistance reflect what occurs in vivo. 
Apart from CQ, a number of other clinically employed antimalarials included 
in our analysis were associated with varied parasite responses attributable to pfcrt 
SNPs (see Table 5.1). These included monodesethyl-amodiaquine (md-AQ; the active 
metabolite of AQ), quinine (QN), piperaquine (PPQ), lumefantrine (LUM), and the 
artemisinin (ART) compound artesunate (AS). As was the case for CQ, differences in 
parasite susceptibilities conferred by these mutations were often mutational milieu-
dependent. With reduced deployment of CQ due to widespread CQR, these and future 
antimalarial compounds will have an increased role in dictating which pfcrt genotypes 
persist and what pfcrt mutations may arise in a particular geographical region. The 
identification of molecular markers reflecting the ever-changing landscape of global 
antimalarials will necessitate continued monitoring of the full-length sequence of the 
parasite pfcrt gene, complemented with whole-genome surveillance. 
 
INSIGHTS INTO PFCRT FUNCTION AND DRUG RESISTANCE 
MECHANISMS 
Our understanding of the molecular basis of CQR was greatly propelled in 2000 by 




studies have provided important insights into the impacts of PfCRT mutations on 
parasite CQ responses, CQ accumulation, drug transport, and digestive vacuole (DV) 
physiology, although many questions still remain.188 The results presented in 
Chapters 2-4 add to this growing body of knowledge.  
 An important aspect of CQ action is interference with parasite heme 
detoxification, causing disrupted Hz formation, with a concomitant increase in 
heme.55 Prior to our study of the heme disposition in isogenic, pfcrt-modified parasites 
(see Chapter 3), the capacity of PfCRT mutations to alter parasite heme disposition 
had not been explored. For lines encoding both CQ-sensitive and CQ-resistant 
variants of PfCRT, we observed a clear relationship between rise in free heme 
concentration and extent of parasite growth inhibition. Interestingly, mutant PfCRT-
encoding lines showed higher levels of undigested hemoglobin as compared with 
isogenic parasites encoding wildtype PfCRT. In addition to CQ, a number of clinically 
important drugs (e.g. AQ, LUM, QN, AS) are also known to perturb parasite heme 
detoxification pathways.55 Their inclusion in future characterizations of pfcrt-
modified lines may uncover mechanistic bases that underlie the various degrees of 
potency of these drugs against both CQ-sensitive and CQ-resistant parasites.   
 Intriguingly, in our analysis of recombinant lines bearing only a single PfCRT 
mutation, we found that the PfCRT K76T mutation confers hypersensitivity to CQ 
and, even more notably, to its active metabolite, md-CQ. Induction of a similar CQ 
hypersensitivity by PfCRT mutations C101F and L272F was recently described by 
Pulcini et al.196 Lone expression of K76T may increase the potency of CQ through 
changes in the physiology of the DV, which may in turn affect CQ partitioning and its 




on PfCRT native function in the absence of compensatory mutations, rendering 
parasites hypersensitive to exogenous sources of stress. DV volume and pH studies, 
such as those applied in studies described in Chapter 3, would clarify if lone 
expression of K76T imparts significant alterations to DV physiology.  
 Comparison of parasite CQ IC50 values (see Chapters 2-4) with published 
PfCRT CQ transport activities, assessed in heterologous expression systems, 
highlights important correlations between these two metrics. In all studies, K76T was 
insufficient for CQR, and distinct contributions to CQR were noted for non-K76T 
mutations, such as N326D.208,312 Of the three-SNP PfCRT isoforms characterized in 
drug transport studies in Xenopus laevis oocytes, EcuACD conferred the highest level 
of CQR, consistent with our data;312 however, the increase in CQ transport associated 
with the EcuACD→EcuABCD trajectory was substantial (>2-fold) in our studies, but very 
subtle in the drug transport studies. A notable disparity concerns PfCRT C72S, the 
single distinction between Ecu1110 and 7G8 PfCRT, which consistently reduced drug 
transport rates, yet increased CQR in our parasite-based studies (see Figure 2.2).208,312
 CQ interference with PfCRT function is suggested by the earlier observation of 
CQ–PfCRT binding.193 We believe that future investigations should leverage 
phenotyping of pfcrt-modified parasites with investigation of PfCRT binding to and 
transport of drug – not just CQ, but also its active metabolite, md-CQ. As seen in 
Chapter 2, md-CQ played a more marked role than CQ in uncovering certain parasite 
CQ responses and in dictating parasite traversal through pfcrt mutational landscapes 
(see Figure 2.7). In the absence of a crystal structure of PfCRT, a combined genetic-
chemical dissection would also clarify roles of PfCRT mutations in drug binding and 




would entail subjecting a panel of pfcrt-modified parasite lines described in our 
studies to a series of CQ-like compounds with altered chemical groups.126 Insights 
from such a study would also provide insights about pfcrt mutational changes that 
could compromise the efficacy of novel quinoline-like compounds.  
 PfCRT is a drug/metabolite transporter (DMT) that is thought to encode 10 
transmembrane domains.233 The majority of the mutations studied herein are 
predicted to occur within these domains, which are collectively implicated in binding, 
translocation, and discrimination between substrates.233 Interestingly, PfCRT 
transmembrane domains 3 and 8, the predicted locations of PfCRT amino acids 144 
and 326, are associated with substrate specificity. In our studies, mutations N326D 
and N326S always had a deleterious impact on parasite growth, raising the possibility 
that they impair the transport of a native substrate. Interestingly, the mutation 
A144F enhanced parasite growth in the context of the mutant Cam734 PfCRT isoform, 
which was associated with enhanced energy utilization as compared to the less fit Dd2 
isoform (see Chapter 3). In addition to challenging the dogma that PfCRT variants 
confer a parasite fitness cost-associated Hb degradation defect, our results suggest 
that future metabolomic comparisons of parasites encoding various PfCRT isoforms 
should include metabolites beyond peptides. It is tempting to speculate that the 
Cam734 PfCRT isoform may have evolved mutations that, together, confer a moderate 
degree of CQ transport and simultaneously accentuate the transport of one or more 
vital endogenous substrates. We also note that the threonine of PfCRT I194T falls 
within a putative helix packing motif (GxxxxT) that may be important for PfCRT 
homodimerization.233 How the various amino acid substitutions studied herein may 




PfCRT should be explored in future work. 
 In a recent heterologous expression study of PfCRT transport performed in E. 
coli, Juge et al. reported the ability of PfCRT isoforms to mobilize organic cations, 
basic amino acids, and polyamines in an electrochemical gradient-dependent 
manner.209 As His-tagged E. coli YbeL proteins were required at the N and C termini 
of PfCRT in order to achieve expression, the direct implications of these studies in 
terms of elucidating native PfCRT function are unclear. Nevertheless, these results 
present the intriguing possibility of PfCRT as a polyspecific substrate/multidrug 
resistance transporter, with transport capacities that are refashioned depending on 
its mutational composition. This is supported by previous reports that have either 
demonstrated or suggested roles for PfCRT in the transport of ions, peptides, and 
chemically distinct compounds.200,201,211,220,232-234,238,372 
As efforts to elucidate PfCRT native function continue to be pursued, an 
important question emerges: Might PfCRT be a modulator of parasite redox state? 
Earlier studies have documented widespread oxidation of parasite proteins in 
response to CQ.373 Of note, altering the redox state of parasites can affect their 
response to CQ; inducers of oxidative stress increase CQ susceptibility, and vice 
versa.374,375 Patzewitz et al. have raised the possibility that PfCRT transports 
glutathione (GSH), which is involved in degrading toxic heme.154 More recently, 
modulation of CQ-induced oxidative stress by pfcrt alleles was observed in 
preliminary studies using isogenic pfcrt-modified lines that encode sensors of GSH-
specific redox state in the parasite cytosol (F. Mohring and K. Becker, personal 
communication). The possibility that PfCRT modulates redox state is further 




show homology to redox-active Fur superfamily proteins, whose functions include 
redox sensing.376,377 
 Compared to quinoline resistance, the role of the pfcrt locus in conferring ART 
resistance is less clear. In Chapter 4, we have seen evidence that PfCRT isoforms can 
differentially protect parasites from the cytocidal action of dihydroartemisinin (DHA), 
the active metabolite of ART. Of note, this modulatory effect was only observed during 
the parasite trophozoite stage, when both PfCRT and the ART activator heme are 
highly abundant. An important aspect of ART action is interference with the 
parasite’s GSH-dependent degradation of toxic heme.378 We hypothesize that PfCRT 
mutations may affect this process, particularly during the trophozoite stage, when the 
role of kelch13 (k13) mutations in conferring ART resistance is less marked. 
Particularly in Southeast Asia, P. falciparum parasites are equipped with multidrug 
resistance mechanisms that are already compromising their susceptibility to first-line 
ARTs and several ACT partner drugs. Efforts to prevent their spread are contingent 
upon our ability to define the multigenic basis of resistance, which includes complex 
and still undefined contributions from the pfcrt locus. 
 
EVOLUTION OF PFCRT ALLELES  
The analysis of various, geographically-distinct pfcrt alleles presented in Chapters 2-
4 lends itself to an overarching question: How did these alleles evolve? Microsatellite 
and pfcrt genotyping data suggest that CQR emerged in a few geographically separate 
foci – in South America, Asia (with subsequent spread to Africa), and Oceania.249,350 
In Chapter 2, we designed a combinatorially complete panel of pfcrt alleles, expressed 




the mutational paths accessible to parasite drug resistance evolution. Our results 
revealed a significantly constrained adaptive landscape in the evolution of pfcrt-
mediated CQR, providing a molecular basis for the infrequent occurrence of variant 
pfcrt alleles in the field, despite the long-standing use of CQ. Consistent with this, 
antimalarial drugs that have a non-pfcrt genetic basis of drug resistance (e.g. 
atovaquone, pyrimethamine) are known to yield resistant parasites with much higher 
frequencies.24 This may be, in part, due to the fact that CQ and other quinoline-type 
compounds target heme, an immutable host factor. 
In South America and Oceania, the mutant pfcrt allele 7G8 is at or near 
fixation.24,256,257,320 In Chapter 2, we showed that the 7G8 allele conferred a 
significantly higher level of CQR and asexual blood-stage parasite fitness, as 
compared with Ecu1110 pfcrt. This data supports the evolutionary success of 
quadruple-SNP Ecu1110 pfcrt and, to a much higher extent, quintuple-SNP 7G8 pfcrt. 
These two alleles have been documented to co-occur in several independent 
geographical regions (e.g. parts of South America, Africa, and Southeast Asia), with 
7G8 pfcrt dominating in each case.259 Of note, our data highlighted the capacity of AQ 
to drive pfcrt evolution, consistent with the use of AQ in many of the regions where 
the Ecu1110 and 7G8 haplotypes have been observed.259 Evidence for ongoing 
evolution of pfcrt in South America is supported by the recent emergence of an isoform 
which bears the mutation C350R in the background of 7G8 PfCRT and which 
completely abolishes CQR (see Appendix B).137  
The three most common Asian PfCRT variants – GB4, Dd2, and Cam734 – are 
substantially more polymorphic (6-9 SNPs; see Table 1.6) than the variants observed 




dissections. Suggesting that pfcrt evolution is operating in Southeast Asia, Cam734 
PfCRT presently represents about one-fifth of the circulating PfCRT variants in this 
region, whereas it had not been detected in earlier (2002) characterizations of the 
origins of PfCRT variants (see Chapter 3 and Appendix A).243,249,262 There is presently 
no evidence that partial pfcrt alleles bearing ≤3 SNPs can be sustained in the field 
setting. Extrapolating from our findings in Chapter 2, we thus postulate that the 
initial steps involved in the evolution of Cam734 (as well GB4 and Dd2 PfCRT) likely 
involved one or more major bursts of multiple mutations in a very short period of time 
and in a very limited number of parasites. The bottleneck exerted by drug pressure 
would have reduced competition with fitter, wild-type pfcrt-expressing parasites, 
allowing mutant parasites to expand. 
In their report of the existence of Cam734 pfcrt among CQ-resistant parasite 
isolates in Cambodia, Durrand et al. also reported a related allele, Cam738 
(equivalent to Cam734 F144A), which we found to confer parasite susceptibility to 
quinoline-type drugs and which imparted a significant fitness cost. Thus, Cam738 is 
a candidate mutational precursor of Cam734, and the A144F mutation that was 
acquired to yield the Cam734 allele may have been selected for by one or more 
quinoline-type compounds (e.g. CQ, AQ, or QN). The enhanced quinoline resistance 
and fitness phenotypes that we observed for Cam734 pfcrt, as compared with the 
Cam738 allele, correctly predict the virtual absence of Cam738 pfcrt in Southeast Asia 
(as assessed by accessing the recent MalariaGEN Pf3k database of P. falciparum 
whole-genome sequences).159 The absence of a Cam734 pfcrt-associated fitness cost, 
an anomaly for a mutant pfcrt allele, calls for vigilance and careful characterization 




It is possible that cytocidal-based assays (e.g. DHA and PPQ survival assays) will 
reveal Cam734 pfcrt-specific responses that were not apparent in our IC50-based 
assays. 
Previous analysis by Wootton et al. of the pfcrt coding region of CQ-resistant 
parasite isolates from Africa and Asia revealed a PfCRT haplotype consisting of 6-8 
mutations with very similar flanking microsatellite haplotypes, suggesting a common 
origin for these CQ-resistant alleles.249 These PfCRT mutations correspond to the 
GB4-to-Dd2 PfCRT mutational spectrum that we investigated in Chapter 4. Of note, 
African CQ-resistant isolates in the study of Wootton et al., as well as another 
independent study, often exhibited the Dd2 T356I PfCRT haplotype (see Table 
1.6).186,249 However, in our studies (see Chapter 4), we found the 6-SNP GB4 and 7-
SNP PfCRT S326N haplotypes to be the most common variants in Africa, suggestive 
of regional evolution. Significant directional selection of pfcrt alleles has also been 
seen in regions of Africa where CQ pressure was withdrawn, leading to the attrition 
of mutant pfcrt-expressing parasites and concomitant resurgence in the wild-type 
pfcrt allele, which now predominates in Africa.332 
In contrast, despite the significant fitness cost associated with the Dd2 pfcrt 
allele that we have consistently observed in vitro (see Chapter 3 and Appendix A), 
Dd2 pfcrt remains the most common allele in Southeast Asia. This may be due to a 
presently unclear drug selective pressure and may be further attributable to the lower 
degree of parasite transmission in Asia as compared with Africa. Interestingly, in a 
recent analysis of blood specimens collected from two African patients infected with 
P. falciparum, Gadalla et al. noted wild-type–mutant hybrid PfCRT haplotypes.379 




suggest that intragenic recombination is in effect in the high-transmission setting of 
Africa. In addition to intragenic recombination and parasite clonality, factors that can 
influence the ability of parasites to evolve drug resistance include genetic changes at 
secondary loci that contribute to resistance and/or compensate for reduced fitness, 
gene amplification events, as well as population genetic-specific differences (e.g. 
immunity) that have an impact on parasite sequence diversity. Whole-genome 
sequencing approaches aid in discerning each of these factors, which are expected to 
differ substantially between Africa and Asia.380,381 
While it has been suggested that Dd2 pfcrt was the ancestral precursor of 
variant alleles in Asia and Africa,249 it is also possible that a less polymorphic 
precursor (e.g. 6-SNP variant GB4) occurred first, spread to both regions, and evolved 
into the Dd2 pfcrt allele in Southeast Asia in the presence of selective pressure. This 
would be consistent with our preliminary evidence that the GB4 pfcrt allele confers a 
level of parasite fitness more comparable to that of the fit, wild-type pfcrt allele than 
that of Dd2 pfcrt (see Chapter 4). A limitation of our study is that the genetic 
background of our pfcrt-modified lines, Dd2, is of Asian origin. Additional analysis in 
African-background parasites might reveal different phenotypes. 
Are forward (i.e. wild-type to mutant) and reverse (i.e. mutant to wild-type) 
evolutionary processes distinct? A recent combinatorial study of a four-SNP P. vivax 
dihydrofolate reductase (dhfr) allelic variant, expressed in yeast, emphasized that 
they are not; upon encountering a fitness valley associated with an intermediate dhfr 
allele, organisms were no longer able to continue mutational trajectories leading to 
the wild-type allele, despite the absence of drug pressure and the fact that the wild-




pressure, restoration of drug susceptibility is more likely to occur via expansion of 
populations encoding the fitter, wild-type allele or through compensatory mutations 
at novel sites within the genome.349 A secondary genetic locus that might have 
epistatic effects on pfcrt evolution is pfmdr1.143,226 It would be interesting to explore 
whether certain pfmdr1 mutations either block or facilitate progression of parasite 
pfcrt evolution. Our understanding of parasite adaptive landscapes would 
undoubtedly be broadened through genetic combinatorial experiments examining 
region-matched pfcrt and pfmdr1 allelic combinations. The genetic tools for carrying 
out such analyses are now at our disposal.143,295 
As the progression of organisms through adaptive landscapes is known to be 
intricately influenced by their drug environment,245 additional genetic combinatorial 
experiments conducted in a wide range of drug concentrations as well as in the 
presence of drug combinations could provide additional insights into parasite pfcrt 
adaptive landscapes. A complementary experimental approach that should be 
employed in future studies is in vitro selection of drug resistance. Specifically, one or 
more P. falciparum isogenic lines encoding a pfcrt allele of interest would be subjected 
to drug pressure, and subsequent sequencing of resistant parasites would either 
recapitulate anticipated mutational trajectories or identify novel ones. We note that 
the ability to induce mutation of the pfcrt locus in vitro was previously demonstrated 
for the drug halofantrine (HF), which caused the K1 (CQ-resistant) parasite line to 
acquire three novel pfcrt mutations.305  
As present first-line antimalarials show signs of reduced clinical efficacy and 
ultimately become replaced with new regimens, and as malaria control efforts escalate 




undergo profound changes. These factors will reshape the adaptive landscapes 
accessible to parasites in their evolution of high-level drug resistance, requiring 
updated resistance markers and refined molecular rationales for new drug design. 
The use of in vitro approaches to dissect parasite adaptive landscapes may uncover 
new, accessible mutational paths and fitness valleys that could be exploited for these 
purposes. 
 
THE RELEVANCE OF PFCRT MUTATIONS TO DRUG 
RESISTANCE SURVEILLANCE 
Following the global rise and spread of P. falciparum resistance to CQ and its 
replacement drug regimen, sulfadoxine-pyrimethamine, the adoption of ART-based 
combination therapies (ACTs) ushered in an era of new drug selective forces, new 
parasite resistance mechanisms, and new molecular markers of resistance. 
Identification of resistance markers will be greatly facilitated by analysis of whole 
parasite genome sequences, complemented with in vitro genetic editing studies. This 
has already revealed k13 as a key genetic mediator of ART resistance.181 In addition 
to the ARTs, our present arsenal of antimalarial compounds includes a number of 
quinoline-type drugs and, in some regions, even CQ itself. Thus, in addition to defining 
novel genetic loci involved in mediating parasite drug resistance, careful assessment 
of pfcrt genotypes should be continued in both the laboratory and the field. 
 The most commonly employed ACT in Africa is artemether (ATM)-LUM. 
Analysis of recurrent infections following ATM-LUM treatment in Burkina Faso 




was recapitulated in a more recent randomized clinical trial in Uganda.149 Of note, a 
16% higher risk of recurrent malaria was documented in patients receiving ATM-
LUM, as compared to the second ACT regimen AS-AQ, which selects for mutant 
PfCRT K76T.149 In Burkina Faso, selection of K76 was also reported for the ACT 
regimen DHA-PPQ.360 However, this is not supported by other reports from Africa, 
which did not observe a clear relationship between PfCRT residue 76 and altered PPQ 
susceptibility.382,383 
 In Asia, a dire situation exists in Cambodia, where treatment failures are 
increasingly noted for the first-line regimen DHA-PPQ.135 Interestingly, comparison 
of the whole-genome sequences with in vitro PPQ survival of parasites derived from 
cases of DHA-PPQ treatment failure by Duru et al. revealed an increased proportion 
of PfCRT mutations H97Y, M343L, and G353V among PPQ-resistant parasites (each 
in the background of Dd2 PfCRT, the most common mutant haplotype in Asia).139 
Given the ambiguous relationship between PPQ susceptibility and PfCRT residue 76 
that is often assessed in isolation, as well as the knowledge that non-K76T PfCRT 
mutations can modulate parasite PPQ susceptibility,137,196,218 it is very possible that 
the novel mutations reported by Duru et al. are driving DHA-PPQ resistance in 
Southeast Asia. Generation and analysis of isogenic, pfcrt-modified lines encoding 
these mutations will help to establish whether they have a causal role in mediating 
parasite PPQ resistance and should be prioritized.  
 The reduced efficacy of AS-AQ in Asia is also worth noting. A recent meta-
analysis documented a seven-fold higher rate of parasite recrudescence following AS-
AQ treatment in Asia as compared to Africa.362 In a randomized trial conducted in 




infections as compared to ATM-LUM, AS-mefloquine (MFQ), and DHA-PPQ.384 The 
work presented herein identified a strong link between parasite susceptibility to the 
clinically relevant in vivo metabolite of AQ, md-AQ, and the mutational status of 
PfCRT residue 326, with both the South American/Western Pacific mutation N326D 
and the African mutation N326S conferring increased md-AQ resistance (see Chapter 
2 and Chapter 4). This begs the question: Could mutant PfCRT 326 be employed as 
an important marker of reduced parasite AQ susceptibility? Monitoring of the 
mutational status of PfCRT 326 would, for example, distinguish between the related 
mutant PfCRT Dd2 and GB4 haplotypes that are both present in Southeast Asia and 
that differ at PfCRT residues 326 and 356 (see Chapter 4). The declining utility of the 
conventional resistance marker K76T calls for continued characterization of non-
K76T mutations, including mutations emerging in regions with documented 
resistance.137,199,208 Identification of new resistance markers would inform region-
specific treatment recommendations and possibly shed light on new “evolutionary 
trap” drug cycling regimens that, like AS-AQ and ATM-LUM (which select for K76T 
and K76, respectively), could be used to slow the expansion of resistant parasite 
populations. 
 The emergence of P. falciparum resistance to first-line antimalarial regimens 
serves as a clear impetus for the development of new drug regimens, some of which 
include drugs bearing the CQ-like quinoline scaffold.328 The discovery of novel 
compounds with antiplasmodial activity and identification of potential genetic 
resistance markers is facilitated through high-throughput screens (HTSs) driven by 
public-private partnerships, including the Medicines for Malaria Venture (MMV).385 




parasite drug resistance and/or that show cross-resistance with current antimalarials 
must be deprioritized. Related to this effort, Chugh et al. evaluated the capacity of a 
panel of sensitive and multidrug-resistant P. falciparum strains to deconvolute cross-
resistance signals when treated with a series of novel 1,2,4-oxadiazole compounds.386 
Characterization of three such compounds revealed that they were inactive against 
mutant pfcrt-expressing drug-resistant strains. Of note, resistance was associated 
with inhibition of the Hb-degrading cysteine protease Falcipain 2 and with little to no 
verapamil reversibility, features distinct from CQR and yet still implicating a role for 
mutant PfCRT-mediated alterations in Hb processing.386 In earlier work, using a HTS 
and genome-wide association study, Yuan et al. demonstrated that the differential 
susceptibilities of P. falciparum parasites to a set of 32 potent and chemically diverse 
compounds could be vastly accounted for by variation at just three genetic loci, one of 
which was pfcrt.387  While pfcrt-mediated resistance mechanisms chiefly affect drugs 
active against asexual blood-stage parasites, intriguing reports from S. cerevisiae and 
X. laevis oocyte heterologous expression studies collectively suggest the ability of 
certain PfCRT isoforms to transport gametocytocidal compounds, namely primaquine 
and methylene blue.208,220  
 Containment of the clinical burden and spread of malaria suffered a setback 
with the rise and spread of CQR. Despite this, CQ remains central to the treatment 
of infections caused by multiple Plasmodium species. Parasite CQR can be overcome 
by augmenting the standard drug dosage, is amenable to chemosensitization by 
certain resistance-reversing compounds, and shares resistance mechanism with a 
number of antimalarial drugs that are clinically employed or in development.114,275 




mutations, some of which await characterization, are subjected to various selective 
forces exerted by first-line ACT component drugs. Decades after the disappointing 
suspension of the Global Malaria Eradication Program, the prospect of malaria 
eradication has resurfaced as a public health goal, with significantly higher 
involvement of the research community. Continued vector control, treatment with 
potent antimalarial drugs, and implementation of aggressive surveillance measures 
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Summary
The widespread use of chloroquine to treat Plasmo-
dium falciparum infections has resulted in the
selection and dissemination of variant haplotypes of
the primary resistance determinant PfCRT. These
haplotypes have encountered drug pressure and
within-host competition with wild-type drug-sensitive
parasites. To examine these selective forces in vitro,
we genetically engineered P. falciparum to express
geographically diverse PfCRT haplotypes. Variant
alleles from the Philippines (PH1 and PH2, which differ
solely by the C72S mutation) both conferred a moder-
ate gain of chloroquine resistance and a reduction in
growth rates in vitro. Of the two, PH2 showed higher
IC50 values, contrasting with reduced growth. Further-
more, a highly mutated pfcrt allele from Cambodia
(Cam734) conferred moderate chloroquine resistance
and enhanced growth rates, when tested against wild-
type pfcrt in co-culture competition assays. These
three alleles mediated cross-resistance to amodi-
aquine, an antimalarial drug widely used in Africa.
Each allele, along with the globally prevalent Dd2 and
7G8 alleles, rendered parasites more susceptible to
lumefantrine, the partner drug used in the leading
first-line artemisinin-based combination therapy.
These data reveal ongoing region-specific evolution of
PfCRT that impacts drug susceptibility and relative
fitness in settings of mixed infections, and raise impor-
tant considerations about optimal agents to treat
chloroquine-resistant malaria.
Introduction
In functionally constrained genes, the rise of non-
synonymous mutations may decrease an organism’s
fitness by steering it away from a long-optimized machin-
ery of closely interacting components. Without a specific
selective pressure, the more fit wild-type usually predomi-
nates at the population level and the less fit variants
are either eliminated or persist at low frequencies
(Mitchell-Olds et al., 2007). An example of selective pres-
sure is the use of drugs to treat human pathogens.As such,
drug-resistant pathogens constitute an ideal group in
which to study the balance between surviving drug pres-
sure and remaining competitive with wild-type organisms.
Generally, fitness costs associated with initial
resistance-conferring mutations will lead to the attrition
of mutants upon the removal of drug pressure, allowing
for the reemergence of surviving wild-type organisms
(Hastings and Donnelly, 2005). However, prolonged drug
exposure can provide pathogens the opportunity to acquire
additional mutations, either within the primary resistance
determinant or within secondary factors, which compen-
sate for the initial fitness cost (Brown et al., 2010). Com-
petition between mutants carrying those compensatory
mutations can then take place, leading to a mutant popu-
lation with a reduced fitness cost that eventually can suc-
cessfully compete with wild-type organisms in a drug-free
environment (Levin et al., 2000). Fitness costs and the
prevalence of initial resistance-conferring mutations can
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also be influenced by the use of other drugs to replace
the failed therapeutic agent, particularly in instances
where their efficacy is impacted by the same resistance
determinants.
The malarial parasite Plasmodium falciparum, which
caused an estimated 198 million clinical cases and
584 000 deaths in 2013 (WHO, 2014), is a prime example
of a human pathogen that repeatedly encounters drug
pressure and within-host competition among parasite
strains. For much of the 20th century, the antimalarial
treatment of choice was chloroquine (CQ), a drug charac-
terized by its rapidity of action, safety and low cost. This
drug prevents the detoxification of reactive iron-containing
heme that is liberated as a result of hemoglobin proteolysis
in the acidic digestive vacuole (DV) of intra-erythrocytic
parasites (Fitch, 2004). CQ resistance (CQR) emerged
slowly, but by the early 1990s had taken hold across
virtually all the malaria-endemic world (Wellems and
Plowe, 2001). The cellular basis for CQR has been attrib-
uted to reduced CQ accumulation in the DV, resulting in
diminished access of CQ to its otherwise toxic heme target
(Saliba et al., 1998).
At the molecular level, CQR has been traced primarily
to amino acid changes in the DV transmembrane protein
PfCRT (Fidock et al., 2000). These include K76T, ubiqui-
tous among CQ-resistant strains and a highly sensitive
marker of CQ treatment failure, as well as three to eight
additional PfCRT polymorphisms that produce region-
specific haplotypes (Ecker et al., 2012). These haplotypes
reflect a handful of origins of mutant pfcrt that dissemi-
nated under drug pressure in selective sweeps across the
world (Nash et al., 2005; Kidgell et al., 2006; Mu et al.,
2010; Park et al., 2012). At least 34 different mutant
PfCRT haplotypes have been reported, contrasting with a
conserved wild-type haplotype in CQ-sensitive parasites
(Isozumi et al., 2010; Ecker et al., 2012; Baro et al.,
2013). In Malawi, the prevalent African mutant form of
PfCRT (CVIET haplotype at positions 72–76, found in
strains including Dd2) largely disappeared within several
years of CQ withdrawal, presumably due to a fitness cost
that rendered this variant less competitive than pfcrt wild-
type parasites in the absence of drug pressure (Kublin
et al., 2003; Mita et al., 2003; Laufer et al., 2010).
The notion that mutation of PfCRT negatively impacts
parasite fitness in field settings is supported by recent in
vitro metabolomic and allelic competition investigations,
which revealed a defect in hemoglobin catabolism and
reduced relative growth rates in vitro, interpreted as a
proxy of fitness costs for the CQ-resistant Dd2 and 7G8
PfCRT haplotypes (Lewis et al., 2014). Consistent with
these findings, a fitness disadvantage was observed for
CQ-resistant parasites during the dry season in The
Gambia, when drug pressure is transiently removed and
transmission is low (Ord et al., 2007). This fitness disad-
vantage was recapitulated in southern Zambia at the level
of vectorial selection, whereby the wild-type (K76) form of
PfCRT was significantly enriched in the infected Anoph-
eles arabiensis mosquitoes compared with its baseline
prevalence in the local infected human populations
(Mharakurwa et al., 2013). Field studies in South America
and Asia, however, have documented no or only modest
attrition in mutant PfCRT forms, including 7G8 (SVMNT
haplotype at positions 72–76), despite the discontinued
use of CQ for the treatment of P. falciparum malaria for
over two decades (Wang et al., 2005; Chen et al., 2008;
Griffing et al., 2010). Those studies have led to the sug-
gestion that the fitness cost of parasites harboring the
72SVMNT76 haplotype may be less severe than that of
parasites carrying the 72CVIET76 signature (Sa and Twu,
2010).
Aside from regional differences in the choice of anti-
malarial drug regimens that may help sustain variant
PfCRT haplotypes (Ecker et al., 2012), studies of human
and murine parasites highlight a potential selective
advantage of mutant pfcrt alleles in enhancing human to
mosquito transmission of parasites following CQ treat-
ment. Among Sudanese parasite isolates bearing the
K76T mutation in PfCRT, a higher gametocyte carriage
rate was observed as compared with parasites encoding
wild-type PfCRT (Osman et al., 2007). Furthermore,
P. berghei parasites engineered to express the P. falcipa-
rum 7G8 pfcrt variant protected early gametocytes
against CQ action and were transmitted at higher levels
compared with drug-sensitive parasites (Ecker et al.,
2011). These observations underscore the complexity of
factors that collectively determine the fitness of Plasmo-
dium parasites, of which relative growth rates in infected
erythrocytes is but one component, with others including
antimalarial drug susceptibility profiles, the impact of host
immunity and transmission dynamics, differences in
gametocyte production and infectivity, competition
between strains within mosquitoes, and growth differ-
ences that could manifest during the liver stages
(Walliker et al., 2005; Rosenthal, 2013).
Here, we dissect the specific contribution of geographi-
cally distinct PfCRT haplotypes to parasite in vitro relative
growth rates and antimalarial drug susceptibility. Our
study includes novel haplotypes that have not been pre-
viously assessed in a controlled genetic background,
including two closely related PfCRT isoforms from the
Philippines (Chen et al., 2005), as well as an allele from
Cambodia that harbors nine mutations, an exceptionally
high number (Durrand et al., 2004). These alleles were
assessed alongside the geographically widespread Dd2
and 7G8 alleles in vitro in drug susceptibility assays as
well as mixed-infection competition assays. We also
investigated how various mutant PfCRT haplotypes
impact CQ accumulation and parasite response to other
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antimalarials in current clinical use. Our results highlight
the importance of regional PfCRT haplotypes in contrib-
uting to parasite fitness and define a novel allele in Cam-
bodia that appears to have overcome the hurdle of
reduced fitness associated with less mutated pfcrt forms
while still maintaining a moderate degree of CQR.
Results
Generation of isogenic parasite lines expressing
Asian pfcrt alleles from the endogenous locus by
allelic exchange
We engineered the mutant pfcrt alleles PH1 and PH2
(from the Philippines) and Cam734 (from Cambodia) into
P. falciparum CQ-sensitive parasites via allelic exchange.
The recipient CQ-sensitive strain C1GC03 was genetically
modified from the GC03 parasite line, a progeny of the
HB3 × Dd2 genetic cross (Su et al., 1997), in a prior round
of transfection. Briefly, the highly interrupted endogenous
wild-type pfcrt gene sequence was replaced with a short-
ened sequence containing all exons and intron 1, render-
ing this line more amenable to pfcrt allelic exchange
(Sidhu et al., 2002). PH1 and PH2 represent two common
PfCRT haplotypes in the Philippines (Chen et al., 2003)
that differ from one another at position 72 and that are
notable for lacking the common A220S mutation but har-
boring the two novel mutations A144T and L160Y
(Table 1). Cam734 comprises ∼ 20% of all pfcrt alleles in
Cambodia and is a highly mutated pfcrt allele, differing
from the wild-type allele at nine positions (Durrand et al.,
2004).
To generate recombinants, C1GC03 parasites were elec-
troporated with the plasmids pBSD-crt-PH1Py3′, pBSD-crt-
PH2Py3′ and pBSD-crt-Cam734Py3′, containing exons 2–13
of the three Asian pfcrt alleles (Fig. 1A). Transfected para-
site cultures were obtained following exposure to blastici-
din and WR99210 to select for expression of blasticidin
S-deaminase (bsd) from the transfection plasmid and
human dihydrofolate reductase (dhfr) in the C1GC03 paren-
tal line respectively.
Polymerase chain reaction (PCR) was used to identify
transfected lines that had undergone homologous
recombination and single-site cross-over into the pfcrt
locus. Recombinant clones were then obtained by limit-
ing dilution. Clones from each successfully integrated
transfection were selected for further characterization
and were termed C8PH1-I, C8PH1-II, C10PH2-I, C10PH2-II,
C12Cam734-I and C12Cam734-II. Following our earlier reports
(Sidhu et al., 2002), the superscript indicates the pfcrt
allele, with the Roman numeral indicating the clone. For
comparison, we included C1GC03, which was generated
using the same allelic exchange strategy (Sidhu et al.,
2002) and which expresses the canonical wild-type
allele (Table 1).
To confirm the clonality of these lines, we performed
PCR with primers P1 and P3 that targeted parasites with
integrated plasmid and primers P1 and P2 that were spe-
cific for the original C1GC03 locus (Fig. 1A and B; Table S1).
Primers P1 and P3 yielded the expected 1.3 kb band from
the clones that had undergone two rounds of recombina-
tion, but not from the first-round C1GC03 or parental GC03
parasites. PCR with primers P1 and P2 resulted in
expected bands of 3.3 kb from the unmodified genomic
pfcrt locus in GC03 and 1.7 kb from the first round of
recombination present in the C1GC03 line (Fig. 1B). South-
ern blot analysis of genomic DNA (gDNA) digested with
SalI + ClaI revealed band sizes of ∼ 16.3 kb, 8.1 kb,
7.7 kb and 1.2 kb, consistent with plasmid integration into
the C1GC03 pfcrt locus (Fig. 1C). GC03 parasites and lin-
earized plasmid DNA showed the predicted 9.4 kb and
7.7 kb bands respectively.
Sequencing of the functional recombinant pfcrt locus
amplified from gDNA, which was performed shortly after
limiting dilution cloning, confirmed the expected full-length
Table 1. Transformation status and PfCRT haplotype of recombinant and wild-type lines.
Clone Parent Transfection plasmid
Functional PfCRT haplotype
72 74 75 76 144 148 160 194 220 271 326 333 356 371
GC03 HB3 × Dd2 – C M N K A L L I A Q N T I R
C1GC03 GC03 phDHFR-crt-GC03Pf3′ C M N K A L L I A Q N T I R
C8PH1-II C1GC03 pBSD-crt-PH1Py3′ C M N T T L Y I A Q D T I R
C10PH2-I,II C1GC03 pBSD-crt-PH2Py3′ S M N T T L Y I A Q D T I R
C12Cam734-I,II C1GC03 pBSD-crt-Cam734Py3′ C I D T F I L T S E N S I R
C2GC03 C1GC03 pBSD-crt-GC03Pf3′ C M N K A L L I A Q N T I R
C4Dd2 C1GC03 pBSD-crt-Dd2Py3′ C I E T A L L I S E S T T I
C67G8 C1GC03 pBSD-crt-7G8Py3′ S M N T A L L I S Q D T L R
HB3 – – C M N K A L L I A Q N T I R
Dd2 – – C I E T A L L I S E S T T I
7G8 – – S M N T A L L I S Q D T L R
Plasmids harboring different pfcrt allelic sequences were transfected into CQ-sensitive C1GC03 parasites to generate the recombinant mutant and
control lines. Grey shading indicates residues that differ from the wild-type sequence.
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sequence of pfcrt in the individual lines.Amplification of the
pfcrt locus from cDNA and gDNA and subsequent
sequencing of the polymorphic region coding for amino
acids 72–76 confirmed the exclusive expression of the
integrated allele in the new second-round recombinants
(data not shown). Real-time PCR analysis was also per-
formed using two independent preparations of parasite
RNA from synchronized ring-stage cultures. These were
assayed for pfcrt and the housekeeping gene actin
(PFL2215w) on four to eight independent occasions
with each sample tested in triplicate per assay. Kruskal–
Wallis tests showed no significant differences in pfcrt tran-
script levels between any pfcrt-modified lines (Table S2).
The same finding of statistically indistinguishable expres-
sion levels was observed by quantitative Western blot
analysis of protein extracts from these recombinant lines
(Table S2).
Ongoing characterization of these recombinant lines,
during the lengthy period of propagation required to com-
plete their phenotypic assessment, revealed a highly
unusual event in the C8PH1-I clone. Over time, a subpopu-
lation arose that outgrew the original line. This subpopula-
tion was found to have undergone reversion of the N326D
mutation back to the wild-type N326 codon in pfcrt, with the
other three PH1 mutations being retained (K76T, A144T
and L160Y; Table 1). Interestingly, this revertant was found
to be CQ sensitive, implicating N326D as an important
contributor to CQR, consistent with a previous report
(Summers et al., 2014). Nevertheless, the advent of a
spontaneous sequence reversion in this line made us
cautious about using the C8PH1-I line, and it was excluded
from further consideration in this present study. Repeated
sequence analysis of other recombinant lines during long-
term culture confirmed the genotypes of all other lines
pBSD-crt-PH1Py3' (7.7kb)
Py3’ bsd
Pf3’pfcrt e2-13 pfcrt e2-135’UTR 1 hdhfr
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Fig. 1. pfcrt allelic exchange strategy and molecular characterization of clones.
A. Schematic representation of single-site cross-over between a pBSD-based pfcrt transfection plasmid and the functional pfcrt locus of
C1GC03, leading to expression of a recombinant allele (PH1, PH2, or Cam734; see Table 1) from the endogenous full-length promoter. The
diagram illustrates transfection of the CQ-sensitive C1GC03 clone with pBSD-crt-PH1Py3′. This construct contained a pfcrt sequence with a
deletion in exon 1, no introns between exons 2–13 and a downstream 0.7 kb 3′ UTR sequence from the P. yoelii ortholog pycrt. Homologous
recombination upstream of codon positions 74–76 resulted in generation of a functional pfcrt allele containing all the point mutations from the
mutant PH1 allele, under the control of pfcrt 5′ UTR and pycrt 3′ UTR regulatory elements. Downstream remnant pfcrt fragments were
truncated in exon 1, had a 5′ in-frame stop codon and lacked a promoter.
B. PCR-based analysis of the recombinant clones and parental lines (primer positions illustrated in A). Parasite strain and primer details are
provided in Table 1 and Table S1 respectively.
C. Southern blot hybridization of gDNA digested with SalI and ClaI and subsequently probed with a pfcrt fragment from exon 2. The positions
of the restriction sites and exon 2-specific probe are indicated in A. B and C include the clone C8PH1-I, which was subsequently found to have
undergone a spontaneous back mutation in codon 326 and was removed from further analysis.
384 I. Petersen et al. ■
© 2015 John Wiley & Sons Ltd, Molecular Microbiology, 97, 381–395
325
under investigation. Analysis of the PH1 haplotype was
therefore confined to the C8PH1-II clone, whose genotype
was closely monitored and remained stable over time.
Mutant Southeast Asian pfcrt alleles influence
susceptibility to locally used drugs
Using these recombinant isogenic lines, we assayed the
impact of different PfCRT haplotypes (Table 1) on parasite
susceptibility to CQ as well as other antimalarials. For
comparison, we included C2GC03, C4Dd2 and C67G8, which
were generated using the same genetic strategy (Sidhu
et al., 2002). These encode the wild-type GC03 haplotype,
the Dd2 haplotype commonly found in Asia and Africa and
the 7G8 haplotype that is widespread in SouthAmerica and
the Pacific region respectively (Sa et al., 2009). For refer-
ence, we also included the non-recombinant lines GC03,
Dd2 and 7G8.
We note that our CQ values, both for resistant and
sensitive strains, are lower than earlier reports (Sidhu
et al., 2002; Lakshmanan et al., 2005; Valderramos et al.,
2010). One important technical difference is that we
reduced the HEPES concentration from the earlier 50 mM
to the current 25 mM. Our detailed studies have since
revealed that this decrease in the HEPES concentration
leads to a substantial reduction in half-maximal inhibitory
concentration (IC50) values for CQ-sensitive and even
more so for CQ-resistant parasites, as detailed in the
Supporting Information (Supplemental Text and Figs S2–
S4). This is one of the variables that can produce differ-
ences in CQ IC50 values (others include genetic differences
between strains maintained long-term in separate labora-
tories and the choice of assay). Relative differences
between strains in a given dataset are thus recognized to
provide the most informative data (Ekland and Fidock,
2008). Consequently, we also discuss below the relative
differences between parasite lines expressing distinct
pfcrt alleles.
For CQ, all recombinant lines expressing mutant pfcrt
alleles (C8PH1, C10PH2, C12Cam734, C4Dd2 and C67G8) had a
statistically significant, 2.5- to 4.7-fold increase in mean
IC50 value relative to the isogenic recombinant C2GC03 line
expressing the wild-type allele (mean IC50 value of 14 nM)
(Fig. 2A; Table S3). Of note, C10PH2 and C12Cam734 yielded
CQ IC50 values (53–54 nM) that were comparable in these
assays to the recombinant C4Dd2 and C67G8 parasites
expressing the most globally prevalent mutant pfcrt alleles
(Sidhu et al., 2002). We note, however, that C4Dd2 and
C67G8 are no longer as CQ-resistant as when they were
originally generated (in 2002) and characterized by several
groups (Sidhu et al., 2002; Lakshmanan et al., 2005;
Gligorijevic et al., 2008). This has also been observed in an
independent recent study that employed these lines
(Hrycyna et al., 2014). C4Dd2 and C67G8 currently display
CQ IC50 values that are now 51% and 68% of the parental
Dd2 and 7G8 lines respectively (Fig. 2A and Table S3), as
compared with the initial report that documented corre-
sponding values of 76% and 90%. These relative levels of
CQR are illustrated for the original C4Dd2 and C67G8 lines,
alongside the now-attenuated lines, in Fig. 2A. Thus, our
present data with the more recently generated PH1, PH2
and Cam734 pfcrt-expressing lines identify these as only
modestly CQR, with relatively low CQ IC50 values. Strik-
ingly, the two C10PH2 clones demonstrated higher CQ
mean IC50 values as compared with C8PH1-II parasites (53–
54 nM compared with 35 nM). This finding implicates
amino acid 72, which is the only polymorphism that distin-
guishes the PH2 and PH1 alleles (Table 1), as an important
determinant of the degree of CQR.
Similar observations were made with the CQ metabolite
monodesethyl-chloroquine (md-CQ), which yields much
higher IC50 values in CQ-resistant parasites, allowing for
greater discrimination between resistant and sensitive
lines (Sidhu et al., 2002). C10PH2 and C12Cam734 clones all
yielded mean IC50 values (267–346 nM) that were com-
parable with C4Dd2 and C67G8 (282 and 262 nM, respec-
tively; Fig. 2B; Table S3). In comparison, the CQ-sensitive
lines C2GC03 and GC03 showed mean IC50 values of
17–22 nM. Of note, the mean md-CQ IC50 value (164 nM)
of the C8PH1 clone was considerably lower than the IC50
values of the two C10PH2 lines (267 and 305 nM), again
supporting a direct role for the C72S mutation in augment-
ing the degree of CQR.
Prior work has shown that CQ-resistant parasites can be
chemosensitized to CQ and md-CQ by the resistance-
reversing agent verapamil (VP) (Krogstad et al., 1987;
Martin et al., 1987). The primary determinant of this revers-
ibility trait has been mapped by quantitative trait loci analy-
sis to mutant pfcrt (Patel et al., 2010) and is more
pronounced in the presence of the Dd2 allele as compared
with the 7G8 allele (Mehlotra et al., 2001; Sidhu et al.,
2002; Sa et al., 2009). To assess VP reversibility in our
recombinant lines, we performed drug assays in the pres-
ence or absence of 0.8 μM VP and compared IC50 values.
Results showed a high degree of resistance reversal (74–
85%) for C4Dd2 and the reference Dd2 line and an interme-
diate degree (43–56%) for C67G8 and 7G8 parasites
(Fig. 2C). These values were significantly different from the
CQ-sensitive C2GC03 line that along with GC03 showed no
reversibility with this concentration of VP. Intriguingly, both
C8PH1 and C10PH2 showed only a slight degree of reversal,
which did not attain statistical significance. A similar lack of
significant reversal was also observed with the metabolite
md-CQ (Table S3). This agrees with an earlier report of
Philippine isolates (Chen et al., 2003) and is consistent
with a recent study that associated PfCRT N75 (present in
both haplotypes; Table 1) with minimal VP reversal
(Sa et al., 2009). We note that C12Cam734 parasites,
PfCRT impacts antimalarial resistance and growth rates 385
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which harbor the novel N75D mutation, were also subject
to a significant degree (56–72%) of VP reversal of CQ and
md-CQ resistance, at levels intermediate to the Dd2 and
7G8 alleles (Fig. 2C; Table S3).
We extended these studies to monodesethyl-
amodiaquine (md-AQ), the clinically relevant metabolite of
amodiaquine, a 4-aminoquinoline drug formerly used in
monotherapy in many South American, African and Asian
countries, including the Philippines (Sa et al., 2009). This
drug continues to be clinically important because of
its incorporation into the widely used amodiaquine–
artesunate combination (Wells et al., 2009). Our studies
reveal a substantial impact of both Philippine pfcrt alleles,
as well as the Cam734 allele, on md-AQ responses
(Fig. 2D), resulting in a 2.5 to fourfold increase in IC50
values compared with C2GC03. Of all alleles tested, the
smallest gain in md-AQ resistance was afforded by expres-
sion of the recombinant Dd2 allele that mediates relatively
high-level CQR (see C4Dd2 responses in Fig. 2A and D).
These data implicate an important role for the PfCRT
mutations unique to the Philippine and Cambodian alleles
in reducing parasite susceptibility to amodiaquine.
Importantly, every mutant pfcrt allele significantly
increased susceptibility to the arylaminoalcohol drug lume-
fantrine (LMF; Fig. 2E), the partner drug comprising the
most widely used artemisinin-based combination therapy
(ACT), artemether-lumefantrine (Wells et al., 2009). Mean
IC50 reductions were 37–47%, as compared with C2GC03
(Table S3). It is worth noting that a similar decrease in LMF
IC50 values in parasites expressing mutant pfcrt as com-
pared with isogenic parasites expressing the wild-type
allele was earlier found to be associated with a significant
reduction in the prevalence of mutant pfcrt in field isolates



































































































































































































































































































































































































































































































Fig. 2. Susceptibility of pfcrt-modified clones to selected antimalarial drugs. Mean IC50 values ± SEM for the indicated parasite strains
subjected to clinically significant antimalarials, as measured in vitro using [3H]-hypoxanthine incorporation assays. We note that the CQ values,
both for resistant and sensitive strains, are markedly lower than earlier reports (Sidhu et al., 2002; Lakshmanan et al., 2005; Valderramos
et al., 2010), and coincide with our reducing the HEPES concentration from the earlier 50 mM to the current 25 mM (see Supporting
information). CQ values for the original C4Dd2 and C67G8 lines, presented as a proportion of their IC50 values of the reference Dd2 and 7G8
lines, are included to illustrate the attenuation of the CQR phenotypes of these lines over time. The C4Dd2-original CQ mean ± SEM IC50 value of
96.8 ± 8.7 nM is comparable to the values of 91.8 ± 10.7 nM and 100.3 ± 15.5 nM recently reported with two pfcrt-modified GC03 clones
engineered to express the Dd2 allele (i.e. analogous to C4Dd2) using customized zinc-finger nucleases (Straimer et al., 2012). VP reversal was
calculated as the IC50 of CQ + 0.8 μM VP divided by the IC50 of CQ. VP reversal values for CQ, md-CQ and md-ADQ are provided in
Table S4. Mann–Whitney U tests were used to assess for statistically significant differences between a recombinant line expressing mutant
pfcrt and the CQ-sensitive line C2GC03 expressing wild-type pfcrt. *P < 0.05; **P < 0.01; ***P < 0.001. IC50 and IC90 values, numbers of assays
and tests for significance are reported in Table S3.
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lumefantrine (Sisowath et al., 2009). These findings
support the therapeutic advantage of using LMF in areas of
CQ-resistant malaria.
A similar trend was observed with the arylaminoalcohol
mefloquine and the endoperoxide artemisinin. However,
the differences in IC50 values did not attain statistical
significance (Table S3). The PH1 and PH2 pfcrt alleles, but
not Cam734, also significantly increased parasite suscep-
tibility to quinine (Fig. 2F), a centuries-old drug used to
treat severe malaria. Quinine resistance is known to be
multifactorial, with quantitative trait loci analyses implicat-
ing mutant pfcrt and pfmdr1 as major determinants (Ferdig
et al., 2004; Sanchez et al., 2011; 2014). Our data support
the hypothesis that the direction and magnitude of the
effect of mutant pfcrt on quinine response depends on the
genetic background and PfCRT haplotype (Cooper et al.,
2002; 2007; Sidhu et al., 2002; Lakshmanan et al., 2005).
Finally, no differences were observed with piperaquine
(Table S3), an ACT partner drug that comprises two CQ
4-aminoquinoline rings tethered together with a spacer
(Wells et al., 2009), consistent with this drug being equally
potent against parasites expressing wild-type or common
mutant variants of pfcrt (Pascual et al., 2013).
Reduced chloroquine accumulation alone does
not account for differences in the degree of
chloroquine resistance
Resistance to CQ has been associated with reduced drug
accumulation in the DV and has previously been attrib-
uted to mutant PfCRT-mediated efflux of CQ from this
acidic organelle (Krogstad et al., 1987; Martin et al., 1987;
2009; Valderramos and Fidock, 2006). To investigate the
influence of the Southeast Asian pfcrt alleles on CQ accu-
mulation, we measured the kinetics of [3H]-CQ uptake in
cultured parasites. The CQ-sensitive control lines GC03
and C2GC03 showed a rapid increase in CQ accumulation,
as measured by a very high ratio (up to 2300) of total
intracellular CQ to extracellular CQ ([CQin]/[CQout])
(Fig. 3A). In contrast, the four pfcrt-variant recombinant
lines (C4Dd2, C8PH1-I, C10PH2-I and C12Cam734-I) accumulated
minimal levels of CQ ([CQin]/[CQout] values of ∼ 200–300).
Thus, these mutant PfCRT haplotypes, all expressed in
the same genetic background, were associated with a
very similar reduction of intracellular CQ levels (Fig. 3B),
despite marked differences in their CQ IC50 values
(Fig. 2). These data lead us to suggest that reduced CQ
accumulation might represent only one means by which
mutant PfCRT dictates the degree of CQR.
PfCRT haplotypes influence parasite growth rates in
co-culture in vitro competition assays
To measure the extent to which pfcrt mutations influence
the relative growth rates of asexual blood stage parasites,
serving as a partial proxy for assessing fitness costs, we
performed in vitro co-culture competition assays. In these
assays, two lines were mixed in 1:1 ratios, and the pro-
portions of the individual pfcrt alleles were quantified by
pyrosequencing every 4 days, on average, over a two to
three month period. Data from these assays were con-
verted using the ratio of the natural logs of the allelic
frequencies, based on an assumption of exponential
growth, and were subjected to linear regression (Maree
et al., 2000; Mita et al., 2004). Linear regression R 2
values were generally high (average 0.64, reflecting an
acceptable goodness of fit; Table S5). In total, 34
co-culture assays were followed, yielding 518 measure-
ments of pfcrt allelic frequencies over time (Table S5).
From these measurements, we computed the mean rela-
tive growth rate value for each line, as detailed in the
Supporting Information.
Results indicated that the isogenic clones C8PH1-II and
C10PH2-I, expressing the PH1 and PH2 mutant pfcrt alleles
respectively, each displayed reduced in vitro growth when
independently co-cultured with C2GC03 parasites (Figs 4












































Fig. 3. Chloroquine accumulation of pfcrt-modified parasite lines.
[3H]-CQ accumulation is represented as the ratio of the total
intracellular CQ to extracellular CQ ([CQin]/[CQout]). Values
represent the mean ± SEM determined from three independent
experiments performed in duplicate. Data are shown in (A) for the
full set of pfcrt-modified lines and the CQ-sensitive control GC03,
and in (B) exclusively for the lines expressing mutant pfcrt (note the
reduced y-axis scale).
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and 5A). Of the two mutant pfcrt parasites, C10PH2-I para-
sites showed the more substantial loss of relative growth
rate in vitro. This finding was consistent with direct com-
petition assays between C10PH2-I and C8PH1-II, which
revealed reduced relative growth rates with the former
(Table S5). This contrasted with CQ and md-CQ IC50
values that were higher for C10PH2-I (Fig. 2; Table S3).
These results suggest a state of balanced polymorphisms
whereby the PH1 allele could be predicted to fare better
than the more unfit PH2 in mixed infections in the absence
of CQ drug pressure, whereas the moderately more CQR
PH2 allele could be more competitive in the presence of
CQ and thus be retained in the population. Intriguingly,
parallel studies with the CQ-resistant C12Cam734-I line docu-
mented that these parasites were consistently as fit in
terms of growth rates, if not slightly more so, when com-
pared with C2GC03 in vitro. These data suggest that the
Cam734 allele, harboring an unusually high number of
point mutations (Table 1), has achieved a functional state
that might reduce the fitness cost typically observed with
mutant pfcrt alleles in endemic settings.
In contrast to Cam734, we observed a substantial reduc-
tion in relative growth rates associated with the Dd2 pfcrt
allele when comparing C4Dd2 to C2GC03, a finding consistent
with reports of reduced fitness associated with this allele in
African parasite populations (Kublin et al., 2003; Mita
et al., 2003; Ord et al., 2007). A more modest reduction in
relative growth rates was observed with the 7G8 allele
present in C67G8. The reduced relative growth rates of the
Dd2 and 7G8 alleles is consistent with a recent report that
also assessed these recombinant parasite lines in mixed
culture experiments (Lewis et al., 2014). In our studies,
C67G8 consistently outcompeted C4Dd2 in mixed cultures in
four independent experiments (Fig. 4; Table S5). Impor-
tantly, when testing non-recombinant lines, we found the
Dd2 line to have moderately increased growth rates rela-
tive to lines expressing wild-type pfcrt (GC03 and HB3),
suggesting that Dd2 harbors additional compensatory
mutations in its genome that corrected the growth defect
associated with expression of its pfcrt allele. A summary of
the influence of pfcrt alleles on in vitro growth rates in these
co-competition assays is depicted in Fig. 5A. Independent
support for these data came from measurements of in vitro
growth rates for individual lines, which were monitored
daily for 7 days in three independent assays per line.
Calculated multiplication rates per 48 h revealed that in
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Fig. 4. Relative growth rate plots for mixed competition assays between pfcrt-modified lines. Parasite cultures were initiated at ∼ 1:1 ratios,
and allelic proportions were measured over time for up to 45 generations by pyrosequencing. The y-axis illustrates the proportion of the first
listed allele comprising the mixed cultures. Each color represents a separate assay. Data are collectively summarized in Fig. 5A and Table S5.
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comparison with parasites expressing the pfcrt wild-type
GC03 allele, parasites expressing the Cam734 allele
showed an equivalent growth rate, whereas parasites
expressing the PH2, Dd2 and 7G8 alleles displayed slower
rates of growth (Fig. S1).
Discussion
Genome-wide studies of P. falciparum populations have
demonstrated a remarkable degree of recent evolution in
the pfcrt coding sequence, beginning with several inde-
pendent origins of variant alleles. These alleles have
spread across malaria-endemic regions as selective
sweeps driven by intense drug pressure (Wootton et al.,
2002; Kidgell et al., 2006; Volkman et al., 2007; Mu et al.,
2010). Primary origins have been localized to South
America and Papua New Guinea (independent sources of
the 7G8 variant haplotype), the Philippines (PH1 and PH2),
the Thai-Cambodian border (Dd2) and most likely Cambo-
dia (Cam734; Fig. 5B) (Ecker et al., 2012). CQR in Africa
resulted from the introduction of variant pfcrt of Southeast
Asian origin (Ariey et al., 2006), whose insidious impact on
malaria rates was highlighted by reports from Senegal
showing nearly a sixfold increase in malarial deaths follow-
ing the arrival of resistant strains (Snow et al., 2001; Trape,
2001). Our study of geographically distinct PfCRT haplo-
types reveals an intricate balance between CQR and para-
site growth rates, which provide an in vitro proxy of fitness.
Our data also highlight the emergence (in Cambodia) of the
Cam734 allele (Durrand et al., 2004), which appears to
have succeeded in mediating a moderate degree of resist-
ance while concurrently maintaining in vitro growth rates at
least as good if not better than wild-type pfcrt (Fig. 5C).
Notably, Cambodia is a known hotbed of multidrug resist-
ance, beginning with CQ and pyrimethamine-sulfadoxine
and more recently with emerging resistance to artemisinin
derivatives (Dondorp et al., 2011; Ariey et al., 2014;
Straimer et al., 2015). We ascribe the lack of an observable
growth rate defect in the Cam734 allele to its complex set
of mutations (Table 1), which include the L148I, I194T and
T333S mutations not present in other parasites studied
herein. We posit that these mutations have evolved to
compensate for a loss of fitness bestowed by an initial set
of mutations that were sufficient to confer CQR, including
but not limited to K76T (Lakshmanan et al., 2005). The
ability of Plasmodium parasites to acquire a set of muta-



































































































































































Fig. 5. Influence of pfcrt alleles on relative growth rates and
chloroquine resistance.
A. Relative growth rate values for the individual pfcrt-modified
parasite lines were measured following pyrosequencing-based
assessment of changes in pfcrt allele frequencies in mixed cultures
maintained for up to 45 generations. For each combination, 1–6
independent competition assays were performed in duplicate
(summarized in Table S5; data plotted in Fig. 4). The histogram
depicts the relative growth rate of the first line compared with the
second, e.g. for C8PH1-II vs. C2GC03 the negative value reflects the
reduced relative growth rate of C8PH1-II.
B. Distribution of various pfcrt alleles in the major malaria-endemic
regions.
C. Mean relative growth rate differences between wild-type and
mutant pfcrt alleles (in the GC03 background) presented as a
function of the effect of these alleles on CQ IC50 values (based on
data presented in Tables S3 and S5 and depicted in Figs 2 and
5A). Circle size indicates the estimated worldwide frequency of the
pfcrt allele, approximated from literature reports and database
summaries on the number of clinical cases and the distribution of
pfcrt alleles (see Table S6).
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fitness has previously been documented in murine studies,
in which CQ-resistant P. chabaudi parasites outgrew their
sensitive counterparts, even when mice were inoculated
with a ninefold excess of sensitive parasites (Rosario et al.,
1978). Recent metabolomic studies show that the wide-
spread Dd2 and 7G8 alleles cause increased levels of
intracellular peptides in asexual blood stage parasites,
presumably stemming from impaired hemoglobin digestion
that restricts the supply of amino acids required for parasite
proliferation (Lewis et al., 2014). These recent findings
provide a potential mechanistic explanation for the fitness
costs observed with the Dd2 and 7G8 haplotypes. Further
studies are required to assess whether the Cam734 allele
corrects this abnormal accumulation of hemoglobin-
derived peptides.
Our findings also illustrate a singular impact of PfCRT
residue 72, which is the sole sequence distinction between
the Philippine PH1 allele that mediates marginal CQR and
the PH2 allele that is moderately more resistant (Fig. 5C).
This residue is also associated with differences in relative
growth rates in vitro (Figs 4 and 5A). How this single amino
acid difference might impact protein conformation, stability
or post-translational modifications remains to be deter-
mined. During these experiments, we isolated a separate
recombinant C8PH1 parasite, referred to as C8PH1-II, which
underwent a spontaneous loss of the N326D mutation
during extended culture. This reversion back to the wild-
type residue was associated with an increased rate of
parasite propagation and a loss of CQR. The reversion to a
CQS phenotype by the N326D mutation is consistent with
a recent report that showed a lack of CQ transport in
Xenopus oocyte-based heterologous expression assays,
in contrast to the PH1 PfCRT variant that showed CQ
transport behavior (Summers et al., 2014). These data
highlight a requirement for multiple PfCRT mutations in
producing the CQR phenotype, arguing against the notion
that CQR results solely from the K76T mutation and that
the other mutations in this protein compensate solely for
loss of function. This conclusion is supported by transport
studies in an oocyte expression system, which provided
evidence that the K76T mutation needed to be accompa-
nied by either the N75E (Southeast Asian PfCRT variants)
or the N326D mutation (LatinAmerican and oceanic PfCRT
variants) to attain a CQ transport function (Summers et al.,
2014). Although two mutational changes sufficed for a
basal CQ transport activity, additional mutations were
required for full activity. The order in which these mutations
were added was important to avoid reductions in CQ
transport activity (Summers et al., 2014).
Epidemiological studies have found that some para-
sites harboring the PfCRT K76T mutation have low to
moderate CQ IC50 values that do not meet the standard
definition of CQR and in some instances are similar to
values observed with CQ-sensitive parasites, for example
some Cambodian isolates harboring the Cam734 allele
(Durrand et al., 2004). Studies are ongoing to dissect the
role of the PfCRT SNPs that are unique to the Cam734
haplotype. Furthermore, in vitro selection studies have
shown that parasites harboring the Dd2 pfcrt allele
acquired a C101F mutation that resulted in a loss of CQR
despite the presence of K76T (Eastman et al., 2011).
Thus, although K76T continues to be an important
molecular marker of CQR, recent evidence suggests that
additional PfCRT SNPs can substantially modify the CQ
response, in some cases causing an attenuation or loss of
the resistance phenotype. We also note that while PfCRT
is widely recognized to be the primary mediator of CQR,
several studies point to a requirement for secondary
determinants to augment CQR, including pfmdr1 (Sidhu
et al., 2002; Sa et al., 2009; Patel et al., 2010;
Valderramos et al., 2010; Gaviria et al., 2013).
In our mixed infection studies with isogenic pfcrt-
modified clones, we also observed that parasites dis-
played the greatest loss of asexual blood stage growth
when expressing the Dd2 allele, consistent with its pro-
gressive disappearance from high-transmission African
settings in the absence of CQ pressure (Mita et al., 2003;
Ord et al., 2007; Mwai et al., 2009; Laufer et al., 2010;
Frosch et al., 2011). This contrasts with the situation in
Southeast Asia where the Dd2 allele remains at high
frequencies in the absence of CQ pressure. Fewer mixed
infections in Asia compared with Africa likely result in less
opportunity for competition with the wild-type allele. The
lesser fitness cost observed with the 7G8 allele, which is
prevalent in South America and the Pacific region, is
concordant with studies from these regions showing the
continued presence of mutant pfcrt despite minimal CQ
use in recent decades to treat P. falciparum malaria (Mu
et al., 2010). We note that modest selective pressure on
mutant pfcrt may also have come from the use of CQ to
treat P. vivax infections, which are common outside of
Africa (Price et al., 2007). Overall, our in vitro mixed com-
petition relative growth rate data would suggest that the
idea of reintroducing CQ into regions where prolonged
drug removal has led to the near disappearance of
resistant strains (Juliano et al., 2007; Laufer et al., 2010)
is suitable only in areas harboring mutant pfcrt alleles
such as Dd2 that cause reduced fitness and would be less
applicable to regions harboring relatively ‘fit’ alleles such
as Cam734.
The loss of CQ efficacy across the globe, followed by a
short-lived dependence on the sulfadoxine-pyrimethamine
antifolates, has resulted in recent years in the global adop-
tion of ACTs (White, 2008; Eastman and Fidock, 2009).
Notably, our study shows that all mutant pfcrt alleles tested
herein, including the two that are most prevalent (Dd2 and
7G8), increase parasite susceptibility to lumefantrine. This
is particularly significant as this drug, partnered with
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artemether (CoArtem®), is globally the most widely used
antimalarial (Wells et al., 2009). Although the fold change
in lumefantrine IC50 values is relatively low (≤ 2-fold;
Fig. 2E; Table S3), we note that a clinical trial from Tanza-
nia observed significant selection against mutant pfcrt
parasites harboring the 72CVIET76 PfCRT haplotype follow-
ing artemether–lumefantrine treatment (Sisowath et al.,
2009).
Amodiaquine–artesunate is another ACT that is often
used in Africa (Olliaro and Mussano, 2000). We observed
significantly reduced parasite susceptibility to the amodi-
aquine metabolite md-AQ with every tested mutant pfcrt
allele. This includes both Philippine alleles, obtained from
a country where amodiaquine has been used as an anti-
malarial treatment for over 40 years (Sa et al., 2009). We
thus posit that amodiaquine could have been a major
contributor to the emergence and/or maintenance of the
PH1 and PH2 alleles. An important role for amodiaquine
in driving the spread of the 72SVMNT76 PfCRT haplotype
(present in 7G8) has recently been proposed based on
studies of parasites from South America and Asia (Sa
et al., 2009; Beshir et al., 2010), and amodiaquine pres-
sure could conceivably account for the apparent recent
spread of this haplotype into Africa and in India (Alifrangis
et al., 2006; Gama et al., 2010; Mixson-Hayden et al.,
2010). In addition, as with many Asian countries, CQ has
continued to be used to treat patients infected with
P. vivax, thus sustaining local CQ pressure that could
influence the course of mixed infections of P. vivax and
P. falciparum. Overall, our data support the use of
artemether–lumefantrine in preference to amodiaquine-
artesunate to treat CQ-resistant malaria. We also found
no evident effect of mutant pfcrt alleles studied herein on
the efficacy of piperaquine, an ACT partner drug with
excellent clinical efficacy and post-treatment prophylactic
activity (Wells et al., 2009).
Our mechanistic investigations into CQR provide evi-
dence that mutant PfCRT-mediated CQR can be pheno-
typically distinguished from reduced intracellular CQ
accumulation, as also noted by a previous study (Sanchez
et al., 2011). This was particularly evident with C8PH1 para-
sites that, despite having only a nominal degree of CQR,
displayed kinetics of intracellular CQ accumulation that
paralleled the other, more CQ-resistant parasites. In con-
trast, CQ-sensitive parasites showed 7- to 10-fold higher
levels of CQ accumulation (Fig. 4). Thus, all mutant PfCRT
variants shared an ability to reduce CQ accumulation. This
study agrees with recent evidence that reduced CQ accu-
mulation is not the sole cause of CQR (Cabrera et al.,
2009; Sanchez et al., 2011; Baro et al., 2013). We posit
that mutant PfCRT generally reduces CQ accumulation
and that this is an essential feature of CQR but that various
PfCRT haplotypes differ in a second respect that further
contributes to the CQR phenotype. One possibility is that
the higher degree of CQR reflects varying degrees to which
PfCRT functions to also reduce the cellular toxicity associ-
ated with CQ action, possibly by negating the effect of CQ
on preventing the buildup of reactive heme-iron or oxygen
species liberated following hemoglobin proteolysis.
Another possibility is that the drug competes with a yet to
be identified physiological substrate for transport via
PfCRT and that this competition impacts on the natural
function of the transporter. In this context, it is interesting to
note that PfCRT appears capable of simultaneously
accepting different substrates at distinct but antagonisti-
cally interacting binding sites (Bellanca et al., 2014).
Binding of two different substrates might result in an inac-
tive transporter or one with substantially reduced activity,
depending on the nature of the substrates bound (Bellanca
et al., 2014). How a geographic PfCRT variant copes with
its drug and physiological transport functions is likely deter-
mined by its specific amino acid substitutions. Further
dissection of the biochemical parameters associated with
heme detoxification and CQ action can now be achieved
using the series of isogenic pfcrt-modified lines described
herein.
Experimental procedures
Parasite culture, transfection, and selection and
characterization of integrant clones
Parasites were cultured at 37°C in human red blood cells in
Albumax-containing culture medium, as described (Fidock
et al., 1998). Isogenic lines expressing variant pfcrt alleles
were generated following transfection of the C1GC03 clone
(Sidhu et al., 2002). This clone was previously generated
from GC03 (a progeny of the HB3 × Dd2 genetic cross,
Wellems et al., 1990) and expresses wild-type pfcrt from a
recombinant locus lacking introns 2–12 (Fig. 1). C1GC03 para-
sites were propagated to ∼ 8% ring stage parasitemia and
electroporated with 50 μg of plasmid (pBSD-crt-PH1Py3′,
pBSD-crt-PH2Py3′ or pBSD-crt-Cam734Py3′; Table 1; Fig. 1).
Transformed parasites were selected using 2.5 nM WR99210
(Jacobus Pharmaceuticals, Princeton, NJ, USA) and 2.5 μM
Blasticidin HCl (Invitrogen). Successfully transfected para-
sites were detectable in culture 2–3 weeks post-transfection
and cloned by limiting dilution once plasmid integration was
detected. Details of plasmid construction, and of the molecu-
lar characterization of parasite lines, are provided in the Sup-
porting Information (primers listed in Table S1). pfcrt-modified
transgenic lines will be made available upon request and are
being deposited in the MR4 Malaria Reagent Repository.
In vitro drug susceptibility assays
Parasite susceptibilities to antimalarial drugs were assessed
in vitro as described (Fidock et al., 1998) using 72 h [3H]-
hypoxanthine assays (see Supporting Information). IC50
values were calculated by non-linear extrapolation. Statistical
analyses employed Mann–Whitney U tests.
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In vitro mixed culture competition assays,
pyrosequencing and determination of relative
growth rate values
For growth competition assays, two parasite lines were mixed
1:1 and seeded in duplicate or triplicate at an initial para-
sitemia of 0.6% ring stage parasites, in drug-free medium.
Parasitemias were maintained between 0.3% and 8% to
assure optimal growth conditions. Two to six separate com-
petition assays were performed for each drug-free mixture,
and each assay was monitored for an average of 66 days
(range 43–90; Fig. 4; Table S5). To determine the ratio of both
strains in the mixture over time, saponin-lysed parasite
pellets of the mixed cultures were collected on average every
4 days (range 2–9), and DNA was extracted using DNeasy
Blood & Tissue Kits (Qiagen). The DNA was then used for
ratiometric determination of individual allele frequencies in
these mixed cultures by pyrosequencing of codon position 72
or 76 (detailed in the Supporting Information). To calculate the
relative growth rates of individual parasite lines, the relative
proportion of the two distinct pfcrt alleles (whose values were
always between 0 and 1, inclusive) were natural log-
transformed, and linear regression was applied to estimate
the relative growth rate value, as detailed in the Supporting
Information. These values, along with the calculated SEM
and R 2 values, are listed in Table S5.
Chloroquine accumulation assays
These were performed, as previously described (Sanchez
et al., 2003), using magnet-purified, sorbitol-synchronized
trophozoites (detailed in Supporting Information). The
amount of accumulated intracellular [3H]-CQ was calculated
as the ratio of [CQin]/[CQout], normalized to 1 × 106 infected
erythrocytes.
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In regions with high malaria endemicity, the withdrawal of chloro-
quine (CQ) as first-line treatment of Plasmodium falciparum infections
has typically led to the restoration of CQ susceptibility through the
reexpansion of the wild-type (WT) allele K76 of the chloroquine re-
sistance transporter gene (pfcrt) at the expense of less fit mutant
alleles carrying the CQ resistance (CQR) marker K76T. In low-transmis-
sion settings, such as South America, drug resistance mutations can
attain 100% prevalence, thereby precluding the return of WT para-
sites after the complete removal of drug pressure. In French Guiana,
despite the fixation of the K76T allele, the prevalence of CQR isolates
progressively dropped from >90% to <30% during 17 y after CQ
withdrawal in 1995. Using a genome-wide association study with
CQ-sensitive (CQS) and CQR isolates, we have identified a single mu-
tation in pfcrt encoding a C350R substitution that is associated with
the restoration of CQ susceptibility. Genome editing of the CQR ref-
erence strain 7G8 to incorporate PfCRT C350R caused a complete loss
of CQR. A retrospective molecular survey on 580 isolates collected
from 1997 to 2012 identified all C350R mutant parasites as being
CQS. This mutation emerged in 2002 and rapidly spread throughout
the P. falciparum population. The C350R allele is also associatedwith a
significant decrease in piperaquine susceptibility in vitro, suggesting
that piperaquine pressure in addition to potential fitness costs asso-
ciated with the 7G8-type CQR pfcrt allele may have selected for this
mutation. These findings have important implications for understand-
ing the evolutionary dynamics of antimalarial drug resistance.
malaria | drug resistance | evolution | Plasmodium falciparum | PfCRT
The emergence of drug-resistant pathogens is a major threat tohuman health, and Plasmodium falciparum has shown its ca-
pacity to develop resistance to every drug that has been deployed
against it on a large scale. Although Africa carries by far the heaviest
burden of malaria, parasite resistance to chloroquine (CQ), sulfa-
doxine-pyrimethamine (1), and more recently, artemisinins (2) first
emerged in southeast Asia and South America (the latter only for
CQ and sulfadoxine-pyrimethamine), where transmission in-
tensity is low. This evolving situation underscores the importance
of understanding the evolutionary dynamics of antimalarial drug
resistance in distinct transmission contexts. In Central or South
America, where clonal propagation can occur (3), the population
genetic diversity is reduced, with high rates of inbreeding (4). As
a consequence, strong drug pressure can ultimately lead to fix-
ation of drug resistance alleles, even if they generate a fitness cost
to parasites in the absence of drug pressure. Thus, whereas in
high-transmission African settings, changes in drug pressure are
known to alter the relative proportions of mutant and WT alleles
of drug resistance determinants, less is known about how drug-
selective forces operate in low-transmission contexts where resistance
alleles are already fixed. Here, we have examined the evolution of
P. falciparum CQ resistance (CQR) in French Guiana after suc-
cessive changes in therapeutic policy.
French Guiana is a French overseas territory in South America
that is included in the Guiana Shield, a pre-Cambrian geological
formation including Guyana, Surinam, French Guiana, and parts
of Venezuela, Brazil, and Colombia. The region is endemic for
both P. falciparum and Plasmodium vivax (5). In the past 15 y,
this population of ∼250,000 inhabitants has experienced a
greater than 75% decrease in annual cases of malaria: ∼4,500
cases in 2000 compared with fewer than 500 cases in 2014.
French Guiana is currently in a control phase and on track to
soon enter a preelimination phase (fewer than 5% of febrile
patients test positive for Plasmodium), a situation akin to that in 55
other countries around the world (6). Treatment of uncomplicated
P. falciparum malaria cases with the former first-line antimalarial
CQ was officially abandoned in 1995 because of poor clinical effi-
cacy. Quinine (QN) plus doxycycline became the subsequent
treatment of choice until 2007, with sporadic use of halofantrine
and mefloquine (MQ). Artemether-lumefantrine, an artemisinin-
based combination therapy (ACT), was widely implemented in
2008. Although the artemether–lumefantrine combination has been
Significance
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roquine resistance in Plasmodium falciparum from French Guiana
was lost after sustained drug removal, whereas the resistance
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This phenotypic reversion was caused by the acquisition of a
single additional C350R substitution in PfCRT. This genetic change
also impaired susceptibility to piperaquine, suggesting that
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the official first-line treatment since 2008, illegal gold miners living
in the forest are known to self-medicate their fevers with dihy-
droartemisinin (DHA) -piperaquine (PPQ) -trimethoprim (TMP;
DHA + PPQ + TMP; Artecom) tablets.
In South America, the prevalence of the CQR marker K76T in
the drug efflux transmembrane protein PfCRT has remained
high, despite CQ having been abandoned for the treatment of
P. falciparum infections (7–9). This situation contrasts with multiple
settings in Africa, where the majority of molecular studies (10–13)
have documented an increase in the prevalence of WT pfcrt after
CQ withdrawal. An analysis of the diversity of microsatellites
flanking pfcrt in Malawi showed that the return to CQ susceptibility
was caused by a reexpansion of theWT PfCRT haplotype (11). Such
a difference between South America and other endemic regions in
response to CQ withdrawal is generally attributed to other amino
acid changes in PfCRT and PfMDR1 (both present on the parasite
digestive vacuole membrane), which accompany the PfCRT K76T
substitution. Specifically, the SVMNT haplotype of South American
parasites at PfCRT amino acids 72–76 has been found to be less
deleterious than the CVIET haplotype present elsewhere (14, 15).
Another explanation for the virtual fixation of CQR alleles in South
American parasites is that CQ continues to be used to treat P. vivax
infections and therefore, may exert a residual pressure. Lastly, it is
thought that the earlier campaign of adding low-dose amodiaquine
(AQ) to table salt proved highly effective at creating a selective
sweep of AQ and CQR-conferring mutant pfcrt after it had arisen in
the late 1950s and eliminating any vestigial WT pfcrt.
We have previously reported that a significant proportion of
P. falciparum parasites from French Guiana have a CQ IC50 below
the adopted resistance threshold of 100 nM, despite elevated
prevalence of K76T, suggesting a reduced predictive value of this
marker, at least in this region of South America (16). In this study,
we pursued a genotypic and phenotypic survey, including whole-
genome sequencing and gene-editing experiments, which led us to
identify a molecular marker of drug susceptibility. These findings
have important implications for understanding drug resistance
evolution in a low-endemicity context where drug resistance alleles
can reach fixation, a scenario that will become increasingly dom-
inant as successful control efforts progressively reduce the burden
of malaria.
Results
CQ Susceptibility Has Returned to French Guiana After Drug Withdrawal.
We tested the in vitro CQ susceptibility of 1,207 P. falciparum
isolates collected between 1994 and 2012 and compared these data
with those previously reported for the 1983–1987 period (17). The
general trend is that CQ susceptibility followed changes in drug
policy (Fig. 1) and can be divided into three main periods. It took
5 y after the official CQ withdrawal in 1995 to observe a decrease in
the prevalence of in vitro CQR isolates from ∼90% to ∼40% (Fig.
1B). Of note, such a high prevalence of CQR at ∼90% in the 1990s
was already reported in the mid-1980s. From 2000 to 2006, a con-
sistent but small increase in the prevalence of CQR isolates was
observed (up to 70% in 2006), potentially because of an overlap
between the mechanisms of drug response to CQ and the first-line
therapies used at that time (notably QN). This trend toward a re-
surgence of CQR, however, reversed concomitantly with the pro-
gressive introduction of ACT as first-line therapy in 2007. Within
2 y, the prevalence of CQR isolates dropped and thereafter, re-
mained stable at ∼25% (2008–2012).
Mutant PfCRT and PfMDR1 Haplotypes Are Fixed in the Parasite
Population. We genotyped a large panel of patient isolates col-
lected between 1997 and 2012 (Table 1). Of 1,054 isolates
genotyped for the pfcrt gene, the mutant haplotype SVMNT was
present in 97.5%, a far greater proportion than the mean per-
centage of in vitro CQR parasites (48.6%) observed in the same
period. Haplotypes other than SVMNT were very rare (n = 26
of 1,054). For 18 of these 26 patients for whom we had in-
formation, 15 had traveled to West Africa (5 CVIET and 10
CVMNK) and 2 had traveled to Haiti (CVMNK) in the previous
month, leaving a single patient harboring a CVMNK haplotype
that could have been transmitted locally. A similar allelic fixa-
tion could be observed for the pfmdr1 gene, because 86.3% of
861 genotyped isolates displayed the South American re-
sistance-associated NFCDY haplotype (amino acids 86, 184,
1,034, 1,042, and 1,246) (Table 1). Altogether, the sum of
PfCRT/PfMDR1 haplotypes SVMNT/NFCDY (7G8-type; n = 688)
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Fig. 1. Evolution of P. falciparum in vitro CQ susceptibility in French Guiana
from 1983 to 2012. Lines above graphs indicate the successive change in drug
recommendations in French Guiana throughout the study period. (A) Box and
whisker plots showing the distribution of CQ IC50 values. Whiskers show the
10th and 90th percentiles, boxes represent interquartile range, and the
horizontal line is themedian. Isolate numbers per year are listed above the x axis.
(B) Observed percentage of CQR isolates over time defined by an IC50 > 100 nM.
AR, artemether; DX, doxycycline.*1983–1987 data are from ref. 17.
Table 1. Prevalence of PfCRT and PfMDR1 haplotypes of isolates
collected in French Guiana (1997–2012)
Haplotype n Frequency (%)










Haplotypes denote amino acids at positions 72–76 for PfCRT and positions
86, 184, 1,034, 1,042, and 1,246 for PfMDR1.


















isolates sampled during this 16-y period. These results confirmed
that the standard molecular markers, notably PfCRT K76T and
to a lesser degree, PfMDR1, are no longer predictive of CQR in
French Guiana.
Genome-Wide Association Study Identifies PfCRT C350R as the Single
Mutation Associated with CQ Susceptibility. To identify the genomic
variants associated with the reversion of CQR in mutant isolates
harboring PfCRT K76T, we performed whole-genome sequence
analysis of 54 culture-adapted isolates obtained from distinct
malaria-infected patients in French Guiana between 2009 and
2013. We then performed a genome-wide association study
(GWAS) on a final dataset of 35 isolates [18 CQ-sensitive (CQS)
and 17 CQR parasites] containing 34,196 SNPs (Figs. S1 and S2).
Strikingly, a single locus on chromosome 7 achieved genome-
wide significance for association with CQS: a Tgt/Cgt non-
synonymous substitution in exon 10 of the pfcrt gene that leads to
the replacement of a cysteine by an arginine at codon 350 (C350R)
(Fig. 2A).
Genome Editing and Molecular Surveys Show That PfCRT C350R Is
Responsible for a Loss of CQR. To assess the impact of PfCRT
C350R, we edited the pfcrt gene in the CQR reference strain
7G8. This Brazilian strain carries the canonical South American
PfCRT (SVMNT) and PfMDR1 (NFCDY) haplotypes that are
shared by the vast majority of isolates from French Guiana. 7G8
parasites that expressed either the recombinant 7G8 allele
(7G87G8; transfection control) or the 7G8 variant containing the
C350R mutation (7G8C350R) were generated using pfcrt-specific
zinc finger nucleases as previously described (18) (Fig. S3).
Recombinant clones were obtained by limiting dilution and
validated using PCR and sequencing. Drug assay data showed
that the PfCRT C350R mutation caused a 24-fold reduction in
the mean CQ IC50 values from 380 nM in the reference 7G8
7G8
clone to 16 nM in the 7G8C350R variant (P < 0.0001, Student t
test) (Fig. 2B). A similar reversal of resistance to monodesethyl-
CQ, the active in vivo metabolite of CQ, was observed. Parallel
studies with parental 7G8 parasites yielded a mean CQ IC50
value of 386 nM, indicating that the expression of the cDNA pfcrt
locus (lacking most introns) did not itself cause a significant shift
in CQ IC50 values. Of note, the 7G8
C350R clone showed a similar
mean CQ IC50 value as the reference CQS strain D10 (Papua
New Guinea; mean IC50 of 19 nM) that harbors the PfCRT
CVMNK WT sequence.
In parallel, we examined the association of the C350R muta-
tion with CQ susceptibility in PfCRT K76T mutant isolates in a
large set of isolates collected between 1997 and 2012. Exons 2
and 10 were sequenced from 580 isolates. Biallelic samples
(C350 + 350R; n = 7) were excluded from the analysis because of
a putatively biased IC50 value. All PfCRT C350R mutant isolates
(n = 168) were found to be CQS, with a mean CQ IC50 of 23 nM.
This value is significantly lower than the mean CQ IC50 value of
160 nM observed with PfCRT C350 parasites (n = 405; P <
0.0001) (Fig. 2C). Altogether, these results provide compelling
evidence that the emergence of the PfCRT C350R mutation is
primarily responsible for the recent gain of CQ susceptibility in
PfCRT K76T isolates from French Guiana.
PfCRT C350R Emerged in 2002 and Then, Rapidly Spread Throughout
the Parasite Population in French Guiana. Only 54% of the CQS
isolates with the PfCRT SVMNT sequence harbored the addi-
tional C350R mutation in the combined dataset. However, this
general picture obscures important temporal disparities. Al-
though it took 5 y after the official withdrawal of CQ to observe a
significant decrease of CQR (i.e., in 2000), interestingly, the first
PfCRT C350R isolate was not detected until 2 y later in 2002
(Fig. 2D). Thereafter, the prevalence of PfCRT C350R in the
total parasite population increased rapidly from 2.7% in 2002 up
to 58% in 2012. We note that 100% of the CQR isolates har-
bored K76T and the C350 residue. Among the SVMNT CQS
isolates (defined as CQ IC50 < 100 nM), the prevalence of
PfCRT C350R increased from 5% in 2002 to 83% in 2012; the
few other CQS C350 isolates nonetheless showed a significantly
higher mean CQ IC50 than the CQS C350R isolates (62 vs. 23 nM,
respectively; P < 0.001).
Significant Impact of the PfCRT C350R Mutation on Decreased PPQ
Susceptibility. Because PfCRT is known to modulate P. falciparum
response to diverse antimalarial drugs, we investigated whether
the C350R mutation had an impact on other drug susceptibilities
in both the 7G8 genome-edited lines and field isolates collected
during the 2008–2012 period (Fig. 3). For all tested compounds,
the 7G87G8 modified clone displayed IC50 values similar to the
7G8 parental line, confirming that the pfcrt gene editing did not
affect drug responses. Introduction of the PfCRT C350R mu-
tation had no effect on pyronaridine response but significantly
increased 7G8 susceptibilities to monodesethyl-AQ (mdAQ),
QN, MQ, and lumefantrine (LUM) by 2- to 4-fold (P < 0.001)
and induced a moderate but significant 1.6-fold increase in artesunate
susceptibility (3.5 vs. 2.2 nM for 7G87G8 and 7G8C350R, respectively;
P < 0.05). A significant effect of C350R on PPQ response was also





















































































































Genome-edited and reference lines Fig. 2. PfCRT C350R is the determinant of in vitro CQR
reversion. (A) Signal of SNPs associated with CQ sus-
ceptibility. The Manhattan plot shows P values for SNPs
with minor allele frequencies >10%. The horizontal red
line indicates the P value significance threshold. After
adjusting P values for genome-wide inflation (Fig. S2),
a single SNP (red dot) on chromosome 7 displayed a
highly significant association with CQ susceptibility (P <
1E-11; PfCRT C350R; arrow). (B) pfcrt-edited clones and
control reference lines 7G8 and D10 were assayed for
their susceptibilities to CQ and its active in vivo me-
tabolite monodesethyl-CQ (mdCQ). IC50 values are
represented as means ± SEM. Each line was assayed on
at least eight separate occasions in duplicate (Table S1).
(C) IC50 values for P. falciparum isolates from French
Guiana (means ± SEM). Horizontal dashed lines in B
and C denote the resistance threshold of 100 nM. ***P <
0.0001 relative to (B) 7G87G8 or (C) PfCRT C350 isolates
(Student t test). (D) Decreasing prevalence of CQR iso-
lates from 1997 to 2012 and its inverse relationship with
the increasing prevalence of isolates harboring PfCRT
C350R (continuous line). Only isolates carrying the PfCRT
SVMNT haplotype at amino acids 72–76 were included in
the analysis.
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susceptibility (mean PPQ IC50 of 26 vs. 37 nM for 7G8
7G8 and
7G8C350R, respectively; P < 0.001) (Fig. 3A and Table S1).
French Guianan isolates showed a quite different pattern of
drug susceptibilities (Fig. 3B). As expected, C350R mutant iso-
lates were also found to be highly susceptible to mdAQ. Unlike
the 7G8 genome-edited lines, no differences in QN, MQ, and
LUM susceptibilities were found. However, a moderate but sig-
nificant association between the presence of the C350R mutation
and a decrease in DHA susceptibility was observed (1.0 vs. 1.5 nM
for C350 and C350R, respectively; P < 0.001). C350R mutant
isolates also displayed a significantly lower susceptibility to PPQ
compared with WT C350 isolates (mean IC50 of 61 vs. 33 nM for
C350R and C350, respectively; P < 0.001). Overall, both the gene-
edited 7G8C350R line and field isolates harboring a PfCRT
SVMNT+C350R haplotype showed concordant results in their
higher susceptibilities to CQ and mdAQ in contrast with their
decreased susceptibilities to PPQ.
Discussion
In French Guiana, the prevalence of CQR has decreased sig-
nificantly after CQ withdrawal, a pattern also noted in many
other endemic areas worldwide (10–13). Here, we show that this
phenotypic reversion is caused by the acquisition of a single
mutation in the pfcrt gene that completely abolishes the effect
of the K76T resistance mutation as opposed to the alternative
scenario of the WT allele reemerging.
Repopulation by an allele is driven by multiple parameters,
including initial frequency, population size, and the allele’s se-
lective advantage. Our findings clearly show that the WT PfCRT
CVMNK haplotype has been purged from the entire population
and that the few cases of imported parasites from Africa or Haiti
were not sufficient to initiate colonization. The return to CQ
susceptibility was not as straightforward as in Malawi, where
CQR has completely disappeared, and it has been proposed that
CQ treatment could be reintroduced (19). In addition to the fact
that an additional mutation had to emerge and then spread in
French Guiana, the differential rate of CQR reversal might be
related to the clear differences in transmission intensity, population
dynamics, and history of drug use between these two settings. In
French Guiana, 18 y after CQ withdrawal, 25% of isolates are
still CQR in vitro, precluding the reintroduction of CQ as
antimalarial treatment.
Two studies have reported the emergence of polymorphisms
nearby C350R in PfCRT after in vitro drug selection experiments
on CQR strains. Using the 106/176I line, QN single-step selection
experiments generated lines with an additional PfCRT Q352K
or Q352R mutation that had acquired QN resistance but simul-
taneously regained CQ susceptibility (20). Separately, in vitro
selection for resistance to the IDI-3783 compound that is selectively
active against CQR parasites resulted in acquisition of the Q352R
mutation in PfCRT (and concomitantly, a loss of CQR), thus pro-
viding a conceptual framework for the development of combination
therapies that would exploit this evolutionary trap (21). These
mutations occur in pfcrt exon 10, which corresponds to amino acid
substitutions in transmembrane domain 9. This domain is postu-
lated to function in substrate binding and translocation, similar to
transmembrane domain 1, which contains the K76T substitution
(20, 22–24). The functional hypothesis for the regained in vitro CQ
susceptibility by acquisition of mutations in exon 10 is the reintro-
duction of a positive charge (K and R) that would inhibit the
binding of CQ and block its extrusion from the digestive vacuole.
Therefore, an important finding of our study is the demonstration
that these particular adaptive mechanisms observed in individual
strains during in vitro experiments can also be selected in natural
parasite populations where drug resistance alleles are fixed.
Examining the temporal changes in PfCRT haplotype di-
versity, we note that, between 2001 and 2003, the majority of
CQS field isolates did not harbor the C350R mutation. By 2012,
however, almost all of the susceptible parasites harbored the
PfCRT C350R mutation, implying strong selection for this variant.
These results suggest the existence of additional determinants
accounting for the loss of CQR in the early 2000s. In another
study that examined how the parasite genetic background dic-
tates the degree of mutant pfcrt-mediated CQR, the WT pfcrt
md-Amodiaquine Dihydroartemisinin Lumefantrine Piperaquine Pyronaridine
(n=118) (n=96) (n=70)(n=55)(n=59)(n=127)(n=77) (n=105)
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Fig. 3. Impact of PfCRT C350R on antimalarial drug responses (means ± SEM). IC50 values are shown for (A) genome-edited and reference lines (assayed on
four to nine separate occasions in duplicate) (Table S1) and (B) French Guianan field isolates from 2008 to 2012. All isolates analyzed in B have the PfCRT
SVMNT haplotype at amino acids 72–76. Genome-edited lines or field isolates harboring PfCRT C350R show concordant results in their higher susceptibilities
to CQ and mdAQ, contrasting with a decreased susceptibility to PPQ. Asterisks denote the significance level of the difference (A) between 7G8C350R and
7G87G8 or (B) between PfCRT C350R and C350 isolates (Student t test). nd, not determined. *P < 0.05; **P < 0.001; ***P < 0.0001.


















allele in CQS strains was replaced by the mutant 7G8-type pfcrt
(25). The 3D77G8- and D107G8-transfected lines exhibited only a
modest increase in their CQ IC50 values. Nonetheless, these
mutant lines were able to withstand high concentrations of CQ
and showed delayed recrudescence in culture after high CQ
exposure, indicative of a CQ tolerance phenotype. Interestingly,
two CQS isolates from French Guiana with the PfCRT SVMNT
haplotype were assayed in the same study. The isolate G224
(exhibiting PfCRT C350) also displayed the characteristics of CQ
tolerance, whereas the other isolate, H209 (exhibiting PfCRT
C350R), had a more typical CQS phenotype. From these pre-
vious results and our own observation that the few CQS isolates
with WT PfCRT C350 are significantly less susceptible to CQ
than the PfCRT C350R isolates, we can hypothesize that these
SVMNT PfCRT C350 isolates with a CQ IC50 < 100 nM had a
CQ-tolerant phenotype, having already lost robust resistance.
Acquisition of full CQ susceptibility would, therefore, be a
multistep process that proceeds by an accumulation of adaptive
changes, including mutations acquired at other loci, with PfCRT
C350R being the final step of a complete CQR reversal.
The successive implementation over time of various first-line
drugs after the official cessation of CQ use (Fig. 1) has created a
complex selection landscape operating on the pfcrt gene, which is
known to impact the efficacy of multiple antimalarials (20, 26).
Our drug profiling data showed a significant loss of mdAQ re-
sistance in field isolates harboring the PfCRT C350R mutation,
consistent with earlier reports that highlighted the close corre-
lation between CQ and mdAQ responses of PfCRT SVMNT
parasites from South America (14). Our observation that mutant
C350R isolates were nominally less susceptible to DHA, how-
ever, should be interpreted with caution, notably because in vitro
artemisinin susceptibilities, as measured using IC50 values, do
not correlate with the clinical phenotype of delayed parasite
clearance rates in southeast Asia (27, 28).
Our genome-edited 7G8C350R line displayed increased sus-
ceptibility to multiple drugs, including mdAQ (as noted above
for C350R-carrying field isolates), QN, MQ, artesunate, and
LUM. This result reveals a pleiotropic role for this recently
emerged pfcrt allele in modulating parasite susceptibility to clini-
cally important antimalarials. This role differs from what is gen-
erally observed in Africa with the PfCRT CVIET haplotype or
even the PfCRT SVMNT haplotype in Papua New Guinea (29,
30). This effect of C350R on QN and MQ, however, was not
replicated in field isolates, underscoring a complex genetic basis of
susceptibility in the field. Another primary determinant of sus-
ceptibility to these drugs in P. falciparum is the pfmdr1 gene, which
in French Guiana harbors the 86N and 184F residues that are
associated with increased LUM susceptibility (31, 32). Of note, all
isolates remained highly susceptible to LUM, a finding that argues
for maintaining the artemether + LUM combination as first-line
therapy in the region.
Finally, our data provide evidence that the pfcrt genotype
impacts PPQ response. These results suggest that the PPQ
pressure exerted by the erratic consumption of Artecom (DHA +
PPQ + TMP) by thousands of illegal gold miners in French
Guiana since 2002 might be one of the selective forces that drove
the expansion of the PfCRT C350R allele during this same pe-
riod and as a consequence, the return of CQ susceptibility. In
fact, miners on the Guiana Shield readily cross borders between
Brazil, French Guiana, and Suriname and regularly automedi-
cate with Artecom (33–35). This clue to the putative mechanism
of resistance to PPQ is potentially of considerable importance,
because PPQ treatment failure is a major and increasing concern
in southeast Asia (36–38). Therefore, the association between
PfCRT haplotypes and PPQ treatment failure should be further
explored in southeast Asia, where polymorphisms in the pfcrt
gene, notably in exon 10, were found to accompany mutations in
the pfK13 gene associated with artemisinin resistance (39). Given
that increased PPQ pressure is likely under mass drug adminis-
tration campaigns that use DHA–PPQ, it would be also important
to monitor parasite changes at the entire pfcrt locus that may result
in reduced PPQ susceptibility.
In conclusion, this work illustrates a unique evolutionary path
taken by the pfcrt gene as a consequence of an altered drug policy.
In the virtual absence of the competing WT, sensitive pfcrt allele,
drug susceptibility evolved through the acquisition of an additional
amino acid substitution rather than reversion of an existing mu-
tation, such as the critical CQR marker K76T. The extent of this
particular mechanism of CQR reversion, described here for the
first time to our knowledge, should be further assessed to de-
termine whether it reflects a local evolutionary event or is also
happening in other settings or at larger scales. Finally, we provide
evidence that, in regions where P. falciparum parasite populations
are small and malaria elimination efforts will be targeted, the
usefulness of standard molecular markers for drug resistance will
require periodic phenotypic validation to contend with ongoing
parasite evolution.
Materials and Methods
Origin and Collection of French Guianan Isolates. P. falciparum isolates were
collected between 1994 and 2013 from symptomatic patients diagnosed
throughout the network of hospitals, medical laboratories, and health
centers in French Guiana. The GWAS samples were collected during 2009–
2013. To ensure clonality before whole-genome sequencing, isolates were
either assayed with a subset of 15 SNPs from a 24-SNP barcode (40) and
confirmed as monoclonal or cloned by limiting dilution.
Drug Assays. The phenotypes of the isolates were determined ex vivo (i.e., di-
rectly after patient blood sampling) or in vitro (after parasite multiplication in
culture for several days). The ex vivo method was applied if, at the time of
starting phenotypic analysis, the isolate exhibited (i) a P. falciparum infection
without concomitant P. vivax infection, (ii) a parasitemia greater than 0.05%,
(iii) an interval of less than 4 d between sampling and analysis, and (iv) a
quantity of blood sufficient to run the method. Parasite growth was de-
termined by incorporation of tritiated hypoxanthine using a 42-h standard 96-
well candle jar method (41). French Guianan culture-adapted clones selected for
whole-genome sequencing were assayed in a controlled gas atmosphere with
5% (vol/vol) CO2, 10% (vol/vol) O2, and 85% (vol/vol) N2. For 7G8 and D10
clones, in vitro 72-h drug dose–response assays were performed, and parasite
growth was determined using flow cytometry with SYBR Green I and Mito-
Tracker Deep Red (42). Mean IC50 ± SEM values and numbers of repeats are
listed in Table S1. Statistical significance of differences between mean IC50
values was assessed using Student t tests.
DNA Extraction and Genotyping. Genomic DNA was prepared using the QIAmp
DNA Blood Kit (Qiagen). Conditions for PCR and targeted sequencing of pfcrt
exon 2 (harboring codons 72–76) and polymorphic regions of pfmdr1 were
previously described (16). A 121-bp fragment encompassing the complete exon
10 of pfcrt (harboring codon 350) was PCR-amplified and Sanger-sequenced.
Whole-Genome Sequencing and the GWAS. DNA samples weremade into 200-bp
Illumina fragment libraries by the Broad Institute Genomics Platform and se-
quenced with paired-end 101-bp reads on an Illumina HiSeq2000 instrument
using V2 chemistry. This design yielded a 70-foldmean coverage, a level sufficient
to perform SNP calling. Reads were processed through the Picard sequencing
analysis pipeline at the Broad Institute, generating standard sequencing metrics
and demultiplexed sample-specific sequencing read BAM (Binary Alignment
Map) files. Reads were aligned to the 3D7 reference assembly (PlasmoDB v9.0)
using BWA (43), and SNPs were called using the GATK Unified Genotyper (44).
Heterozygous SNP calls were discarded along with all calls exhibiting QUAL
(quality scores) < Q30. Principal components analysis on called SNPs led to the
exclusion of six confounders because of perfect genome identity (n = 4; implying
clonal infection in different patients) and population stratification (n = 2; out-
liers) to find an unstructured sample of unique individual genomes (Fig. S1). We
further filtered the dataset to exclude samples exhibiting either a low fraction of
genotypable bases because of low sequencing coverage or SNP sites exhibiting a
call rate of less than 50% in the remaining samples and/or a minor allele fre-
quency of less than 10%. Samples were excluded from the GWAS if they
exhibited calls for fewer than 90% of the SNP loci matching the criteria just
described. The GWAS was performed in PLINK v1.07 (pngu.mgh.harvard.edu/
purcell/plink/) (45). To avoid false-positive associations, we applied a genomic
control correction to adjust P values for genome-wide inflation (Fig. S2).
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Generation of pfcrt-Edited 7G8 Clones. To generate recombinant isogenic lines
differing only at their pfcrt locus, we used a previously validated zinc
finger nuclease-mediated genome editing strategy (18). A schematic and a
description of this approach are shown in Fig. S3.
Ethical Considerations. Analyzed samples were all obtained by blood collections
performed as part of the standard medical care for any patient presenting with
fever on hospital admission in FrenchGuiana. Specimen collection compliedwith
Article L.1211–2 and related articles of the French Public Health Code, which
states that biobanking and secondary use for scientific purpose of remaining
human clinical samples are justified with the informed consent of the patient.
Moreover, in compliance with French legislation (article L.1243–3 and related
articles of the French Public Health Code), samples received at the Malaria NRC
(National Reference Center) had been registered for research purposes in the
NRC Biobank declared to both the French Ministry for Research and a French
Ethics Committee, which both approved and registered this thematic biobank
(declaration number DC-2010–1223; collection no. 2). No institutional review
board approval is required according to the French legislation.
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Fig. S1. Principal component analysis of a pairwise distance matrix between the genomes of parasites collected in French Guiana from 2008 to 2012. This two-
component graph shows the relatively homogeneous distribution of the parasite genomes included in the study and the absence of population stratification.
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Fig. S2. Quantile–quantile plots of expected vs. observed P values of individual SNPs associated with the CQ-susceptible phenotype. This plot was generated
after correction for inflated P values. The SNP with the most important deviation from the expected P value (upper right corner) corresponds to the PfCRT
C350R mutation found in CQ-susceptible parasites.
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Fig. S3. Site-specific genome editing strategy to introduce pfcrt modifications into the 7G8 reference line; 7G8 parasites were electroporated with a donor
plasmid (pfcrt-hdhfr) encoding a desired compacted (exons 2–13) pfcrt haplotype and pressured with 2.5 nM WR99210. Transformed parasites were sub-
sequently electroporated with a zinc finger nuclease (ZFN) -encoding plasmid (pZFNcrt-bsd) and pressured for 6 d with 2.5 μg/mL BSD + 2.5 nM WR99210
followed by culture in 2.5 nM WR99210. Our pfcrt-specific ZFNs were linked using a viral 2A peptide that permits translation of the two separate ZFNs from a
single transcribed mRNA. Binding of these customized DNA binding ZFNs to adjacent sites of intron 1 results in pairing of their split FokI endonucleases, which
as an obligate heterodimer form, causes a double-stranded break in intron 1. These events are repaired using the donor template present on the second
plasmid that contains 5′ and 3′ regions of homology with DNA resection and donor template strand invasion-dependent DNA repair and resynthesis, thus
exchanging the endogenous pfcrt allele with the plasmid-borne variant that contains the entire coding sequence that removes all introns except for intron 1.
The presence of ZFN binding site mutations on the plasmid sequences ensures that both the plasmid and the subsequently gene-edited locus are refractory to
the ZFNs that can only cleave the original genomic copy. Editing of pfcrt was assessed by PCR analysis of bulk cultures. Cultures showing editing were cloned by
limiting dilution and flow cytometrically assessed for growth after 20 d by SYBR Green I and MitoTracker Deep Red (Invitrogen) staining. Presence of the
desired pfcrt sequence was validated by PCR and RT-PCR.
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Table S1. Detailed antimalarial drug susceptibilities in genome-edited and reference lines
Drug and IC values (nM) D10 7G8 7G87G8 7G8C350R
CQ
Mean IC50 ± SEM 19.5 ± 1.5 386.2 ± 24.8 379.6 ± 24.4 16.2 ± 1.8
Mean IC90 ± SEM 35.1 ± 3.8 694.0 ± 67.3 676.9 ± 65.7 46.3 ± 4.4
Nb of assays 8 8 8 8
P value vs. 7G87G8 <0.0001
mdCQ
Mean IC50 ± SEM 35.1 ± 3.2 1,571.0 ± 228.0 1,559.5 ± 146.7 53.3 ± 5.7
Mean IC90 ± SEM 89.0 ± 10.9 2,273.2 ± 241.1 2,242.1 ± 237.8 179.1 ± 16.5
Nb of assays 8 9 9 9
P value vs. 7G87G8 <0.0001
mdAQ
Mean IC50 ± SEM 24.2 ± 1.2 77.9 ± 9.0 73.9 ± 5.5 21.1 ± 1.5
Mean IC90 ± SEM 34.8 ± 3.3 122.9 ± 9.2 121.3 ± 9.1 34.6 ± 4.0
Nb of assays 8 8 8 8
P value vs. 7G87G8 <0.0001
QN
Mean IC50 ± SEM 35.1 ± 2.2 275.4 ± 23.4 285.1 ± 24.2 76.4 ± 5.1
Mean IC90 ± SEM 151.8 ± 39.1 768.0 ± 83.5 847.6 ± 92.2 260.5 ± 19.6
Nb of assays 8 7 7 7
P value vs. 7G87G8 <0.0001
LUM
Mean IC50 ± SEM 6.6 ± 1.6 2.3 ± 0.4 2.4 ± 0.5 0.6 ± 0.1
Mean IC90 ± SEM 19.8 ± 3.4 9.4 ± 0.9 9.7 ± 0.9 2.7 ± 0.3
Nb of assays 7 4 4 4
P value vs. 7G87G8 <0.01
MQ
Mean IC50 ± SEM nd 9.0 ± 0.9 11.1 ± 0.7 6.0 ± 0.9
Mean IC90 ± SEM nd 27.4 ± 3.8 30.7 ± 3.9 20.4 ± 2.0
Nb of assays nd 4 4 4
P value vs. 7G87G8 <0.01
AS
Mean IC50 ± SEM 3.7 ± 0.3 3.4 ± 0.4 3.5 ± 0.4 2.2 ± 0.2
Mean IC90 ± SEM 8.0 ± 1.1 6.3 ± 0.9 6.7 ± 0.9 5.5 ± 0.4
Nb of assays 7 7 7 7
P value vs. 7G87G8 <0.05
PPQ
Mean IC50 ± SEM 22.2 ± 2.6 25.6 ± 2.1 26 ± 2.1 36.5 ± 2.4
Mean IC90 ± SEM 43.1 ± 5.2 57.4 ± 3.6 60.0 ± 3.7 77.9 ± 7.2
Nb of assays 8 9 9 9
P value vs. 7G87G8 <0.001
PND
Mean IC50 ± SEM 6.1 ± 0.3 4.7 ± 0.4 4.9 ± 0.4 4.5 ± 0.5
Mean IC90 ± SEM 10.1 ± 1.0 7.6 ± 0.5 8.7 ± 0.5 7.7 ± 0.5
Nb of assays 8 9 9 9
P value vs. 7G87G8 ns
Student t tests were used to compare 7G87G8 with 7G8C350R mean IC50 values. AS, artesunate; mdCQ, mono-
desethyl-CQ; Nb, number; nd, not determined; ns, not significant; PND, pyronaridine.
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